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Abstract 
Objectives To develop an alcohol intervention model that predicts life years 
(LYs), quality adjusted life years (QALYs), and healthcare costs classified by the 
Alcohol Use Disorder Identification Test (AUDIT) screening tool and other 
various risk factors related to alcohol consumption. Furthermore, the 
developed model was transferred to the Thai setting.  
Methods Eight Scottish Health Surveys from 1995-2012 were linked to Scottish 
morbidity records and death records for the period 1981 to the end of 2013. 
Parametric survival analysis was used to estimate the hazard risks of first 
alcohol-related and non-alcohol related hospitalisations and deaths. For men 
and women, multivariate data analyses were applied separately for each gender 
in modelling the utility score, risks of subsequent hospitalisation and annual 
healthcare costs within the follow-up period. Risk profiles were used for the 
covariates of the models as follows: age, socio-economic status, health 
condition, alcohol drinking (i.e. AUDIT and binge drinking), smoking, body mass 
index, and physical activity. According to the under-reporting bias of alcohol 
consumption among the survey population, this study adjusted the reported 
alcohol consumption using alcohol sales data. Multiple imputation approach was 
applied to deal with missing data. A health-state transition model with annual 
cycle length was developed to predict LYs, QALYs, lifetime costs, and cost-
effectiveness. Probabilistic sensitivity analysis was also performed to deal with 
parameter uncertainty. Moreover, a methodological transferability protocol of 
the Thai study was detailed.    
Results The sample size of the cohort was 46,230. The developed model showed 
the association between drinking and alcohol-related and non-alcohol related 
hospitalisations and deaths which were calculated as LYs and QALYs. Other risk 
factors were also taken into account that would likely affect the outcomes of 
interest. The modelling showed that an increasing AUDIT score and the number 
of cigarettes per day were associated with an increased risk of first alcohol-
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attributable hospitalisation. Predicted outcomes for a male aged 30 year with 
high-risk drinking levels (AUDIT >7) were worse than males with low risk drinking 
(AUDIT ≤7), with approximately 5 LY gained and 7 QALY gained. The same 
results for females were obtained for high-risk drinking (AUDIT >4) compared 
to low-risk drinking (AUDIT ≤4), with approximately 10 LY gained and 12 QALY 
gained. Furthermore, an economic evaluation was performed to compare the 
no-intervention situation with a hypothetical health promotion intervention - 
which aimed to stop drinking (measured by the AUDIT) and smoking (measured 
by the number of cigarettes per day) behaviours. To compare the costs and 
benefits of the hypothetical intervention and no intervention over the lifetime 
period, a within-trial analysis combined with the developed model was able to 
capture both short- and longer-term consequences (i.e. LYs, QALYs, and 
healthcare costs) of the intervention. Finally, the model was able to compare 
cost-effectiveness ratio between risk behaviours without the new intervention 
and the modified risk behaviours when the new intervention is implemented.  
Conclusions The study highlights the potential and importance of developing 
health economic models utilising data from routine national health surveys 
linked to national hospitalisation and death records. The developed framework 
can be used for further economic evaluation of alcohol interventions and other 
health behaviour change interventions. The framework can further be 
transferred to other country settings.
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Structure of thesis 
The thesis consists of ten chapters, and each chapter starts with an 
introduction section of an overview and outline to orientate the reader as 
following.  
Chapter 1 establishes the background information about alcohol drinking 
problems and burden of alcohol-related harms. Then, an overview evidence of 
alcohol policies in global and country levels, and the economic evaluation 
guidelines of public health and health promotion programme and applicable 
transferability of economic evaluation to other settings are presented. Due to 
increasing interest of alcohol policy evaluation, the importance of filling a 
knowledge gap in this area are described as well as a synopsis of the research 
methods and the implication of research findings. 
Chapter 2 reviews the published literature of existing models for economic 
evaluation of alcohol intervention. Then, the rationale of developing a new 
alcohol intervention model is addressed.   
Chapter 3 then describes the conceptual framework and objectives of the 
study. An analytical framework including input data sources, analytical 
methods, and expected output is addressed to outline the key methods used in 
this study. A health state transition model for estimating LYs, QALYs and 
lifetime healthcare cost is illustrated. The key data sources are identified and 
explained. Although this study has not required ethical approval due to the 
analysis using anonymised data with no identifiers, the ethical approval process 
for primary data collection is raised in this chapter.     
Chapter 4 starts the first stage of analysis based on the analytical framework 
in Chapter 3 which is predicting the Alcohol Use Disorder Identification Test 
(AUDIT) score using SHeS to complete the AUDIT score where it is missing in 
SHeS waves 1995-2011. This chapter demonstrates a comparison of alternative 
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models for predicting AUDIT scores, and identifies the best predictive 
performance model to be used for the remaining analyses. 
Chapter 5 presents the analysis of associations between alcohol-related 
hospitalisation and health-related quality of life in terms of utility decrement. 
The results will be used for estimating QALYs in the health state transition 
model.        
Chapter 6 demonstrates the statistical analysis of SHeS-SMR linkage data to 
develop hazard function models of first event after survey date and death 
following the first hospitalisations using selected modifiable risk factors of 
study population. This chapter also describes the model validation and 
predicted life expectancy from the alcohol intervention model which is also re-
calibrated by the latest Scottish life tables. The results are presented in term 
of predicted LYs for different risk profiles. 
Chapter 7 describes how the developed health state transition model   
generates lifetime QALYs and healthcare costs. Modelling secondary events 
after first hospitalisation until death are carried out; moreover, modelling 
hospitalisation costs of all episodes following first admission is conducted.  The 
key input parameters derived from previous analyses (described in Chapter 5) 
can be used for the health state transition model to generate lifetime QALYs 
and healthcare costs, and the results are also presented as subgroup by selected 
risk profiles. 
Chapter 8 demonstrates how the alcohol intervention model could be used for 
economic evaluation of interventions which aim to change the selected risk 
factors, and the demonstration presents the impact of an intervention on 
changing LYs, QALYs and lifetime health service costs. 
Chapter 9 discusses a developed protocol of further study in Thailand and 
methodological problem surrounding transferability to Thai context e.g. what 
Thai context specific data is required, working with limited data sources and 
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Thai’s policy maker and public interest. The Thai study will evaluate the alcohol 
intervention and intervention implemented in Thailand. 
Chapter 10 is a discussion and conclusion chapter to summarise the aims, 
approach and applications of developed alcohol intervention model not only for 
Scottish context but also opportunity of transfer to the Thai context.  
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Chapter 1: Introduction 
1.1 Factors associated with alcohol consumption and 
alcohol-related harm 
Alcohol-related harm is determined by the volume of alcohol consumed, the 
pattern of drinking, and the quality of alcohol consumed (Rehm et al., 2010a). In 
the context of the global burden of alcohol consumption, which is primarily 
concerned with alcohol’s role in disease and injury, these three harms play 
different roles (WHO, 2014). For example, the toxic effect of alcohol is considered 
to cause many chronic conditions. For these conditions, alcohol shows a dose-
response relationship, where the risk of onset of or death from the disease or 
condition depends on the total volume of alcohol consumed (Rehm et al., 2010a). 
This figure was also shown in a large cohort study in eight European countries, 
namely the European Prospective Investigation into Cancer and Nutrition 
(EPIC) study which found that alcohol consumption, especially drinking level higher 
than the upper recommended units, can result in higher incidences of cancer in 
both men (18.5%) and women (4%) (Schutze et al., 2011). In global burden 
estimates (WHO, 2014), dependence primarily appears as a mental disorder rather 
than as a risk factor for other health harms. The effect of dependence on other 
health harms is accounted for through the high volume and excessive patterns of 
consumption, for which dependence presumably contributes a large extent.  
Furthermore, the pattern of drinking over time increases the risks of harm, 
particularly in heavy episodic drinking, which is defined as the consumption of 60 
or more grams of pure alcohol (or >= 5 drinks per occasion in most countries) on 
at least one single occasion at least once a month (Roerecke and Rehm, 2010). The 
pattern of drinking is an important factor for many acute consequences of drinking 
such as alcohol poisoning, injury and violence, and intoxication (Rehm et al., 
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2010a, Shield et al., 2013). Lastly, the quality of alcoholic beverages may also 
impact health and mortality, e.g. when home-made or illegally produced alcoholic 
beverages are contaminated with methanol or other very toxic substances (Rehm 
et al., 2010b). Unrecorded products are often available outside the regulated 
market (resulting, for example, in cheaper prices, different controls or no controls 
on availability), may increase overall consumption, and have also been linked to 
more heavy drinking episodes (Rehm et al., 2010b). 
Figure 1-1 illustrates the conceptual causal model of alcohol consumption, 
intermediate mechanisms, and long-term consequences, as well as the influence 
of societal and demographic factors of alcohol consumption and alcohol-related 
harms (Shield et al., 2013, Rehm et al., 2010a). A variety of factors have been 
identified at societal- and individual-levels which affect the volume and patterns 
of consumption and can increase the risk of alcohol use disorders and other 
alcohol-related problems in individual drinkers and others such as family members 
(Babor et al., 2010a, Shield et al., 2013, Rehm et al., 2010a). 
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Figure 1-1  Conceptual causal model of alcohol consumption related to harms and 
vulnerability factors, i.e. societal and individual factors.   
Adapted from (Rehm et al., 2010a, Shield et al., 2013) 
1.1.1 Societal vulnerability factors 
The societal factors include the following. First, economic development is 
the most important of the societal vulnerability factors related to alcohol 
consumption, as well as to alcohol-attributable disease burden (WHO, 2014, OECD, 
2015). Emerging economies have seen a major relative increase in alcohol 
consumption (OECD, 2015). However, a recent published study concluded that the 
effects of declining macroeconomic conditions (represented by the increased 
unemployment rate) also increased problems related to alcohol consumption such 
as binge drinking, alcohol abuse, alcohol dependence and drink-driving (Davalos et 
al., 2012). These problems resulted in high mortality, burden of disease, and injury 
in the societies (WHO, 2014).  
 The second societal factor which affects alcohol consumption is the 
drinking environment such as private residences, licensed premises and other 
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settings such as parks and beaches. These environments may contribute to high 
levels of alcohol consumption resulting in higher risk of alcohol-related harms 
(WHO, 2014). For instance, alcohol consumption in commercial drinking 
environment, e.g. bars, pubs, and clubs - which are licensed for retail sales - may 
lead to high-risk drinking (Babor et al., 2010a). Thus, many establishments make 
these drinking locations prime targets for alcohol policies aimed at the prevention 
of alcohol-related problems.  
 The third factor is the level and effectiveness of alcohol control for 
production and distribution of alcohol, and alcohol regulations (Babor et al., 
2010b). The scope and nature of alcohol-attributable disease burden and alcohol-
related social harms provide a solid rationale for tackling harmful use of alcohol 
through national and international alcohol policies and interventions. The 
systematic review findings indicated that population-based policy options, which 
use taxation to regulate the demand for alcoholic beverages as well as restricting 
their availability and implementing bans on alcohol advertising, show effective and 
cost-effective results in reducing alcohol use disorders, alcohol attributable 
deaths, and disabilities at the population level (Anderson et al., 2009a, Anderson 
et al., 2009b, Chisholm et al., 2004). 
1.1.2 Individual vulnerability factors 
 Many individual factors can influence alcohol consumption and alcohol-
related harms (WHO, 2014). The first factor is the difference in age (Bonnie and 
O'Connell, 2004, Healey et al., 2014, Richter et al., 2015, Hingson, 2010, Donovan, 
2013, Delker et al., 2016). Young people were associated with a greater proportion 
of total alcohol consumed (Marshall, 2014), and underage drinking (less than aged 
18 years) increased risks for alcohol dependence and abuse at later ages, alcohol-
related motor vehicle crashes, and other unintentional injuries (Healey et al., 
2014, Bonnie and O'Connell, 2004, Richter et al., 2015, Hingson, 2010, Miller et 
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al., 2006). However, alcohol-related harm among elderly people is due to 
somewhat different factors than alcohol-related harm among young people (WHO, 
2014). While alcohol consumption generally declines with age, older drinkers 
typically consume alcohol more frequently than other age groups. Also, as people 
grow older, their bodies are typically less able to handle the same levels and 
patterns of alcohol consumption as in previous life years, leading to a high burden 
from unintentional injuries such as alcohol-related falls. 
 The second individual factor is the difference in gender. Alcohol 
consumption and its related harms among men have been greater than women 
(WHO, 2014, Delker et al., 2016, Probst et al., 2015b). Factors contributing to this 
include the fact that men are less often abstainers, and drink more frequently and 
in larger quantities. Harmful use of alcohol is the leading risk factor for death in 
males aged 15–59 years (Whiteford et al., 2013), yet there is evidence that women 
may be more vulnerable to alcohol-related harm from a given level of alcohol use 
or a particular drinking pattern (Wilsnack et al., 2013). The vulnerability of 
females to alcohol-related harm is a major public health concern because alcohol 
use among women has been increasing steadily in line with economic development 
and changing gender roles (Richman et al., 1995), and because it can have severe 
health and social consequences for newborns (McBride, 2014, Wilsnack et al., 
2013).  
 The third individual factor is family history of alcohol use disorders. This 
is considered as a major vulnerability factor for both genetic and environmental 
reasons (Reboussin et al., 2012, Bellis et al., 2007, Guerrini et al., 2014). Multiple 
genes influence alcohol use initiation, metabolism, and reinforcing properties in 
different ways, contributing to increased susceptibility to the toxic, psychoactive, 
and dependence-producing properties of alcohol. Parents with alcohol use 
disorders display particular patterns of alcohol consumption and thereby increase 
the likelihood that their children will develop drinking patterns associated with 
Chapter 1: Introduction  6 
 
 6 
high risks when they are introduced to alcohol (Reboussin et al., 2012, Bellis et 
al., 2007). In addition, heavy drinking by parents affects family functioning, the 
parent–child relationship, and parenting practices, which in turn affects child 
development adversely. 
 The fourth is socioeconomic status (SES) related to alcohol drinking and 
its consequences. A range of national and international survey studies found that 
people in higher SES groups were more often drinkers and drank smaller amounts 
more frequently, whereas those in lower SES groups had a higher proportion of 
abstainers; however, those who drank did so more often in problematic ways 
(Grittner et al., 2013, Grittner et al., 2012, Bloomfield et al., 2006). Moreover, 
the recent systematic reviews examined the association between socioeconomic 
factors, mortality, and morbidity for a range of alcohol-attributable conditions 
(Jones et al., 2015b, Probst et al., 2014, Probst et al., 2015b). The reviews 
identified that people with lower SES appear to be more vulnerable to alcohol-
related problems. These figures showed that lower SES is associated with higher 
mortality for alcohol-attributable causes – despite lower socioeconomic groups 
often reporting lower average levels of alcohol consumption defined as the Alcohol 
Harm Paradox (Smith and Foster, 2014). The potential vulnerabilities among lower 
SES groups are possibly due to the following: heavy drinking occasions more often, 
under-reporting of consumption, multiple ‘unhealthy’ behaviours, barriers to 
accessing health and alcohol related services, and the effects of poverty on health 
inequalities (Probst et al., 2014, Probst et al., 2015b, Smith and Foster, 2014). 
1.1.3 Multiple alcohol-related behaviours 
A growing evidence base suggests that risk behaviours often cluster or co-
occur within individuals such as smoking, alcohol use, unhealthy diet, and lack of 
physical activity (McAloney et al., 2013, Schuit et al., 2002). Co-occurrence refers 
to concurrent (but independent) engagement in two or more risk behaviours; 
Chapter 1: Introduction  7 
 
 7 
clustering refers to underlying associations between co-occurring risk behaviours 
(Noble et al., 2015, McAloney et al., 2013). Systematic reviews of cross-sectional 
and longitudinal studies that investigated the most common combinations of risk 
behaviours were as follows: alcohol and smoking, physical activity and smoking, 
and diet and smoking (Meader et al., 2016, Noble et al., 2015, McAloney et al., 
2013). The review findings concluded that among general adult populations, 
alcohol misuse and smoking was the most commonly identified risk behaviour 
cluster (Meader et al., 2016). Among young adults, there was consistent evidence 
of clustering found between sexual risk behaviour and substance misuse (Meader 
et al., 2016). Moreover, socio-economic status was the strongest predictor of 
engaging in multiple risk behaviours, which several studies showed that health-risk 
behaviours in adulthood are predicted by life-course characteristics such as 
originating from a family in a low socio-economic position, having a low 
educational level or being in a low socio-economic position as an adult (Meader et 
al., 2016, Hair et al.). Modifying multiple unhealthy behaviours was suggested by 
previous RCTs to be more effective than single-targeted behaviour changes 
(Prochaska et al., 2012, Kruger et al., 2014, Schulz et al., 2014). 
1.2 Burden of disease related to alcohol consumption 
Alcohol use disorder is recognised as a worldwide public health concern 
(Whiteford et al., 2013). The WHO reported in the Global status report on alcohol 
and health in 2012 that about 3.3 million deaths or 5.9% of all global deaths were 
attributable to alcohol (WHO, 2014). There are significant sex differences in the 
proportion of global deaths attributable to alcohol, e.g. in 2012, 7.6% of deaths 
among males and 4.0% of deaths among females were attributable to alcohol. The 
high levels of alcohol consumption and drinking patterns (e.g. binge drinking) likely 
have a causal impact on the mortality and morbidity related to many diseases 
(Grant et al., 2009, Jones and Bellis, 2014, Jones et al., 2008, Kendler et al., 2016, 
Rehm and Roerecke, 2013, Roerecke and Rehm, 2013). There are a wide range of 
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diseases and injuries associated with alcohol consumption as defined by the WHO 
ICD-9 and ICD-10 codes (Appendix 1). In 2010, the impact of alcohol use disorder 
was also the global leading cause of premature death - equivalent to 8.6 million 
years of life lost (YLLs) attributable to mental and substance use disorders as 
illustrated in Figure 1-2 (Whiteford et al., 2013). The largest burden of disease 
related to alcohol use disorders occurred at age 25-50 years - approximately 2 
million disability-adjusted life years (DALYs) across these age groups and - 
gradually declined for older aged (Figure 1-3). Moreover, the data derived from 
187 countries as shown in Figure 1-4 is the burden attributable to mental and 
substance use disorders as a proportion of all disease burden classified by region. 
Alcohol use disorder’s DALYs varied more than 10 time between regions, and the 
largest proportion of its DALYs was illustrated in Eastern Europe followed by other 
parts of Europe, Latin America, and Asia.   
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Figure 1-2 Proportion of YLDs (A), YLLs (B), and DALYs (C) as explained by 
each mental and substance use disorder group in 2010. Data are % (95% CI). 
 
DALYs = disability-adjusted life years. YLDs=years lived with disability.  
YLLs = years of life lost. 
Source: (Whiteford et al., 2013) 
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Figure 1-3  Disability-adjusted life years (DALYs) for each mental and 
substance use disorder in 2010, classified by age. 
Source: (Whiteford et al., 2013) 
 
 
Figure 1-4  Rates of disability-adjusted life years (DALYs) per 100,000 
individuals for mental and substance use disorders in 2010, classified by region. 
Source: (Whiteford et al., 2013) 
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1.2.1 Socioeconomic consequences of alcohol use for drinkers 
Alcohol use disorders, i.e. alcohol dependence and harmful use of 
alcohol as outlined in the ICD-10 (WHO, 2007a), is often associated with 
socioeconomic consequences as shown in Figure 1-1. These consequences 
include loss of earnings, unemployment, homelessness, poverty, family 
disruption, and stigmatisation (WHO, 2004, Schmidt et al., 2010). Regarding the 
stigmatisation of alcohol problems, in a 14-country WHO cross-cultural study of 
disabilities, key informants assigned “alcoholism” an average rank of 4th out of 
18 conditions in terms of the degree of social disapproval or stigma in society -  
which was a greater disapproval than for having “chronic mental disorder” 
(Room et al., 2001). Moreover, the effects of stigma often lead to other 
socioeconomic consequences as mentioned above. For instance, most of the 
people with alcohol use disorders who were receiving treatment were not in 
the workforce and did not have a fully stable living situation (Storbjörka and 
Room, 2008). In addition, alcohol problem drinkers perceived as “drunks” have 
difficulties obtaining healthcare services since people felt that heavy drinkers 
should receive less priority in healthcare  and contribute to their own illness 
(Bird et al., 2002, Strong, 1980, Olsen et al., 2003). The economic consequences 
of expenditures on alcohol are significant, especially in high poverty areas (de 
Silva et al., 2011). Besides money spent on alcohol, a drinker with alcohol use 
disorders also suffers other adverse economic effects. These include lowered 
wages (because of missed work and decreased efficiency on the job), lost 
employment opportunities, increased medical expenses for illnesses and 
accidents, legal costs of drink-related offences, and decreased eligibility of 
loans. Thus, alcohol use disorder may further impoverish the drinker, the 
drinker’s family, or the whole community due to increasing health or social 
harms (Schmidt et al., 2010).  
1.2.2 Alcohol use harms to other individuals 
Other individual(s) affected may include a spouse or partner, child, 
relative, friend, neighbour, co-worker, person living in the same household or 
a stranger as this is particularly common in the case of traffic accidents. The 
harms may be relatively mild - such as being awakened by drunken carousers 
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outside - or may be very severe, including death or a lifelong disability. A 
number of studies have shown an association between exposure to heavy 
drinkers and reduced well-being, mental health (e.g. anxiety and depression), 
and poorer general health status (Casswell et al., 2011a, Dussaillant and 
Fernandez, 2015, Laslett et al., 2011, Ferris et al., 2011, Livingston, 2009, 
Livingston et al., 2010, Casswell et al., 2011b).   
1.3 Social and economic costs of alcohol use disorder 
 Alcohol use disorder significantly increases the social and economic costs 
on society  as shown in Table 1-1 (Single et al., 2003). There are two main major 
categories of alcohol-attributable costs i.e. tangible and intangible costs (WHO, 
2009). The tangible costs can be easily measured in money terms and are 
divided into two types (Single et al., 2003):  
1) Direct costs are expenses incurred because of alcohol consumption and 
related problems. Depending on the society, many of the direct costs are borne 
by governments. Direct costs attributable to alcohol consumption include 
healthcare costs, law enforcement costs, and costs of property damage due to 
traffic accidents. (Thavorncharoensap et al., 2009, Rehm et al., 2009). These 
estimates are typically derived from registration data of the major institutions 
of societal response to alcohol use problems such as the healthcare  system and 
the police and criminal justice system (Thavorncharoensap et al., 2009, Rehm 
et al., 2009). In addition, the direct costs for estimating economic costs of 
alcohol consumption also include the costs of research and prevention, costs of 
property damage due to fire and vandalism, and costs of incarceration.  
However, these costs may lack reliable data in various study settings 
(Thavorncharoensap et al., 2010).   
2) Indirect costs - or lost production - are associated with reduced work time 
due to morbidity and mortality (WHO, 2009). Indirect costs include the 
following: 1) cost of premature mortality; 2) cost of reduced productivity, 
which includes both the cost of productivity loss due to absenteeism and 
presenteeism (when an employee comes to work but is not productive); 3) cost 
of loss of employment or early retirement; and 4) costs associated with crime, 
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i.e. time loss for victims due to crime. These indirect costs are typically borne 
by society at large because their impact can affect the economic viability of an 
entire society (WHO, 2014).  
The intangible costs are costs assigned to pain and suffering, and more 
generally related to a diminished quality of life. As much of the efforts of the 
healthcare system are focussed on the reduction of intangible costs (e.g. pain 
and suffering), it is apparent that these costs are very important but are 
difficult to quantify. The most important characteristic of intangible costs is 
that when they are reduced, e.g. any reduction of pain and suffering, they do 
not permit a direct transfer of these benefits to any other person regardless of 
how important the benefit is. An important implication of this characteristic is 
that there is no market for the benefits of cost reduction as the benefits cannot 
be bought and sold. Thus, it is extremely difficult to place a value upon 
intangible costs, and intangible costs are generally not included in economic 
cost estimation studies (Thavorncharoensap et al., 2009, Single et al., 2003). 
The contingent valuation method (e.g. willingness-to-pay approach) can be 
used for valuing intangible costs but there still remain considerable difficulties 
in its reliability and validity of estimates using this approach (Venkatachalam, 
2004).  
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Table 1-1 Types of social costs attributable to substance abuse 
Costs 
Private costs (not 
generally included) Social costs (generally included in cost estimates) 
Costs to users Costs to users and individuals 
Costs to federal and other 
government agencies 
Costs to businesses and 
other private entities 
1. Tangible costs 
1.1 Consequences to health and welfare system 
- Treatment for substance abuse  
user-paid insurance; out-
of-pocket costs 
excess insurance premiums hospital + other health costs 
contribution to health 
insurance 
- Treatment for comorbidities and 
trauma 
user-paid insurance; out-
of-pocket costs 
excess insurance  hospital + other health costs 
contribution to health 
insurance 
- Prevention, research, health, and 
welfare services 
    
research, training, prevention, 
welfare 
corporate research + 
prevention 
1.2 Productivity costs, i.e. consequences to the workplace 
- Premature mortality     forgone taxes 
production losses due to 
premature death 
- Lost employment or productivity 
forgone income net and 
taxes 
victims' forgone income net of 
taxes 
forgone taxes 
workman's company, 
reduced productivity 
1.3 Law enforcement and criminal justice costs 
- Criminal justice response penalties (e.g. fines) victim's time 
enforcement, court 
incarceration costs 
victim's time 
(productivity loss); 
criminal careers 
1.4 Other costs, e.g. property destruction 
  
unreimbursed property 
damage 
fire losses, accident property 
damage 
accident and fire prevention, 
fire 
fire losses + accident 
damage to industry 
2. Intangible costs (not generally included) 
  
pain and suffering to 
user, quality life years 
lost 
suffering to dependents crime 
victims + restrictions of public's 
legal right to expedite 
    
Source: (Single et al., 2003)
Chapter 1: Introduction  15 
 
 15
 
Monitoring social and economic costs is increasingly important as it 
provides essential information regarding the full social consequences of alcohol 
consumption at the global and national levels in terms of monetary unit. Thus, 
a number of studies in many settings have been conducted to estimate the 
social and economic costs attributable to alcohol consumption and alcohol use 
disorder (Baumberg, 2006, Bouchery et al., 2011, Jones et al., 1995, Konnopka 
and Konig, 2007, Laramee et al., 2013, Matzopoulos et al., 2014, Mohapatra et 
al., 2010, Varney and Guest, 2002, Rehm et al., 2009, Thavorncharoensap et 
al., 2009, Thavorncharoensap et al., 2010). In the US, the estimated economic 
cost of excessive alcohol consumption was $223.5 billion in 2006 (72.2% from 
lost productivity, 11.0% from healthcare costs, 9.4% from criminal justice costs, 
and 7.5% from other effects) (Bouchery et al., 2011), and binge drinking 
resulted in costs of $170.7 billion (76.4% of the total costs). In the Republic of 
South Africa, the estimated total economic cost of harmful use of alcohol was 
10-12% of the 2009 gross domestic product (GDP) (Matzopoulos et al., 2014). 
The direct and indirect costs of morbidity and mortality attributable to alcohol 
consumption in Germany was estimated at €24.398 billion, or 1.16% of the 2002 
GDP (Konnopka and Konig, 2007). Meanwhile, in Scotland, alcohol misuse 
imposes a substantial burden on society, costing £1.071 billion per year at 
2001/2002 prices, and the greatest burden on the individual and society as a 
whole was arising from lost productivity (Varney and Guest, 2002). At the global 
level, the economic costs attributable to alcohol in selected high-income (4 
countries) and middle-income countries (2 countries) were estimated at 2-2.5% 
GDP based on the international dollar ($PPP) in 2007, of which indirect cost due 
to productivity losses was the predominant cost (approximately 70%-80% of 
total costs) category of all alcohol-attributable social costs (Rehm et al., 2009, 
Mohapatra et al., 2010). 
1.4 Alcohol consumption measurement and under-
reporting  
Alcohol consumption measurement aims to link consumption with 
alcohol-related problems such as per capita alcohol consumption compared 
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with mortality rates over time (WHO, 2014). Thus, it is important to determine 
consumption as accurately as possible. Measured consumption at the aggregate 
level (e.g. derived from alcohol sales) is useful in demonstrating links between 
a large population’s consumption and consequences (Robinson et al., 2015). In 
contrast, individual level alcohol consumption data retrieved from general 
population surveys have advantages over aggregate level. The volume and 
patterns of individual alcohol consumption as well as other potentially related 
characteristics (e.g. socioeconomic status, smoking, and family member 
drinking) can be measured. Therefore, researchers can link individual alcohol 
consumption and other characteristics with alcohol-related problems (Dawson, 
2003). Moreover, individual level data can be used for comparison of alcohol 
drinking between population subgroups such as males and females.  
A systematic review identified four international guidelines that provide 
recommendations for measuring alcohol consumption in general population 
surveys as follows (Nugawela et al., 2016): the International Guide for 
Monitoring Alcohol Consumption and Related Harm by the WHO (WHO, 2000); 
the Agreement on ways to measure alcohol consumption by the Kettil Bruun 
Society (Dawson and Room, 2000) - an international organization of scientists 
engaged in research on alcohol use and alcohol problems; the Recommended 
Alcohol Questions by the National Institute on Alcohol Abuse and Alcoholism 
(NIAAA, 2003); and the Standardized Measurement of Alcohol-Related Troubles 
Project Guidelines by the European Commission (Moskalewicz and Sierosławski, 
2010).  
All four guidelines emphasise that surveys measuring alcohol 
consumption need to contain items on alcohol drinking status (past year and 
lifetime), average volume of alcohol consumption (past year), and frequency 
and volume of heavy episodic drinking, where the volume of alcohol is 
calculated by multiplying the quantity and frequency of relevant drinking 
occasions over the past year (Moskalewicz and Sierosławski, 2010, NIAAA, 2003, 
Dawson and Room, 2000, WHO, 2000). For measuring the average volume of 
alcohol consumption, Beverage Specific Quantity Frequency (BSQF) questions 
were identified as the most appropriate survey instrument, whereas Quantity 
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Frequency (QF) questions were identified as adequate when surveys have 
limited resources and space for alcohol questions. QF questions measure how 
often alcohol was consumed and how much on each occasion, whereas BSQF 
questions do the equivalent for different types of alcohol beverage separately. 
All guidelines recommended Graduated Quantity Frequency (GQF) questions to 
assess heavy episodic drinking. GQF questions start by asking for the highest 
level of consumption on any occasion in the past year (alternatively last week) 
and then, based on the answer, ask a series of follow-up questions on frequency 
of consuming lesser quantities (e.g. frequency of consuming more than 144, 96, 
60, 36 or 24 g of pure alcohol). Moreover, questions about drinking context were 
also recommended to ask whether participants drank with or without a meal, 
alone or with others as well as the place of drinking. 
Heavy episodic drinking, or binge drinking refers to a drinking pattern of 
consuming an intensive volume of alcohol over a short period of time that is 
likely to lead to intoxication and acute consequences (WHO, 2014). According 
to the WHO, heavy episodic drinking is defined as ‘drinking at least 60 g (7.5 
units) or more of pure alcohol on at least one occasion in the past 30 days’, 
where 60 g is an approximate cut-off value for high-risk drinking. In the UK, 
binge drinking is defined as drinking twice or more than the sensible drinking 
limits of 3–4 units per day for men and 2–3 units per day for women in the last 
week, where a unit represents about 8 g of ethanol (Lifestyle Statistics of 
Health and Social Care Information Centre, 2014, Office for National Statistics, 
2013, Rutherford et al., 2013a). One unit is equivalent to one shot of a spirit, 
a glass of wine or half a pint of beer. However, the shorter reference period of 
last week is likely to greatly underestimate the proportion of heavy drinkers 
and miss infrequent drinkers (Moskalewicz and Sierosławski, 2010, NIAAA, 2003, 
WHO, 2000).  
The guidelines recommend that total alcohol consumption from surveys 
should be calculated by combining the average volume of consumption and 
consumption due to binge drinking occasions (Moskalewicz and Sierosławski, 
2010, WHO, 2000). Survey respondents did not normally include heavy drinking 
occasions in estimates of their average consumption (Stahre et al., 2006). 
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Therefore, using the average volume of alcohol consumption generated by BSQF 
questions on its own can contribute towards the underestimation of alcohol 
consumption in surveys.  
The assessment of self-reported alcohol consumption typically indicates 
deliberate underestimation (ranging from 40% to 60%) compared to per capita 
sales data (Babor et al., 2010a, Meier et al., 2013, Livingston and Callinan, 
2015). This underestimation of self-reported alcohol consumption is likely to 
occur mainly due to the following reasons: 1) drinking by people outside the 
sampling frame e.g. under 16 years, homeless, military personnel and prisoners, 
people in care homes, and university students living in residence halls - some 
of which are more likely to be involved in heavy drinking (Makela and Huhtanen, 
2010, Kelfve and Ahacic, 2015, Meier et al., 2013); 2) drinking non-responders 
to the survey, e.g. students and dependent drinker, and proxy interviewees 
(Gorman et al., 2014, Maclennan et al., 2012, Meiklejohn et al., 2012); and 3) 
under-reporting bias such as selective reporting, recall bias and accidental 
under-estimation (Boniface and Shelton, 2013, Stockwell et al., 2014, 
Livingston and Callinan, 2015). In addition, the survey tools themselves and the 
framing of questions are likely to influence the adequacy of survey measures of 
alcohol consumption (Dawson, 2003, Bloomfield et al., 2013, Nugawela et al., 
2016).  
1.5 Alcohol Use Disorder Identification Test (AUDIT) 
The AUDIT consists of 10 questions about recent alcohol use consistent 
with the ICD-10 definitions of alcohol dependence and harmful alcohol use. 
Once computed, the total score ranges between 0 and 40 (World Health 
Organization, 1993, Babor et al., 1989). Table 1-2 shows the questions, 
conceptual domains, item content, and the score ranges of the AUDIT (Babor 
et al., 2001, Babor et al., 1989). It is conceptualised to have three different 
domains: 1) quantity and frequency of drinking - which can detect hazardous 
alcohol use, i.e. average frequency and quantity of drinking - and frequency of 
six or more standard drinks on one occasion – also known as binge drinking 
behaviour; 2) possible alcohol dependence symptoms as defined by the WHO 
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ICD-10 code, i.e. unable to stop, failing normative expectations, and morning 
drinking; and 3) harmful alcohol use, i.e. guilt, blackout, injury, and concern 
of others such as the doctor or family members. 
 
Table 1-2 Questions, domains, item content, and the score ranges of the Alcohol 
Use Disorders Identification Test (AUDIT)  
 
Domain Question Item content 
Hazardous 
alcohol use 
1 Frequency of drinking 
2 Typical quantity 
3 Frequency of heavy drinking 
Possible alcohol 
dependence 
symptoms 
4 Impaired control over drinking 
5 Increased salience of drinking 
6 Morning drinking 
Harmful 
alcohol use 
7 Guilt after drinking 
8 Blackouts 
9 Alcohol-related injuries 
10 Others concerned about drinking 
Total score   
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1.5.1 Use of the AUDIT in the healthcare setting 
The AUDIT has been recommended as a screening tool for detecting 
problematic alcohol use in the healthcare setting, and it has been 
recommended for screening and treatment of alcohol use disorders in the 
primary healthcare setting in the UK and many other countries (National 
Collaborating Centre for Mental Health, 2011, Dybek et al., 2006, Gache et al., 
2005, Li et al., 2011). It has also been recommended for use for the same 
purpose in other settings, e.g. emergency departments (Neumann et al., 2004) 
and outpatient departments in hospitals (Pradhan et al., 2012, Obadeji et al., 
2015). The WHO guidelines for interpreting AUDIT scale scores are as follows  
(Babor et al., 2001): 
• 0 to 7: low-risk drinking behaviour, or abstinence; 
• 8 to 15: medium level of alcohol problems, with increased risk of developing 
alcohol-related health or social problems (sometimes described as hazardous 
drinking behaviour); 
• 16 to 19: high level of alcohol problems, for which counselling is 
recommended (harmful drinking behaviour); 
• 20 or above: warrants further investigation for possible alcohol dependence. 
Furthermore, from reviews of both English and non-English studies of the 
AUDIT’s performance characteristics, the standard value of 8 consistently 
yielded lower sensitivities and higher specificities for women than for men in 
detecting alcohol misuse (Reinert and Allen, 2007, Gache et al., 2005, Aalto et 
al., 2009, Neumann et al., 2004, Dybek et al., 2006). These studies concluded 
that the cut-off points for effective detection of alcohol use disorder in women 
need to be lower than the original recommended value of 8. The optimal cut-
off points were found to be ≥ 8 for males (sensitivity range of 0.75-0.80 and 
specificity range of 0.81-0.94) and ≥ 5 for females (sensitivity range of 0.76-
0.96 and specificity range of 0.81-0.95) (Reinert and Allen, 2007). Thus, the 
current study applies the new recommendations to categorise the AUDIT score 
using different cut-offs between males and females as follows: 
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• 0 to 7 for males and 0 to 5 for females: low-risk drinking behaviour, or 
abstinence; 
• 8 to 15 for males and 6 to 12 for females: medium level of alcohol problems, 
with increased risk of developing alcohol-related health or social problems 
(sometimes described as hazardous drinking behaviour); 
• 16 to 19 for males and 13 to 16 for females: high level of alcohol problems, 
for which counselling is recommended (harmful drinking behaviour); 
• 20 or above for males and 17 or above for females: warrants further 
investigation for possible alcohol dependence. 
1.5.2 Use of the AUDIT in general population surveys 
Although the AUDIT was originally developed for use in the primary 
healthcare setting, it has also been applied for estimating alcohol use disorder 
prevalence in general population surveys as a means of supporting policy-
making (Aalto et al., 2009, Knibbe et al., 2006, Assanangkornchai et al., 2010). 
Three validation studies of the AUDIT in general population surveys were 
conducted in Sweden (Lundin et al., 2015), Germany (Rumpf et al., 2002), and 
the US (Dawson et al., 2005); in the US study, an abbreviated version of the 
AUDIT was used, or AUDIT-C. These studies compared the AUDIT to the fourth 
version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) - 
the gold standard for diagnosing alcohol misuse, alcohol dependence, and at-
risk drinking (American Psychiatric Association, 1994). The results showed the 
agreeability between the DSM-IV and the AUDIT, which was measured by the 
area under the receiver operator characteristic curve (ROC). In the general 
population sample, the AUDIT and AUDIT-C showed outstanding discrimination 
for alcohol dependence (area under ROC>0.9), and excellent discrimination for 
alcohol use disorder (area under ROC between 0.85-0.92) and at-risk drinking 
(area under ROC between 0.80-0.86) (Lundin et al., 2015, Rumpf et al., 2002, 
Dawson et al., 2005). Using the WHO recommended cut-off AUDIT score of 8, 
the AUDIT showed low sensitivity for alcohol misuse (0.37) but specificity was 
high (0.94) (Rumpf et al., 2002). For using different cut-offs of alcohol use 
disorder between men (AUDIT score of 6 or 7) and women (AUDIT score of 4 or 
5), there was a higher range for sensitivity from 0.71-0.79 for men and 0.66-
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0.74 for women but specificity was at a slightly lower range from 0.77-0.82 for 
men and 0.82-0.83 for women (Dawson et al., 2005, Lundin et al., 2015). In 
conclusion, the findings of the validation studies suggest that not only can the 
AUDIT be used for identifying alcohol use disorders in healthcare settings but it 
can also be used in measuring alcohol use disorders in general population 
settings. 
A recently published systematic review and meta-analysis examined the 
association of alcohol use disorders and all-cause mortality (Roerecke and 
Rehm, 2013). The study compared the mortality risk of alcohol use disorder and 
non-alcohol use disorder differentiated by sex and age. Moreover, the meta-
analysis performed a subgroup analysis by studying the population that had 
alcohol use disorders identified from the clinical setting and those identified 
from the general population survey. The results showed that alcohol use 
disorder in the clinical setting had higher mortality risk than those in the 
general population. In men, the relative risk (RR) among clinical samples was 
3.38 (95% confidence interval (CI): 2.98-3.84); in women, RR was 4.57 (95% CI: 
3.86-5.42). For the general population surveys, the RR of alcohol use disorder 
mortality was lower at 1.91 (95% CI 1.51-2.42) in men; however, no data were 
available for women. Presumably, high-risk drinkers in the clinical setting who 
seek treatment might have more severe conditions compared to those with 
untreated alcohol use disorder in the general population. Unfortunately, due to 
insufficient data available for the survey population, stratified analyses based 
on grouped age, sex, and different follow-up period could not be performed 
(Fichter et al., 2011, Perala et al., 2010, Min et al., 2008, Ojesjo et al., 1998, 
Dawson, 2000, Neumark et al., 2000).  
In particular, these eligible survey studies contained various 
measurements of identifying alcohol use disorder depending on the country 
settings. Each setting selected their own validated questionnaire for the alcohol 
consumption population survey such as the Composite International Diagnostic 
Interview (CIDI) (Kessler and Ustun, 2004), the Munich Alcoholism Test (MALT) 
(Feuerlein et al., 1977), the Severity of Alcohol Dependence Questionnaire 
(SADQ) (Stockwell et al., 1983) or the Michigan Alcoholism Screening Test 
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(MAST) (Selzer, 1971). The alcohol use disorder results reported in these studies 
might not have been the same, leading to heterogeneity between studies – 
shown by high heterogeneity where a pooled result was performed (p-value of 
heterogeneity<0.001 and I2=88.1). Furthermore, there was no eligible study 
using the AUDIT for identifying alcohol use disorders which was included in the 
meta-analysis. As a result, evidence is scarce on the use of the AUDIT for alcohol 
misuse assessment in the general population. Moreover, there is no evidence 
that reveals an association between the measured AUDIT score and alcohol-
related consequences (e.g. mortality and morbidity) in national representative 
samples.   
1.6 Effectiveness and cost-effectiveness of alcohol 
interventions  
Alcohol interventions can be evaluated in two terms: effectiveness and 
cost-effectiveness. Effectiveness is defined as a measure of the extent to which 
a specific policy, programme or intervention, when deployed in the real world, 
does what it is intended to do for a specified population. Meanwhile, cost–
effectiveness is defined as an economic evaluation that compares the costs of 
two or more interventions with differences in one single measure of outcome. 
The general principles on which particular alcohol interventions work are fairly 
well understood and can often be applied across societies. This section 
summarises effectiveness and cost-effectiveness of alcohol interventions:   
1.6.1 Provision of information and education 
 The provision of information and education on alcohol-related harms and 
alcohol interventions is important to raise awareness and impart knowledge. 
Providing information and education particularly in an environment in which 
many competing messages are received in the form of marketing and social 
norms supporting drinking, and in which alcohol is readily accessible - does not 
lead to sustained changes in alcohol-related behaviour (WHO, 2007b). 
Moreover, systematic reviews have shown that school-based interventions (e.g. 
classroom-based programmes, combined classroom-based with family-based 
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and/or community based intervention components, and other approaches 
delivered outside of lesson time including brief interventions and peer support 
programmes) lack clear evidence on which types of programmes are most 
effective based on effectiveness reviews (Jones et al., 2007, Petrie et al., 
2007). In addition, long-term follow-up data were not available for the majority 
of programmes so it is difficult to determine the value of school-based 
interventions in terms of longer-term impacts of adolescent alcohol use as there 
is no clear evidence to determine the relationship between alcohol use in 
adolescence and adulthood (Jones et al., 2007).  
 Moreover, there was a lack of economic evaluation studies in the field 
potentially due to insufficient effectiveness data e.g. students reporting 
hazardous/harmful drinking and data on alcohol-related outcomes in young 
people such as injuries, violence and disorder, unintended pregnancies, and 
school attendance. Media advocacy can lead to a reframing of the solution to 
alcohol-related problems, which is a coordinated approach by relevant sectors, 
and results in increased attention to alcohol within political and public agendas 
(Babor et al., 2003). In addition, social marketing interventions are associated 
with changes in alcohol-related behaviour; however, a recent systematic review 
concluded that it was inconclusive whether applying the principles of social 
marketing in alcohol prevention interventions was indeed effective in changing 
this behaviour (Janssen et al., 2013). However, public information campaigns 
have been found to be ineffective in reducing alcohol-related harms (Babor et 
al., 2010a). Exceptions for this are mass media campaigns to reduce drinking 
and driving, for which systematic reviews and economic evaluation studies have 
found them to be effective and cost-effective when implemented in the 
presence of strong drinking and driving countermeasures (Cobiac et al., 2009, 
Ditsuwan et al., 2013, Doran et al., 2008, Elder et al., 2004, Yadav and 
Kobayashi, 2015).  
1.6.2 Community-based programmes  
 Two literature reviews reported multi-component community-based 
interventions for controlling accessibility – including the environmental 
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contexts of selling, encourage responsible retailing, involved enforcement of 
public health polices for drinking and driving, manage licensed premises and 
their surrounding environments and better enforce alcohol legislation – can 
reduce high-risk alcohol consumption and alcohol-related injuries resulting 
from motor vehicle crashes and assaults (Giesbrecht, 2003, Jones et al., 2011). 
In addition, a longitudinal time series analysis explored the impacts of a 
combination of communities and media mobilisation, responsible beverage 
service, strengthened licensing legislation, increased enforcement of the ban 
on sales of alcohol to under-age customers and of drink-driving, and licensing 
legislation (Holder et al., 2000). The combined interventions were associated 
with reductions in alcohol consumption, assaults, and road traffic accidents.  
 Only one cost-effectiveness study was found that was about a larger 
community-based programme called Stockholm prevents Alcohol and Drug 
problems (STAD). Essentially, it studied community mobilisation which aimed 
to increase awareness of the problems associated with alcohol consumption; 
conducted a two-day responsible beverage service training course for servers, 
doormen, and restaurant owners; and increased enforcement of alcohol laws 
(Wallin and Andreasson, 2004, Wallin et al., 2005, Wallin et al., 2003, 
Warpenius et al., 2010). The STAD programme was found to have been effective 
and cost-saving (Mansdotter et al., 2007). However, the uncertainty analysis 
was restricted to the impact of the low response rate to the survey.  
1.6.3 Workplace intervention 
 The workplace offers advantages as a setting for interventions that result 
in primary prevention of alcohol abuse. Such programmes have the potential to 
reach broad audiences and populations that would otherwise not receive 
prevention programmes, and thereby benefit both the employee and employer, 
e.g. reduction of sickness absence and unemployment, and lost outputs due to 
early death (Ames and Bennett, 2011). A systematic review of workplace 
interventions for alcohol-related problems identified a wide range of 
interventions (Webb et al., 2009). Most of studies conducted in the US consisted 
of psychosocial skills training; brief interventions including feedback of results 
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of self-reported drinking, lifestyle factors, and general health checks; and 
alcohol education delivered via an Internet website. The psychosocial 
interventions included peer referral, teambuilding, stress management, and 
skills derived from the social learning model. Ultimately, there were variations 
of self-reported alcohol consumption measurements among included studies 
(Webb et al., 2009). In addition, two systematic reviews focussed on the effects 
of alcohol and drug abuse screening at the workplace for preventing injury or 
work-related effects such as sickness absence related to injury (Cashman et al., 
2009, Pidd and Roche, 2014). Most of the studies reported significant reductions 
in alcohol consumption, alcohol-related problems, and occupational accident 
or injury rates. However, the reviews raised some methodological problems of 
the individual studies, e.g. allocation bias, a lack of exposure to the 
intervention, contamination of the intervention due to change in work-place 
policies, and a lack of reliance on self-reported alcohol drinking over the follow-
up period (Webb et al., 2009, Cashman et al., 2009, Pidd and Roche, 2014).  
 There is still a limited number of cost-effectiveness studies for workplace 
interventions. Only one cost-benefit analysis was shown to have cost-savings 
from reduction in the injury rate of peer-based workplace substance abuse (e.g. 
alcohol abuse) in a US transportation company (Miller et al., 2007). In addition, 
a cost-benefit modelling study of an alcohol intervention in the UK quantified 
a monetary valuation of workplace harms, which includes absence due to 
sickness and unemployment combined with other harms caused by alcohol 
consumption, i.e. health and crime (Brennan et al., 2014a). However, this study 
did not only focus on workplace interventions but also applied the model for 
macro-level interventions.   
1.6.4 Addressing the availability of alcohol 
 A greater density of alcohol outlets was found to be associated with higher 
alcohol consumption leading to harms caused by alcohol drinking such as 
assault, homicide, child abuse and neglect, self-inflicted injury, and road 
traffic accidents (Huckle et al., 2008, Hughes et al., 2011, Roche et al., 2013).  
Thus, many countries implemented policies related to availability of alcohol, 
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e.g. hours and days of sales and change in alcohol outlet density – which is 
measured as the number of licenses per kilometre of roadway (Campbell et al., 
2009, Fone et al., 2016, Livingston et al., 2007, Popova et al., 2009). The 
policies led to fewer alcohol-related problems, including homicides and assaults 
(Duailibi et al., 2007). There are also widely dispersed bans on the use of 
alcohol in particular locations and circumstances, such as drinking in parks or 
streets, hospitals or at the workplace (Babor et al., 2010a). Public monopolies 
on the sale of alcohol can also reduce alcohol-related harms (Holder et al., 
2008, Babor et al., 2003). Such systems tend to have fewer outlets open for 
shorter hours than private retailers. An implementation of laws that set a 
minimum age for the purchase of alcohol ranging typically from aged 16 to 20 
years, in conjunction with enforcement of the alcohol sellers (Grube and 
Stewart, 2004), show a reduction in alcohol-related harms and drink-driving 
casualties (Wagenaar and Toomey, 2000). 
  For cost-effectiveness evidence, licensing controls - including hours of 
operation for outlets selling alcohol, types of outlet permitted to sell alcohol, 
density of outlets within an area, and age at which alcohol can be legally 
purchased or consumed - were a cost-effective intervention in the Australian 
and Danish contexts (Doran et al., 2008, Holm et al., 2014b). In addition, the 
UK modelling study also showed that outlet density and licensing hour policies 
are able to reduce both alcohol consumption and alcohol-related harms in term 
of monetary unit; however, ICER was not reported due to the lack of 
information about intervention costs (Purshouse et al., 2009 ).     
1.6.5 Addressing the marketing of alcoholic beverages 
 Alcohol advertising is one of the many factors that have the potential to 
encourage young people to drink. Two of the most recent systematic reviews 
reported an association between alcohol marketing (e.g. alcohol promotion 
(mainly advertising), product attributes, and place of sale/availability) and 
drinking behaviours among young people (under legal drinking age) including 
drinking initiation, continuation, frequency, and intensity (Scott et al., 2017, 
Jernigan et al., 2017). The reviews consistently found evidence of a positive 
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association between the level of marketing exposure and level of youth alcohol 
consumption, i.e. initiation of alcohol use for the exposure group (OR 1.00 - 
1.69) and subsequent binge or hazardous drinking (OR 1.38 - 2.15) (Jernigan et 
al., 2017). The expectancies of young people who have not started to drink are 
influenced by normative assumptions about teenage drinking as well as through 
observation of drinking by parents, peers, and models in the mass media 
(Anderson et al., 2009b, Rossow et al., 2016, Leung et al., 2014). A number of 
RCTs and interrupted time series studies of restricting alcohol during the 
control period or banning alcohol advertising (partial or full) to reduce alcohol 
consumption in adults and adolescent were reviewed, but the evidence was 
determined to be very low quality due to a high risk of bias, serious indirectness 
of study population, and serious level of imprecision in the results (Siegfried et 
al., 2014). Thus, there was a lack of robust evidence for recommending or 
discouraging against or recommended the implementation of these inventions 
for alcohol advertising.  
 Although the effectiveness of alcohol advertising bans remains unclear, two 
cost-effectiveness models assumed that if advertising increases consumption, 
and if a set of certain media bans on alcohol advertisement (via billboards, 
television, radio, etc.) reduces total advertising, then advertising bans will 
have a negative effect on alcohol consumption by an applied 4-6.5% g/day 
reduction in consumption of the entire population (Cobiac et al., 2009, Holm 
et al., 2014b, Chisholm et al., 2004). The alcohol advertising bans was shown 
to be cost-saving. For the UK study, there was a disagreement in the literature 
concerning whether advertising bans (in the absence of other legislation) 
reduces alcohol consumption or increases it by having the unintended side-
effect of increased price competition between competitors, so the effects of a 
complete ban in alcohol advertising estimated an overall change in consumption 
ranging from –26.9% to +4.9%, and a financial value of accumulated harm 
avoided over 10 years ranging from a gain of £33.5bn to a loss of £7.1bn 
(Purshouse et al., 2009 ). These figures can present the need for further 
research on alcohol advertising impacts. 
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1.6.6 Drink-driving policies  
 Drink-driving policies – such as the setting of a blood alcohol concentration 
(BAC) level, and intensive random breath-testing - do reduce alcohol-related 
injuries and fatalities (Babor et al., 2010a). In these scenarios, police regularly 
stop drivers on a random basis to check their BAC level, and establish 
checkpoints where all cars are stopped and drivers suspected of drink–driving 
are breath-tested. The majority of the lower limit introduced and evaluated is 
ranged from 0.2 - 0.8 g/litre (Shults et al., 2009, Shults et al., 2001, Fell and 
Voas, 2006). However, the results from reducing BAC levels found that lowering 
BAC levels combined with law enforcement in practice by utilising random 
checks on the road could reduce alcohol-related crashes, fatalities or injuries 
(Albalate, Andreuccetti et al., 2011, Chang et al., 2012, Fell and Voas, 2006, 
Sebego et al., 2014). A difference of a time lag (range from 1 to 5 years) to 
observe the effectiveness among countries was shown because the results may 
have been affected by time when aggressive policies and other activities (e.g., 
education, enforcement) were implemented (Albalate, Andreuccetti et al., 
2011, Fell and Voas, 2006, Sebego et al., 2014).  
 A meta-analysis of nine research studies of sufficient design quality and 
level of implementation found that laws setting a legal BAC level of 0.8 g/litre 
resulted in a median reduction of 7% in alcohol-related motor vehicle fatalities, 
and unrestricted and selective breath-testing resulted in fewer accidents 
thought to have involved alcohol (Shults et al., 2001).  Moreover, many alcohol 
policies can reduce alcohol-related road traffic fatalities including higher prices 
for alcohol, minimum purchase age laws, controls over the density of outlets, 
promotion and advertising of alcohol, and opening hours of sales and outlet 
density, and mass media campaigns supporting drink-driving policies (Grube and 
Stewart, 2004). An economic evaluation of a drink-driving policy was found to 
be very cost-effective due to preventing premature death and harms to 
accident victims (Cobiac et al., 2009, Ditsuwan et al., 2013). 
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1.6.7 Screening and brief intervention  
 Alcohol screening and brief intervention (SBI) is the most effective 
evidence-based treatment (Babor et al., 2010b, Babor et al., 2007). Systematic 
reviews and meta-analyses of the effectiveness of SBIs for hazardous and 
harmful alcohol consumption have been found to have a positive impact on 
alcohol consumption, mortality, morbidity, alcohol-related injuries, and 
alcohol-related social consequences (Kaner et al., 2009, Mdege et al., 2013, 
Angus et al., 2014a). SBI policies have been examined in many setting such as 
primary care, accident and emergency units, workplaces, and community 
pharmacies (Barbosa et al., 2015, Angus et al., 2014a, Alvarez-Bueno et al., 
2015, Elzerbi et al., 2015).  
 Primary healthcare is the most extensively studied setting for the 
evaluation of SBIs, and these studies consistently reported that SBIs could 
reduce hazardous and harmful consumption at 6 months and 12 months 
(Alvarez-Bueno et al., 2015, Elzerbi et al., 2015). For SBIs in emergency 
departments, a meta-analysis reported that it was effective at reducing mean 
weekly alcohol consumption at 6 months and 12 months (Elzerbi et al., 2015, 
Schmidt et al., 2016). Workplace SBIs were effective but it is not clear for which 
type of employee SBIs may be most beneficial for (Schulte et al., 2014); 
furthermore, employees may be anxious about the potentially negative 
consequences of self-disclosing heavy drinking to their employer. A literature 
review found little empirical support for the effectiveness of SBI in community 
pharmacies (Watson and Blenkinsopp, 2009); the evidence showed a possibility 
that pharmacists were undertrained in the delivery of SBIs.  
 In term of cost-effectiveness, SBIs  is considered as cost-effective, and 
several examples are estimated as being cost-saving (providing additional 
health benefits and reducing health service costs overall) when compared 
against a ‘do nothing’ option (Purshouse et al., 2013, Holm et al., 2014b, Doran 
et al., 2008, Cobiac et al., 2009). 
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1.6.8 Pricing policies 
 Drinkers respond to changes in the price of alcohol as they do to changes in 
the prices of other consumer products. When other factors such as income and 
prices of other goods are held constant a rise in alcohol prices leads to less 
alcohol consumption and less alcohol-related harms in many settings (Gallet, 
2007, Wagenaar et al., 2009, Pan et al., 2006, Parry et al., 2003). A meta-
analysis of 132 studies found that the impact of an increase in alcohol price 
tends to be stronger in the longer- rather than the shorter-term – as shown by 
a median price elasticity for all beverage types of -0.52 in the short-term and -
0.82 in the long-term (Gallet, 2007). An elasticity of -0.52 means that for every 
10% increase in price, consumption would fall by 5.2%.  
 Another meta-analysis of 112 studies found mean price elasticities for beer 
to be -0.46, -0.69 for wine, and -0.80 for spirits (Wagenaar et al., 2009). If 
prices are raised, consumers reduce their overall consumption and tend to shift 
to cheaper beverages, with heavier drinkers tending to buy cheaper products 
within their preferred beverage categories (Gruenewald and Treno, 2000). 
Therefore, influencing prices of the cheapest drinks on the market by raising 
floor prices has a larger impact on total consumption than increasing the prices 
of more expensive drinks (Gruenewald and Treno, 2000). Moreover, increasing 
the price of alcohol through taxes also showed potential to reduce health 
inequalities (Meier et al., 2016, Holmes et al., 2014a). Low SES groups tend to 
drink less but are more likely to suffer from alcohol-related harms than less-
deprived people; defined as the Alcohol Harm Paradox (Smith and Foster, 
2014). As such, this might have a greater financial impact on alcohol 
expenditure when alcohol price increases, leading to a reduction of alcohol 
consumption as well as alcohol-related harms (Meier et al., 2016, Holmes et 
al., 2014a).  
 A systematic review on public policies affecting the price of alcoholic 
beverages suggested that doubling the alcohol tax would reduce alcohol-related 
mortality by an average of 35%, traffic crash deaths by 11%, sexually 
transmitted disease by 6%, violence by 2%, and crime by 1.4% (Wagenaar et al., 
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2010). Economic modelling studies have predicted that taxation and pricing 
policy (e.g. minimum unit pricing) leads to large gains in health and life 
expectancy. In addition, these policies have been a cost-effective approach to 
preventing alcohol-related harms and increasing health outcome gained, even 
though these studies were conducted in different settings and used different 
methodological approaches (Angus et al., 2015, Doran et al., 2008, Holm et al., 
2014b, Byrnes et al., 2010, Stockwell et al., 2012).  
 
1.7 Methodological issues of effectiveness and cost-
effectiveness evaluation of public health 
interventions 
Since most of public health interventions involve complex multi-levels of 
components, i.e. the policy, environment, and individual levels, evaluating 
these interventions requires evidence beyond efficacy trials to measure the 
potential impacts of the interventions, especially in real-world settings (Koorts 
and Gillison, 2015, Thomas et al., 2014).  An intervention that works well in a 
given setting may be ineffective elsewhere, presenting a huge challenge to 
international health recommendations (Victora et al., 2004). While the 
interventions and outcomes of clinical medicine operate at the biomedical 
level, the outcomes of public health interventions do not always occur at the 
same operational level as the intervention. In other words, the outcomes of 
some interventions operating at the individual level (e.g. provision of 
information and education) can appear at the population level (e.g. social 
norms) (Jones et al., 2007, Petrie et al., 2007). Similarly, some interventions 
operating at the population level such as legislation and mass media campaigns 
can have effects at the individual level (e.g. service provision, changes in 
behaviour or knowledge) (Janssen et al., 2013, Fell and Voas, 2006). 
1.7.1 Evaluation of public health intervention effectiveness 
The assessment of causality for public health interventions has been a 
persisting controversy in term of the reliance on the study design as the main 
criterion for the credibility of evidence (Rychetnik et al., 2002). An 
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experimental design as RCT is suggested to be conducted, because it is the most 
robust method of preventing bias (Craig et al., 2008). If either individually or 
cluster randomised trials are not appropriate due to practical or ethical 
objections to experimentally evaluating, other experimental design for 
evaluating complex interventions should be considered as follows (Craig et al., 
2008):  
o Stepped wedge cluster designs (Hemming et al., 2015) — This design 
involves a random and sequential crossover of clusters from control to 
intervention until all clusters are exposed. Observations are made during 
a baseline period (before any cluster is randomised to receive the 
intervention) and again in a post-intervention period (where clusters 
randomised to the intervention have switched to receiving the 
intervention). It allows a trial to be conducted without delaying roll-out 
of the intervention. Eventually, the whole population receives the 
intervention but with randomisation built into the phasing of 
implementation. 
o Preference trials and randomised consent designs — Practical or 
ethical obstacles to randomisation can sometimes be overcome by using 
non-standard designs. When patients have strong preferences among 
treatments, basing treatment allocation on patients’ preferences or 
randomising patients before seeking consent may be appropriate. 
o  N of 1 designs — Conventional trials aim to estimate the average 
effect of an intervention in a population. N of 1 trials, in which 
individuals undergo interventions with the order or scheduling decided 
at random, can be used to assess between and within person change and 
to investigate theoretically-predicted mediators of that change. 
If an experimental approach is not feasible, because the intervention is 
irreversible, applies to the whole population by necessity, or because large 
scale implementation is already under way, a quasi-experimental or an 
observational design may be considered. Moreover, resources for public health 
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research and evaluation are scarce, so more attention must be given to 
assessing the cost and feasibility of various study designs despite the investment 
of RCTs relative to public health intervention effectiveness in producing data 
sufficient for sound decision-making. 
For evaluating effectiveness of large-scale public health interventions, 
there are three broad types of evaluations: process, impact, and outcome 
(Round et al., 2005). Firstly, process evaluation is used to assess the elements 
of intervention development and delivery. Process evaluation will usually aim 
to capture fidelity (whether the intervention was delivered as intended) and 
dose (the quantity of intervention implemented) (Moore et al., 2015). In a 
feasibility and piloting phase after an intervention has been developed, process 
evaluation will focus on the quality and appropriateness of the materials and 
approaches used (Round et al., 2005). In the implementation stage, process 
evaluation can be useful in tracking the reach of the intervention (whether the 
intended audience comes into contact with the intervention and how) and the 
level of implementation of all aspects, and in identifying potential or emerging 
problems (Round et al., 2005). Process evaluations may test hypothesised 
causal pathways using quantitative data as well as using qualitative methods to 
better understand complex pathways or to identify unexpected mechanisms 
(Bonell et al., 2012).  
Secondly, impact evaluation is used for the assessment of intermediate 
effects, and can therefore be used at the completion of implementation stages 
(Round et al., 2005). Impact evaluation may also determine what interventions 
are worthy of sustained investment and for identifying those that work in real-
world settings. A widely-used impact evaluation framework is the RE-AIM 
framework. It consists of five dimensions, namely Reach, Effectiveness, 
Adoption, Implementation and Maintenance (Glasgow et al., 2006, Glasgow et 
al., 1999, Harden et al., 2015). Impact evaluation assesses the degree to which 
programme objectives were met, e.g. changes in health literacy, behaviours or 
behavioural intentions, social action, service delivery, organisational change, 
environmental change or policy development (Round et al., 2005).  
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Lastly, outcome evaluation is applied for measurement of the longer-
term effects of interventions and is related to assess whether a programme’s 
goal has been achieved (Round et al., 2005). The long-term effects may include 
reductions in incidence or prevalence of health conditions, changes in 
mortality, sustained behaviour change, and improvements in quality of life. The 
outcome evaluation has been an important challenge for public health 
intervention evaluations due to the context of such intervention, particularly 
the multifaceted, complex, and long-term nature of anticipated programme 
benefits; and the shortage of sensitive or suitable outcome measures 
(Weatherly et al., 2009). 
Evaluation designs include quantitative designs - which rely on a 
collection of numerical data (e.g. pre/post surveys, with or without a 
comparison group, and trend analysis), and qualitative designs - which rely on 
a collection of written or spoken data (e.g. interviews, focus groups, case 
studies, document analysis, and participatory action research) (Round et al., 
2005). Quantitative designs are frequently used to measure impacts while 
qualitative designs are useful in process evaluation; however, this distinction is 
not definitive. Frequently, impact evaluation will look for differences in the 
target group or community setting before and after the programme, and 
sometimes seek to compare this with a ‘control group’ that did not take part in 
the programme. It is not always appropriate, or financially feasible, to conduct 
such experimental research in the evaluation of integrated health promotion, 
where the effect of the program in the intervention group is compared to a 
control group. However, practitioners should try to ensure their evaluation 
designs are rigorous. This involves using validated tools where possible and 
using triangulated evaluation designs (where a range of evaluation methods is 
incorporated). 
1.7.2 Economic evaluation of public health intervention  
Economic evaluations of public health interventions have been gaining 
increasing attention from public health policy-makers. An economic evaluation 
is defined as a tool to compare the costs and benefits of alternative 
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interventions, treatments or policy options. Even though the principles and 
methodological guidelines of clinical interventions have been well-established, 
there have been challenges in applying those guidelines for the economic 
evaluation of public health interventions (Briggs et al., 2006c, Drummond MF 
et al., 1997, Gray et al., 2011a, ISPOR, 2014, NICE, 2013, Chaikledkaew and 
Kittrongsiri, 2014, Teerawattananon and Chaikledkaew, 2008). The most 
challenging aspects of applying the principles of cost-effectiveness analysis for 
public health evaluations were identified in the public health context from the 
policy-maker's perspective (Chalkidou et al., 2008, Lorgelly et al., 2010). These 
include: 
• Measuring benefits: the use of quality adjusted life years (QALYs) (and 
EQ-5D) and the possible need for evaluations to have more than one 
outcome measure; 
• Public versus individual: the role of individual choice in population-
based interventions, and how to account for any resulting externalities; 
• Equity versus efficiency: public health programmes frequently target 
health inequalities such that the issue of weighting outcomes may need 
to be addressed together with other distributional concerns; 
• Perspective: the perspective for public health evaluations has been 
broadened to include the public sector, and this may lead to 
inconsistencies when making comparisons with clinical interventions; 
• Extrapolation: defining the appropriate time horizon and how 
meaningful such extrapolations will be in the absence of robust 
evidence; 
• Quality of evidence: the evidence base is weaker in public health, and 
controlled trials are often impossible; 
• Cost effectiveness threshold: whether the same threshold should be 
applied to both clinical and public health interventions. 
Moreover, a more rigorous assessment of the issues for applying standard 
economic analysis techniques to public health evaluations has also been 
undertaken (Weatherly et al., 2009). Weatherly et al. identified four main 
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methodological challenges and recommendations for the cost-effectiveness 
analysis of public health interventions as follows:  
1) Attribution of effects: Compared to healthcare interventions, it would 
require different approaches to estimate the costs and outcomes of public 
health interventions while avoiding biased estimates. RCTs can be conducted 
to assess the intervention effects and measured within-trial or short-term 
effect, while the effects of public health programme often become noticeable 
many years after implementation. As a result, the key challenges were how to 
best obtain true estimates of effect, what the existing literature can offer by 
way of evidence, how primary research can generate quality evidence, and 
defining the appropriate time frame within which to measure success (Lorgelly 
et al., 2010). Hence, conducting RCTs should be a source of evidence on relative 
effectiveness when evaluating public health interventions’ effectiveness, 
where possible. 
   However, the extrapolation of outcomes beyond the end of the trial 
should be considered, and the outcome measured should match between 
within-trial and available in longer-term observational studies. Where RCTs 
cannot be undertaken, gaps in the evidence-base may be filled through data 
from natural experiments and non-experimental data. In analysing data used 
for economic evaluations, all relevant evidence should be considered including 
the evidence synthesis of different study designs. Furthermore, econometric 
approaches can be employed for analysing non-experimental data (Blundell and 
Dias, 2000), and these include various matching techniques such as propensity 
scores, difference in differences techniques, synthetic controls method, time-
series analyses of natural experiments, and, where appropriate, more 
sophisticated econometric modelling and structural simulation modelling. 
Further research might be undertaken to develop the methods for synthesising 
all relevant data, both experimental and non-experimental, for use in economic 
evaluations of public health interventions (Blundell and Dias, 2000).    
2) Measuring and valuing outcomes: Long-term outcome (measured in life 
expectancy or QALYs) is usually required for economic evaluation, so estimating 
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these health-related outcomes requires extrapolation and valuation. Moreover, 
some public health interventions affect the health outcome of other individuals 
who are not being targeted (e.g. co-workers or family members), and the 
interventions might also involve non-health related outcomes such as 
educational outcomes; it may be possible to include some of the outcomes 
within a QALY-type framework but not for others. The issues would be 
considered as what can be measured versus what should be measured, the need 
for a more generic measure of wellbeing, sector-specific generic measures of 
outcome, and greater consideration for alternative evaluation approaches 
(Lorgelly et al., 2010). Therefore, it would be important to examine which 
other outcome measurement and valuation methods are valid. The 
recommendations for measuring and valuing outcomes are that a CBA is based 
on standard welfare economics and considers all costs and benefits, and the 
valuation of benefits are based on individuals' willingness-to-pay, which may be 
limited to ability to pay. Therefore, this approach would consider and value the 
non-health attributes of a public health intervention such as individuals' ability 
to return to work or impacts on education and criminal justice systems. In 
contrast, a CUA is based on a non-welfarist approach, where the benefits of 
health programmes are measured in terms of health gain (i.e. in QALYs). In 
addition, the perspective for measuring costs and cost-offsets is covered by the 
health (and social services) budget on the basis that the objective of the 
healthcare decision maker is to maximise health gain given the budget 
constraint. This approach would ignore the impacts of public health 
interventions on other sectors. Thus, for the broad range of measured costs and 
outcomes from public health interventions, a cost-consequence analysis (CCA) 
should be performed following either a CBA or CUA. Moreover, discrete choice 
experiments (DCE) may provide a useful approach to examining the relative 
valuation and trade-offs between various attributes including non-health 
attributes (HM Treasury, 2003, Ryan and Gerard, 2003, Lancsar and Louviere, 
2008, Fujiwara and Campbell, 2011). In addition, two methods might be 
developed as follows: 1) development of sector-specific generic outcomes 
outside individuals' health (e.g. crime victim QALY, education QALY), and 2) 
development of a single all-purpose multi-dimensional well-being index or a 
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uni-dimensional measure of happiness (Dolan et al., 2006). Another alternative 
approach might be a multi- decision criteria analysis (MCDA), which is a formal 
approach to make the multiple criteria explicit and to help decision-makers 
explore different options (Marsh et al., 2014).     
3) Identifying intersectoral costs and consequences: The impacts of public 
health interventions are not only occurred at the individual level, but its effects 
are also often broad at the community and population levels. As a result, the 
costs and benefits of those interventions can be associated with many parts of 
the public sector. Expenditure in some sectors may reduce expenditures in 
others, e.g. improvements in housing could reduce illness and injuries, with 
consequent reductions in health care utilisation; the consideration of these 
issues was limited in the literature reviewed (Weatherly et al., 2009). 
Therefore, a CCA is suggested to quantify the intersectoral impacts of public 
health interventions in a way that makes the most sense for each sector. 
Ideally, each sector would use a well-understood generic measured outcome in 
reference to whether the shadow price of the budget constraint in the sector 
could be expressed. Further research to assess an intersectoral compensation 
test approach was introduced by Claxton et al. (Claxton et al., 2007), and this 
requires an evaluation of the benefits net of costs which fall on different sectors 
of the economy; the need for budgetary transfers could then be assessed. 
Considering broader views, although the public sector is mostly concerned with 
the impacts of interventions, there should be more consideration of costs on 
non-profit organisation sector and on private individuals, including the impacts 
of these costs on the effectiveness of interventions and the need for incentives. 
In addition, an analyst should consider the costs and consequences by 
beneficiary group. These groups could be defined in terms of health status, 
socio-economic status or other characteristics, depending on policy relevance. 
Finally, research should be conducted to assess whether a general equilibrium 
approach, which simultaneously considers the consequences of different 
interventions across all sectors of the economy, is more suitable for the 
evaluation of public health interventions having a broad range of intersectoral 
costs and consequences.      
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4) Incorporating equity considerations: Impacts on equity is important for 
public health interventions as in many cases, the main objective of the 
intervention is to tackle health inequalities. Therefore, the distribution of 
QALYs gained among population subgroups is particularly important in public 
health. However, there were rarely any mentioned in the studies reviewed 
(Weatherly et al., 2009). Consequently, primary research should be conducted 
on the effectiveness of interventions designed to undertake health inequality. 
It would also be useful to pilot studies to estimate the opportunity cost of a 
particular equity consideration in terms of population health sacrifice such as 
the QALYs forgone by pursuing the equitable option compared with the QALY-
maximising option. Further research is also required to explore public and 
stakeholder views on equity weighting in a public health context in order to 
provide quantitative guidance to policy-makers about how much sacrifice in 
efficiency (total population health) is merited to pursue particular equity goals. 
The important issues for this research should also examine socio-economic 
status, the degree of voluntariness or personal responsibility for health risk, 
and the value of treatment current illness versus prevention of future health 
risk.  
 Furthermore, Edwards et al. conducted a systematic review of the UK 
and international guidance for the economic evaluation of public health 
interventions (Edwards et al., 2013). The review described the methodological 
issues surrounding the economic evaluation of these interventions derived from 
seven UK guidelines and five international guidelines. The main issue of the 
methodologies concerns the nature of public health interventions that are 
complex public health interventions (i.e. involving more than one group or 
organisation level that is targeted by the intervention). Thus, those guidelines 
highlighted the methods to deal with a wide range of social and environmental 
costs and benefits of the interventions, which should ultimately be a broader 
range of outcomes than focussing solely on QALYs. This is reflected in the 
common theme of extra-welfarism that underpins the majority of guidance 
found in the review (Kelly et al., 2003, Weatherly et al., 2009, Payne et al., 
2013, HM Treasury, 2003, Byford et al., 2003).  
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In addition, to capture the equity issues related to the public health 
interventions, a capability theory was addressed as a means of including equity 
considerations in the economic analyses of public health interventions (Payne 
et al., 2013, Lorgelly et al., 2010), since the capability theory considers the 
distribution of capability across society.  Although the argument that further 
research should focus beyond QALYs is introduced, it should also consider 
usefulness of measured QALYs. Decision-making could be difficult without the 
information to inform whether public health interventions are cost-effective 
compared to the cost-effectiveness threshold (National Institute for Health and 
Care Excellence (NICE), 2012). In conclusion, a 12-point checklist for 
considering the methodological guidance of economic evaluation of public 
health interventions was proposed to highlight the additional key challenges 
related to public health interventions. Further research needs to address these 
issues in the study design and reporting of economic evaluations of public health 
interventions as shown in Table 1-4 (Edwards et al., 2013).  
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Table 1-3 Checklist of considerations when considering published guidance for 
the economic evaluation of public health interventions  
1 
 
What is the appropriate theoretical framework for analysis, e.g. welfarist, 
extra-welfarist, capability theory? 
2 
 
What is the setting of the public health intervention under evaluation? (e.g. 
environmental change; infectious disease control; screening; supporting 
behaviour change; supporting government legislation or policy) 
3 
 
Is this best described as a primary, secondary or tertiary prevention 
intervention, i.e. upstream or downstream? 
4 
 
What is the main agency (government; health service; local government; 
voluntary sector) responsible for implementation and who are the key 
stakeholders? 
5 If this is an intervention aimed at behaviour change, what are the key levels 
of change (legislation; price; changing social norms; choice architecture and 
nudging)? 
6 
 
What is the appropriate time horizon of analysis and what is the most 
appropriate discount rate for costs and outcomes? 
7 
 
If the public health intervention aims to “shift the curve”, are we most 
interested in the centre or tails of the distribution? 
8 
 
How is this public health intervention likely to impact inequalities in health? 
9 
 
Will subgroup analysis help identify the range of cost-effectiveness estimates 
across different settings, delivery methods and population groups? 
10 
 
What are the main outcome measures of interest, e.g. QALYs/DALYs or a large 
range of outcome measures relating to health and wider social outcomes? 
11 
 
How important is it to value costs, benefits and returns in monetary terms? Is 
it reasonable to expect the intervention to be cost saving in the short, 
medium or long term? 
12 How relevant will it be to compare an ICER with the NICE threshold of 
£20,000-30,000 or an international equivalent? 
Source: (Edwards et al., 2013) 
1.8 Modelling approach for economic evaluation of 
public health interventions 
Public health policy-makers have been faced with decision problems of 
how best to allocate scarce resources in order to maximise value for money. 
Modelling is frequently being applied as a method of depicting the complexity 
of decision making with respect to interventions and to more accurately capture 
the associated costs and benefits in economic evaluations. A modelling 
approach for an economic evaluation of a public health intervention has been 
increasingly applied for policy analysis to support the design of efficient and 
effective policy options for complex public health problems (Ashley et al., 2015, 
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Atkinson et al., 2015, Brennan et al., 2014a, Brennan et al., 2014b, Cadilhac et 
al., 2011, Chisholm et al., 2004, Galea et al., 2009). The approach would allow 
simulated experimentation of policy scenarios to test their comparative impact 
and cost over the short, medium, and longer term (Atkinson et al., 2015). The 
policy analysis tool could test the effectiveness and cost-effectiveness, equity 
of policy responses, exposing unintended consequences and perverse incentives 
in the system through computer simulation, and averting the need for costly 
trial and error approaches. This alternative approach should be considered to 
support decision-making for future strategies to address complex problems.  
1.8.1 Classification of model structure for economic 
evaluation 
There are several existing classification systems for health economic 
models. This chapter applied the model classification adapted from Brennan et 
al. (2006). The classification was based on whether a model is cohort- or 
individual-based, discrete or continuous time-dependent, and whether it allows 
for interactions between individuals, for example, infectious diseases – which 
are transmitted from person to person by direct or indirect contact (Brennan et 
al., 2006). The range of available modelling approaches for model-based 
economic evaluations are shown in Table 1-5.  
  
Chapter 1: Introduction  44 
 
 44
 
Table 1-4 Classification of model structures 
 Cohort/Aggregate level Individual level 
No interaction 
allowed 
Decision tree/Markov model Individual sampling model 
(ISM)/Individual-based 
microsimulation 
Interaction 
allowed 
System dynamics 
model/Markov chain model 
Agent-based model/Discrete 
event simulation 
Adapted from (Brennan et al., 2006) 
The most common types of model that do not involve interaction are 
decision trees and Markov models for the cohort or aggregate level, which 
allocate individuals to compartments that are homogeneous (Barton et al., 
2004). The decision tree is the simplest structure where all plausible patient 
pathways are shown on decision trees together with associated probabilities 
and outcome measures. The decision tree model is generally used for the short 
time horizon. However, there is a limit to manageable size of a probability tree 
such as recurrence event and survival time after treatment. To avoid an infinite 
number of branches in the decision tree, it is necessary to consider survival 
times, and the tree can be simply drawn as a Markov model.  
Markov models are commonly used in economic evaluations. The main 
benefit is the easy representation of recurrent events with a fixed time cycle 
but they do not allow for interaction between individuals. For the individual 
level without interaction, an individual sampling model and individual-based 
microsimulation have potentially heterogeneous characteristics that affect 
their progression through the model (Barton et al., 2004, Brennan et al., 2006). 
Its key advantage lies in modelling multiple co-morbidities which depends on 
multiple attributes or covariates. Individual-based models can simulate 
complex patterns of disease evolution to emerge and allow for more realistic 
scenarios. For example, an individual-based microsimulation can simulate the 
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life-time trajectories of participants and record participants’ histories. The 
transitions across different states may be conditional upon previous 
events/history that participants have gone through.  
In contrast, interaction between individuals needs to be taken into 
account in two main circumstances: when modelling infectious diseases - where 
the risk of an individual catching the disease depends on how many other people 
already have it; and when constraints on resources means that the choice of 
treatment for one patient affects what can be given to another (Barton et al., 
2004, Brennan et al., 2006). Where interaction is an important issue in 
modelling and individual characteristics may be heterogeneous, two methods 
are suggested: 1) an agent-based model allows agents (people who have certain 
heterogeneous features) to act autonomously within their own behaviour rules 
and to interact with each other and their environment (Chhatwal and He, 2015); 
and 2) a discrete event simulation model can be used for modelling disease 
progression as a continuous process with time-varying event rates and prior 
events affecting subsequent event rates.  
For the aggregate level, system dynamics are required. System dynamics 
is a simulation modelling method used for representing the structure of complex 
systems and understanding their behaviour over time (Marshall et al., 2015). 
The model provides a cross-sectional view of a system by counting the number 
of people exhibiting particular combinations of characteristics or in specific 
transitional health states over time. System dynamics and agent-based 
modelling can be used to develop a tool for policy analysis (Atkinson et al., 
2015). The models take into account the interrelations, reciprocity, 
discontinuity, and dynamic nature of influences on health and health 
behaviours within a broader context (Marshall et al., 2015). They allow for 
virtual experimentation of policy scenarios to test their comparative impacts 
and costs over the short, medium, and longer term. The policy analysis tool 
could test the efficiency, effectiveness, and equity of policy responses, 
exposing unintended consequences and perverse incentives in the system 
through computer simulation and averting the need for costly trial and error 
approaches (Hoang et al., 2016). 
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1.8.2 Incidence-based versus prevalence-based economic 
evaluation  
There are two main approaches for conducting economic evaluation that 
have been used to provide important information when a new healthcare  
intervention is introduced to a target population (Mauskopf, 1998): 
 1) An incidence-based economic evaluation follows a disease cohort for 
the duration of the disease and estimates discounted and health gains with 
alternative interventions. The cost-effectiveness ratio is based on individual 
utility maximization and provides information to decision-makers about the 
efficiency of a new intervention compared to societal willingness-to-pay for 
health gains. It does not estimate annual budget impacts, and generally does 
not capture indirect effects on the population. 
2) A prevalence-based approach provides estimates of costs and health 
benefits for the total population for either 1 year or over a longer time horizon 
on a cumulative basis. Appropriate threshold values for these ratios are those 
based on a percentage of Gross Domestic Product (GDP) as recommended by 
the WHO (Single et al., 2003). The prevalence-based cost-effectiveness ratio 
provides information to decision-makers on the affordability of the new 
intervention and the value for money over the selected time horizon. The 
prevalence-based analysis can take into account both direct and indirect 
effects of healthcare interventions, and is therefore frequently used for 
economic evaluations of vaccine programmes (Capri et al., 2011, Kawabayashi 
et al., 2013) as well as cost-of-illness studies such as social cost estimates of 
substance abuse (John et al., 2009, Xie et al., 1998, Saar, 2009, Jarl et al., 
2008).  
Table 1-6 compares the key features of the two method (Mauskopf, 
2012). The prevalence-based approach is more suitable for ascertaining the 
total current economic burden of a disease (WHO, 2009, Rehm et al., 2009, 
Collins et al., 2006), whereas an incidence-based approach is more useful for 
ascertaining the expected impact of a disease in the future (and its potential 
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prevention or elimination). For ongoing health and social problems such as illicit 
drug use, the results of prevalence-based and incidence-based estimates are 
often similar (WHO, 2009). For health problems that are declining in magnitude 
(such as smoking in some countries), prevalence-based estimates will generally 
be higher than incidence-based estimates. For emerging health issues such as 
HIV or hepatitis infection epidemics, incidence-based estimates generally 
provide higher estimates than prevalence-based estimates because many 
infected persons may still be in the latency phase of the diseases.  
Prevalence-based economic evaluations might be of greater use for 
healthcare and public health policy-makers than incidence-based methods 
because it estimates value for money and provides estimates of budget impact 
as well as population health impact (both direct and indirect effects) 
(Mauskopf, 1998, Mauskopf, 2012). However, the economic evaluation results 
derived from the prevalence-based approach are not comparable for the cost-
effectiveness threshold. Many cost-effectiveness studies using incidence-based 
method could produce incremental cost-effectiveness ratio compared with the 
threshold to determine whether the new intervention for the specific health 
problem is a good value for the money (Drummond MF et al., 2005). This type 
of value measure is also very useful if decision-makers are trying to determine 
the best way to allocate healthcare budget between alternative uses; that is, 
they should allocate the budget to the new intervention with the lowest cost-
effectiveness ratios first. In conclusion, conducting both prevalence-based and 
incidence-based analyses can give a complete picture of the efficiency and 
affordability of a new intervention, and provide a useful tool for policy-makers 
to determine optimal resource allocation and good value for money. Thus, both 
approaches should be conducted for all types of healthcare interventions 
(Mauskopf et al., 2007).    
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Table 1-5 A comparative analysis of incidence-based and prevalence-based 
methods for economic evaluations 
MODEL CHARACTERISTIC INCIDENCE-BASED 
ECONOMIC EVALUATION 
PREVALENCE-BASED 
ECONOMIC EVALUATION 
Basis in economics theory Utility maximisation None 
Threshold value Societal willingness-to-pay 
per QALY gained 
Affordability thresholds, e.g. 
relative to GDP 
Population Single cohort, can represent 
different population 
subgroups 
Total population or 
population subgroups 
Time horizon Duration of treatment 
impact on the single cohort 
After approval for use, 
annual values or cumulative 
value 
for a specified number of 
years or to steady state 
Treatment comparators Current practice compared 
with a new intervention 
Current mix of interventions 
compared with a predicted 
mix of interventions, 
including the new 
intervention 
Market shares 100% with each comparator Current intervention mix 
based on observed market 
shares; new mix with new 
intervention available based 
on predicted market shares 
Indirect health effects  Generally not considered Generally considered 
Catch-up effects when first 
approved 
Not considered May or may not be 
considered 
Uptake/coverage Uptake/coverage has no 
effect on the results 
because only direct effects 
are considered 
If indirect effects are 
included, uptake/coverage 
impacts the results 
Outcomes Cumulative costs for single 
cohort for chosen time 
horizon; cumulative 
effectiveness measured in 
natural units or QALYs for 
chosen time horizon; ratio of 
costs to effectiveness; 
results do not vary with 
market share; results may 
vary for population 
subgroups 
Annual or cumulative 
population costs; annual or 
cumulative population 
effectiveness measured in 
natural units or QALYs; ratio 
of costs to effectiveness; 
results will vary with market 
share and for population 
subgroups 
Value to decision-maker Estimates the efficiency of a 
therapy compared with a 
standard of care for target 
cohorts, and incremental 
cost-effectiveness ratio 
Estimates population budget 
impact over time for budget 
planning, health outcomes 
over time for the 
population, and ratio of 
costs to health outcomes 
Source: (Mauskopf, 2012)  
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1.8.3 Time lag of alcohol consumption changes and alcohol-
related harm changes 
In recent literature, studies are using time series analyses to show the 
association between per capita alcohol and changes in rates of alcohol-related 
harms over a period of time (Bye, 2007, Engdahl and Ramstedt, 2011, Jiang et 
al., 2015, Ramstedt, 2001, Ramstedt, 2008). However, alcohol use, particularly 
heavy episodic drinking, is associated with several short-term negative 
consequences (such as injuries and violence) as well as long-term effects, 
including greater risk of alcohol dependency and other chronic diseases (Grant 
et al., 2009, Jones and Bellis, 2014, Jones et al., 2008, Kendler et al., 2016, 
Rehm and Roerecke, 2013, Roerecke and Rehm, 2013). An important 
methodological issue has been raised as the time lag between alcohol 
consumption and its related harm changes i.e. the time to first effect, the 
duration to full effect, and the functional form of the accumulation of effect 
(Holmes et al., 2012). 
 A recent review summarised the derived time lag specifications when 
modelling the effects of aggregate alcohol consumption on the rates of various 
alcohol-related harms (Holmes et al., 2012). It showed limited consistency 
across studies as well as a limited number of the alcohol-related conditions 
which were under evaluated. The lag structures used typically specified the 
immediate effect as the greatest single year effect, with effects of declining 
magnitude seen in subsequent years. The size of the first-year effect showed 
approximately 20-60% of the total effect but the reason for the different effect 
was unclear.  The variation of lag time for the full effect of changes in 
aggregate alcohol consumption was found to be five years and over. Based on 
the best available evidence, an aggregate-level alcohol policy model applied 
no lag time for the effect of alcohol consumption change on acute alcohol-
related harms; however, for such effect on chronic alcohol-related conditions, 
the alcohol policy model specified an immediate effect with linear functional 
form and ten years to full effect (Brennan et al., 2014a, Brennan et al., 2014b). 
Holmes et.al. (2012) suggested the further work that might investigate 
aetiology of alcohol-related harms at individual-level with awareness given to 
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the relevance of initial volume and patterns of consumption; moreover, other 
issues might be considered, i.e. exposure period for disease development, 
evidence of protective effects, influence of competing risks, risks for different 
social groups and the functional form of those risks (Holmes et al., 2012). At 
the population-level, one challenge is to address whether lag response differs 
for consumption increases and decreases and the examination of age, period, 
and cohort trends - which may also distort temporal processes. Future research 
attention needs to be given to the rationale for choosing or applying particular 
lag specifications and the inherent complexity of the processes which aggregate 
to create time lag effects. 
1.8.4 Review methods for modelling cost-effectiveness in 
public health intervention 
To conduct a modelling cost-effectiveness study of a public health 
intervention, the methodological problems include (Marsh et al., 2012): 1) 
difficulty in estimating for how behaviours change over time for a modifying 
risk behaviour intervention, e.g. whether a short-term improvement in diet is 
likely to be maintained (Alayli-Goebbels et al., 2014); 2) how the long-term 
health impacts of behaviours is estimated and the time lag between behaviour 
changed and incidence of disease when a risk behaviour is modified, e.g. the 
impact of sedentariness on the incidence of heart disease (Alayli-Goebbels et 
al., 2014, Holmes et al., 2012); 3) what the impacts are of population 
interactions for a population-level intervention, e.g. sexual behaviour and herd 
immunity (Marshall et al., 2015, Martineau et al., 2013); and 4) for 
heterogeneity among individuals, how their multiple co-morbidities or risk 
behaviours are taken into account such as conditions associated with alcohol 
use disorder (Caro et al., 2010, Chhatwal and He, 2015). Moreover, many 
literature identified these fundamental features of modelling approaches that 
can be used to guide the implementation public health economic evaluation 
modelling (Brennan et al., 2016, Briggs et al., 2016, Marsh et al., 2012, 
Martineau et al., 2013, Alayli-Goebbels et al., 2014).  
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For behavioural interventions, models can be built where simulations 
take place at a cohort or aggregate level, or to allow the behaviour of 
individuals to be tracked separately. Cohort-level models - such as cohort 
Markov models often employed by health economists - allocate individuals to 
compartments, and require that individuals within a compartment or cohort are 
homogeneous (Barton et al., 2004, Brennan et al., 2006). Such cohort models 
are easier and less resource-intensive to construct than individual-level models 
but there are limitations when the models are applied for public health 
interventions. First, the homogeneity assumption is often not satisfied, e.g. if 
future model states depend on an individual’s history. For example, the health 
impact of an individual quitting smoking will depend on the individual’s 
historical consumption of tobacco and alcohol. Second, cohort models become 
very complex if they need to capture multiple co-morbidities such as those 
associated with alcohol use disorder - which has been linked with multiple 
health problems.  
In response to these challenges with cohort-level models, a number of 
individual-level modelling techniques have been proposed including individual-
level Markov models, Discrete Event Simulations, and agent-based models (Caro 
et al., 2010). Of particular interest to public health economic evaluations is 
agent-based models, which allows agents to act autonomously with their own 
behavioural rules. Many public health interventions are designed to influence 
peoples’ behaviour such as improving physical activity levels or causing people 
to quit smoking. The economic evaluation of such interventions will require an 
understanding of how peoples’ behaviours respond to these interventions, and 
how these behavioural impacts are maintained, or otherwise, over time. Agent-
based models have an important role to play in such assessments (Alayli-
Goebbels et al., 2014). Therefore, the selection and implementation of 
appropriate modelling approaches will be supported by the development of a 
better empirical understanding of behavioural dynamics and the relationship of 
behaviour and health (Marsh et al., 2012). For instance, existing panel survey 
data should be analysed to determine the dynamics of relevant public health 
behaviours such as physical activity, diet, smoking, alcohol consumption, and 
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sexual behaviour. This evidence should also be analysed to determine the 
impact of these behaviours on health outcomes by age and accumulated 
behaviour.  
1.9 Transferability of economic evaluations across 
jurisdictions: methodological challenges and 
recommendations 
An increasing number of national decision-making processes have 
requested economic evaluations for developing reimbursement packages of 
pharmaceuticals and other health interventions. Since there are many factors 
that would affect the cost-effectiveness of health technologies under 
evaluations between jurisdictions (Sculpher et al., 2004), most of the national 
HTA guidelines recommend to conduct the economic evaluation relevant to the 
local context; moreover, decision-makers also prefer cost-effectiveness studies 
that are applicable in their own setting. However, a full economic evaluation 
using local data requires substantial resources both in terms of finance and time 
consumed as well as technical health economics expertise. These are  
challenging problems faced by those involved in the decision-making process, 
especially for low- and middle-income countries (Drummond et al., 2015).  
Therefore, decision-makers might need to use analyses or data from 
other countries and consider whether the results are generalisable or 
transferable. Studies are considered generalisable when they are able to be 
applied to a range of jurisdictions without any adjustment needed for 
interpretation (Barbieri et al., 2010, Drummond et al., 2009). Moreover, some 
studies are transferable if they can be adapted to apply to other settings. 
Finally, some of them are so specific to a given jurisdiction that they are simply 
not transferable to other jurisdictions.  
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1.9.1 Summary of HTA guidelines related to transferability of 
economic evaluation 
There are a number of reviews of existing national HTA guidelines 
(Barbieri et al., 2010, Drummond et al., 2015, Drummond et al., 2009, Goeree 
et al., 2007, Goeree et al., 2011). These reviews assessed the wide range of 
the HTA guidelines related to the transferability of economic evaluations and 
HTA across jurisdictions (also referred to as geographic transferability). Barbieri 
et al. summarised and classified the level of transferability of key data input 
used in economic evaluation from 37 guidelines, i.e. baseline risk, treatment 
effect, health state preference values (utilities), resource used, and unit costs 
(prices) as shown in Figure 1-6 (Barbieri et al., 2010). For baseline risk and 
treatment effect, no details were given in 4 cases while they were discussed in 
12 cases. For health utilities, no information was given in 16 cases. Resource 
use and unit costs were discussed together in 5 cases while no details were 
given in 2 cases for unit costs and in 6 cases for resource use.  
 
Figure 1-5 Level of transferability of data inputs (as summarised from 37 
national HTA guidelines) 
Note: “High transferability”: elements of economic evaluation from other locations 
can be used in local analyses; “Low transferability”: data from other jurisdictions are 
not accepted or there is a strong preference for local data; and “Not stated”: no 
details were given or the item of interest was not discussed separately from another 
item.          
Source:  (Barbieri et al., 2010) 
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There was great variation in detail and significance given to the issue of 
the transferability of data. It appeared that there was a general agreement 
among guidelines on which data were more or less likely to be transferable 
between jurisdictions (Barbieri et al., 2010). The review provides the full list 
of 37 national HTA guidelines including the most recent year of updated version 
at 
http://www.ispor.org/publications/value/vihsupplementary/vih13i8_drummo
nd.asp.   
1) Clinical data baseline risk and relative treatment effect: In all cases where 
baseline risk and treatment effect were discussed separately, baseline risk was 
considered to have low transferability while treatment effect was generally 
considered to have high transferability. Even in cases of high transferability, 
the guidelines suggested giving attention to the applicability of trials to the 
local context (e.g. differences between trial patients and local population, and 
adequacy of comparators). The main reason for using country-specific data for 
baseline measures of clinical events was the potential difference in 
epidemiological data between locations where the use of estimates from other 
settings could be misleading. In contrast, treatment effect (e.g. relative risk of 
an intervention with respect to a comparator) was transferable between 
locations. In this case, the use of high quality data (e.g. from systematic 
reviews or large RCTs) was recognised as a key factor and more important than 
the use of local data. Therefore, one recommendation was to obtain treatment 
effects from multinational RCTs and then adjust the estimates of baseline risk 
derived from local population-based sources. Nevertheless, in some cases, the 
guidelines highlighted the need for potential adjustment of the results obtained 
from a clinical trial to the local context, given the potential differences 
between settings (mainly in terms of population characteristics). Those 
guidelines generally suggested that clinical data are transferable, but with 
adaption to account for differences in some factors. Among these factors, 
epidemiological data, patient characteristics, comparators used, and clinical 
practice are often considered.  
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2) Health state preference values (health state utilities): A variation of 
recommendations were made about the transferability between locations of 
utility estimates; these differences were mainly caused by different degrees of 
flexibility in the various national HTA guidelines for accepting data from other 
locations based on the availability of these data in the country. In many cases, 
health state preference values are not available for the country of interest such 
as countries where the use of economic evaluations might be less developed so 
it is often recognised that utilities need to be obtained from other countries. 
In these cases, great attention is given to the need for transparency, in that 
the data sources and instruments used should be stated together with a 
discussion of their applicability to the country of interest. Finally, sensitivity 
analyses are often recommended when utility values are obtained from studies 
performed in other settings. 
3) Resource use and unit costs: The majority of the guidelines 
recommended obtaining resource use from the local setting, since the variation 
of clinical practices, incentives and regulations, health financing, healthcare 
systems and schemes, and distribution of resources were often mentioned as 
the reasons of different resource use between locations. These guidelines 
suggest that it is fundamental to use local data for resource consumption and 
estimates obtained from other locations are often not considered as an 
appropriate and valid source. In general, these guidelines stated that if 
resource utilisation estimates are obtained from published studies performed 
in other locations, they should be adapted to the country of interest, e.g. by 
means of expert opinion. Also, they suggested that any method used to adjust 
resource use from other locations to the country of interest should be explained 
and justified. Regarding unit costs, most guidelines that analysed these data 
separately from resource use agreed that they must be jurisdiction-specific 
because of differences in relative and absolute prices between countries. Some 
guidelines also provided sources for unit costs in form of an official list. Most 
guidelines recommend presenting quantities of resource use separately from 
unit costs to increase the transparency of the analysis. 
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1.9.2 Methods recommended for addressing issues of 
transferability  
 There are two methods to deal with the issue of transferability of data 
classified by types of economic evaluation (Barbieri et al., 2010):  
1) Economic evaluations based on individual patient data: Most guidelines 
did not make any recommendations on methods for transferring data from 
clinical trials carried out in other countries or multinational trials (with or 
without the inclusion of the reference countries). Some guidelines 
recommended that clinical data from trials performed in other settings were 
acceptable based on in particular of the relative treatment effect, while 
absolute risk estimates or resource consumption from these studies were 
difficult to transfer to other settings. Those guidelines also suggested that 
clinical data from multinational trials could be pooled - although this may not 
be the case for all interventions - while economic data are unable to be pooled 
because of the potential differences in resource use and clinical practice 
patterns between centres and countries.  
The NICE guidelines in England and Wales state that statistical pooling of 
clinical data should be accompanied by an assessment of clinical heterogeneity. 
Emphasis is also given in the Australian guidelines to the need for assessing the 
heterogeneity of patients by means of subgroup analysis or meta-regression, 
while the Canadian guidelines are the only ones that recommended the use of 
multilevel models (in addition to other methods such as multivariate regression 
models) to address the issue of clinical and economic differences between 
centres and countries in a multinational study.   
2) Economic evaluations based on decision models: The use of a decision 
model is often viewed by the guidelines as a method to handle the variability 
and differences among settings. For example, both the Dutch and Swedish 
guidelines explicitly stated that modelling is the key method for transferring 
data obtained from other countries to the local context. Other guidelines also 
said that the use of modelling should help to address the issue of transferability 
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among jurisdictions (mainly by means of sensitivity analyses). The need for 
adapting the model structure to the local context is explicitly mentioned only 
in the Belgian and Spanish guidelines where it is stated that adjustments to 
models may be needed, especially when there are differences in practice 
patterns.  
Nevertheless, most of the guidelines state that an external validation of 
the model should be conducted to confirm that the model structure adequately 
reflects the clinical patterns and underlying nature of the disease in the local 
context. Study selection and methods to synthesise data are considered 
important issues for appropriately populating decision models. In general, it 
seems that the guidelines gave more importance to the quality of the studies 
used as the source of effectiveness data rather than to their specific setting. 
RCTs are generally preferred as the source of clinical data even when they were   
the reference country; however, it is often stated that clinical estimates need 
to be appropriate for the study question and target population. In addition, 
some of the most detailed guidelines (Canada, United States, England, and 
Wales) stated that the preferred method for incorporating estimates of 
treatment effectiveness was to combine relative risk estimates from 
international RCTs with estimates of baseline risk from local epidemiological 
data. When data from more than one trial are available, meta-analysis is the 
preferred method for synthesising clinical data. Some guidelines (Australia, 
England, and Wales) stated that it was important to take account of the 
heterogeneity among studies included in the meta-analysis, e.g. by means of 
random-effect models or meta-regressions.  
The NICE guidelines also suggested that some studies included in the 
meta-analysis could be excluded in a sensitivity analysis to assess the impact of 
different sources of data on cost-effectiveness results. The need for local 
sources of economic data to include in the decision model is highlighted by most 
of the guidelines, often recommending the use of expert opinion when no valid 
published data are available. Finally, most guidelines stated that the issue of 
transferability between countries should be addressed by means of sensitivity 
analyses.   
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Chapter 2: Review methods for modelling 
economic evaluation of an alcohol intervention 
2.1 Introduction 
 As mentioned in Chapter 1, there are methodological issues surrounding 
model-based economic evaluation of public health interventions, e.g. 
comprehensive evidence for effectiveness which incorporate programme 
complexity, time lag between behaviour changes and its related harm changes, 
use of incidence-based versus prevalence-based approaches, and measurement 
and valuation of health outcomes and wider benefits. This chapter reviews the 
previous model-based economic evaluation studies of alcohol interventions. 
The next section presents the methods used for the systematic search where 
the selection criteria and search strategy are reported. This is followed by the 
methods used for the methodology extraction of the selected studies. The 
following two sections report the results of the systematic search and the 
results of the methodology extraction. The limitations of the methodological 
review are then considered. The last section presents a critique of the method 
used in the studies reviewed. This methodological review is used to inform the 
development of an economic model for alcohol intervention in the following 
chapters. 
2.2 Research questions 
The research questions are: 
1. What are the current evidence of modelling economic evaluations of alcohol 
interventions? 
2. What are the methodological challenges of economic evaluations of alcohol 
interventions to inform public health policy about value for money? 
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2.3 Objectives of the review 
This literature review aims to examine and compare the modelling 
methods used in published economic evaluations of alcohol interventions, i.e. 
types of economic evaluations, types of models, approaches for measurement 
and valuation of the consequences, identification of the individual-level and 
population-level consequences, and other economic evaluation components 
(e.g. perspective and time horizon). Moreover, the review aims to define the 
evidence gap of developing alcohol policy and intervention modelling so the 
current study can likely be used to fulfil the gap.    
2.4 Methods   
Only full economic evaluations – which capture both relevant costs and 
benefits – were considered in this review (Drummond MF et al., 2005). The 
following two sections present the methods for the systematic search, the 
selection criteria, the assessing quality of eligible studies, and the data 
extraction. 
2.4.1 Systematic search 
Studies of model-based economic evaluations of alcohol interventions were 
identified by searching the following sources:  
1) Electronic databases - NHS Economic Evaluation Database (EED), which 
identifies potential economic evaluations by searching the following databases: 
MEDLINE (from 1995 to the end of December 2014), EMBASE (from 2002 to the 
end of December 2014), PsychINFO (from 2006 to the end of December 2014) 
and CINAHL (from 1995 to the end of December 2014). Afterward, the search 
of additional studies from MEDLINE and EMBASE was conducted starting from 
December 2014 to December 2016.  
2) Reference lists and citation tracking - bibliographic search for reference lists 
of retrieved studies and citation tracking of key papers using MEDLINE and 
EMBASE. 
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The search terms are presented in Appendix 2. Searches of electronic 
databases used free-text terms and MESH headings. The search terms were 
conducted using keywords included type of intervention, study design, and type 
of costs/ consequences. The search terms were: (alcohol-related disorders or 
alcohol dependence or heavy drinking or alcohol misuse) and (economic 
evaluation or value for money) and (health promotion or behaviour therapy or 
harm reduction or treatment or brief intervention). The retrieved citations 
were managed using Endnote X7.  
2.4.2 Selection criteria 
The selection criteria (Table 2-1) were applied to screened and selected 
eligible studies. Both inclusion and exclusion criteria are defined in terms of 
type of study, type of modelling approach, types of participants, types of 
interventions, and types of costs and consequences. Decisions about the 
inclusion or exclusion of studies are made according to these criteria.  
2.4.3 Assessing quality of eligible studies 
No specific quality assessment tools were developed to assess the quality 
of economic modelling studies of public health interventions. As mentioned in 
Chapter 1, there were key methodological challenges surrounding economic 
evaluations of public health interventions. Thus, this review applied the 
recommendations of two systematic reviews of economic modelling studies. 
The first review was conducted by (Philips et al., 2004) that developed the 
quality assessment tool of decision-analytic models. In addition, the second 
review summarised the key challenges for developing the structure of public 
health economic models (Squires et al., 2016). In conclusion, the main issues 
for assessing quality of eligible studies were as follows: model structure, data 
identification, data modelling, assessment of uncertainty, inclusion of non-
healthcare costs and outcomes, inclusion of equity, and internal- and external-
consistency.   
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2.4.4 Data extraction 
Study participants and level of implementation (i.e. individual, 
community, and population levels) were extracted. Moreover, the alternative 
alcohol interventions – which were in specific settings or national level - of each 
study are described. Studies were classified as the full economic evaluation 
type, i.e. cost-effectiveness analysis (CEA), cost-utility analysis (CUA), and 
cost-benefit analysis (CBA). The different study types affected how the costs 
and outcomes were identified, measured, and valued. The modelling 
approaches were defined based on classification of the model structure in 
Chapter 1 as well as other components such as time horizon and perspective on 
cost and benefits (e.g. patients’ perspective, healthcare sector perspective, 
and societal perspective). Moreover, a level of consequences considered 
whether alcohol-related harms affected others including alcohol-related 
victims and drinkers’ families – which arose from individual’s drinking problems. 
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Table 2-1 Inclusion and exclusion criteria 
 Inclusion criteria Exclusion criteria 
Types of studies Only full economic evaluations are included. Included studies 
are classified as CEA, CUA, and CBA and incorporated a 
modelling approach (as shown in Table 2-1). 
Partial economic evaluations are not included. Partial economic 
evaluations include studies such as cost-offset analysis, cost-outcome 
description, cost description, efficacy or effectiveness evaluations, 
and outcome descriptions. Also excluded are systematic reviews and 
methodological studies. 
Types of participants Study population is the target of an alcohol intervention at 
both individual and population levels. 
The population of interest is not the target of a specific alcohol 
intervention. Foetal alcohol spectrum disorder patients are also 
excluded. 
Types of 
interventions 
Included interventions are alcohol interventions that aim to 
reduce alcohol consumption, i.e. screening followed by 
counselling problem drinker, alcohol use disorder treatment, 
and interventions delivered at a population level such as: 1) 
alcohol policy and legislative interventions (alcohol taxes, 
drink driving controls, licensing provisions, and alcohol 
advertising policy); 2) enforcement measures of legislation; 
and 3) prevention of alcohol misuse (school-based interventions 
and mass media campaigns). 
Studies that evaluate treatment for alcohol-related disease and do 
not aim to reduce consumption are excluded. Mixed interventions of 
modified risk behaviours and alcohol mixed with other substance use 
disorders are not included due to the difficulty of separating 
identification, measurement and evaluation procedures for the 
different treatments or target population. Screening and detection 
studies (screening instruments for the detection of problem drinking, 
alcohol abuse and dependence and the laboratory tests that confirm 
results or monitor abstinence) are excluded. 
Types of costs and 
consequences 
Economic evaluations that allow an assessment of the 
identification, measurement and valuation of outcomes, and 
cost domains are included. 
Studies that are a methodological extension of another one are 
excluded and only the published study with a more complete 
description of the methodology applied is selected. 
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2.5 Results 
As presented in Figure 2-1, the initial search of databases yielded 1,370 
articles, and 1,338 duplicates and non-relevant studies were removed by 
screening titles and abstracts. The full articles of 37 studies were reviewed to 
assess eligibility based on inclusion criteria. Subsequently, 26 studies were 
eligible for further methodological review, and the following number of  studies 
were conducted in these respective countries: the US (n = 5), Australia (n = 5), 
the UK (n = 4), the Netherlands (n = 2), Denmark (n = 2), Italy (n = 1), Sweden 
(n = 1), Thailand (n = 1), Estonia (n = 1), East Africa (n = 1), Germany (n = 1), 
Canada (n = 1), and 12 WHO sub-regions (n = 1). Table 2-2 and Table 2-3 present 
the approach used for model-based economic evaluations of alcohol 
interventions.  
2.5.1 Interventions  
The majority of interventions were targeted at specific at-risk drinkers 
and in healthcare settings (n = 17), e.g. primary care, emergency department, 
and outpatient department. Ten studies assessed population-level 
interventions, and a study evaluated an intervention at the community-level 
setting (the number of study settings was greater than the total number of 
eligible studies due to some studies evaluating multiple settings). The most 
commonly modelling studies evaluated the cost-effectiveness of screening and 
brief intervention (SBI) for alcohol use disorder, where the efficacy of the 
intervention was also reported in terms of reducing alcohol drinking problems 
(Angus et al., 2014a, Barbosa et al., 2015, Barbosa et al., 2010b, Gentilello et 
al., 2005, Kapoor et al., 2009, Kessler et al., 2015, Mortimer and Segal, 2005, 
Neighbors et al., 2010, Purshouse et al., 2013, Quanbeck et al., 2010, Zur and 
Zaric, 2016, Smit et al., 2011). Those studies examined the relationships 
between SBI and changes of consumption and/or alcohol-related harms within 
the follow-up period; moreover, the changes of consumption level were 
modelled to estimate the changes of alcohol-related diseases and/or other 
harms over time. Furthermore, the studies conducted economic evaluations 
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alongside RCTs with a short-term follow-up period and used the modelling 
approach to extrapolate the costs and outcomes beyond the end of clinical trial 
(Barbosa et al., 2015, Barbosa et al., 2010b, Braithwaite et al., 2014, Brodtkorb 
et al., 2016, Laramee et al., 2014, Navarro et al., 2011, Navarro et al., 2014, 
Palmer et al., 2000, Purshouse et al., 2013, Tariq et al., 2009). In addition, the 
mathematical modelling evaluated the cost-effectiveness of population-level 
interventions such as pricing and taxation policies, drink-driving policies, 
advertising bans, and licensing controls (Byrnes et al., 2010, Chisholm et al., 
2004, Cobiac et al., 2009, Holm et al., 2014b, Holm et al., 2014a, Ditsuwan et 
al., 2013, Bye, 2007).  
2.5.2 Types of economic evaluation and modelling approaches 
Most of these modelling studies used CUAs (n = 19) as the analytical 
method, followed by CEAs (n = 6), and only two studies used CBAs. In terms of 
the type of model used, decision trees (6 studies) and cohort-based Markov 
models or multistate cohort population models (16 studies) were commonly 
used, followed by system dynamics model (2 studies) where both studies 
evaluated interventions for people living with HIV/AIDS and the effect of HIV-
related morbidity and mortality - and individual based microsimulation model 
(2 studies); there was no agent-based model/discrete event simulation model. 
The time horizon used for a majority of the modelling studies was more than 
30 years (n = 14), followed by less than 10 years (n = 8) and >10-30 years (n = 
4). The long-term evaluations allowed the model to capture the benefits of the 
public health interventions. Input parameters for conducting model-based 
economic evaluations were gathered from multiple sources of epidemiological 
studies as well as meta-analyses of previous trials to estimate future costs and 
outcomes.    
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Figure 2-1 Flow chart of literature search 
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 Additional records identified 
through MEDLINE and EMBASE 
sources  
(n = 1,358) 
Records after duplicates removed  
(n = 1,370) 
Titles and abstracts 
screened  
(n = 1,370) 
Records excluded  
(n = 1,338) 
Full-text articles assessed for 
eligibility  
(n = 37) 
Full-text articles excluded, 
with reasons 
• Non-alcohol /mixed 
intervention (n = 2) 
• Non-modelling study (n = 4) 
• Partial economic evaluation  
   (n = 2) 
• Duplicate study (n = 2) 
• Non-English language (n = 1) 
 
Studies included for detailed 
review  
(n = 26) 
Citation searching  
(n = 5) 
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Table 2-2 Summary of eligible studies 
Models used 
Decision 
tree 
Cohort 
Markova 
System 
dynamics 
individual based 
microsimulation 
model Total 
 n=6 n=16 n=2 n=2 n=26 
      
Type of economic 
evaluationb     
CEA 3 2 1 - 6 
CUA 4 13 1 1 19 
CBA - 1 - 1 2 
Level of implemented intervention    
Individual 5 10 - 2 17 
Community 1 - - - 1 
Population 2 6 2 - 10 
Level of consequences    
Individual 4 15 - 1 20 
Others - - - 1 1 
Individual and 
others 2 1 2 - 5 
Perspectivec       
Employer - - - 2 2 
Healthcare sector 7 12 2 - 21 
Societal 1 4 - - 5 
Time horizon      
0.5-10 years 3 4 - 1 8 
>10-30 years - 2 2 - 4 
>30 years  3 10 - 1 14 
a Includes a decision tree combined with Markov model 
b One study used both a CEA and CUA. 
c Two studies used both healthcare sector and societal perspectives.  
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Table 2-3 Characteristic of 26 eligible economic modelling studies  
 
 
 
Author, 
year 
Country Study participants Implementation 
levels 
Intervention Study 
type 
Modelling 
approach: 
time horizon 
level of 
consequence  
Perspectiv
e 
Summary of quality assessment 
(Angus et 
al., 2014b) 
Italy The screening of 
patients when they 
next registered 
with a new GP and 
screening when 
they have their 
next standard GP 
consultation 
(subgroup by age, 
sex and mean 
alcohol 
consumption at 
baseline) 
Individual level 10 years SBI programmes in 
primary health care in Italy 
(screening annually and not 
more than once) screening is 
modelled using the AUDIT-C 
questionnaire with a threshold 
of 4 for women and 5 for men 
with a brief intervention 
lasting 10 minutes for all 
patients who screen positive 
CUA Aggregate 
model 
/Sheffield 
Alcohol 
Policy Model 
(SAPM): 30 
years 
Individual  Italian 
National 
Health 
Service 
(INHS) 
 
 
The SAPM developed in the UK was 
employed using an Italian baseline data 
on consumption, morbidity, mortality, 
and cost. Model structure was that the 
intervention affected consumption. Then, 
morbidity and mortality risks related to 
consumption were derived from SAPM. 
Harms to others were not included, and 
only health outcome was measured (i.e. 
QALYs). Sensitivity analyses were 
conducted by varied discount rate, model 
assumptions, and implementation options 
(Barbosa et 
al., 2015) 
The US Patients in 
Emergency 
Department and 
OPD 
Individual level Delivering alcohol screening, 
brief intervention, and 
referral to treatment (SBIRT) 
in emergency departments 
(ED) when compared to 
outpatient medical settings 
CUA Decision 
tree: 6 
months 
Individual 
and others 
(criminal 
activity, 
accident, 
and income 
loss) 
Provider 
and 
societal 
A probabilistic decision analytic tree 
categorized patients into three health 
states based on drinking level. Data were 
observational and administrative, 
supplemented by survey data and the 
literature. Social costs were also 
estimated. Health outcome was measured 
(i.e. QALYs). Probabilistic sensitivity 
analyses were conducted.   
(Barbosa et 
al., 2010b) 
The UK Males who are 
seeking alcohol 
treatment 
Individual level Based on UK alcohol 
treatment trial (UKATT), 
social behaviour and network 
therapy compared to 
motivational enhancement 
therapy  
CUA Markov: 
Lifetime 
Individual Healthcare 
sector  
The study used a cohort based 
probabilistic lifetime Markov model where 
alcohol consumption and drinking history 
are used for classifying patients into 5 
Markov states: hazardous drinking, ex-
hazardous drinking, harmful drinking, ex-
harmful drinking, and death. Input 
parameters were derived from many 
literature. The main outcomes were 
QALYs and lifetime costs.  
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Table 2-3 Characteristic of 26 eligible economic modelling studies (cont.)  
Author, 
year 
Country Study participants Implementation 
levels 
Intervention Study 
type 
Modelling 
approach: 
time horizon 
level of 
consequence  
Perspective Summary of quality assessment 
(Braithwait
e et al., 
2014) 
Kenya Kenya population Population level Cognitive behavioural 
therapy-based intervention  
CEA System 
dynamics: 
20 years 
Individual and 
others 
(population-
level HIV 
transmission) 
Healthcare 
sector  
An impact of hypothetical interventions 
directed at unhealthy alcohol use on HIV 
infections and deaths was investigated. 
Input parameters were based on 
assumptions on intervention and evidence 
synthesis. The model calibration and 
validation were analysed. One-way 
sensitivity analysis was performed by 
varied effectiveness and ART 
nonadherence and STI prevalence.  
(Brodtkorb 
et al., 
2016) 
The UK Alcohol-dependent 
patients 
Individual level Nalmefene plus psychosocial 
support compared with 
psychosocial intervention 
alone 
CUA Markov: 5 
years  
Individual 
(crime, 
unemploye, 
and absent 
work) 
Societal  A Markov model (five drinking states, five 
related conditions, and death) was 
constructed. Health-related and societal 
costs were drawn from public data and 
the literature. The individual risk event 
was employed from SAPM. One-way 
sensitivity and probabilistic sensitivity 
analyses (PSA) were performed. Quality-
control procedure was confirmed by 
verifying of all input data.   
(Byrnes et 
al., 2010) 
Australia Australian 
population 
Population level Volumetric taxation CUA Aggregate 
model 
/Multistate 
life table 
model: 
Lifetime  
Individual Healthcare 
sector  
To model the potential benefits of 
volumetric taxation to alcohol 
consumption, data on cost and 
intervention effect were derived from the 
literature. The main health outcomes 
were DALYs. PSA was performed.    
(Chisholm 
et al., 
2004) 
12 
epidemiolo
gical WHO 
sub- 
regions of 
the world 
12 WHO sub-
regions population 
Population level Brief physician advice, 
taxation, roadside random 
breath testing, restricted 
sales access, and advertising 
bans 
CUA Aggregate 
model 
/State 
transition 
cohort 
population 
model: 
Lifetime  
Individual Healthcare 
sector  
A population model was used to estimate 
the impact of four interventions aimed at 
reducing hazardous alcohol use. 
Population-level intervention effects were 
gauged in terms of DALYs. Model 
parameters were from the literature. Best 
and worst cases and PSA were performed.   
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Table 2-3 Characteristic of 26 eligible economic modelling studies (cont.) 
Author, 
year 
Country Study participants Implementation 
levels 
Intervention Study 
type 
Modelling 
approach: 
time horizon 
level of 
consequence  
Perspective Summary of quality assessment 
(Cobiac et 
al., 2009) 
Australia Australian 
population 
Population level volumetric taxation, 
advertising bans, an increase 
in minimum legal drinking 
age, licensing controls on 
operating hours, brief 
intervention (with and 
without general practitioner 
telemarketing and support), 
drink driving campaigns, 
random breath testing and 
residential treatment for 
alcohol dependence (with and 
without naltrexone) 
CUA Aggregate 
model 
/Multi-
state, 
multiple 
cohort life 
table 
model: 
Lifetime 
Individual Healthcare 
sector  
Selected 8 interventions for reducing 
alcohol-attributable harm were compared 
and determined the optimal intervention 
mix. Health outcome was DALYs and 
adjusted under-reported alcohol 
consumption. Model parameters were 
from the literature. Sensitivity of key 
assumptions was investigated i.e. 
sustainability of intervention health effect 
over time.      
(Ditsuwan 
et al., 
2013) 
Thailand Thai population Population level Random breath testing, 
selective breath testing, and 
mass media campaigns, both 
current and intervention 
scenarios, were compared 
with a ‘‘do-nothing’’ 
scenario. 
CUA Decision 
tree: 
Lifetime 
Individual 
and other 
(i.e. road 
traffic 
injuries’ 
victims) 
Healthcare 
sector  
To determine the cost-effectiveness of 
interventions to reduce road traffic injuries 
caused by driving under the influence of 
alcohol in Thailand, the model considered 
road traffic crash victims who were 
injured, disabled or died. Intervention 
effectiveness was derived from published 
reviews and a study in one province of 
Thailand. PSA was performed.  
(Gentilello 
et al., 
2005) 
The US Trauma patients 
treated in hospital 
and emergency 
department aged 
18 and over 
Individual level Screening and brief alcohol 
intervention 
CBA Decision 
tree and 
Markov: 3 
years 
Individual Healthcare 
sector  
To determine if brief alcohol 
interventions in trauma centres reduce 
healthcare costs, the analysis was 
restricted to direct injury related medical 
costs only. Model parameters were 
retrieved from the literature and 
examined 1-way sensitivity and PSA.  
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Table 2-3 Characteristic of 26 eligible economic modelling studies (cont.) 
Author, 
year 
Country Study participants Implementation 
levels 
Intervention Study 
type 
Modelling 
approach: 
time horizon 
level of 
consequence  
Perspective Summary of quality assessment 
(Holm et 
al., 2014a) 
Denmark Adult Danish 
population  
Population level Three different scenarios of 
changed taxation of alcoholic 
beverages in Denmark (20% 
and 100% increase and 10% 
decrease) 
CUA Aggregate 
model/ 
Multi-state 
population 
life table: 
Lifetime 
Individual Healthcare 
sector  
Model structure was classified into 
healthy, diseases, and dead. The lifetime 
consequences were estimated as the 
difference in DALYs between current 
alcohol consumption and an identical 
population that changes their alcohol 
consumption due to changes in taxation. 
One-way sensitivity and PSA were 
performed. 
 (Holm et 
al., 2014b) 
Denmark Adult Danish 
population 
Individual and 
population levels 
30% increased taxation, 
increased minimum legal 
drinking age, advertisement 
bans, limited hours of retail 
sales, and brief and longer 
individual interventions 
CUA Decision 
tree: 
Lifetime 
Individual Healthcare 
sector  
Potential consequences were evaluated as 
changes in incidence, prevalence and 
mortality of alcohol-related diseases and 
injuries using a multiple cohort, multi-
state life table approach. Health outcome 
was measured in DALYs. One-way 
sensitivity testing model assumptions and 
PSA were performed.  
(Kapoor et 
al., 2009) 
The US Adult men and 
women (aged 18-
100 years) in 
primary care 
Individual level 4 strategies for detecting 
unhealthy alcohol use in adult 
primary care patients: 1) 
questionnaire; 2) % 
Carbohydrate deficient 
transferrin (CDT); 3) 
questionnaire followed by 
%CDT if the questionnaire is 
negative; and 4) no screening 
CUA Decision 
tree and 
Markov: 
Lifetime  
Individual Societal  Model structure combined a decision tree 
(compared screening options) and Markov 
(defined by consumption and the 
presence of an alcohol use disorders). 
Model parameters were obtained from the 
literature and Medicare reimbursement 
data. Model calibration was performed by 
comparing transition drinking state with 
the published information. QALYs were 
measured. One- and two-way sensitivity 
analyses were used to assess the 
uncertainty of individual parameter value.   
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Table 2-3 Characteristic of 26 eligible economic modelling studies (cont.) 
Author, 
year 
Country Study participants Implementation 
levels 
Intervention Study 
type 
Modelling 
approach: 
time horizon 
level of 
consequence  
Perspective Summary of quality assessment 
(Kessler et 
al., 2015) 
East 
Africa 
Persons living with 
HIV/AIDS as 4 
different strategies 
for targeting 
intervention—(i) all 
HIV-infected 
persons attending 
clinic; (ii) only 
patients in the pre-
antiretroviral 
therapy (ART) 
stages of care; (iii) 
only patients 
receiving ART; and 
(iv) only patients 
with detectable 
viral loads (VLs) 
regardless of 
disease stage. 
Population level 
(HIV infection) 
Screening for hazardous 
alcohol consumption using the 
AUDIT and offering the 
cognitive behavioural therapy 
(CBT)-based intervention to 
those who screened positive 
CUA System 
dynamics: 
20 years 
Individual and 
others 
(population-
level HIV 
transmission) 
Healthcare 
sector  
The model simulated the course of the 
HIV epidemic over varying time horizons 
and tracked benefits of potential 
interventions. Outcome measured 
included number of infections averted, 
AIDS-related deaths averted, and QALYs. 
Model parameters were derived from the 
literature. Model calibration was 
analysed. One- and two-way sensitivity 
analyses were used to assess the 
uncertainty of individual parameter value.   
(Lai et al., 
2007) 
Estonia General population 
and at-risk drinker 
Population level Excise tax on alcoholic 
beverages; reduced access to 
alcoholic beverage retail 
outlets; a comprehensive 
advertising ban (TV, radio and 
billboards) on alcoholic 
products; roadside breath-
testing for blood alcohol 
content in motor vehicle 
driver; and brief interventions 
involving counselling to at-risk 
drinkers by a primary care 
physician 
CUA Aggregate 
model/ WHO 
cost-
effectiveness 
modelling: 
Lifetime 
Individual Societal To evaluate the costs, health effects and 
cost-effectiveness of interventions to 
reduce smoking and hazardous alcohol use 
in Estonia based on locally available data. 
The study showed how to utilize existing 
WHO-CHOICE tools and adapt region level 
information down to the national level. 
DALYs was a health outcome. All 
interventions were compared to no 
intervention. Best and worse-case 
scenarios were used for uncertainty 
analysis.  
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Table 2-3 Characteristic of 26 eligible economic modelling studies (cont.) 
Author, 
year 
Country Study participants Implementation 
levels 
Intervention Study 
type 
Modelling 
approach: time 
horizon 
level of 
consequence  
Perspective Summary of quality assessment 
(Laramee 
et al., 
2014) 
England 
and Wales 
Alcohol-dependent 
patients with 
high/very high 
drinking risk levels   
Individual level Nalmefene combined with 
psychosocial support 
compared to psychosocial 
support alone 
CUA Markov: 5 
years  
Individual NHS To evaluate the public health benefit of 
reducing harmful alcohol-attributable 
diseases, injuries and death. Treatment 
effect was obtained from three clinical 
trials (1-year trial) of nalmefene. Baseline 
characteristics of the model cohort, 
resource utilisation, and utilities were 
also from those trials. Published 
epidemiological studies were used for 
modelling alcohol-related events 
occurring at different levels of alcohol 
drinking level. QALYs was measured. One-
way and PSA were performed.  
(Mortimer 
and Segal, 
2005) 
Australia Problem alcohol 
drinker and alcohol 
dependence 
Individual level 1) Brief interventions for 
problem drinking; 2) 
psychotherapy for mild to 
moderate dependence; and 3) 
drug-therapy adjuvant to 
counselling for detoxified 
patients with a history of 
severe physical dependence 
CEA Markov: 
Lifetime 
Individual Societal  The study used a time-dependent state-
transition model to compare 
complementary and competing 
interventions for prevention or treatment 
of alcohol misuse and dependence; 
compares usual care with interventions. 
QALY was estimated. Model parameters 
were from the literature. Univariate 
sensitivity analysis was performed by 
varied cost and effectiveness.  
 
(Navarro et 
al., 2014) 
Australia Risky drinkers who 
visit a community 
pharmacy annually 
in 10 rural 
communities  
Community level Current practice and nine 
possible scenarios with 
differences of 10%,20% and 
100% either in screening or in 
BI or combination of both 
CEA Decision 
tree: 1 year  
Individual Provider  A decision model was developed to assess 
costs and changes in outcomes from 
pharmacist-delivered screening and BI on 
alcohol consumption using 1-year data 
from a survey. Outcome measure was 
risky drinker reducing alcohol 
consumption. One-way sensitivity analysis 
was analysed by varied effectiveness of 
alternative interventions.  
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Table 2-3 Characteristic of 26 eligible economic modelling studies (cont.) 
Author, 
year 
Country Study participants Implementation 
levels 
Intervention Study 
type 
Modelling 
approach: 
time horizon 
level of 
consequence  
Perspective Summary of quality assessment 
(Navarro et 
al., 2011) 
Australia Risky drinkers in 10 
rural communities 
in New South 
Wales 
Individual level  Nine difference scenarios 
with incremental increase in 
screening, brief intervention, 
or a combination of screening 
and brief intervention was 
compared to the current 
practice. 
CEA Decision 
trees: 1 year 
Individual Healthcare 
sector  
A decision model was developed to assess 
costs and changes in outcomes from 
pharmacist-delivered screening and BI on 
alcohol consumption using 1-year data 
from a survey. Outcome measure was 
risky drinker reducing alcohol 
consumption. One-way sensitivity analysis 
was analysed by varied effectiveness of 
alternative interventions. 
(Neighbors 
et al., 
2010) 
The US Alcohol-involved 
youth (aged 18-19) 
in the emergency 
department (ED) 
Individual level 1) Assessment of alcohol 
status conducted by hospital 
staff during routine ED intake 
(standard screening); and 2) 
added procedures to 
proactively scan the ED for 
youth and solicit information 
about alcohol involvement 
(enhanced screening) 
CEA 
and 
CUA 
Decision 
trees: 
Lifetime 
Individual and 
others 
(accident 
fatality related 
to medical, 
legal, 
administrative, 
property 
damage) 
Provider 
and 
societal 
A decision modelling was conducted using 
data - which were derived from an RCT 
(6-month follow up period). QALYs and 
social costs related to accident fatalities 
were estimated. One-way and PSA were 
conducted.  
(Palmer et 
al., 2000) 
Germany Detoxified 
alcoholic patients 
Individual level 1) Standard counselling 
therapy, and 2) standard 
counselling therapy with 
adjuvant accamprosate 
CEA Markov: 
Lifetime 
Individual Healthcare 
sector  
The study used a Markov model to explore 
the long term clinical and economic 
outcomes of alcohol maintenance with 
counselling or counselling plus 
accamprosate. Data were obtained from 
the published literature. One-way 
sensitivity was used for test model 
assumptions. 
(Purshouse 
et al., 
2013) 
England Risky drinkers who 
are screened 
through GP’s visits 
Individual level Universal alcohol screening 
and brief intervention 
programmes in primary care 
CUA Aggregate 
model 
/Sheffield 
Alcohol 
Policy Model 
(SAPM): 30 
years 
Individual Healthcare 
sector  
To develop a health economic model 
combining the healthcare resource 
requirements for alcohol screening and 
brief intervention with an epidemiological 
model of relationships between alcohol 
consumption and health harms. Health 
outcome was measured (i.e. QALYs). 
Sensitivity analyses were conducted by 
varied implementation options. 
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Table 2-3 Characteristic of 26 eligible economic modelling studies (cont.) 
Author, 
year 
Country Study participants Implementation 
levels 
Intervention Study 
type 
Modelling 
approach: 
time horizon 
level of 
consequence  
Perspective Summary of quality assessment 
(Quanbeck 
et al., 
2010) 
The US Adult population 
with an alcohol 
problem 
Individual level Screening, brief intervention, 
and referral to treatment 
(SIBRT) 
CBA Monte Carlo 
simulation 
model/indivi
dual-based 
micro-
simulation: 
4 years 
Others Employer This study developed a cost-benefit model 
that includes the employer’s perspective 
by considering the costs of absenteeism 
and impaired presenteeism due to 
problem drinking. No uncertainty analysis 
was performed. 
(Smit et 
al., 2011) 
The 
Netherlands 
Alcohol use 
disorder  
Population level eHealth intervention: 1) 
'DrinkTest' is a brief online 
intervention consisting of 
screening one's alcohol use by 
automated personalized 
advice; 2) 'DrinkingLess' is an 
online four-step cognitive 
behavioral intervention; and 
3) an online therapist-led 
treatment for problem 
drinking, termed Online 
Treatment henceforth. 
CUA Alcohol 
model 
(ALCMOD): 
12 months 
Individual Healthcare 
sector  
To estimate the cost-effectiveness of 
competing healthcare systems in curbing 
alcohol use at the national level. This was 
illustrated for scenarios where new 
eHealth technologies for alcohol use 
disorders were introduced in the Dutch 
healthcare system. ALCMOD assessed 
short-term (12-month) DALYs and 
healthcare budget impact. Probabilistic 
model was presented using ALCMOD.  
(Tariq et 
al., 2009) 
The 
Netherlands 
Risky drinkers aged 
between 20 and 65 
who visit GP yearly 
(50%) 
Individual level Opportunistic screening and 
brief intervention for at-risk 
drinkers 
CUA Markov: 80 
years  
Individual Healthcare 
sector  
The study used the RIVM Chronic Disease 
Model (CDM) to conduct a CEA of 
screening and brief intervention for 
alcohol in primary care targeting at risk 
drinkers. Outcome measured was QALYs. 
PSA was performed. 
(Zur and 
Zaric, 
2016) 
Canada General population 
aged 17 years and 
over 
Individual level SBI (screening tools were 
AUDIT and AUDIT-C)  in the 
primary care setting 
compared to No SBI   
CUA Microsimulation 
(100,000,000 
individuals): 
Lifetime 
Individual NHS The study developed a microsimulation 
model to estimate the consequences of 
SBI in the primary care setting. Drinking 
states were classified as lifetime 
abstainer, former drinker, drinker, and 
death. Binge drinking was also incorporate 
when determining average alcohol 
consumption per year. Model calibration 
was performed to compare alcohol 
consumption to a survey.  
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2.5.3 Measurement and valuation of consequences 
The majority of the eligible studies modelled intermediate and longer-
term health consequences including alcohol consumption status, alcohol-
related diseases and death. These health outcomes were eventually converted 
into life years, QALYs, and DALYs (Angus et al., 2014b, Barbosa et al., 2015, 
Barbosa et al., 2010a, Byrnes et al., 2010, Chisholm et al., 2004, Cobiac et al., 
2009, Holm et al., 2014b, Holm et al., 2014a, Kapoor et al., 2009, Kessler et 
al., 2015, Lai et al., 2007, Laramee et al., 2014, Purshouse et al., 2013, Smit 
et al., 2011, Tariq et al., 2009, Zur and Zaric, 2016). Non-health consequences 
of individual drinkers were also included in two studies e.g. crime, unemployed, 
and income loss (Barbosa et al., 2015, Brodtkorb et al., 2016). In addition, 
alcohol-related consequences to others were measured in two studies in terms 
of social costs (e.g. accident fatalities related to medical, legal, administrative, 
and property damage), and health consequences of drink-driving’s victims 
(Ditsuwan et al., 2013, Neighbors et al., 2010). Almost all of the studies 
employed the healthcare sector perspective (n = 20), and only six studies used 
societal as the analytical perspective. The perspective used for analysis 
identifies the cost that are only considered as relevant to such perspective.      
2.5.4 Other economic evaluation components 
The economic models used in previous literature were constructed as 
‘drinking states’ to examine the average levels of consumption (e.g. 
absenteeism, low risk, moderate risk, and high risk consumptions) and alcohol-
related diseases classified by drinking levels (Barbosa et al., 2015, Barbosa et 
al., 2010b, Purshouse et al., 2013, Cobiac et al., 2009). The models can be used 
to estimate only the consequences based on average consumptions; however, 
there was only one study that considered episodic heavy drinking or binge 
drinking which was only considered a factor in death due to injury (Zur and 
Zaric, 2016).  
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Sensitivity analyses were mostly conducted to examine the uncertainty 
of cost-effectiveness results. PSA (see detailed Appendix 8) and one-way 
sensitivity analyses were typically used (Angus et al., 2014a, Barbosa et al., 
2015, Barbosa et al., 2010b, Braithwaite et al., 2014, Brodtkorb et al., 2016, 
Byrnes et al., 2010, Chisholm et al., 2004, Holm et al., 2014b, Holm et al., 
2014a, Laramee et al., 2014, Neighbors et al., 2010, Smit et al., 2011, Tariq et 
al., 2009). Best and worse-case scenarios were also conducted based on specific 
research questions such as varied implementation options (Cobiac et al., 2009, 
Kapoor et al., 2009, Kessler et al., 2015, Lai et al., 2007, Mortimer and Segal, 
2005, Navarro et al., 2011, Navarro et al., 2014, Palmer et al., 2000, Purshouse 
et al., 2013). In addition, model calibration for internal consistency was also 
conducted and compared to baseline country-specific alcohol consumption and 
alcohol-related epidemiology (Braithwaite et al., 2014, Kapoor et al., 2009, 
Kessler et al., 2015, Zur and Zaric, 2016). No external consistency was 
performed in the included studies.      
In addition, self-reporting alcohol consumption was often used for 
measuring behaviour change due to receiving alcohol intervention, whereas the 
assessment of self-reported alcohol consumption indicated deliberate under-
reporting. Nevertheless, there were limited cost-effectiveness studies that 
adjusted for under-reporting of alcohol consumption (Chisholm et al., 2004, 
Cobiac et al., 2009). The adjustment led to improvements in cost-effectiveness 
for some interventions: population-wide interventions (taxation, advertising 
bans and licensing controls on operating hours) improved most, and targeted 
interventions (brief intervention and residential treatment with naltrexone) 
improved slightly but interventions based on reductions in road traffic accidents 
rather than reported consumption (increasing the minimum legal drinking age, 
drink driving mass media and random breath testing) were not effective. 
Overall, the adjustment did not alter the order of interventions in the optimal 
intervention mix. 
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2.6 Discussion  
2.6.1 Evidence gap of modelling cost-effectiveness in alcohol 
interventions 
  There are various methodological challenges related to developing an 
economic evaluation of alcohol intervention using modelling approaches. To 
tackle a range of alcohol-related consequences and alcohol intervention 
effects, these challenges should be considered. Firstly, the evidence of 
effectiveness derived from RCTs was not appropriate for alcohol interventions 
such as pricing policy, drink-driving policy, and law enforcement (e.g. random 
breath testing of drivers). Thus, intervention effectiveness for previous 
modelling studies were obtained from published studies (i.e. the change in 
consumption, and the relationships of consumption level and alcohol-related 
harms occurring at different consumption levels); however, this may lead to 
the potential for bias and/or confounding in the underlying studies of 
effectiveness (Byrnes et al., 2010, Chisholm et al., 2004, Cobiac et al., 2009, 
Holm et al., 2014b, Holm et al., 2014a, Ditsuwan et al., 2013, Bye, 2007). Even 
though measured alcohol consumption at the individual level was assessed to 
be intervention’s effectiveness, the adjustment under-reporting consumption 
was just presented in a few studies (Chisholm et al., 2004, Cobiac et al., 2009). 
Moreover, the mathematical model that gathered multiple sources of evidence 
on a range of parameters to estimate the costs and outcomes, so this may 
possibly increase the degree of parameter uncertainty (Appendix 8).  
Secondly, the most common modelling approaches were decision tree 
and Markov model using the incidence-based approach and QALY (or DALY) 
framework. This was due to the objectivity of healthcare decision-making to 
compare across different alcohol policies and interventions with country-
specific thresholds (Brodtkorb et al., 2016, Byrnes et al., 2010, Cobiac et al., 
2009, Ditsuwan et al., 2013, Holm et al., 2014b, Holm et al., 2014a, Purshouse 
et al., 2013). Using these methods, there were three main issues related to 
modelling over time horizon which were broadly discussed: 1) the change of 
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drinking status over time, 2) the time lag between alcohol consumption changes 
and changes in its related harm; and 3) the morbidity and mortality incidence 
data over time. These issues required longitudinal data on individuals’ drinking 
patterns and their alcohol-related consequences - which was not readily 
available in many study settings.  
Thirdly, existing studies constructed health state transition model based 
on average drinking levels to describe the plausible consumption within the 
cohort e.g. abstainer, low-, moderate- and high- consumption levels; each level 
applied the risk of potentially relevant events. The relative risk of alcohol-
related consequences - which are commonly defined as alcohol-attributable 
conditions – were roughly classified based on a few average consumption levels 
based on availability of evidence (Grant et al., 2009, Jones and Bellis, 2014, 
Jones et al., 2008, Kendler et al., 2016, Rehm and Roerecke, 2013, Roerecke 
and Rehm, 2013). Nevertheless, there was a lack of modelling studies that 
considered heavy episodic drinking to be a drinking state that causes acute 
alcohol-related conditions, e.g. accidents and injuries. 
Finally, there were no included studies which addressed health equity in 
their evaluations. However, the effects on health inequalities were conducted 
from effectiveness studies using the Sheffield Alcohol Policy Model which 
stratified the impacts of taxation and price policies by lower income group and 
socioeconomic status (Meier et al., 2016, Holmes et al., 2014a). The reduction 
of health inequality has been an area of interest for public health policy 
research. Particularly, lower SES has been associated with higher mortality for 
alcohol-attributable causes – despite lower socioeconomic groups often 
reporting lower average levels of alcohol consumption defined as the Alcohol 
Harm Paradox (Smith and Foster, 2014). Thus, it is desirable if an economic 
evaluation of interventions introduced by public health researchers is able to 
assess the impact on inequalities.  
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Cookson and colleagues proposed four methods for considering inequality 
and equity within economic evaluations of public health interventions (Cookson 
et al., 2009): 1) identification of relevant equity considerations and a review 
of existing literature to provide qualitative discussion on equity issues; 2) 
quantitative analysis of key subgroup data from trials, where available, around 
the impact of the intervention upon health inequities; 3) estimating the 
opportunity cost of including equity considerations in terms of health foregone 
(i.e. the comparison of health foregone if adopting the equitable option with 
that of maximising health); and 4) valuing health inequality reduction by 
quantitatively weighting health outcomes according to equity considerations. 
However, there is currently no agreement over the most appropriate approach. 
However, there were also limitations of the reviews to find the evidence 
gaps. First, the review did not conduct an exhaustive search of the grey 
literature. The results relied on published, peer-reviewed studies reported in 
English-language journals. Second, screening titles and abstracts may have 
neglected some articles for which economic evaluation results would have been 
reported in the results section. Finally, publication bias would have likely 
occurred due to cost-effective interventions tend to be published. Further 
review to explore the knowledge gap of evaluation methods should 
comprehensively search grey literature such as theses, evaluation reports, and 
methodological reports.   
2.6.2 Rationale of developing current alcohol intervention 
model for cost-effectiveness analysis  
In this study, an alcohol intervention model will be developed to 
evaluate the costs, outcomes, and cost-effectiveness of alcohol interventions 
to inform healthcare policy-making. To produce a cost-effectiveness result that 
can be compared to the ceiling threshold, this current alcohol intervention 
model will apply the QALY framework (National Institute for Health and Care 
Excellence (NICE), 2012). Although alcohol consumption can cause wider effects 
in terms of both non-health consequences and harms to other, this current 
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study will not capture them. In response to the challenges of modelling 
heterogeneity cohort (e.g. differentiated by age and risk behaviours) and its 
consequences on health outcomes and relevant costs, individual-level input 
data and modelling techniques were required (Caro et al., 2010). These issues 
required longitudinal data on individuals’ drinking patterns and their alcohol-
related outcomes and costs - which is not readily available in many study 
settings. Thus, the model input parameters will be retrieved from a single 
longitudinal dataset (Scottish linkage dataset as described in Chapter 3) at the 
individual-level; data needed for developing all the component parts of the 
decision-analytic model (e.g. baseline risk classified by alcohol consumption in 
terms of the AUDIT score and binge drinking, morbidity and mortality incidence 
data over time, health related quality of life, and healthcare costs) to 
determine the impact of these factors on health outcomes, by age and risk 
profiles, were also retrieved from this dataset.  
The AUDIT score measured in the Scottish Health Surveys (SHeS) will be 
used for classifying drinking states in the analysis so the estimated plausible 
range of alcohol-related consequences can be classified based on many levels 
of drinking consumption. This is because the AUDIT has become the gold 
standard for screening for alcohol use disorders in the UK (National 
Collaborating Centre for Mental Health, 2011) and many other countries 
including Thailand (Dybek et al., 2006, Gache et al., 2005, Babor et al., 2001, 
Pradhan et al., 2012, Kawada et al., 2011, Li et al., 2011, Areesantichai et al., 
2010, Assanangkornchai et al., 2010). Moreover, the Thai public health and 
health promotion policy-makers are considering adopting the screening and 
treatment for alcohol use disorders, and they are monitoring the magnitude of 
alcohol use disorder among the Thai population using routine national health 
surveys (Aekplakorn et al., 2015). In addition, the AUDIT was frequently used 
as the outcome measure in existing alcohol intervention studies (McCambridge 
and Day, 2008, Kaner et al., 2013, Shiles et al., 2013). This is the first study 
which explores the association of the AUDIT score and alcohol morbidity and 
mortality. Moreover, according to the under-reporting bias of alcohol 
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consumption surveys (Babor et al., 2010a, Meier et al., 2013, Boniface and 
Shelton, 2013), this study will adjust under-reported alcohol consumption 
among survey participants using alcohol sales data and incorporate this into the 
cost-effectiveness analysis  (HM Revenue and Customs, 2012, Robinson et al., 
2013) as this was lacking in the previous economic modelling study.  
 In addition, other behaviours that often cluster or co-occur within 
individual drinkers will be allowed to influence potentially relevant 
consequences of study cohorts, i.e. smoking status (Aekplakorn et al., 2008, De 
Leon et al., 2007, Falk et al., 2006, Harrison et al., 2008, McKee et al., 2010), 
physical activity (Kendzor et al., 2008), and body mass index (Hart et al., 2010). 
Including these modifiable behaviours in alcohol model has not been applied in 
the previous alcohol modelling study due to a lack of comprehensive health 
behaviour at the individual-level. Finally, the current model will consider 
health inequality and equity issues by including the standard measurement of 
socioeconomic status (Scottish Index multiple deprivation: SIMD) in all analyses 
(Cookson et al., 2009, Office of the Chief Statistician, 2004). 
Furthermore, this study proposes to transfer the developed alcohol 
intervention model in Scottish setting to the Thai setting.  Alcohol consumption 
and related-harm in Thailand has also increased steadily in the past decade, 
although still lower than in most Western countries (Rehm et al., 2009, 
Whiteford et al., 2013). Similar to Scotland, alcohol drinking problems were 
found, especially with men living in the most deprived areas in Thailand; 
approximately half of young men reported binge drinking behaviour, leading to 
high rates of acute alcohol-related harms such as accidents and violence 
(Aekplakorn et al., 2008, Assanangkornchai et al., 2010, Beeston C et al., 2014, 
Rehm et al., 2009). In addition, Thailand has widely applied the translated and 
validated the AUDIT in both health care setting and national health surveys for 
many years (Aekplakorn et al., 2015, Assanangkornchai et al., 2010). Based on 
these contextual factors, the adaptation approach of the Scottish model was 
possible by comparing population alcohol-related problems and AUDIT scores 
between two settings.     
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Chapter 3: Conceptual framework and data 
sources 
3.1 Introduction  
 This chapter will describe the conceptual framework of this study via 
five main points. Firstly, a conceptual framework of the alcohol intervention 
evaluation will illustrate how to evaluate intervention effectiveness using 
intermediate outcomes to predict the final outcomes of interest, i.e. life years 
(LYs), quality-adjusted life years (QALYs), and lifetime healthcare costs. To 
demonstrate the predictive ability of selected surrogate indicators, this study 
developed an alcohol intervention model to show how these surrogate outcomes 
can accurately predict the final outcomes (to be explained in the following 
parts). Secondly, the study objectives and analytical framework are described 
to outline the data set and stages of approach used for developing the model. 
Thirdly, the model of alcohol-related harms used for estimating LYs, QALYs, 
and costs is shown in the form of a health state transition model, and details 
how the health states were identified. Fourthly, the key data source used for 
the input parameters of the developed alcohol intervention model are 
identified. Lastly, ethical issues related to the population sample recruited in 
this study are also raised. 
3.2 Conceptual framework of alcohol control 
programme evaluation  
Figure 3-1 presents a conceptual framework of the alcohol intervention 
model adapted from the Biomarkers Definitions Working Group 2001 
(Biomarkers Definitions Working Group, 2001, Buyse et al., 2010). The 
biomarker measurements (as compared to risk behaviour in this study) can help 
explain the empirical results of clinical trials by investigating the relationship 
between the effects of interventions on molecular and cellular pathways and 
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overall clinical responses. The biomarkers that represent highly-sensitive and 
specific indicators of disease pathways have been used as substitutes for the 
final outcomes in clinical trials when evidence indicates that they predict 
clinical risk or benefit. An alcohol intervention would have direct and indirect 
effects on a wide range of an individual drinker’s modifiable risk factors such 
as changing alcohol drinking patterns and other related risk behaviours (e.g. 
number of cigarettes per day). Consequently, the mathematical analyses 
revealed that the subset of those risk factors represented in the figure by a 
quadrant could achieve surrogate endpoint status in terms of accuracy 
(correlation of measure) and precision (reproducibility) - which is required to 
be reasonably likely to predict an endpoint such as alcohol-related 
hospitalisation and death. These outcomes can then be converted to LYs, 
QALYs, and long-term costs, and intervention cost-effectiveness can 
subsequently be estimated.  
The alcohol intervention model was structured using a health state 
transition model to characterise the plausible consequences (i.e. 
hospitalisation and death) of different drinking behaviours (as described in 
section 3.6). The model was developed using the key features of economic 
evaluation such as perspective, time horizon, and measured costs and outcomes 
(Briggs et al., 2006c, Drummond MF et al., 1997, Gray et al., 2011a). Afterward, 
LYs, QALYs and lifetime economic costs can be estimated and categorised by 
alcohol drinking patterns. The estimated health outcomes and costs of different 
levels of drinking risks are able to show the consequences of alcohol drinking. 
Then, cost-effectiveness can be compared between the new alcohol 
intervention -which changes the risk of alcohol drinking from the baseline to 
the existing intervention. These estimated outcomes are widely recommended 
for the purpose of conducting economic evaluations of health interventions to 
inform policy-making (ISPOR, 2014, NICE, 2013, Chaikledkaew and Kittrongsiri, 
2014, Teerawattananon and Chaikledkaew, 2008).  
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Figure 3-1 Conceptual framework of the alcohol intervention model which 
signifies the relationship between alcohol intervention and its measured 
effects on modifiable risk factors, surrogate endpoints, and endpoints  
*adapted from the (Biomarkers Definitions Working Group, 2001)  
3.3 Study objectives 
1. To investigate hospitalisations and deaths among alcohol drinking 
patterns classified by the Alcohol Use Disorder Identification Test or AUDIT 
(Babor et al., 2001) as well as to examine the relationship between alcohol-
related harms and other related risk factors e.g. socioeconomic status and 
smoking.  
2. To develop an alcohol intervention model for the estimation of LYs, 
QALYs, and lifetime costs of different alcohol drinking patterns inclusive of 
those other risk factors so the model can be used for further economic 
evaluation of alcohol policies and interventions to inform policy-makers. 
3. To develop a protocol of methodological transferability to other settings.  
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3.4 Analytical framework of this study 
An analytical framework of this study is illustrated in Figure 3-2. The first 
stage of analysis consisted of assessing how alcohol drinking status was 
measured in the Scottish Health Surveys cohorts (SHeS). A variation of alcohol 
drinking assessments among survey years was observed. CAGE questionnaires 
combined with weekly unit alcohol consumption were included to assess a 
potential problem drinking in the SHeS from 1995-2011. However, CAGE has 
been excluded from the alcohol consumption questionnaire since 2012 and 
replaced by the AUDIT. The AUDIT questionnaire was developed to define 
alcohol use disorder in terms of hazardous, harmful, and probable dependence 
based on the WHO ICD-10 definition(as described in Chapter 1) (World Health 
Organization, 1993). Nowadays, the AUDIT has been widely validated and 
recommended for alcohol use disorder screening and treatment in the primary 
healthcare setting in the UK (National Collaborating Centre for Mental Health, 
2011) and translated into many languages including a Thai version (Dybek et 
al., 2006, Gache et al., 2005, Babor et al., 2001, Pradhan et al., 2012, Kawada 
et al., 2011, Li et al., 2011, Areesantichai et al., 2010, Assanangkornchai et al., 
2010). . Moreover, the Thai public health and health promotion policy makers 
are considering to adopt the screening and treatment programmes for alcohol 
use disorders, and they are monitoring the magnitude of alcohol use disorder 
among Thai population using routine national health survey (Aekplakorn et al., 
2015). This can be seen that using AUDIT seems to be suitable for this current 
study which ultimately aims to inform these policy makers who are focussing 
on drinker with alcohol use disorder rather than alcohol consumption volume in 
general. 
Thus, the use of the AUDIT score for modelling can extrapolate the health 
impact caused by alcohol use disorders which are generally defined as the same 
WHO ICD-10 across countries (World Health Organization, 1993). The AUDIT 
score measured in the SHeS was used for classifying drinking states in the 
analysis so the estimated plausible range of alcohol-related consequences can 
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be classified based on many levels of drinking consumption. This would be an 
advantage to adapt the current model to other jurisdictions where the AUDIT 
is applied in both the healthcare setting as well as in general population survey 
for estimating alcohol use disorder prevalence (Aalto et al., 2009, Knibbe et 
al., 2006, Assanangkornchai et al., 2010). Ideally, the AUDIT would have been 
used for all SHeS survey waves; to work around this issue, the AUDIT scores of 
the SHeS from 1995-2011 were predicted using a statistical model developed 
from the SHeS 2012 data set. The development of the AUDIT score prediction 
model will be described in Chapter 4:.  
In the next stage, The data linkage element has contributed to estimate 
the input parameters needed for the health state transition model (Figure 3-3) 
as follows: 1) the cause-specific hazard function of alcohol-related harms as 
well as non-alcohol related harms as described in Chapter 6; 2) the utility 
decrement related to hospitalisations (see details in Chapter 5) for QALY 
estimation as described in Chapter 7; and 3) the modelling healthcare costs 
used to predict lifetime costs as described in Chapter 7.  Moreover, the linkage 
of survey and hospitalisations has allowed the modelling approach to identify 
SHeS cohorts with no prior alcohol-related hospitalisation and develop an 
incidence-base model. 
 
  
 
   
8
7
 
Method: Develop the predicted AUDIT score 
model using the SHeS 2012 data set 
Data: SHeS 2012: Alcohol consumption 
-AUDIT score measured 
Data: SHeS 1995, 1998, 2003, 2008-
2011: Alcohol consumption 
-AUDIT score not measured 
Data: SMR/NRS records 1981-2013 
-SMR 01 (IPD& day cases) 
-NRS (death) 
Method: Data-linked SHeS-NSS/NRS provided 
by the Information Services Division (ISD) 
Scotland  
 
Method:  Develop cause-specific hazard 
model, secondary event probability model, 
utility decrement estimation, and 
hospitalisation cost model  
Output: Predicted AUDIT scores for the SHeS 
1995, 1998, 2003, 2008-2011 data set 
Output: Individually consented SHeS 
respondent records linked to the SMR and 
mortality records and accessed through the 
national data security system or ‘Safe 
Haven’ 
 
Data: Linkage records 
- SHeS 1995, 1998, 2003, 2008-2011 
(including predicted AUDIT) and SHeS 
2012 
Linked to SMR/NRS 1981-2013 
-SMR01 (IPD& day cases) 
-NRS (death) 
 
Output: Input parameters of the alcohol 
intrevention model  
Output: Life years, QALYs, and lifetime 
healthcare costs of different alcohol 
drinking pattern inclusive of related risk 
profiles 
Method: Health state transition modelling 
Data: Input parameters 
-Hazard function of plausible events 
- Utility decrement related to 
hospitalisations 
- Annual health care cost 
Figure 3-2 Analytical framework of this study 
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3.5 Health state transition model structure 
 The overall purpose of a health state transition model structure is to 
characterise the plausible consequences in a way that is appropriate for the 
decision problems and boundaries of the model (Briggs et al., 2006c, Drummond 
MF et al., 2005, Gray et al., 2011a, Roberts et al., 2012, Siebert et al., 2012). 
The first step in the development of the analytical model for alcohol 
intervention is the selection of the type of model as mentioned in Chapter 1 
(Barton et al., 2004, Brennan et al., 2006). The choice about type of model and 
its structure complexity is always a trade-off between descriptive realism and 
tractability in terms of computational burden and data requirements (Briggs et 
al., 2016). The selected type of model and model structure was developed 
based on the three main reasons listed below.  
Firstly, the chosen structure focussing on health state transition was 
employed for estimates of expected costs and effects in the health sector, and 
health states were based on recent evidence of the relationship between 
alcohol consumption and the risk of alcohol-related conditions and death (Jones 
and Bellis, 2014, Jones et al., 2008, Grant et al., 2009). Moreover, other 
plausible health statuses such as non-alcohol related condition were included 
to capture all relevant following events which could possibly occur over the 
follow-up period.  
Secondly, non-health consequences (e.g. including crime and 
unemployment) and harm to others were not taken into account due to the 
limited study duration and accessibility of data. Hence, a cross-sectoral model 
was not considered, and this study could probably apply either a cohort model 
or an individual simulation model with no interaction (Barton et al., 2004, 
Brennan et al., 2006). When comparing both models, individual simulation 
models would be more time-consuming to develop and run so a multistate life 
table was used with a cohort Markov model to simulate multiple diseases 
including hospitalisations and death over lifetime. Moreover, the input 
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parameters of the cohort model were derived from analysing individual-level 
linked health data which could generate a wide range of subpopulation results 
differentiated by age, gender, and risk profiles as recorded in the linkage data.  
Finally, the other objective of the developed alcohol intervention model 
is to transfer it to Thai setting so the main components of this study were 
determined through consultation with Thai alcohol research experts (Appendix 
7). These experts agreed with the methodology including model structure, 
applying the AUDIT - which is commonly used for alcohol problem screening in 
the health-care setting as well as in the national health surveys, and possibility 
of using available health data in Thailand to adjust the Scottish model. 
According to the limited study period and data sources in Thailand, the 
completed transferability of this study to the Thai context would likely need a 
further study in Thailand.  
An incidence-based approach was applied for people who have never had 
alcohol related condition (from 1981 to 2013) to simulate the further health 
impact of alcohol drinker using survival analysis classified by individual risk 
factors e.g. age, sex, socioeconomic status and multiple alcohol-related factors 
(i.e. smoking, physical activity and BMI). Then, these factors were used for 
cause-specific hazard model of first competing events (hospitalisation and 
death). Time lag effect was dealt with time-to-first event analysis. However, 
alcohol consumption and other health behaviours can change over time, which 
the change of individual risk behaviours could not be captured in a cross-
sectional health survey. The analysis could not define whether people have 
drunk heavily for many years or have started recently. However, the former 
drinker with alcohol-related condition is unlikely because the analysis included 
in particular of people who have never had alcohol related condition. Thus, the 
key assumption of study cohort for individual risk behaviours (i.e. alcohol 
consumption and related behaviours) was that their behaviours were stable 
over time within same age group classified by gender. The individual risk 
profiles including these factors were defined based on survey participants’ 
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characteristics as varied by age and gender. The generated risk profiles 
modelled the consequences over lifetime. For a death event that was not the 
first event, selected modifiable risk factors were not included in the survival 
analysis, and age at first hospitalisation, sex, SIMD, and chronic conditions (at 
baseline) were used for modelling risk of death after the first hospitalisation as 
presented in equation 2 (Figure 3-3). 
The disease states included in the alcohol model were derived from 
existing meta-analyses of data describing the relationship between alcohol 
consumption and the risk of alcohol related conditions as classified to be 
wholly- and partly-alcohol attributable conditions as identified by the alcohol-
attributable fraction (AAF) (Jones and Bellis, 2014, Jones et al., 2008, Grant et 
al., 2009). For wholly alcohol-attributable morbidity and mortality, i.e. no 
cases would exist in the absence of alcohol consumption, AAF was assigned a 
value of 1, whereas partly alcohol-attributable conditions, i.e. a proportion of 
cases that could be avoided in the absence of alcohol, was given a score 
between 0 and 1. Using SHeS-SMR/NRS linkage dataset at individual-level, the 
selected covariates related to individual SHeS cohort were derived from eight 
survey years; they included the age at survey date, gender, SIMD, alcohol 
consumption including the AUDIT score and binge drinking, smoking status (i.e. 
the number of cigarettes per day), self-reported health condition (i.e. having 
CVD and diabetes), physical activity, and BMI. These covariates were included 
in the risk functions of competing first events after survey date defined by SMR 
records for hospitalisation and NRS records for death (as shown in equation 1 
Figure 3-3). In addition, following hospitalisations and death after first 
hospitalisations were modelled using covariates i.e. age at first hospitalisation, 
CVD condition (Y/N), diabetes (Y/N), and SIMD quintile (as shown in equation 2 
Figure 3-3).  
The study cohort consisted of general population survey participants who 
had never experienced an alcohol-related hospitalisation prior to the survey 
date. Then, the risk of competing first events after the interview date of those 
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participants was simulated and classified by the SHeS baseline risk profiles as 
mentioned above (as shown in equation 1 Figure 3-3). Moreover, other non-
alcohol related hospitalisations and deaths were taken into account to be 
competing first events after the survey date, and these events were states 
categorised into four categories by emergency/non-emergency admission - 
where the relevant cost and health outcome would be different - and 
cardiovascular diseases (CVD)/non-CVD as defined by ICD-9 and ICD-10 codes 
(Appendix 1). These combinations were set up to focus on the association 
between alcohol consumption and CVD (excluded CVD categorised as a partly 
alcohol-attributable condition). CVD was included due to the controversy of 
risks and benefits of alcohol consumption on CVD (Rehm et al., 2010a, Holmes 
et al., 2014b). 
 
Figure 3-3 Structure of the health state transition model 
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Figure 3-3 presents the modelled health state of alcohol-related 
hospitalisation and death of participants with no prior alcohol-related 
hospitalisation at the SHeS survey date (total cohort size of 46,230 comprising 
20,729 males and 25,501 females). There were eight competing first events for 
the primary diagnosis after the survey date classified by ICD-9 and ICD-10: 1) 
wholly alcohol-attributable hospitalisation (21 conditions); 2) partly alcohol-
attributable hospitalisation (26 conditions); 3) alcohol-related death defined as 
an alcohol-related hospitalised patient who died within 28 days; 4) non-alcohol 
related death defined as a non-alcohol related hospitalised patient who died 
within 28 days; 5) non-emergency (EM) admission and non-cardiovascular 
disease (CVD); 6) non-EM admission with CVD; 7) EM admission and non-CVD; 
and 8) EM admission with CVD (Jones and Bellis, 2014, Jones et al., 2008, Grant 
et al., 2009). Although the health state transition model (Figure 3-3) showed 
only first hospitalisation and death, the subsequent hospital admissions were 
part of the model, and the risk of having subsequent admissions were 
contributed to estimate QALY (reduction of HRQoL or dis-utilities) and total 
hospitalisation costs. The follow-up time for each participant was defined as 
the time from the interview date until either the date when the competing 
event occurred or until 31st December 2013 (censoring date).    
After first hospitalisations, the risk of following hospitalisations and all-
cause death were modelled and classified by age at first hospitalisation, CVD 
condition (Y/N), diabetes (Y/N), and SIMD quintile as shown in equation 2 
(Figure 3-3). The after first hospitalisation event analysis considered following 
admissions and death after patients experienced the first hospitalisation, and 
this was divided into two groups: 1) hospitalised patients who had first alcohol-
related hospitalisation after the survey date (either wholly or partly alcohol-
attributable hospitalisation); and 2) hospitalised patients who had first non-
alcohol related hospitalisation after the survey date. Thus, the follow-up time 
for each hospitalised patient was defined as the date of first hospitalisation 
until either the date of death or until 31st December 2013 (censoring date). 
Accordingly, it was found that there were differences in alcohol drinking 
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patterns and risks related to alcohol consumption between males and females 
(Schulte et al., 2009, Probst et al., 2015b, Richman et al., 1995). As such, males 
and females were modelled separately for all analyses. 
3.6 Data identification 
3.6.1 Scottish Health Survey (SHeS) 
This study used the Scottish Health Survey (SHeS), which is a cross-
sectional clustered, stratified multi-stage sample design. The SHeS aims to 
estimate the prevalence of health conditions and health-related behaviours and 
to monitor trends in the population's health over time (Dong and Erens, 1997, 
Shaw et al., 2000, Bromley et al., 2005, Bromley et al., 2009, Bromley et al., 
2010, Bromley and Given, 2011, Bromley et al., 2012, Rutherford et al., 2013b). 
Thus, the surveys were carried out in 1995, 1998, 2003, and annually from 2008 
onwards. The survey respondents are a representative sample of the Scottish 
population living in private households in Scotland. The age range for the 1995 
wave was adults aged 16 to 64 years old. In the 1998 wave, the age range was 
extended to people aged between 2 and 74 years old. From 2003 onwards, the 
age range included children aged 0 to 15 and adults aged 16 years old and over 
as well. All analyses of this study particularly included adults aged 16 years and 
over since their alcohol consumption were measured, i.e. weekly unit alcohol 
consumption (units/week), unit consumed on the heaviest day, and the AUDIT 
(2012 only).  
Topics included in the survey are core questions (i.e. dental health, 
general health, and mental well-being) and measurements, i.e. BMI (derived 
from weight and height), blood pressure, waist circumference, urine and saliva 
samples, as well as modules of self-reported specific health conditions and 
related risk factors, e.g. alcohol consumption, smoking, diet, physical activity, 
and obesity. In particular, since the SHeS from 2012 onwards measured 
participants’ AUDIT scores, predicting AUDIT score models for the SHeS 1995-
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2011 was done using other potential covariates, i.e. age, marital status, 
parental status, weekly unit alcohol consumption (units/week), unit consumed 
on the heaviest day (units/day), smoking status, general health condition (GHQ 
score), long-term condition (having cardiovascular condition), equivalised 
income, Scottish Index of multiple Deprivation or SIMD quintile (Office of the 
Chief Statistician, 2004), NSSEC of household reference person (five groups 
professional), NSSEC of parental (five groups professional and selected highest 
level compared between parents), economic activity, and highest educational 
qualification; these covariates were analysed sub-grouped by gender. The 
predicted AUDIT score will be described in Chapter 4. 
Additionally, this study also investigated alcohol-related harms caused 
by binge drinking, i.e. heavy episodic drinking. However, since there is no 
standard definition of binge drinking in the UK, the SHeS uses the Health Survey 
for England and the General Lifestyle Survey’s definition (Lifestyle Statistics of 
Health and Social Care Information Centre, 2014, Office for National Statistics, 
2013) to enable comparisons between the SHeS and other major surveys of 
alcohol consumption in Britain. Both these surveys define binge drinking as 
consuming more than six units in one occasion for women and more than eight 
units for men (Rutherford et al., 2013a). In the UK, one unit is equivalent to 
one shot of a spirit, a glass of wine, or half a pint of beer. SHeS participants 
who are current drinkers were also interviewed to determine the number of 
units consumed on the heaviest day in the past seven days; this would be used 
to classify whether the drinker would qualify as a binge drinker.  
3.6.2 Scottish Morbidity Records and National Records Scotland 
(SMR/NRS) 
The SMR data set is currently held by the Information Services Division 
(ISD) of the National Health Services Scotland (Information Services Division, 
Fleming et al., 2012). The SMR hospital records include: SMR00 Outpatient 
Attendance; SMR01 General/Acute Inpatient & Day Case; SMR02 Maternity 
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Inpatient & Day Case; SMR04 Mental Health Inpatient & Day Case; and SMR06 
Cancer Registration. The SMR also holds data on mortality in Scotland from the 
NRS. SMR data includes patients’ personal information, demographic details, 
and information on health conditions. The diagnoses of patients’ health 
condition are identified by the ICD-9 (prior to 1996) and ICD-10 (1996 onwards). 
The data held in the SMR system links each patient’s various records together 
via the Scottish Record Linkage System; this system is in place to ensure the 
record linkage is done accurately. Due to errors in recording, exact matchings 
between records can miss up to 15% of exact matches. Therefore, the linkage 
system uses probability matching by calculating the likelihood that a pair of 
records matches by comparing first initial, surname, sex, year, month and date 
of birth, and postcodes. 
To ensure that the SMR data set are accurate, consistent, and 
comparable across time and between sources, the ISD monitors accuracy levels 
by undertaking routine quality assurance assessments, and the minimum target 
for accuracy is 90%. The Data Quality Assurance assessment of SMR01 inpatients 
and day cases were conducted in 2007 and 2012. The 2007 assessment examined 
records during 2004-2006; the report revealed that the accuracy of coding the 
main diagnosis was 88% in both inpatient and day case SMR01 episodes; and the 
accuracy rate for coding of the main operation was 92% for inpatient episodes 
and 95% for day cases (Information Services Division (ISD) and NHS National 
Services Scotland, 2007). The following assessment in 2012 investigated SMR 
records during 2010-2011; the overall accuracy rate of coding the main 
condition across Scotland remained the same at 88% and increased by 1% for 
main operation coding. For alcohol condition coding, the assessment of SMR01 
reported that the accuracy rate was 95.9% in 2007 and 92.9% in 2012 
(Information Services Division (ISD) and NHS National Services Scotland, 2012). 
3.6.3 SHeS -SMR/NRS linkage data set 
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During face-to-face interviews, SHeS respondents were asked to give 
consent for their name, address, and date of birth to be sent to the ISD of NHS 
Scotland. This allowed for their Health Survey responses to be linked with the 
SMR data, i.e. medical diagnoses, in-patient and out-patient hospital visits, 
cancer registration, GP registration, and death records obtained from the NRS. 
Where consent is not given, the linkage does not take place. Then, the 
electronic Data Research and Innovation Service (eDRIS) links the consented 
SHeS participant data set to the SMR/NRS records via personal identifiers using 
established probability matching techniques (Information Services Division). 
This study used the SHeS-SMR/NRS linkage data for the 1995, 1998, 2003, 2008-
2012 SHeS data sets, particularly SMR01 - which is the national data schemes 
that records comprehensive information including inpatient/day case activity, 
procedures and diagnoses, day surgery and outpatient procedures, multiple and 
all emergency admissions, and unintentional injuries admitted to National 
Health Service (NHS) hospitals in Scotland - and mortality, and follow-up from 
1981 to the end of 2013 as shown in Figure 3-4. The selected covariates related 
to the baseline characteristics of the study cohort were derived from eight 
survey years of the SHeS; they included the age at survey date, gender, SIMD, 
alcohol consumption including the AUDIT score and binge drinking, smoking 
status (i.e. the number of cigarettes per day), self-reported health condition 
(i.e. having CVD and diabetes), physical activity, and BMI. In addition, prior 
non-alcohol related hospitalisation was examined to be a SHeS cohort baseline 
characteristic so the SMR records before the interview date of SHeS respondents 
who consented were used to define prior non-alcohol related hospitalisation. 
Finally, the SMR records were also used for identifying hospitalisation after the 
interview date, and NRS mortality records were defined as death of consenting 
SHeS participants.  
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Figure 3-4 Scottish Health Survey (SHeS)/Scottish Morbidity Records (SMR) 
linkage data set 
3.6.4 Dealing with missing data of SHeS -SMR/NRS linkage data 
A comparison of survey estimates of population-level alcohol 
consumption with per-capita figures derived from data on national alcohol sales 
reveals a coverage gap of 30%-45% in Scotland (Hinchliffe, 2013, HM Revenue 
and Customs, 2012, Robinson et al., 2013). The under-reporting alcohol 
consumption in population surveys could be explained via drinking by people 
outside the sampling frame and non-responders to the survey, in particular, 
individuals with more problematic alcohol consumption patterns are typically 
underrepresented in health survey (Makela and Huhtanen, 2010, Kelfve and 
Ahacic, 2015, Meier et al., 2013, Gorman et al., 2014, Maclennan et al., 2012, 
Meiklejohn et al., 2012). For the SHeS, a lower response rate of individuals was 
found in males compared to females (Gray et al., 2013). The SHeS-SMR/NRS 
linkage data for the 1995, 1998, 2003, 2008-2010 reported lower rates of 
alcohol-related harm and all-cause mortality compared with population 
counterparts in a series of health surveys in Scotland, and greater non-response 
bias was associated with increased deprivation (Gorman et al., 2014). This study 
considered the nature of missingness (i.e. whether the data are missing or not) 
with reference to the classification of missing data mechanisms, i.e. data can 
be missing at random (MAR) or missing not at random (MNAR) (Rubin, 1987, 
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Gorman et al., 2017). MAR is the case where the probability of missingness is 
unrelated to the unobserved data taking the observed data into account. 
Alternatively, if the missingness depends upon unobserved data (even after all 
the information in the observed data are taken into account), the observations 
are MNAR. Note that data which are MNAR can become MAR if additional 
variables are observed and used in the analysis.  
To apply this method to this study - which investigates alcohol-related 
hospitalisations and deaths among SHeS-SMR/NRS linkage data - Missing data 
are definitely not missing completely at random (MCAR) because the 
missingness was associated with measured variables. MNAR is still a possibility, 
but it was not considered due to the limitation of additional external 
information. Then, in this study MAR was assumed to impute missing data. 
Following Gray et.al., an imputation techniques, namely multiple 
imputation (MI), is considered to be superior as it makes reliable estimation of 
variances and CIs relatively easy (Gray et al., 2013, Rubin, 1987). MI with 
chained equation is a scientifically robust way of dealing with missing data if 
MAR or MCAR holds (Clark and Altman, 2003). MI approach using chained 
equations was employed to fill missing data (Little and Rubin, 2002, Royston 
and White, 2011). The information in the observed values of hospitalisation and 
death records of the SHeS-SMR/NRS linkage data were used to predict the 
missing values i.e. age at survey date, alcohol drinking status at survey date 
with adjusted under-reporting alcohol consumption - the AUDIT score (0-40) 
and binge drinking (Y/N), number of cigarettes per day, CVD condition (Y/N), 
diabetes (Y/N), general health condition (3 groups of GHQ score), physical 
activity (no activity/low activity/medium activity/high activity), BMI 
(underweight/normal or BMI < 25, overweight or BMI 25 ≤ BMI < 30, obesity or 
BMI ≥ 30), prior non-alcohol related hospitalisation, and SIMD quintile (Office of 
the Chief Statistician, 2004). Once all missing values were multiply-imputed, 
the datasets were then analysed using standard techniques for complete data 
and combined using standard rules. 
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3.7 Ethical Issues 
As this study uses secondary data, those who initiated the SHeS 
previously dealt with the ethical aspects of the survey (Dong and Erens, 1997, 
Shaw et al., 2000, Bromley et al., 2005, Bromley et al., 2009, Bromley et al., 
2010, Bromley and Given, 2011, Bromley et al., 2012, Rutherford et al., 2013b).  
The study protocol was circulated to a Multi-Centre Research Ethics Committee 
in Scotland who approved the ethical aspects of the survey. During the survey 
period, all respondents were informed about scope of the SHeS (i.e. the study 
objectives, the use of survey data, and confidentiality) and then signed 
informed consent forms before the interview was undertaken.  
Moreover, SHeS participants were asked to sign another consent form 
indicating whether they wished to consent for linking their SMR records with 
the interview data. The form explained that the research would be more useful 
as an eligible researcher would be able to determine how people’s lifestyles 
and circumstances can have an impact on future health and use of hospital 
services; it also stated that the information would be confidential and used for 
research purposes only. Therefore, by signing the form, participants were only 
giving permission for the linking of this information to routine administrative 
data and nothing else.  
In terms of information governance, this study protocol was approved by 
the NHS National Services Scotland Privacy Advisory Committee for accessing 
the NSS-NRS data set through the national data security system or Safe Haven 
provided by eDRIS (Information Services Division). The researchers who were 
granted access to this individual patient data have undergone appropriate 
training which is necessary to gain the ‘approved researcher’ status (Appendix 3).  
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Chapter 4: Predicting Alcohol Use Disorder 
Identification Test (AUDIT) score using Scottish 
Health Surveys  
4.1 Introduction  
This study investigates alcohol-related hospitalisations and deaths 
among alcohol drinkers in the Scottish Health Surveys (SHeS) participants, 
particular those with alcohol use disorders including harmful use, hazardous 
use, and probable alcohol dependence. To assess alcohol use disorder, the 
Alcohol Use Disorder Identification Test (AUDIT) is widely considered to be the 
screening tool used for detecting problematic alcohol use. It was developed to 
identify alcohol problem drinkers in terms of alcohol use disorders by the WHO’s 
ICD-10 definition (World Health Organization, 1993). The AUDIT has been 
translated into many languages and is recommended for use in the primary 
healthcare setting for alcohol use disorders screening and treatment in the UK 
(National Collaborating Centre for Mental Health, 2011) as well as many other 
countries (Dybek et al., 2006, Gache et al., 2005, Babor et al., 2001, Pradhan 
et al., 2012, Kawada et al., 2011, Li et al., 2011, Areesantichai et al., 2010, 
Assanangkornchai et al., 2010).  
Moreover, the use of the AUDIT in general population surveys was 
introduced to identify alcohol misuse in non-clinical samples which might be 
used in the policy context rather than the clinical context (Aalto et al., 2009, 
Dawson et al., 2005, Lundin et al., 2015, Rumpf et al., 2002). The SHeS 2012 
implemented the AUDIT for estimating the prevalence of alcohol use disorders 
among survey participants; nevertheless, it was not used in the 1995-2011 
waves of the SHeS (Dong and Erens, 1997, Shaw et al., 2000, Bromley et al., 
2005, Bromley et al., 2009, Bromley et al., 2010, Bromley and Given, 2011, 
Bromley et al., 2012). To conduct further analyses, predicting the AUDIT scores 
for 1995-2011 would require modelling based on the SHeS  2012 data set as the 
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AUDIT was first measured in that year (Rutherford et al., 2013b). This chapter 
describes the approach used for the development of the prediction AUDIT score 
model to generate the predicted AUDIT scores for the SHeS in 1995, 1998, 2003, 
and 2008-2011.  
4.2 Methods 
4.2.1 Data sources  
The SHeS from 1995, 1998, 2003, and 2008-2012 were analysed, using 
the SHeS 2012 to develop a fitted prediction model for predicting the AUDIT 
scores in all other waves (as described in Chapter 3 section 3.7.1). The SHeS 
2012 on alcohol consumption among adults consisted of weekly units of alcohol 
consumption, unit consumption on the heaviest drinking day within the last 
week, problem drinking using the AUDIT, and social context of drinking (where 
respondents usually are when they drink and who they usually drink with) 
(Catto, 2008). The study population were adults aged group 16 years old and 
over since the collected information needed for the prediction model 
development was available, e.g. weekly unit alcohol consumption, unit 
consumption on the heaviest drinking day, and other related risk factors. 
4.2.2 Modelling method 
Alternative approaches were employed as demonstrated in Table 4-2, 
and these approaches were evaluated based on their predictive ability. From 
the SHeS 2012 data set, the AUDIT score distribution is presented in Figure 4-1. 
The AUDIT scores ranged from 0 to 36 (mean 3.98), and the distribution showed 
positive skewness with a large number of zeros (non-drinker) at approximately 
26% of respondents and a very small number of high scores. These baseline 
figures can be used to guide the candidate models for predicting AUDIT scores.  
Firstly, an ordinary least squares (OLS) regression was considered as it is 
the most common model used for continuous outcome under the normal 
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distribution assumption. OLS has shown to be a very robust method, especially 
with large data sets (Lumley et al., 2002).  Although transformation is used to 
improve linearity and homogeneity of variance so that a standard linear model 
can be applied, the transformation has some drawbacks: 1) the response 
variable has changed, and has back-transformation problems; 2) the 
transformation must simultaneously improve the linearity and homogeneity of 
variance; and 3) the transformation does not overcome the protocol of point 
probability mass at the zero value.   
Moreover, an alternative to transformation is the use of the generalised 
linear model (GLM) framework, of which OLS is equivalent to the GLM Gaussian 
families with identity function (McCullagh and Nelder, 1989, Dobson and 
Barnett, 2008). Hence, the GLM approach was the second candidate model, and 
it represents a re-parameterisation of the model that retains the original scale 
(in this case, the AUDIT score) of the response variable, so it has minimal 
assumptions and eliminates the need to transform the data. Moreover, GLMs 
can accommodate skewness in the AUDIT score distribution. This study 
performed a comparison between the three GLM families, i.e. Gaussian, 
gamma, and negative binomial, and the log-link function was used for these 
families.    
Thirdly, to address the problem generated by zero-AUDIT score 
observations or non-drinkers (approximately 26% of respondents), two-part 
models were combined (Jones, 2000): 1) a binary logistic regression to predict 
the probability of being non-drinker (AUDIT score=0) and drinker (AUDIT score 
≥1), and 2) the following part of the model included only drinkers (AUDIT score 
≥1) using OLS regression and GLMs to estimate the predicted AUDIT score in 
score range of 1-40. Then, the overall predicted AUDIT score was derived from 
both part models as shown in Table 4-2. 
Finally, the AUDIT questionnaire required a respondent to complete the 
10 questions which were categorized into five levels of problems (score of 0, 1, 
2, 3, and 4) for question 1 to 8, and 3 levels of problems (score of 0, 2, and 4) 
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for questions 9 and 10 (as shown in Table 3-1). Thus, an ordinal logistic 
regression was performed as the fourth alternative approach where the analysis 
examined the probability of answering the score for each of the 10 questions. 
Then, the total predicted score would be calculated by the weighted score of 
all AUDIT items. All statistical analyses were performed using STATA program 
version 12 (StataCorp. 2011. Stata Statistical Software: Release 12. College 
Station, TX: StataCorp LP). 
 
Figure 4-1 Distribution of AUDIT scores from the Scottish Health Surveys in 
2012 (Skewness 2.14 Kurtosis 11.17) 
4.2.3 Potential explanatory variables for AUDIT score modelling 
 The selection of explanatory variables particularly considered the 
variables which were measured in the SHeS during 1995-2011. Based on 
literature review, 15 variables which were found to be associated with alcohol 
drinking were considered in model selection process. These comprised age,  
marital status, parental status, weekly unit alcohol consumption (unit/week), 
unit drunk on heaviest day within last week (unit/day), smoking status 
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(Aekplakorn et al., 2008, De Leon et al., 2007, Falk et al., 2006, Harrison et 
al., 2008, McKee et al., 2010), general health condition (GHQ score), long-term 
condition (having cardiovascular condition), equivalised income, SIMD 2012 
quintiles (Office of the Chief Statistician, 2004), NSSEC of household reference 
person (five groups professional), NSSEC of parental (five groups professional 
and selected highest level compared between parents), economic activity and 
highest educational qualification; these variables were analysed sub-grouped 
by gender. 
  
   
1
0
5
 
Table 4-1 Candidate models for predicting the AUDIT score using the SHeS 2012 data set 
 
*AUDIT: Alcohol Used Disorders Identification Test; OLS: ordinary least square; GLM: generalised linear model; RMSE: root mean square error 
Model Method Predicted AUDIT score (?̂?𝒊) calculation 
1 OLS regression 
?̂?𝑖 = ?̂? + ∑ ?̂?𝑗𝑋𝑖𝑗
𝑘
𝑗=1
  
2 GLM, Gaussian family, log-link function 𝐸(?̂?𝑖) = 𝜇?̂? 
𝑔(𝜇?̂?) =  ?̂? + ∑ ?̂?𝑗𝑋𝑖𝑗    
𝑘
𝑗=1
 
3 GLM, gamma family, log-link function 
4 GLM, negative binomial family, log-link function 
5 2-part model: standard logistic regression & OLS regression First part model: probability (π) of being drinker or AUDIT score ≥ 1 
  𝜋 =
exp{𝛼𝜋+ ∑ 𝛽𝑗
𝜋𝑋𝑖𝑗
𝑘
𝑗=1 }
1+exp{𝛼𝜋+ ∑ 𝛽𝑗
𝜋𝑋𝑖𝑗
𝑘
𝑗=1 }
 
Second part model: predicting AUDIT score ≥ 1, 𝐴𝑖
1+  
𝐴𝑖
1+ =  ?̂? + ∑ ?̂?𝑗
𝐴1+𝑋𝑖𝑗
𝑅
𝑟=1
 
 ?̂?𝑖 =  ?̂??̂?𝑖
1+ =  
exp{?̂?𝜋 + ∑ ?̂?𝑗
𝜋𝑋𝑖𝑗
𝑅
𝑟=1 }
1 + exp{?̂?𝜋 +  ∑ ?̂?𝑗
𝜋𝑋𝑖𝑗
𝑅
𝑟=1 }
∎ [?̂? + ∑ ?̂?𝑗
𝐴1+𝑋𝑖𝑗
𝑅
𝑟=1
] 
6 2-part model: standard logistic regression & GLM Gaussian family, log-
link function 
7 2-part model: standard logistic regression & GLM Gamma family, log-
link function 
8 2-part model: standard logistic regression & GLM, Negative binomial 
family, log-link function 
9 Ordered logistic regression for 10-item AUDIT questionnaire The AUDIT score of each 10-question (A) was divided into c categories, 
where P(A ≤ c), c = 1, 2,… , k.  
𝑃(𝐴𝑖 ≤ 𝑐) =  𝑝𝑖1  + ⋯ + 𝑝𝑖𝑐     
𝑃(𝐴𝑖 ≤ 𝑐) =  
exp{𝛼𝑖
𝑃𝑐 + ∑ 𝛽𝑗
𝑃𝑐𝑋𝑖𝑗
𝑘
𝑗=1 }
1 + exp{𝛼𝑖
𝑃𝑐 + ∑ 𝛽𝑗
𝑃𝑐𝑋𝑖𝑗
𝑘
𝑗=1 }
   
The predicted scores of each question were calculated using weighted 
score by predicted probabilities 
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4.2.4 Model selection and validation 
 All candidate prediction models of the AUDIT score were assessed based 
on their performance (predictive ability) for predicting AUDIT scores using split-
sample validation (Steyerberg et al., 2009). The sample was divided into two 
groups where the prediction model was developed from the first part of the 
data (training set) and then the predicted values of the second part (test data 
set) were derived from the developed model. This study systematically split the 
SHeS 2012 data set into two groups via the given archive serial number of the 
individual; a typical split is 2/3:1/3 for training and test samples, respectively 
(Steyerberg et al., 2009, Picard and Berk, 1990). Then, the predicted AUDIT 
scores were derived from the test data set of each alternative model. This study 
adopted a validation criterion for alternative models from the previous cost 
prediction study (Lipscomb et al., 1998) using a squared-error loss function 
(corresponding to the root mean square error, or RMSE):  
𝑅𝑀𝑆𝐸𝑗 = √
1
𝑛
∑(
𝑛
𝑖=1
𝐴𝑖 − ?̂?𝑖
𝑗
)2  
 where Ai is the observed AUDIT score and ?̂?𝑖
𝑗   is the predicted score for j=1, 
.., 9 of models under evaluation. The RMSE of the candidate models was 
calculated to compare their performance in predicting the AUDIT score as the 
better fit models minimise the RMSE. 
4.3 Results  
4.3.1 Comparing predicted AUDIT scores of the alternative 
models 
The results of the predicted value and predictive ability of each model 
are shown in Table 4-3. Compared to the observed values, the predicted AUDIT 
scores from almost all models showed out-of-range scores which were either a 
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negative value or greater than 40, range from 0.03% to 1.9% of predicted values. 
Thus, an additional analysis was conducted to adjust the predicted values so 
that they would be in range of the observed scores of 0 to 36; the given RMSEs 
of the adjusted value were also presented. From an unadjusted RMSE 
standpoint, the OLS regression model showed the best predictive ability for the 
AUDIT score (RMSE=2.74), although its predicted value showed a negative value 
(-0.045). Comparatively, the 2-part model of binary logistic regression 
combined with OLS regression also showed good predictive performance 
(RMSE=3.02), and there was no out-of-range predicted score, followed by the 
2-part model GLM Gaussian family log-link function (RMSE=3.27), ordered 
logistic regression (RMSE=3.34), and GLM Gaussian family log-link function 
(RMSE=3.81). On the contrary, the models which show the worst predictive 
ability were the log-link function of GLM gamma (RMSE=794) and negative 
binomial (RMSE=223) families as well as the 2-part model for those (RMSE=12.55 
for GLM gamma family and RMSE=10.18 for negative binomial family). 
Ultimately, after adjusting for out-of-range scores, the OLS regression model 
showed the best predictive performance (RMSE=2.73) even though the RMSE of 
all candidate predictions models was able to be minimised.      
4.3.2 Subgroup analysis by gender of the AUDIT score prediction 
model 
 Additionally, a subgroup analysis by gender was performed for predicting 
AUDIT scores using gender-specific explanatory variables for all nine candidate 
models. After that, the overall RMSEs of males and females were also computed 
to compare between the observed AUDIT score and the combined predicted 
values from the various models. Table 4-4 shows the results of the predicted 
AUDIT score of the 9 candidate models. Comparing the RMSEs between the two 
analyses (the subgroup and without the subgroup) found that the subgroup 
analysis was able to slightly improve the predictive performance of all 
candidate models. OLS regression also achieved the best predictive 
performance model for subgroup analysis by gender where the RMSE decreased 
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to 2.68 and there were no out-of-range scores in males. For other alternative 
models, the rank of their predictive performance was similar to the order of 
the previous analysis with decreasing RMSEs. Thus, the OLS regression subgroup 
by gender was selected to carry out the prediction of AUDIT scores for the SHeS 
in 1995, 1998, 2003, and 2008-2011 due to its accuracy. 
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Table 4-2 Predictive ability of prediction model in the test data set (1/3) 
Model 
AUDIT score 
RMSE 
% of prediction 
out of range 
RMSE of 
adjusted 
prediction Mean SE Min Max 
 
Observed value 3.938 0.110 0 36 
   
1 OLS regression 3.979 0.098 -0.045 37.65 2.74 0.3% 2.729 
2 GLM Gaussian, log-link 4.259 0.116 0.727 76.76 3.81 0.1% 3.140 
3 GLM Gamma, log-link 36.873 23.351 0.559 24293 794 1.9% 4.427 
4 GLM Negative binomial, log-link 13.753 6.575 0.686 6738 223 1.2% 4.028 
5 2-part OLS regression 3.683 0.073 0.307 27.17 3.02 NA NA 
6 2-part GLM Gaussian, log-link 3.950 0.070 0.425 37.84 3.27 0.03% 3.259 
7 2-part GLM Gamma, log-link 4.310 0.386 0.400 383 12.55 0.3% 3.312 
8 2-part GLM Negative binomial, log-link 4.189 0.315 0.407 310 10.18 0.3% 3.258 
9 Ordered logistic regression 3.950 0.125 0.338 40 3.34 0.3% 3.306 
OLS: ordinary least square; GLM: generalized linear model; RMSE: root mean square error; NA: not applicable 
 
 
 
  
   
1
1
0
 
   Table 4-3 Predictive ability of prediction model in the test data set (1/3), subgroup males and females 
Model 
 
AUDIT score 
 
 
Mean SD SE Min Max RMSE 
 
Males 4.89 4.64 0.19 0.00 36.00 
 
 
Females 3.25 3.70 0.13 0.00 33.00 
 
Model 1 Males 4.94 3.74 0.17 0.06 34.25 2.680 
OLS regression Females 3.23 2.66 0.11 -0.15 21.64 
 
Model 2 Males 5.24 4.15 0.19 1.26 56.53 3.366 
GLM Gaussian, log link Females 3.42 2.79 0.11 0.66 36.58 
 
Model 3 Males 21.71 261.89 11.92 0.76 5352.01 173.886 
GLM Gamma, log link Females 4.97 22.62 0.89 0.37 526.38 
 
Model 4 Males 12.23 109.45 4.98 0.94 2168.33 72.363 
GLM Negative binomial, log link Females 3.95 10.06 0.40 0.54 210.98 
 
Model 5 Males 4.54 2.57 0.12 0.38 19.87 2.995 
2-part OLS regression Females 2.96 2.09 0.08 0.26 19.64 
 
Model 6 Males 4.82 2.36 0.11 0.66 26.05 3.204 
2-part GLM Gaussian, log link Females 3.14 2.02 0.08 0.33 25.48 
 
Model 7 Males 5.06 8.46 0.38 0.65 165.37 5.660 
2-part GLM Gamma, log link Females 3.07 3.05 0.12 0.34 52.46 
 
Model 8 Males 4.98 7.29 0.33 0.65 140.48 4.998 
2-part GLM Negative binomial, log link Females 3.06 2.82 0.11 0.35 46.41 
 
Model 9 Males 4.85 4.63 0.21 0.47 38.87 3.304 
Ordered logistic regression Females 3.27 3.69 0.146 0.19 35.56 
 
OLS: ordinary least square; GLM: generalized linear model; RMSE: root mean square error
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4.4 Discussion  
This study explored the use of the AUDIT for detecting alcohol use 
disorder in general population surveys, i.e. SHeS from 1995-2012 for a total of 
eight surveys. The reason for this is because the AUDIT will also be employed 
in further analyses to investigate alcohol use-related morbidity and mortality 
of SHeS participants. This chapter describes the method used for developing 
the prediction of AUDIT scores since the AUDIT was not measured in the SHeS 
from 1995-2011 as it was only introduced in the SHeS 2012 onwards. The fitted 
prediction models of the AUDIT score were developed and evaluated using the 
SHeS 2012 data set. A comparison of alternative prediction models was 
demonstrated. Nine candidate models using a different standard linear 
framework, GLM framework and two-part models were compared for their 
predictive abilities. The main finding showed that the best predictive AUDIT 
model was the OLS regression model using subgroup analysis by gender.  
 The best-fitted model was able to generate the overall score, yet each 
AUDIT question could not be specifically predicted. This is an important concern 
because the main score comprises the total score from the 10 different 
questions with three main contents (i.e. hazardous use, harmful use and 
possible dependence). Having different scores for sub-questions compared to 
the observed values while still having the correct total score will definitely lead 
to inaccuracies and could result in improper analysis. Moreover, the OLS 
regression model might not be the perfect model to predict the AUDIT as shown 
by its RMSE of 2.68, meaning that the predicted AUDIT score could be over- or 
underestimated by approximately three units. Based on the cut-off for alcohol 
use disorder (Reinert and Allen, 2007), the three different scores might be 
clinically significant for moderate-risk drinkers as their predicted score might 
be erroneous because their drinking risk might be of a higher risk or lower risk. 
 Moreover, the observed AUDIT scores were derived from general 
population surveys, i.e. SHeS 2012. There are specific issues which were 
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addressed when using the AUDIT in the context of surveys, especially using 
overall scores for interpretation rather than each AUDIT item (Knibbe et al., 
2006). Firstly, the interpretation of responses to the AUDIT items is more 
controlled in a healthcare setting than general population surveys so using the 
AUDIT in population surveys might lead to the possibility of a false positive in 
the total score (Kypri et al., 2002). Secondly, compared with the population in 
a healthcare setting, the general population are likely to be much more 
heterogeneous in their drinking patterns and the related consequences due to 
alcohol consumption. Moreover, under-reporting bias of alcohol consumption 
has been frequently raised as an important issue in alcohol consumption surveys 
(Babor et al., 2010a, Meier et al., 2013, Boniface and Shelton, 2013).  
4.5 Conclusions 
This study focuses on alcohol use disorders identified by the AUDIT in 
general population surveys, so a model to predict AUDIT scores for the study 
population of the SHeS surveys from 1995, 1998, 2003, and 2008-2011 was 
generated to allow for further analyses. This analysis thoroughly developed 
statistical approaches to select the best predictive performance model of 
predicting AUDIT scores among all plausible candidate models. Although the 
selected AUDIT score prediction model (i.e. the OLS regression separated model 
by gender) could properly predict the scores, these scores for most of the SHeS 
study samples (7 of 8 surveys) is still an important assumption that will be used 
for estimating predicted life expectancy, quality-adjusted life year, and 
lifetime cost. The limitations of the interpretation of the relationship between 
the predicted AUDIT score and outcomes of interest should be noted, and this 
has been raised in this chapter.  
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Chapter 5: Estimation of the health-related 
quality of life among alcohol use 
5.1  Introduction 
Recently, researchers have shown an increased interest on economic 
evaluations of alcohol consumption control programmes to assess their 
effectiveness to inform policy makers (Anderson et al., 2009a, Watson et al., 
2013, Doran et al., 2010, Barbosa et al., 2010b, UKATT Research Team, 2005b). 
A generic health outcome of quality-adjusted life years (QALY) is recommended 
as an estimation measure of effectiveness among health interventions in health 
technology assessment guidelines in the UK and many other countries (ISPOR, 
2014, NICE, 2013). QALY captures two main aspects: the quantity (time the 
patient spent alive) and health-related quality of life (HRQoL) in term of utility 
(the component of QoL that health and health care can influence).  To quantify 
the health utility score, different domains related to HRQoL are combined and 
converted them into a single preference-based HRQoL score. In general, the 
utility score varies from 0 (death) to 1 (full health). It is also possible to have 
states regarded as worse than death, which are represented by a negative value 
(NICE, 2013, Thavorncharoensap, 2014).  
The commonly-used outcome measurements for alcohol consumption 
control programmes are alcohol consumption levels, episodic drinking, and 
assessment of alcohol drinking problems, e.g. the AUDIT (NICE, 2011, Watson 
et al., 2013, Babor et al., 2001). Moreover, HRQoL measured by utility score is 
becoming increasingly important in terms of an outcome measurement for cost-
utility analyses of alcohol interventions which aim to reduce alcohol-related 
harm and improve HRQoL of alcohol use disorders, especially in alcohol-
dependent patients (Donovan et al., 2005, Essex et al., 2014, Gunther et al., 
2008). The measured outcome can not only be used to compare the 
effectiveness between alcohol interventions, but can also apply the utility 
index as a single unit outcome measurement in the health policy context, so 
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that comparisons across health interventions for different target populations 
can be made for policy decision-making. As discussed in Chapter 4, differences 
were found in consequences associated with alcohol use between the 
population in the clinical setting and survey population, including the 
assumption about alcohol use disorder severity. It can be implied that HRQoL 
related to alcohol use disorder between the two groups would also be different 
as well as the outcome evaluation of the alcohol intervention provided in the 
clinical setting and population level. However, the current study focuses solely 
on the outcome measurement in the general population.     
Four previous studies used a cross-sectional design and examined the 
association between different alcohol consumption levels and HRQoL in the 
general population survey (Petrie et al., 2008, Saarni et al., 2008, Valencia-
Martin et al., 2013, Van Dijk et al., 2004). Preference-based HRQoL instruments 
as EQ-5D and Medical Outcomes Study Short Forms (i.e. SF-6D, SF-12 and SF-36) 
were used to calculate HRQoL as health utility index. The initial results of 
studies on the relationship between alcohol consumption patterns and HRQoL 
from multiple countries have been inconsistent. A major challenge in such 
research is the use of different methods of categorising alcohol consumption 
patterns (e.g. the AUDIT, Quantity-Frequency-Variability methods, Weekly 
drinking Recall, or binge drinking episodes), which creates difficulty in 
comparing study results, and possibly produces differing results regarding the 
potential positive effects of moderate alcohol consumption on HRQoL. The 
initial findings were that HRQoL was slightly worse than low- and moderate-risk 
drinkers after adjusting for confounders of abstainers (never drinkers) and 
former drinkers, and only high-risk drinkers reported the worst HRQoL. 
A cost-utility analysis of alcohol interventions will be carried out to 
determine the health benefits from reducing alcohol use or alcohol-related 
harms, e.g. QALY gained. Thus, this study aims to estimate the health 
consequences of different alcohol use classified by AUDIT measurements; this 
chapter will focus on HRQoL in terms of utility values. The main issue addressed 
in this chapter is the estimation of HRQoL among different AUDIT scores. The 
results will subsequently be used for QALY calculations in further analyses. 
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5.2 Methods 
5.2.1 Study sample 
The SF-12 from the SHeS 2003 was measured among respondents aged 18 
and over (Gray and Leyland, 2005). The SF-12 is a widely used self-reported 
generic measure of health status, yielding both physical component (PCS) and 
mental health component (MCS) summary scale scores (Ware et al., 2001). All 
eligible respondents were asked about eight concepts comprising aspects of 
their general health, physical functioning, limitations to normal activities due 
to physical health problems or emotional problems, bodily pain, vitality 
(energy/fatigue), social functioning, and mental health (psychological distress 
and psychological well-being) as shown in Appendix 4. 
5.2.2 Data analysis 
Utility estimation  
Although SF-12 measures HRQoL, it cannot be used for calculating QALY 
as it requires a preference-based single index measure of health. As such, 
Brazier and Roberts (2004) developed an estimation of a preference-based 
measure of health from SF-12. Firstly, the number of dimensions was reduced 
from 12 to 6 - namely SF-6D (SF-12) - by including physical functioning, social 
functioning, pain, mental health, and vitality, combining the limitations 
(physical and emotional) into a single dimension, and excluding the general 
health item. From then, seven of the SF-12 items were assigned to the six 
dimensions of SF-6D (SF-12) as shown in Appendix 5. Lastly, the estimation of 
preference-based values for each health state was calculated using coefficients 
of the developed model as shown in Table 5-1 (Brazier and Roberts, 2004).  
For example, the shortened SF-12 to SF-6D of a SHeS respondent is 
reported as follows: Physical functioning [PF2]=2 (a little limitation in moderate 
activities), Role limitations [RL4]=4 (limitations of physical health and having 
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emotional problems, ‘most severe’), Social functioning [SF3]=3 (limitation of 
social activities some of the time), Pain [PAIN2]=2 (a little bit of pain), Mental 
health [MH3]=3 (feeling downhearted and low some of the time), and Vitality 
[VIT4]=4 (having a lot of energy not very often). Then, the total SF-6D (SF-12) 
score is calculated using the equation below: 
SF-6D (SF-12) score = 1- 0[PF2] - 0.063[RL4] - 0.066[SF3] - 0[PAIN2] - 0.059[MH3] 
- 0.078[VIT4] - 0.077[MOST SEVERE]  
          =   0.657    
The overall SF-6D (SF-12) scores of SHeS participants were presented as 
the average score classified by age groups, gender, and SIMD to represent the 
baseline utility values of a normal population.   
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Table 5-1 SF-6D (SF-12) model for valuing health state index  
(Brazier and Roberts, 2004) 
Dimension Coefficient 
Constant (full health) 1.000 
Physical functioning 
 
3* -0.045 
Role limitations (physical and emotional 
health) 
2 -0.063 
3* -0.063 
4* -0.063 
Social functioning 
 
2 -0.063 
3 -0.066 
4* -0.081 
5* -0.093 
Pain 
 
3 -0.042 
4* -0.077 
5* -0.137 
Mental health 
 
2 -0.059 
3 -0.059 
4* -0.113 
5* -0.134 
Vitality 
 
2 -0.078 
3 -0.078 
4 -0.078 
5* -0.106 
Most severe* 
 
 
-0.077 
*When 1 or more dimension of health state is at the “most severe” level, an additional effect is taken into 
account with a value of -0.077.  
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Multivariate analysis 
A multiple linear regression was conducted to examine the relationship 
between alcohol use in terms of the AUDIT score and HRQoL; however, the 
AUDIT was not measured in the SHeS 2003. The prediction model developed in 
Chapter 4 was employed for predicting the AUDIT scores of the SHeS 2003 data 
set using 15 covariates, i.e. age, gender, marital status, parental status, weekly 
unit alcohol consumption (units/week), units consumed on the heaviest day 
(units/day), smoking status, general health condition (GHQ score), long-term 
condition (having cardiovascular condition), equivalised income, SIMD, NSSEC 
of household reference person (five groups professional), NSSEC of parental 
(five groups professional and selected highest level compared between 
parents), economic activity, and highest educational qualification. The 
predicted AUDIT scores at survey date range from 0-40, where 0 defines a 
current non-drinker – including those who are former drinkers and those who 
have never consumed alcohol.  
Moreover, other covariates which were measured in the SHeS and have 
been found to have an independent relationship with HRQoL were included in 
the multiple linear regression of the SF-6D (SF-12) index (Gray and Leyland, 
2005); these are age at survey date and SIMD (Office of the Chief Statistician, 
2004). To estimate the impact of alcohol-related and non-alcohol related 
hospitalisation on HRQoL in terms of utility decrement, prior hospitalisation 
was also included in the multivariate analysis compared to no prior 
hospitalisation (reference group) and was classified into four groups:  1) prior 
wholly alcohol-related hospitalisation; 2) prior partly alcohol-related 
hospitalisation; 3) prior CVD hospitalisation; and 4) prior non-CVD 
hospitalisation using the ICD-9 and ICD-10 of primary diagnosis (Appendix 1). 
Only the most recent hospitalisation was used to determine an individual 
participant’s group. Moreover, the period of each hospitalisation was also 
categorised to be either within the last year or more than one year ago. To 
define each hospitalisation before the interview date, the linkage data between 
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the SHeS 2003 and the NHS National Services Scotland (NSS) data sets was 
explored (see more details in Chapter 3:) using the ICD-9 and ICD-10 list to 
classify prior hospitalisation of SHeS participants (Jones and Bellis, 2014, Jones 
et al., 2008, Grant et al., 2009). The NHS-NSS data set used in the analysis 
included the Scottish Morbidity Record (SMR) 01 (inpatients and day cases). All 
statistical analyses were performed using STATA program version 12 (StataCorp. 
2011. Stata Statistical Software: Release 12. College Station, TX: StataCorp LP). 
A two-side test with a ρ-value of less than 0.05 was considered statistically 
significant.  
Dealing with missing data 
A multiple imputation approach using chained equations was undertaken 
to replace missing data (Little and Rubin, 2002, Royston and White, 2011). The 
information in the observed values of the covariates was used to predict the 
missing values. To apply this method to the study, missing at random (MAR) was 
assumed to impute missing data based on all predictors used in the multivariate 
analysis. Once 100 imputation data sets are created and analysed, the results 
are combined using standard rules (Rubin, 1987).  
5.3 Results 
SF-6D (SF-12) HRQoL scores of the SHeS 2003 respondents are shown in 
Table 5-2. These results revealed differences in HRQoL classified by gender due 
to age, alcohol drinking status (classified by the grouped AUDIT score), SIMD, 
and prior alcohol-related and non-alcohol related hospitalisations. The 
predicted AUDIT score ranges from 0-40 and are categorised into four groups as 
follows: 1) Low risk drinker: predicted AUDIT score=1-7 for males and 1-5 for 
females; 2) Hazardous drinker: predicted AUDIT score=8-15 for males and 6-12 
for females; 3) Harmful drinker: predicted AUDIT score=16-19 for males and 13-
16 for females; and 4) Probable dependence: predicted AUDIT score>=20 for 
males and >=17 for females (Reinert and Allen, 2007, Gache et al., 2005, Aalto 
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et al., 2009, Neumann et al., 2004, Dybek et al., 2006). The results showed 
that current non-drinkers, i.e. those who are former drinkers or have never 
consumed alcohol before, reported worse HRQoL scores than low-risk drinkers, 
while high-risk drinkers - who are categorised to be probable alcohol dependent 
patients in terms of the AUDIT - showed the worst HRQoL compared to other 
groups. 
  Figure 5-1 presents the observed mean and 95% CI of SF-6D (SF-12) score 
of HRQoL across each unit of predicted AUDIT score (0 to 15 and over). In both 
males and females, the higher AUDIT scores demonstrated a slight decrease of 
HRQoL with different magnitudes specific to the gender. To estimate the QALYs 
of different subgroups for further analyses which will use the alcohol 
intervention model that was developed in Chapter 3, the baseline HRQoL scores 
of the general population were also estimated and classified by gender, aged 
groups, and SIMD as shown in Table 5-3 for males and Table 5-4 for females. 
Compared to the baseline HRQoL scores, it is shown that a decreasing score is 
correlated with an increase in age and higher deprivation (shown as lower SIMD 
quintile) in both males and females.  
  Furthermore, the results obtained from the multiple linear regression 
using the multiple imputation approach of SF-6D (SF-12) HRQoL score classified 
by gender are presented in Table 5-5. For females, in all cases apart from 
wholly alcohol-related hospitalisation, HRQoL was more affected for those who 
were hospitalised within the last year compared to if they had undergone 
hospitalisation further back. For males, wholly alcohol-related hospitalisation 
impacted HRQoL more than partly alcohol-related hospitalisation but this was 
not seen for females. Moreover, prior alcohol-related hospitalisation had a 
similar impact on HRQoL as prior CVD hospitalisation, demonstrating the 
severity of impact of alcohol-related consequence. The AUDIT score had a 
stronger association with HRQoL for males than it did for females. For both 
males and females, the SIMD had a dose-response type of association with 
HRQoL where the more deprived SIMD correlated to a statistically significant 
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decrease in the SF-6D (SF-12) HRQoL score. The means of the R-square values 
derived from the imputations were 0.089 (min-max: 0.077-0.109) for males and 
0.125 (min-max: 0.107-0.153) for females.  
To investigate the impact of hospitalisation on current HRQoL, the scores 
were compared between those who had no hospitalisation before the survey 
date and those who had any alcohol-related and non-alcohol related 
hospitalisations within last year and over one year. For males, the reduction of 
HRQoL score due to hospitalisation ranged from 0.072 (SE=0.021, p=0.001) to 
0.123 (SE=0.046, p=0.008) for wholly alcohol-related condition, 0.027 
(SE=0.008, p=0.001) to 0.069 (SE=0.026, p=0.008) for partly alcohol-related 
condition, was 0.043 (SE=0.001, p<0.001) for non-alcohol related and non-CVD 
condition, and ranged from 0.078 (SE=0.009, p<0.001) to 0.134 (SE=0.022, 
p<0.001) for non-alcohol related with CVD condition.    
For females, the impact of prior hospitalisation on current HRQoL are 
presented as the decrement HRQoL score due to different conditions. There 
scores were 0.08 (SE=0.021, p<0.001) for wholly alcohol-related condition, 
range from 0.043 (SE=0.006, p<0.001) to 0.126 (SE=0.024, p<0.001) for partly 
alcohol-related condition, between 0.017 (SE=0.005, p<0.001) and 0.048 
(SE=0.007, p<0.001) for non-alcohol related and non-CVD condition, and a range 
from 0.097 (SE=0.01, p<0.001) to 0.109 (SE=0.026, p<0.001) for non-alcohol 
related with CVD condition. 
Chapter 5: Estimation of the health-related quality of life among alcohol use 122 
 
   
Table 5-2 SF-6D (SF-12) score of HRQoL of the SHeS 2003 participants aged 18 
years and over, classified by gender  
  SF-6D (SF-12) HRQoL score 
 Males  Females  
  N Mean SD 
 
N Mean SD 
Age at survey date (years) 
      
18-24 131 0.83 0.101 
 
193 0.815 0.111 
25-34 393 0.823 0.119 
 
529 0.811 0.115 
35-44 639 0.821 0.127 
 
781 0.806 0.126 
45-54 529 0.809 0.139 
 
703 0.787 0.134 
55-64 540 0.802 0.148 
 
651 0.79 0.142 
65-74 423 0.788 0.15 
 
450 0.776 0.15 
>=75 240 0.778 0.146 
 
357 0.728 0.165 
Alcohol drinking status* 
      
Never drinker 94 0.823 0.145 
 
268 0.752 0.163 
Former drinker 129 0.726 0.182 
 
184 0.705 0.163 
Low risk drinker 1413 0.823 0.126 
 
1332 0.811 0.121 
Hazardous drinker 322 0.803 0.123 
 
431 0.800 0.122 
Harmful drinker 18 0.749 0.162 
 
9 0.751 0.143 
Probable dependence 13 0.668 0.151 
 
9 0.743 0.148 
Prior wholly AR hospitalisation  
     
No prior hospitalisation  2847 0.809 0.136 
 
3626 0.79 0.137 
 last year 8 0.606 0.163 
 
1 0.922 - 
 over 1 year 40 0.712 0.166 
 
37 0.693 0.158 
Prior partly AR hospitalisation   
 
   
No prior hospitalisation  2579 0.810 0.135 
 
3153 0.797 0.134 
 last year 21 0.717 0.163 
 
29 0.631 0.151 
 over 1 year 295 0.786 0.149 
 
482 0.752 0.149 
Prior non-CVD hospitalisation    
 
   
No prior hospitalisation  1359 0.810 0.139 
 
1517 0.799 0.132 
 last year 231 0.749 0.16 
 
351 0.738 0.156 
 over 1 year 1305 0.815 0.128 
 
1796 0.791 0.136 
Prior CVD hospitalisation    
 
   
No prior hospitalisation  2608 0.815 0.13 
 
3425 0.795 0.134 
 last year 35 0.677 0.175 
 
25 0.686 0.166 
 over 1 year 252 0.738 0.167 
 
214 0.706 0.162 
Scottish Index of Multiple Deprivation (SIMD) 
    
5th (Least deprived) 545 0.831 0.118  672 0.833 0.109 
4th 651 0.83 0.118  825 0.808 0.122 
3rd 689 0.81 0.136  830 0.791 0.137 
2nd  531 0.796 0.146  692 0.771 0.145 
1st (Most deprived) 465 0.759 0.157   634 0.739 0.156 
*Low risk drinker: predicted AUDIT score=1-7 for males and 1-5 for females; Hazardous drinker: predicted 
AUDIT score=8-15 for males and 6-12 for females; Harmful drinker: predicted AUDIT score=16-19 for 
males and 13-16 for females; and Probable dependence: predicted AUDIT score>=20 for males and >=17 
for females; AUDIT: Alcohol Use Disorders Identification Test 
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Figure 5-1 Observed mean and 95% CI of SF-6D (SF-12) HRQoL score across the 
predicted AUDIT score (0 to 15 and greater than 15) among SHeS 2003 
participant aged 18 years and over, classified by gender 
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Table 5-3 Baseline SF-6D (SF-12) HRQoL scores of SHeS 2003 participants across 
SIMD quintile: males  
 
 
 
 
 
 
Aged group 
(years) 
Scottish Index of Multiple Deprivation (SIMD) 
5th 
(least  deprived) 4th 3rd  2nd  
1st  
(most deprived) 
All (N) (634) (701) (691) (597) (482) 
Mean 0.831 0.826 0.81 0.795 0.754 
95% CI (0.808, 0.854) (0.803, 0.849) (0.785, 0.836) (0.766, 0.825) (0.719, 0.79) 
18-24 (N) (23) (27) (27) (32) (31) 
Mean 0.822 0.853 0.834 0.857 0.787 
95% CI (0.787, 0.857) (0.824, 0.881) (0.795, 0.873) (0.828, 0.887) (0.745, 0.83) 
25-34 (N) (75) (88) (88) (104) (70) 
Mean 0.848 0.849 0.823 0.816 0.774 
95% CI (0.826, 0.871) (0.83, 0.867) (0.796, 0.85) (0.794, 0.839) (0.741, 0.807) 
35-44 (146) (164) (155) (125) (97) 
Mean 0.834 0.838 0.823 0.811 0.777 
95% CI (0.816, 0.852) (0.82, 0.855) (0.805, 0.841) (0.787, 0.835) (0.744, 0.81) 
45-54 (128) (139) (126) (82) (96) 
Mean 0.825 0.827 0.808 0.791 0.762 
95% CI (0.805, 0.845) (0.806, 0.849) (0.783, 0.833) (0.756, 0.826) (0.729, 0.794) 
55-64 (138) (127) (121) (111) (80) 
Mean 0.845 0.803 0.82 0.782 0.718 
95% CI (0.826, 0.865) (0.78, 0.826) (0.796, 0.843) (0.751, 0.813) (0.68, 0.757) 
65-74 (86) (89) (107) (92) (72) 
Mean 0.813 0.822 0.802 0.761 0.732 
95% CI (0.784, 0.841) (0.791, 0.853) (0.775, 0.83) (0.729, 0.792) (0.697, 0.768) 
> 74 (38) (67) (67) (51) (36) 
Mean 0.797 0.802 0.756 0.775 0.732 
95% CI (0.75, 0.843) (0.77, 0.835) (0.722, 0.791) (0.731, 0.818) (0.685, 0.779) 
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Table 5-4 Baseline SF-6D (SF-12) HRQoL scores of SHeS 2003 participants across 
SIMD quintile: females 
Aged group 
(years) 
Scottish Index of Multiple Deprivation (SIMD) 
 5th 
 (least deprived) 4th 3rd  2nd 
1st  
(most deprived) 
All (N) (784) (873) (858) (749) (685) 
Mean 0.826 0.807 0.785 0.769 0.737 
95% CI (0.806, 0.846) (0.786, 0.828) (0.761, 0.809) (0.743, 0.795) (0.707, 0.766) 
18-24 (N) (30) (37) (36) (48) (59) 
Mean 0.846 0.81 0.78 0.799 0.816 
95% CI (0.813, 0.88) (0.779, 0.842) (0.739, 0.821) (0.765, 0.832) (0.787, 0.845) 
25-34 (N) (105) (122) (114) (128) (104) 
Mean 0.839 0.816 0.822 0.803 0.775 
95% CI (0.822, 0.856) (0.795, 0.836) (0.803, 0.841) (0.78, 0.825) (0.749, 0.8) 
35-44 (N) (176) (198) (172) (150) (142) 
Mean 0.837 0.827 0.794 0.788 0.748 
95% CI (0.823, 0.852) (0.812, 0.841) (0.773, 0.815) (0.769, 0.808) (0.722, 0.774) 
45-54 (N) (180) (166) (157) (128) (117) 
Mean 0.827 0.793 0.78 0.769 0.736 
95% CI (0.812, 0.843) (0.773, 0.812) (0.758, 0.802) (0.745, 0.792) (0.708, 0.764) 
55-64 (N) (133) (162) (167) (126) (105) 
Mean 0.835 0.815 0.791 0.769 0.701 
95% CI (0.816, 0.854) (0.798, 0.832) (0.768, 0.814) (0.742, 0.796) (0.67, 0.732) 
65-74 (N) (96) (102) (118) (86) (87) 
Mean 0.827 0.803 0.792 0.742 0.702 
95% CI (0.803, 0.851) (0.776, 0.83) (0.766, 0.818) (0.709, 0.776) (0.668, 0.736) 
> 74 (N) (64) (86) (94) (83) (71) 
Mean 0.741 0.765 0.715 0.693 0.689 
95% CI (0.702, 0.779) (0.732, 0.798) (0.681, 0.748) (0.655, 0.731) (0.652, 0.726) 
 
 
 
 
 
  
  
1
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Table 5-5 Multiple linear regression using multiple imputation approach of SF-6D (SF-12) HRQoL score of SHeS 2003 participants aged 18 years and 
over, classified by gender 
  Males   Females 
Covariate* Coefficient SE p-value 95%CI  Coefficient SE p-value 95%CI 
Age at survey date -0.001 0.0002 <0.001 -0.001 0.000  -0.001 0.0002 <0.001 -0.001 -0.001 
Predicted AUDIT score -0.004 0.001 <0.001 -0.006 -0.002  -0.002 0.001 0.030 -0.005 -0.0002 
Prior wholly alcohol-related hospitalisation    
 
 
    
 last year -0.123 0.046 0.008 -0.212 -0.033  0.031 0.099 0.755 -0.163 0.225 
 over 1 year -0.072 0.021 0.001 -0.113 -0.031  -0.080 0.021 <0.001 -0.121 -0.039 
Prior partly alcohol-related hospitalisation  
    
 
    
 last year -0.069 0.026 0.008 -0.121 -0.018  -0.126 0.024 <0.001 -0.172 -0.080 
 over 1 year -0.027 0.008 0.001 -0.043 -0.012  -0.043 0.006 <0.001 -0.056 -0.031 
Prior non-CVD  hospitalisation  
     
 
    
 last year -0.043 0.008 <0.001 -0.059 -0.026  -0.048 0.007 <0.001 -0.062 -0.033 
 over 1 year -0.009 0.005 0.085 -0.020 0.001  -0.017 0.005 <0.001 -0.027 -0.008 
Prior CVD hospitalisation    
     
 
    
 last year -0.134 0.022 <0.001 -0.178 -0.091  -0.109 0.026 <0.001 -0.160 -0.059 
 over 1 year -0.078 0.009 <0.001 -0.097 -0.060  -0.097 0.010 <0.001 -0.115 -0.078 
Scottish Index of Multiple Deprivation (SIMD)   
  
   
  
4th 0.006 0.008 0.445 -0.009 0.020  -0.018 0.007 0.007 -0.032 -0.005 
3rd -0.009 0.007 0.205 -0.024 0.005  -0.029 0.007 <0.001 -0.043 -0.016 
2nd -0.020 0.008 0.013 -0.037 -0.004  -0.049 0.007 <0.001 -0.063 -0.035 
1st (Most deprived) -0.048 0.008 <0.001 -0.064 -0.032  -0.077 0.007 <0.001 -0.091 -0.063 
Constant 0.895 0.012 <0.001 0.872 0.918   0.904 0.012 <0.001 0.880 0.928 
R2 mean (min-max) 0.089 (0.077- 0.109)    0.125 (0.107- 0.153)   
Adjusted R2 (min-max) 0.087 (0.074- 0.106)    0.123 (0.105- 0.151)   
*Covariate reference: aged 18 years, predicted AUDIT score =0, least deprived (5th SIMD), and no prior hospitalisation 
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5.4 Discussion 
This chapter presents the estimation of HRQoL scores using SF-6D (SF-12) 
preferences-based index of different alcohol drinking status classified by the 
AUDIT score. The results show that current non-drinkers, i.e. those who have 
never consumed alcohol before and former drinkers reported worse HRQoL 
scores than low-risk drinkers, while high-risk drinkers who are probable alcohol 
dependent patients based on AUDIT showed the worst HRQoL compared to 
others. These findings further support the J-shaped morbidity curve, where 
those who have never consumed alcohol reported a worse HRQoL than low-risk 
drinkers (Petrie et al., 2008, Saarni et al., 2008, Valencia-Martin et al., 2013, 
Van Dijk et al., 2004). However, the published studies revealed the HRQoL score 
when other confounders were controlled for changed only small magnitude for 
those who had never consumed alcohol and low-risk drinkers. For the HRQoL of 
high-risk drinkers, the findings of the current study were consistent with those 
of previous studies; those also found that high-risk drinkers and alcohol-
dependent patients had the worst HRQoL (Nogueira and Rodriguez-Miguez, 
2014, Saarni et al., 2008, Petrie et al., 2008).  
In addition, prior alcohol-related hospitalisations impacted the current 
HRQoL similar to prior CVD-related conditions in both males and females. 
However, this analysis might not be comparable to previous studies due to the 
different number of conditions included in the classification as this study 
included and other studies used for 8 to 47 alcohol-related conditions (Laramee 
et al., 2014, Jones and Bellis, 2014, Jones et al., 2008, Grant et al., 2009). 
Nevertheless, for females, wholly-alcohol related admission in the last year did 
not have any impact on the HRQoL because of the lack of event among females 
(only one case). 
These findings have certain limitations. Firstly, selection bias and non-
response bias of the health survey might be found since healthy people are 
more likely to be recruited in the health survey. At the same time, if unhealthy 
heavy drinkers were recruited, they would be less likely to respond regardless 
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of their alcohol drinking levels. As a result, the probability that this study lacks 
data from unhealthy people is high, which would underestimate the effect of 
high-risk drinking on health. The second limitation relates to the AUDIT score 
which was not measured in the SHeS 2003. The analysis required the use of a 
predicted AUDIT score to investigate the association between HRQoL and the 
AUDIT score for that year. Subsequently, the HRQoL scores were adjusted using 
the same covariates as the predicted AUDIT score, i.e. age and SIMD, since 
these covariates were also independently related to health status. 
Consequently, this might result in double adjusting.  
Thirdly, HRQoL status might vary among individuals with the same health 
status since other variables related to health status were not taken into account 
in the analysis (e.g. marital status and smoking status). Even though other 
plausible confounders could not be controlled for, some covariates have been 
shown to have an effect on the relationship of alcohol drinking status and 
predicted AUDIT scores. Thus, excluding those variables seemed to reduce the 
overestimated effect of alcohol drinking on health, and the R-square values 
were very low in both male and female models. Lastly, the cross-sectional 
design of the health survey could not establish cause and effect. This is an 
important issue for further research interested in a health outcome 
measurement of alcohol drinking control intervention; therefore, these studies 
should prospectively investigate the change of HRQoL along with the AUDIT over 
time. Moreover, these studies should consider the measurements for alcohol 
use and HRQoL since they should be able to capture the effect of alcohol 
consumption on HRQoL unless it is found that the reduction of alcohol drinking 
risk does not show any significant improvement in HRQoL (Essex et al., 2014, 
UKATT Research Team, 2005b). 
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5.5 Conclusions 
These results can be applied to the estimated HRQoL related to alcohol 
drinking pattern in terms of the AUDIT score. Moreover, the baseline HRQoL 
scores of the general population as well as the decrement of HRQoL scores 
involved in alcohol-related and non-alcohol related hospitalisations before the 
interview date can be used to develop an alcohol intervention model that 
processes QALY estimations.  
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Chapter 6: Development and validation of an 
alcohol intervention model for predicting life 
years  
6.1 Introduction 
In the past decade, public health policy makers have shown an increased 
interest in reducing alcohol-related harms through a wide range of alcohol 
policies and intervention (Babor et al., 2010b, Anderson et al., 2009a, 
Martineau et al., 2013, Room et al., 2003). The evaluation of alcohol policies 
and interventions has also become increasingly important - especially in terms 
of effectiveness and cost-effectiveness - to assess the achievement of those 
policies (Room et al., 2003). The expected outcomes of those interventions 
should be changes in epidemiological measures, e.g. mortality, morbidity, and 
health-related quality of life (HRQoL) in the population as well as in economic 
aspects where the impact of the intervention on costs can be considered 
(Tones, 1992, Martineau et al., 2013).  
Nevertheless, it is still methodologically problematic to predict these 
final outcomes, especially when measured as LYs, QALYs, and lifetime 
economic costs - which are widely recommended for the purpose of health 
intervention economic evaluations (ISPOR, 2014, NICE, 2013, Chaikledkaew and 
Kittrongsiri, 2014, Teerawattananon and Chaikledkaew, 2008). Moreover, 
conducting RCTs for evaluation of these outcomes would likely not be practical 
for measuring long-term outcomes due to the limited follow-up period and large 
investment required for conducting RCTs. Thus, modelling studies are often 
necessary to predict longer-term outcomes (Briggs et al., 2006c, Drummond MF 
et al., 1997, Gray et al., 2011a). Chapter 2 also highlighted the limitations of 
previous alcohol modelling studies and the rationale behind developing this 
current alcohol intervention model. In this study, the term “alcohol 
intervention model” is used and defined as a model that can evaluate the long-
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term effectiveness and cost-effectiveness of alcohol interventions to inform 
health policy decision-making (Lewsey et al., 2015).   
The aim of this chapter is to describe the development and validation of 
the Scottish alcohol intervention model for predicting health outcomes in terms 
of LYs for different selected risk profiles related to alcohol consumption. 
Firstly, the conceptualisation and model structure of the alcohol intervention 
model used for alcohol intervention evaluation are specified to demonstrate all 
plausible events of the SHeS cohort. Secondly, the SHeS-SMR linkage data set 
will be analysed using three stages of data modelling. The statistical modelling 
approach will be applied for the development of the cause-specific hazard 
functions of plausible first events after the survey date and death following 
hospitalisation. Observed events and predicted events will then be compared 
to assess the model’s performance. Thirdly, the predicted survival of the study 
cohort will be compared to the Scottish life table to calibrate the model. 
Finally, predicting life expectancy will be estimated using the health state 
transition model and cause-specific hazard models of the different individual 
risk profiles.     
6.2 Methods 
6.2.1 Conceptualisation of alcohol intervention model 
To estimate the long-term effects of alcohol intervention on LYs, QALYs, 
and lifetime costs, alcohol-related morbidity and mortality were investigated 
using the alcohol intervention model. To factor in the range of related risk 
factors that would likely affect alcohol-related hospitalisations and death, 
developing the intervention model of alcohol-related harms not only focussed 
on the association between drinking patterns and harms caused by alcohol but 
also on other related factors to predict the LYs and QALYs of different health 
risk profiles. These risk factors were identified as the pattern and level of 
alcohol consumption, socioeconomic status (Probst et al., 2015a, Jones et al., 
2015b), and other factors which were found to have a relationship with alcohol 
drinking such as smoking status (Aekplakorn et al., 2008, De Leon et al., 2007, 
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Falk et al., 2006, Harrison et al., 2008, McKee et al., 2010), physical activity 
(Kendzor et al., 2008), and body mass index or BMI (Hart et al., 2010).  
This study investigated alcohol-related and non-alcohol related 
hospitalisations and deaths among alcohol drinking patterns as well as other 
selected health risk factors. The linkage data set which was linked between the 
routine national health surveys and health administration records was employed 
to examine whether the selected risk factors would accurately predict 
hospitalisation and death. Then, the model of alcohol-related harms would be 
developed to estimate LYs, QALYs, and lifetime healthcare costs, and those 
outcomes would be presented in different risk profiles. Moreover, the findings 
could be used for the evaluation of interventions which aim to change those 
selected risk factors, and it could also show the association between the 
modified risk factors (intermediate outcome) and the final health outcomes of 
interest.   
6.2.2 Health state transition model 
 This section summarises the overview of the health state transition 
model (more details are described in section 3.5 of Chapter 3:). The study 
cohort was a participant of the general population who had never experienced 
an alcohol-related hospitalisation prior to the survey date. Then, the structure 
of the alcohol intervention model (Figure 6-1) was defined as the key features 
of first competing consequences after the interview date. To estimate alcohol-
related harms of different drinking patterns including other selected risk 
factors (equation 1), alcohol attributable hospitalisations and deaths identified 
by AAF were used, i.e. wholly alcohol-attributable conditions and partly 
alcohol-attributable conditions (Appendix 1). Moreover, other non-alcohol 
related hospitalisations and deaths were considered to be a competing risk of 
first events after the survey date; these events were categorised by 
emergency/non-emergency admission and cardiovascular diseases (CVD)/non-
CVD defined by the ICD-9 and ICD-10 codes. The follow-up time for each 
participant was defined as the time from the initial interview date until either 
the date of occurring first events or until 31st December 2013 (censoring date). 
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Figure 6-1 Structure of the alcohol-related harms health state transition 
model 
For estimating LYs and QALYs, this analysis also factored in all-cause 
deaths after patients experienced the first hospitalisations (equation 2). Thus, 
the follow-up time for each hospitalised patient was defined as the time from 
their date of first hospitalisation until either the date of death or until 31st 
December 2013 (censoring date). Males and females were modelled separately 
for all analyses. 
6.2.3 Data sources: SHeS-SMR/NRS linkage data 
As described in section 3.7 of Chapter 3:, the electronic Data Research 
and Innovation Service (eDRIS) links the consented SHeS participant data set to 
SMR/NRS records via personal information using established probability 
matching techniques (Information Services Division). This study used the SHeS-
SMR/NRS linkage data where the SHeS data sets from 1995, 1998, 2003, and 
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2008-2012 were linked to the SMR/NRS records, particularly SMR01 (inpatients 
and day cases) and mortality, and follow-up from year 1981 to the end of year 
2013 as shown in Figure 6-2. This study protocol was approved by the NHS 
National Services Scotland Privacy Advisory Committee for accessing the 
SMR/NRS linkage data set through the national data security system or Safe 
Haven provided by the eDRIS (Information Services Division). Researchers able 
to access individual patient data must have undergone appropriate training 
necessary for obtaining an ‘approved researcher’ status (Appendix 3).   
The selected covariates related to the baseline characteristics of the 
study cohort were derived from 8 survey years of the SHeS (see details in section 
3.7.1 of Chapter 3:); these were age at survey date, gender, SIMD, alcohol 
consumption including the AUDIT score and binge drinking, smoking status (i.e. 
the number of cigarettes per day), health condition (i.e. having CVD and 
diabetes), physical activity, and BMI. In addition, prior non-alcohol related 
hospitalisation was designated as the SHeS cohort baseline characteristic so the 
SMR records (see details in section 3.7.2 of Chapter 3:) of individually 
consenting SHeS respondents before the interview date were used to define 
prior non-alcohol related hospitalisation. The SMR records were also used for 
identifying hospitalisation after the interview date, and the NRS mortality 
records were used to track the deaths of consenting SHeS participants.  
 
Figure 6-2 Scottish Health Survey (SHeS)/Scottish Morbidity Records (SMR) 
linkage data set 
Chapter 6:Development and validation of an alcohol intervention model for predicting life years 135 
 
  
6.2.4 Adjusting under-reported alcohol unit consumption 
The assessment of self-reported alcohol consumption typically indicates 
deliberate under-reporting, so previous studies suggested adjusting for under-
reported consumption in the surveys using per capita sales data (Babor et al., 
2010a, Meier et al., 2013). Therefore, this study employed adjusting for under-
reported units consumed from the self-reported alcohol consumption of the 
SHeS data using a technique from a published study (Boniface and Shelton, 
2013).  Boniface and Shelton’s study investigated the implications of under-
reporting for alcohol consumption among the respondents of national private 
household surveys 2008 in England. It adjusted for under-reporting of 
consumption using a multiplying factor derived from matching alcohol sales 
data. Although under-reporting is also likely to vary by demographic and social 
factors, there is no evidence to suggest the magnitude or the direction of these 
associations. Based on available evidence, a previous study generated three 
scenarios of under-reporting adjusted (Boniface and Shelton, 2013): 1) an equal 
proportion of under-reporting among all drinkers based on comparison of survey 
and sales data; 2) heavy drinkers under-report proportionally more than light 
drinkers that recall accuracy is lower among heavier drinkers; and 3) alcohol 
consumption as a proportion of alcohol sales was calculated by drink type. 
Average weekly alcohol intake or heaviest drinking day in the last week was 
revised accordingly. The study concluded that adjusting under-report equally 
by 40% (scenario 1) could highlight the potential impact that underreporting 
has. For differentiated adjusting factor by drinking level (scenario 2) and type 
of alcohol beverage (scenario 3), scenario 2 showed over-estimates alcohol 
consumption (average weekly alcohol consumption exceeded per capita alcohol 
sales), and scenario 3 was very similar to scenarios 1. 
As such, this study using the Scottish setting compared self-reported 
alcohol consumption (Hinchliffe, 2013) and UK sales data (HM Revenue and 
Customs, 2012, Robinson et al., 2013) of each year to generate the multiplying 
factors for adjusting under-reporting alcohol consumption as shown in Table 
6-1. These multiplying factors were applied across all SHeS’ participants to 
adjust for average weekly alcohol intake and units consumed on the heaviest 
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day so binge drinking could be reclassified after adjustment. The predicted 
AUDIT scores would be also adjusted since the weekly units consumed and units 
consumed on the heaviest day were the covariates of the predicted AUDIT 
scores (see details in Chapter 4:). However, non-drinkers are not included in 
the revision. Assessing misclassification of self-reported non-drinkers was 
beyond the scope of this study.    
Table 6-1 Comparison of self-reported alcohol consumption (SHeS) and UK 
sales data to calculate under-reporting level 
Year 
UK sales dataa SHeSb 
Under-
reporting 
level 
Multiplying 
factorc 
Litre of pure 
alcohol per adult 
(aged+16) 
Unit per 
adult 
 
Unit per 
week per 
adult 
(aged +16) 
1995 9.71 (1994/95) 18.64 13 30.3% 1.43 
1998 10.15 (1997/98) 19.49 12.5 35.9% 1.56 
2003 11.43 (2002/03) 21.94 14.1 35.7% 1.56 
2008 11.51 (2007/08) 20.5 13.1 36.1% 1.56 
2009 10.66 (2008/09) 20.46 12.4 39.4% 1.65 
2010 10.83 (2009/10) 20.79 11.6 44.2% 1.79 
2011 10.53 (2010/11) 20.21 11.1 45.1% 1.82 
2012 10.24 (2011/12) 19.65 11.3 42.5% 1.74 
a. HM Revenue and Customs. (2012). Table 2.3 Alcohol clearances per adult (1986/87-
2010/11). Alcohol factsheet: March 2012: Office for National Statistics. 
b. Hinchliffe, S. (2013). Chapter 3: Alcohol Consumption. In L. Rutherford, S. Hinchliffe & C. 
Sharp (Eds.), The Scottish Health Survey: 2012 edition Volume 1 Main Report: A National 
Statistics Publication for Scotland: The Scottish Government. 
c. Boniface, S., & Shelton, N. (2013). How is alcohol consumption affected if we account for 
under-reporting? A hypothetical scenario. Eur J Public Health.  
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6.2.5 Data modelling 
Modelling stage I: Estimating risk of having first events  
During the follow-up period, a Cox proportional hazard model (Cox, 
1972) - a semi-parametric method - was used to model the cause-specific 
hazard functions of the 8 competing first events as mentioned above (presented 
as equation 1 in Figure 6-1). For extrapolation beyond the period of follow-up, 
parametric proportional hazard models were also used (Cleves et al., 2010, 
Gray et al., 2011a, Hosmer et al., 2008). The causes of hospitalisations and 
deaths were classified by the ICD-9 and ICD-10 in Appendix 1 (Jones and Bellis, 
2014, Jones et al., 2008, Grant et al., 2009). A Gompertz parametric regression 
survival analysis was used to model the cause specific hazards of the competing 
first events - defined as an event whose occurrence precludes or alters the 
probability of occurrence of a main event under examination (Cleves et al., 
2010, Gray et al., 2011a, Hosmer et al., 2008, Putter et al., 2007, Coviello and 
Boggess, 2004); the Gompertz is the standard choice when modelling the risk 
of death (Gray et al., 2011a). The selected risk factors used for modelling the 
first events were age at survey date, alcohol drinking status at survey date with 
adjusted under-reporting alcohol consumption, i.e. the AUDIT score (0-40) and 
binge drinking (Y/N), number of cigarettes per day, CVD condition (Y/N), 
diabetes (Y/N), general health condition (3 groups of GHQ score), physical 
activity (no activity/low activity/medium activity/high activity), BMI 
(underweight/normal or BMI<25, overweight or BMI 25≤BMI<30, obesity or 
BMI≥30), prior non-alcohol related hospitalisation, and SIMD quintile (Office of 
the Chief Statistician, 2004). Males and females were modelled separately for 
all analyses since the reviewed literature reported that males and females have 
diverse alcohol drinking risks, morbidity, and mortality risk related to alcohol 
drinking (Schulte et al., 2009, Probst et al., 2015b, Richman et al., 1995).  
For the Cox proportional hazard model (Cox, 1972), the hazard function 
ℎ(𝑡|𝑥𝑖 ) of each competing first event for the i th individual in the data is  
ℎ(𝑡|𝑥𝑖 ) =  ℎ0 (𝑡) exp(𝑥𝑖𝛽𝑥) 
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where  ℎ0 (𝑡)  is the baseline hazard of each event and 𝛽𝑥  are the 
regression coefficients indicating the effect of each covariate 𝑥𝑖. The baseline 
hazard is the hazard when all 𝑥𝑖=0 as the relative hazard is equal to one (Cleves 
et al., 2010, Gray et al., 2011a).  
For extrapolation beyond the period of follow-up, a parametric 
proportional hazard model using a Gompertz regression was also considered 
(Cleves et al., 2010, Gray et al., 2011a), and the function of baseline hazard 
ℎ0 (𝑡) is illustrated as:  
ℎ0 (𝑡) = exp(𝛽0)exp (𝛾𝑡)           
where 𝛾  is the ancillary shape parameter estimated from the data. A 
Gompertz model allows for flexible specification of the hazard: when γ >0 the 
hazard is increasing with time and when γ < 0 the hazard is decreasing with 
time. The models can then be reduced to the exponential model, i.e. hazards 
constant over time if γ = 0. Then, the function of the baseline hazard of 
exponential model is shown as:  
ℎ0 (𝑡) = exp(𝛽0) 
Furthermore, the cause-specific hazard function derived from the 
parametric proportional hazard model would be used to estimate the predicted 
cumulative incidence CI (t) of first event k as follows: 
𝐶𝐼𝑘(𝑡) =  ∑ 𝑝𝑘( 𝑡𝑢) 
where ∑ 𝑝𝑘( 𝑡𝑢) is the cumulative sum of the unconditional probabilities 
of occurring first event k at time 𝑡𝑢  up to and including time t. The 
unconditional probabilities are derived from: 
𝑝𝑘( 𝑡𝑢) =  ℎ𝑘(𝑡𝑢)𝑆(𝑡𝑢−1) 
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where ℎ𝑘(𝑡𝑢) is the cause specific hazard of event k as derived from the 
parametric models. 𝑆(𝑡) is the survival function from any 8 competing events k 
at time t as shown below:  
𝑆(𝑡) = ⊓ (1 − ∑ ℎ𝑘(𝑡𝑗 ))  
where ∑ ℎ𝑘(𝑡𝑗 ) is the sum of the eight cause specific hazards at time t. 
All statistical analyses were performed using STATA version 12 
(StataCorp. 2011. Stata Statistical Software: Release 12. College Station, TX: 
StataCorp LP). Two-sided tests with a p-value of less than 0.05 was considered 
statistically significant. 
Modelling stage II: Estimating survival following hospitalisations  
A Gompertz model was also used to model the hazard functions of all– 
cause deaths following the first hospitalisation classified as alcohol-related and 
non-alcohol related hospitalisations (presented as equation 2 in Figure 6-1). The 
covariates for modelling the cause-specific death were age at first 
hospitalisation, CVD condition (Y/N), diabetes (Y/N), and SIMD quintile (Office 
of the Chief Statistician, 2004); these were grouped by gender. A predicted 
survival curve of different risk profiles was extrapolated until the probability 
of surviving beyond the follow-up time point became zero; this was classified 
by gender and condition of the first hospitalisation. The area under the 
predicted survival curve was used to estimate the remaining life expectancy 
using the trapezoidal rule with half cycle correction (Gray et al., 2011a). 
  
Modelling stage III: Estimating total life years  
 The health state transition model (Figure 6-1) with a one-year cycle 
period for 100 years was developed using Microsoft Excel® (Microsoft Corp., 
Redmond, WA). At the end of a model cycle, an individual risk profile can either 
remain in the no-event state or move to one of the first eight competing events, 
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i.e. hospitalisation or death states. There were three stages to estimate overall 
LYs of individual risk profiles. Firstly, the health state transition model 
estimated LYs remaining upon entering model (after the survey date) for each 
competing event that occurred. To calculate for these remaining LYs for each 
of the eight events, the analysis model summed the survival time before the 
first events (derived from Modelling stage I), and the survival time of following 
hospitalisations (derived from Modelling stage II) of each respective event. 
Secondly, the probability of having each first event within an annual cycle was 
estimated using the cause-specific hazard models; the sum of these estimated 
probabilities across all 100 cycles is always equal to 1. Thirdly, the LYs from 
the first stage were weighted by the probabilities of having a particular event 
from the second stage, and the remaining LYs adjusted by probabilities of 
having the event were summed.  Finally, to estimate the overall LYs of the 
survey cohort in a particular risk profile, the additional LYs were combined with 
the age at survey date.     
6.2.6 Dealing with missing data 
A multiple imputation approach using chained equations was employed 
to fill missing data (Little and Rubin, 2002, Royston and White, 2011). The 
information in the observed values of the covariates was used to predict the 
missing values. To apply this method to this study - which investigates alcohol-
related hospitalisations and deaths among SHeS-SMR/NRS linkage data due to 
the limitation of additional external information - missing at random (MAR) was 
assumed to impute missing data based on all predictors used in the survival 
analysis. As suggested by Royston and White (2009), this analysis also included 
the follow-up status and the Nelson-Aalen estimate of the cumulative hazard 
to the survival time as predictor covariates for the regression models (White 
and Royston, 2009). Once 100 imputed complete data sets were created and 
analysed, the results were combined using standard rules (Rubin, 1987).  
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6.2.7 Assessment of model performance  
The developed model is considered to be a theoretical representation of 
a complex problem, and hence underwent a validation process that included 
measuring how accurately the model could represent ‘real world’ patterns. This 
important validation step helps build confidence in the structure and 
predictions of the model. For discrimination of the cause-specific hazard 
model, Harrell’s C statistic was used (Steyerberg, 2009); this was proposed as 
measures of the general predictive discrimination of a survival regression model 
by Harrell et al. (Harrell et al., 1982, Harrell et al., 1996). The Harrell’s C 
statistic estimates the probability of concordance between predicted and 
observed responses. A value of 0.5 indicates no predictive discrimination and a 
value of 1.0 indicates perfect discrimination of the study population with 
different outcomes (Harrell et al., 1982, Harrell et al., 1996).   
It is noted that this study only assessed the discrimination compared 
between observed events – which occurred starting from the interview date to 
31st December 2013 (censoring date) – and the model-predicted events during 
this period. Thus, this analysis is unable to determine how well the model could 
predict the event in the extrapolated period (beyond the censored date). 
Predicted life expectancies were obtained from the model where the risk 
factors were provided using the average values from the SHeS-SMR/NRS linkage 
data. Then, to calibrate the survival curve derived from the model, a 
calibration factor (range from 0-1) was applied for adjusting the linear 
predictor of the model, separated into male and female models. The predicted 
life expectancies of males and females were compared with the Scottish life 
table (National Records of Scotland, 2014), and a squared-error loss function 
(corresponding to the root mean square error, or RMSE) was calculated to select 
the calibration factors that minimise RMSE.      
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6.3 Results 
6.3.1 Baseline characteristic of the study population 
Table 6-2 presents the baseline characteristic of consenting SHeS 
participants from 1995, 1998, 2003, and 2008-2012, where individual survey 
information was linked with the SMR and death records of the NRS during the 
corresponding survey year. For the health state transition modelling analysis, 
SHeS participants who had no prior alcohol-related hospitalisation were defined 
as the initial health state of cohort. There were 46,230 SHeS participants 
(20,729 males and 25,501 females) with an average age of 47 years for both 
males and females. Most of participants were current drinkers (91% for males 
and 86% for females) with an average weekly drinking unit of 17 and 7 for males 
and females, respectively; these were adjusted for under-reported alcohol 
consumption using alcohol sales data. The average AUDIT score and binge 
drinking proportion of males was higher than females for both unadjusted and 
adjusted data. For smoking status, males and females were very similar in terms 
of the proportion of current smokers (28% for males and 26% for females) and 
number of cigarettes per day (5 for males and 4 for females). Approximately 
one-third had CVD in both male and female participants, and less than 5% of 
them had diabetes. A representative sample of Scotland was approximately 20% 
in each SIMD quintile. Additionally, 61% of males and 56% of females reported 
best general health condition as measured by the GHQ score. The highest 
proportion (40%) of physical activity was reported at the high level for males 
and medium level for females. Of all participants that measured BMI, two-thirds 
of the total population were classified as overweight (39% for males and 30% 
for females) and obese (23% for males and 24% for females). Over half of the 
respondents experienced non-alcohol related hospitalisation before the survey 
date. 
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Table 6-2 Demographics of SHeS participants who had no prior alcohol-related 
hospitalisation 
  Males   Females   
Cohort size 20,729 
 
25,501 
 
     
Age (years) 47.2 (17.4) 47.3 (17.7) 
Drinking status 
    
Never drinker 732 4% 1828 7% 
Former drinker 1042 5% 1650 6% 
Current drinker 18834 91% 21891 86% 
missing  121 
 
132 
 
     
Average weekly drinking unit (include 
non-drinker) 17.1 (23.7) 7.13 (11.5) 
Grouped weekly drinking unit 
    
0 1,915 9.2% 3,717 14.6% 
>0-10 7,873 38.0% 15,446 60.6% 
>10-20 4,523 21.8% 3,807 14.9% 
>20-30 2,797 13.5% 1,363 5.3% 
>30-40 1,299 6.3% 455 1.8% 
>40-50 857 4.1% 291 1.1% 
>50-60 448 2.2% 85 0.3% 
>60-70 267 1.3% 61 0.2% 
>70-80 166 0.8% 22 0.1% 
>80-90 128 0.6% 15 0.1% 
>90-100 71 0.3% 11 0.0% 
>100 203 1.0% 31 0.1% 
missing 182 
 
197 
 
AUDIT score     
SHeS 2012 (observed value) 5.1 (4.6) 3.4 (3.7) 
 n   1,469   1,787   
SHeS 1995-2011 (predicted value) 5.4 (3.8) 3.1 (2.8) 
 n   16,755   20,518   
missing 2,505  3,196  
Binge drinking (included non-drinker) 5,054  24% 3,325  13% 
missing 333  467  
*Statistics are mean (SD). 
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Table 6-2 Demographics of SHeS participants who had no prior alcohol-related 
hospitalisation (cont.) 
 
Males   Females 
 
Adjusted under-reported 
    
Average weekly drinking unit (include 
non-drinker) 27.7 (38.3) 11.7 (18.9) 
Grouped weekly drinking unit (units) 
    
0 1,915 9.2% 3,717 14.6% 
>0-10 5,790 27.9% 12,338 48.4% 
>10-20 3,213 15.5% 4,322 16.9% 
>20-30 2,941 14.2% 2,265 8.9% 
>30-40 1,973 9.5% 1,093 4.3% 
>40-50 1,405 6.8% 581 2.3% 
>50-60 857 4.1% 332 1.3% 
>60-70 663 3.2% 179 0.7% 
>70-80 439 2.1% 221 0.9% 
>80-90 326 1.6% 75 0.3% 
>90-100 225 1.1% 43 0.2% 
>100 800 3.9% 138 0.5% 
AUDIT score 6.8 (5.4) 4.1 (4.2) 
Binge drinking (included non-drinker) 8,449  40.8% 7,315  28.7% 
Smoking status 
    
Never smoke  8,594  41.5% 11,945  46.8% 
Ex-smoker   6,264  30.2% 6,738  26.4% 
Current smoker 5,830  28.1% 6,760  26.5% 
missing 41 
 
58 
 
Cigarette per day 4.5 (9.2) 3.8 (7.5) 
missing  214 
 
123 
 
     
*Statistics are mean (SD).
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Table 6-2Demographics of SHeS participants who had no prior alcohol-related 
hospitalisation (cont.) 
 Males  Females  
Having CVD 6,424  31.0% 7,639  30.0% 
Having diabetes 1,000  4.8% 960 3.8% 
     
SIMD quintile 
    
1st (most deprived) 4,043  19.5% 5,385  21.1% 
2nd 4,098  19.8% 5,157  20.2% 
3rd 4,387  21.2% 5,280  20.7% 
4th 4,501  21.7% 5,239  20.5% 
5th(least deprived) 3,683  17.8% 4,422  17.3% 
missing 17 
 
18 
 
     
GHQ score 
    
Score 0 (best) 2,737  61.4% 14,318  56.1% 
Score 1-3 4,700  22.7% 6,111  24.0% 
Score 4+ (worst) 2,452  11.8% 4,013  15.7% 
missing 840 
 
1,059  
 
     
Physical activity 
    
No activity 3,316  16.0% 4,403  17.3% 
Low activity 2,458  11.9% 2,936  11.5% 
Medium activity 6,823  32.9% 10,321  40.5% 
High activity 8,114  39.1% 7,804  30.6% 
missing 18 
 
37 
 
     
BMI (mean, SD) 27.3  (4.6) 27.4  (5.7) 
<25 6,236  30.1% 8,821  34.6% 
25- <30 (overweight) 7,991  38.5% 7,610  29.8% 
>=30 (obesity) 4,758  23.0% 6,167  24.2% 
missing 1,744  
 
2,903  
 
Prior non-alcohol related hospitalisation 
  
No hospitalisation 6,889 33.2% 7,542 29.6% 
within last year 2,450 11.8% 3,035 11.9% 
over 1 year 11,435 55.2% 14,924 58.5% 
          
*Statistics are mean (SD).
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Table 6-3 illustrates the observed events of SHeS cohorts who had no 
prior alcohol-related hospitalisation. These events were indicated using 
SMR/NRS records starting from the interview date to 31st December 2013 with 
the maximum follow-up period of 19 years. For both males and females, 
approximately 50% of the cohorts had first-observed events (8 competing first 
events) during the follow-up period. The highest proportion of those first events 
was non-emergency admission and non-CVD condition (25% vs. 29%, males vs. 
females) followed by emergency admission and non-CVD condition (15% vs. 
15%), partly alcohol attributable hospitalisation (1.8% vs. 2.3%), and emergency 
admission and CVD condition (2.4% vs. 1.3%). Following the first alcohol-related 
hospitalisation (445 events for males and 614 events for females), the total 
number of deaths were 133 males (30% of hospitalised patients) and 119 females 
(19% of hospitalised patients). For non-alcohol related hospitalised patients 
(9,053 males and 11,666 females), the total death post-hospitalisation were 
1,296 males (14% of those patients) and 1,426 females (12% of those patients).  
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Table 6-3 Hospitalisation and death events after survey date until 31st 
December 2013 
 
Males (20,729 ) Females (25,501)  
  Number 
% of baseline 
cohort Number 
% of 
baseline 
cohort 
Alive and no event 11,005 53.1% 13,024 51.1% 
First events 
    
Wholly alcohol attributable hospitalisation 68 0.3% 38 0.1% 
Partly alcohol attributable hospitalisation 377 1.8% 576 2.3% 
Emergency admission and non-CVD 
condition  3,090 14.9% 3,805 14.9% 
Emergency admission and CVD condition  507 2.4% 343 1.3% 
Non-emergency admission and non-CVD 
condition  5,198 25.1% 7,369 28.9% 
Non-emergency admission and CVD 
condition  258 1.2% 149 0.6% 
Alcohol-related death 47 0.2% 44 0.2% 
Non-alcohol related death 179 0.9% 153 0.6% 
Death following first hospitalisation 
    
Death post alcohol-related hospitalisation 133 0.6% 
(30% of alcohol–
related 
patients) 
119 0.5% 
(19% of 
alcohol–
related 
patients) 
Death post non-alcohol related 
hospitalisation 
1,296 6.3% 
(14% of non-
alcohol related 
patients) 
1,426 5.6% 
(12% of non-
alcohol 
related 
patients) 
 Figure 6-3 and Figure 6-4 illustrate the graphs of observed cumulative 
incidence of first events after the survey date over a 19-year follow-up period 
classified by gender. The graphs reveal that emergency and non- emergency 
admission with non–CVD gradually increased the cumulative incidence until the 
end of the follow-up period, and the incidence of these events were higher than 
other events which likely remained steady over time.        
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Figure 6-3 Observed cumulative incidence of first events: males 
 
Figure 6-4 Observed cumulative incidence of first events: females 
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6.3.2 Modelling stage I:  Risk of having first events 
The hazard ratios (HRs) of having each first event are shown in Table 6-4, 
Table 6-5, Table 6-6, and Table 6-7, classified by gender and alcohol-
attributable conditions. All cause-specific hazard ratios were derived from a 
Gompertz regression and multiple imputation using chained equations. The 
modifiable risk factors were selected to fit the model, i.e. alcohol consumption 
(AUDIT score and binge drinking), number of cigarettes per day, BMI, and 
physical activity. The results revealed that the selected modifiable risk factors 
likely affected the risk of first events (i.e. hospitalisation and death) after the 
survey date. When other covariates were adjusted, the HRs of an increase in the 
unit of AUDIT score were: 1.062 for males (95% CI [1.022, 1.102], p=0.002) for 
wholly alcohol-attributable hospitalisation, 1.021 (95% CI [0.994, 1.049], 
p=0.132) for partly alcohol-attributable condition, 1.049 (95% CI [0.997, 1.104], 
p=0.066) for alcohol-related death, and 1.013 (95% CI [1.004, 1.022], p=0.007) 
for emergency admission and non-CVD condition. For females, there were no 
statistically significant increasing risks of having those events for a unit increase 
in the AUDIT score. Binge drinking was also not shown to be an increasing risk of 
hospitalisation and mortality among SHeS participants.  
An increase in the number of cigarettes per day was found to be 
significant in increasing risks of alcohol-related events for both males and 
females. For wholly alcohol–attributable hospitalisations, HRs were 1.029 (95% 
CI [1.018, 1.040], p<0.001) for males and 1.045 (95% CI [1.018, 1.074], p=0.001) 
for females. For partly alcohol–attributable hospitalisations, HRs were 1.012 
(95% CI [1.004, 1.020], p=0.004) for males and 1.015 (95% CI [1.005, 1.025], 
p=0.002) for females. For alcohol–related death, HRs were 1.018 (95% CI [0.999, 
1.038], p=0.062) for males and 1.044 (95% CI [1.017, 1.072], p=0.001) for 
females. Moreover, the increase in cigarettes per day revealed an increase in 
risk of non–alcohol related events in males at a p-value<0.001. HRs were 1.008, 
95% CI [1.005, 1.011] for emergency admission and non-CVD condition, 1.024, 
95% CI [1.019, 1.030] for emergency admission and CVD condition, and 1.020, 
95% CI [1.012, 1.029] for non-alcohol related death. Likewise, for females, HRs 
of increasing cigarettes per day were 1.011 (95% CI [1.008, 1.015], p<0.001) for 
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emergency admission and non-CVD condition, 1.041 (95% CI [1.030, 1.052], 
p<0.001) for emergency admission and CVD condition, 1.003 (95% CI [1.000, 
1.006], p=0.027) for non-emergency admission and non-CVD condition, 1.026 
(95% CI [1.007, 1.045], p=0.034) for non-emergency admission and CVD 
condition, and 1.053 (95% CI [1.037, 1.069], p<0.001) for non-alcohol related 
death.      
When selecting explanatory variables to fit the model, BMI was included 
particularly for the Gompertz models of non-alcohol related hospitalisation but 
was excluded from the models of alcohol-related hospitalisation and death 
caused by alcohol-related and non-alcohol related factors. Being overweight 
(25≤BMI<30) was found to increase the risk of emergency admission and CVD 
condition with an HR value of 1.402 (95% CI [1.103, 1.781], p=0.006) for males 
and higher risk for females with an HR value 1.556 (95% CI [1.183, 2.048], 
p=0.002). Moreover, obese females (BMI≥30) was found to increase the risk of 
emergency admission with non-CVD condition (HR=1.147, 95% CI [1.052, 1.250], 
p=0.002). For non-emergency admission, there were different risks between 
overweight males and females. Overweight males had increased risk of having 
non-emergency admission with non-CVD condition (HR=1.112, 95% CI [1.039, 
1.191], p=0.002) while overweight females were estimated to have double the 
risk of having non-emergency admission with CVD condition (HR=1.894, 95% CI 
[1.203, 2.981], p=0.006).  
Physical activity was revealed to have positive effects on hospitalisations 
and deaths in both males and females. High physical activity was shown to 
decrease risk by approximately 35 % for partly alcohol-related hospitalisation 
(HR=0.671, 95% CI [0.479, 0.941], p=0.021 for males and HR=0.635, 95% CI 
[0.482, 0.837], p=0.001 for females). In addition, high physical activity 
decreased the risk of emergency CVD admission by 26% and 35% for males and 
females, respectively (HR=0.744, 95% CI [0.560, 0.990], p=0.042 for males and 
HR=0.647, 95% CI [0.449, 0.931], p=0.019 for females). All levels of physical 
activity significantly decreased the risk of emergency non-CVD admission, 
ranging from 29% to 46% at p-value<0.001 (HRs ranged from 0.690 to 0.716 for 
males and 0.537 to 0.649 for females). Moreover, for decreasing mortality risk, 
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all levels of physical activity reduced the risk of non-alcohol related death 
ranging from 43% to 61% at a p-value<0.01 (HR range of 0.391 to 0.573 for males 
and 0.291 to 0.542 for females). For females in particular, medium and high 
physical activity were also found to significantly decrease the risk of alcohol-
related death (HR=0.183, 95% CI [0.058, 0.580], p=0.004 for high activity and 
HR=0.373, 95% CI [0.177, 0.785], p=0.009 for medium activity).  
In addition, when considering hospitalisations and deaths among different 
socioeconomic status as measured by the deprivation index (most 
deprivation=1st SIMD quintile to least deprivation=5th SIMD quintile), less 
deprivations revealed benefits for alcohol-related and non-alcohol related 
events as well. For men, compared to the highest level of deprivation, people 
who were less deprived at the 4th SIMD quintile showed 55% less risk of only 
wholly alcohol-related hospitalisation (HR=0.450, 95% CI [0.208, 0.973], 
p=0.042), and the 3rd SIMD quintile revealed 74% less risk of alcohol-related 
death (HR=0.260, 95% CI [0.086, 0.783], p=0.017).  However, deprivation had no 
effect on alcohol-related events in women. Moreover, deprivation showed 
effects on non-alcohol related conditions in both men and women. For 
emergency and non-CVD condition, lower deprivation presented less risk ranging 
from 12% to 30% for men and 20% to 37% for women at a highly significant level 
(p<0.001). Additionally, women with the least deprivation (5th SIMD quintile) 
was 67% less at risk from non-alcohol related death (HR=0.433, 95% CI [0.221, 
0.848], p=0.015).   
Furthermore, modifiable risk factors were selected to predict the 
cumulative incidence of having first event classified by gender after the follow-
up period as shown in Figure 6-5 for males and Figure 6-6 for females. For males, 
the selected risk profile was aged 30 years, AUDIT score=10, binge drinking, 
overweight, no CVD, no diabetes, 7 cigarettes per day, medium physical activity, 
3rd SIMD, prior hospitalisation more than one year ago, and the best GHQ score. 
For females, the selected risk profile was aged 30 years, AUDIT score=6, binge 
drinking, overweight, no CVD, no diabetes, 6 cigarettes per day, low physical 
activity, 3rd SIMD, prior hospitalisation over last year, and the best GHQ score. 
The predicted cumulative incidence was consistent with the observed 
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cumulative incidence (Figure 6-3 and Figure 6-4), and it revealed that emergency 
and non-emergency admission with non–CVD condition gradually increased over 
time, with females showing a higher cumulative incidence than males. The 
incidence of those events was higher than other events which likely remained 
steady both males and females.  
6.3.3 Assessment of model performance for predicting first 
events after survey date 
Model discrimination of first events 
For discrimination of the cause-specific hazard model, Harrell’s C– 
statistic was assessed (Steyerberg, 2009, Harrell et al., 1996, Harrell et al., 
1982), where the general predictive discrimination of models used selected 
modifiable risk factors as explanatory variables. This analysis showed that the 
model discriminated in the follow-up period. Harrell’s C–statistic values of 
cause-specific hazard models are shown in Table 6-4, Table 6-5, Table 6-6, and 
Table 6-7, classified by gender and alcohol-related conditions. Harrell’s C–
statistic of models for alcohol-related first events ranged from 0.66 to 0.81, and 
the regression models of males predicted discrimination better than the females’ 
models. Moreover, for non–alcohol related hospitalisations, the predictive 
discrimination of these models ranged from 0.63 to 0.87. The best predictive 
discrimination was the non-alcohol related death models with a Harrell’s C–
statistic value of 0.91 for males and 0.92 for females. 
Internal validity of predicting first events  
 The cause-specific hazard models were internally validated by comparing 
the numbers of predicted and observed first events across the linear predictors 
quintile (e.g. the highest fifth of linear predictors are those individuals at highest 
risk). Table 6-8 and Table 6-9 present the compared events of alcohol-related 
conditions while Table 6-10 and Table 6-11 present the compared events of non-
alcohol related condition classified by gender. Then, a pair t-test was used to 
determine whether there was a difference in the number of predicted events 
compared with the observed events across the risk quintile. As the p-values were more 
than 0.05 across all quintiles, it can be concluded that there was no difference in the 
number of predicted first events compared to observed first events.           
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  Table 6-4 Cause-specific hazards of alcohol-related first event after survey date: males 
 *Covariate reference: aged 16 years, AUDIT score=0, non-binge drinking, no CVD, no diabetes, non-smoking, no physical activity, most deprived (1st SIMD), no prior 
hospitalisation, and GHQ score=0 (best) 
 
a) wholly alcohol-related hospitalisation 
 
b) partly alcohol-related hospitalisation 
 
c)  alcohol-related death 
Covariate* Hazard ratio p-value 95%CI 
 
Hazard ratio p-value 95%CI 
 
Hazard ratio p-value 95%CI 
Age at survey date 0.999 0.923 0.981 1.018 
 
1.055 <0.001 1.046 1.063 
 
1.030 0.010 1.007 1.053 
AUDIT score 1.062 0.002 1.022 1.102 
 
1.021 0.132 0.994 1.049 
 
1.049 0.066 0.997 1.104 
Binge drinking 0.695 0.259 0.369 1.308 
 
1.095 0.528 0.826 1.451 
 
1.529 0.271 0.717 3.256 
CVD 1.535 0.135 0.876 2.689 
 
1.488 0.001 1.179 1.876 
 
1.277 0.491 0.637 2.559 
Diabetes 0.342 0.294 0.046 2.542 
 
1.028 0.900 0.672 1.570 
 
2.268 0.117 0.815 6.310 
Cigarettes per day 1.029 0.000 1.018 1.040 
 
1.012 0.004 1.004 1.020 
 
1.018 0.062 0.999 1.038 
Low physical activity 1.127 0.765 0.513 2.479 
 
0.952 0.782 0.673 1.348 
 
0.421 0.138 0.134 1.320 
Medium physical activity 0.587 0.143 0.287 1.198 
 
1.015 0.920 0.760 1.355 
 
0.528 0.127 0.233 1.199 
High physical activity 0.611 0.194 0.291 1.285 
 
0.671 0.021 0.479 0.941 
 
0.713 0.432 0.307 1.656 
2nd SIMD 0.569 0.099 0.291 1.112 
 
0.925 0.641 0.666 1.284 
 
0.941 0.868 0.456 1.939 
3rd SIMD 0.506 0.057 0.251 1.021 
 
1.286 0.100 0.953 1.737 
 
0.260 0.017 0.086 0.783 
4th SIMD 0.450 0.042 0.208 0.973 
 
0.734 0.083 0.518 1.041 
 
0.509 0.143 0.206 1.257 
5th SIMD (least deprived) 0.477 0.073 0.212 1.070 
 
1.036 0.832 0.745 1.442 
 
0.505 0.162 0.193 1.317 
Hospitalised last year 1.602 0.273 0.690 3.717 
 
1.672 0.003 1.191 2.349 
 
4.419 0.001 1.897 10.292 
Hospitalised over 1 year 1.354 0.280 0.781 2.346 
 
1.235 0.078 0.976 1.563 
 
1.440 0.322 0.700 2.965 
GHQ score (1-3) 1.459 0.231 0.787 2.707 
 
1.031 0.817 0.798 1.332 
 
1.287 0.492 0.627 2.639 
GHQ score (4+worse) 2.777 0.001 1.528 5.044 
 
1.046 0.795 0.745 1.469 
 
1.596 0.254 0.715 3.562 
Constant -7.452 <0.001 -8.786 -6.118 
 
-8.906 <0.001 -9.595 -8.217 
 
-9.755 <0.001 -11.540 -7.969 
Gamma -0.033 0.324 -0.099 0.033 
 
0.043 0.002 0.016 0.070 
 
0.038 0.309 -0.035 0.112 
Harrell's C-statistic 0.814 
    
0.758 
    
0.752 
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Table 6-5 Cause-specific hazards of non-alcohol related first event after survey date: males 
 
a) emergency admission and non-CVD condition        b) emergency admission and CVD condition  
Covariate* Hazard ratio p-value 95%CI 
 
Hazard ratio p-value 95%CI 
Age at survey date 1.017 <0.001 1.014 1.019 
 
1.066 <0.001 1.058 1.074 
AUDIT score 1.013 0.007 1.004 1.022 
 
0.996 0.746 0.970 1.022 
Binge drinking 0.853 0.002 0.771 0.943 
 
1.020 0.882 0.785 1.326 
BMI (25-<30) 0.936 0.140 0.857 1.022 
 
1.402 0.006 1.103 1.781 
BMI (>=30) 0.894 0.032 0.807 0.990 
 
1.283 0.075 0.975 1.690 
CVD 1.196 <0.001 1.095 1.305 
 
1.732 <0.001 1.410 2.126 
Diabetes 1.468 <0.001 1.266 1.703 
 
1.537 0.004 1.152 2.050 
Cigarettes per day 1.008 <0.001 1.005 1.011 
 
1.024 <0.001 1.019 1.030 
Low physical activity 0.716 <0.001 0.629 0.815 
 
1.054 0.710 0.798 1.392 
Medium physical activity 0.694 <0.001 0.625 0.770 
 
0.926 0.532 0.728 1.178 
High physical activity 0.690 <0.001 0.619 0.771 
 
0.744 0.042 0.560 0.990 
2nd SIMD 0.886 0.022 0.798 0.983 
 
1.028 0.832 0.795 1.329 
3rd SIMD 0.709 <0.001 0.636 0.791 
 
0.820 0.145 0.628 1.071 
4th SIMD 0.752 <0.001 0.674 0.839 
 
0.795 0.104 0.602 1.049 
5th SIMD (least deprived) 0.704 <0.001 0.626 0.791 
 
0.728 0.039 0.539 0.983 
Hospitalised last year 2.504 <0.001 2.231 2.811 
 
1.681 0.001 1.252 2.256 
Hospitalised over 1 year 1.548 <0.001 1.423 1.684 
 
1.295 0.018 1.044 1.606 
GHQ score (1-3) 1.170 <0.001 1.073 1.276 
 
1.073 0.540 0.857 1.342 
GHQ score (4+worse) 1.388 <0.001 1.251 1.541 
 
1.249 0.111 0.951 1.641 
Constant -4.141 <0.001 -4.353 -3.930 
 
-9.461 <0.001 -10.105 -8.816 
Gamma -0.021 <0.001 -0.031 -0.011 
 
0.050 <0.001 0.025 0.075 
Harrell's C-statistic 0.645 
    
0.836 
   
*Covariate reference: aged 16 years, AUDIT score=0, non-binge drinking, BMI<25, no CVD, no diabetes, non-smoking, no physical activity, most deprived (1st SIMD), 
no prior hospitalisation, and GHQ score=0 (best) 
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Table 6-5 Cause-specific hazards of non-alcohol related first event after survey date: males (cont.) 
 
c) non-emergency admission and non-CVD condition  d) non-emergency admission and CVD condition  e) Non-alcohol related death 
Covariate* Hazard ratio p-value 95%CI 
 
Hazard ratio p-value 95%CI 
 
Hazard ratio p-value 95%CI 
Age at survey date 1.023 <0.001 1.021 1.025 
 
1.051 <0.001 1.040 1.062 
 
1.095 <0.001 1.080 1.110 
AUDIT score 1.0003 0.946 0.993 1.008 
 
0.992 0.665 0.955 1.030 
 
1.013 0.579 0.968 1.061 
Binge drinking 0.921 0.037 0.853 0.995 
 
1.074 0.703 0.744 1.551 
 
0.896 0.648 0.560 1.434 
BMI (25-<30) 1.112 0.002 1.039 1.191 
 
1.140 0.422 0.829 1.568 
     
BMI (>=30) 1.027 0.507 0.948 1.113 
 
0.882 0.516 0.605 1.288 
     
CVD 0.999 0.976 0.933 1.069 
 
3.065 <0.001 2.273 4.133 
 
1.464 0.031 1.035 2.070 
Diabetes 1.197 0.006 1.053 1.360 
 
1.215 0.355 0.804 1.834 
 
1.452 0.115 0.913 2.307 
Cigarettes per day 1.000 0.789 0.997 1.003 
 
1.007 0.208 0.996 1.019 
 
1.020 <0.001 1.012 1.029 
Low physical activity 1.057 0.289 0.954 1.171 
 
1.081 0.692 0.735 1.590 
 
0.490 0.006 0.296 0.811 
Medium physical activity 0.998 0.956 0.915 1.088 
 
0.926 0.657 0.659 1.302 
 
0.573 0.004 0.391 0.840 
High physical activity 0.987 0.782 0.902 1.081 
 
0.767 0.186 0.517 1.137 
 
0.391 <0.001 0.236 0.650 
2nd SIMD 1.038 0.401 0.951 1.133 
 
0.793 0.238 0.540 1.165 
 
0.831 0.417 0.530 1.301 
3rd SIMD 1.007 0.882 0.923 1.097 
 
0.800 0.244 0.549 1.165 
 
0.844 0.451 0.542 1.313 
4th SIMD 1.053 0.238 0.966 1.148 
 
0.954 0.802 0.659 1.380 
 
0.902 0.652 0.576 1.413 
5th SIMD (least deprived) 0.933 0.144 0.851 1.024 
 
0.812 0.316 0.540 1.220 
 
0.748 0.260 0.452 1.239 
Hospitalised last year 2.586 <0.001 2.369 2.823 
 
2.484 <0.001 1.719 3.589 
 
2.077 0.011 1.181 3.651 
Hospitalised over 1 year 1.464 <0.001 1.373 1.561 
 
1.086 0.600 0.798 1.476 
 
2.322 <0.001 1.509 3.575 
GHQ score (1-3) 1.225 <0.001 1.147 1.309 
 
1.252 0.149 0.923 1.698 
 
1.152 0.475 0.782 1.696 
GHQ score (4+worse) 1.285 <0.001 1.179 1.400 
 
1.662 0.005 1.166 2.368 
 
1.883 0.003 1.241 2.855 
Constant -4.315 <0.001 -4.488 -4.143 
 
-9.286 <0.001 -10.165 -8.406 
 
-12.161 <0.001 -13.342 -10.981 
Gamma -0.029 <0.001 -0.037 -0.021 
 
0.029 0.109 -0.007 0.065 
 
0.098 <0.001 0.054 0.142 
Harrell's C-statistic 0.657 
    
0.852 
    
0.911 
   
*Covariate reference: aged 16 years, AUDIT score=0, non-binge drinking, BMI<25, no CVD, no diabetes, non-smoking, no physical activity, most deprived (1st SIMD), 
no prior hospitalisation, and GHQ score=0 (best) 
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Table 6-6 Cause-specific hazards of alcohol-related first event after survey date: females 
 a) wholly alcohol-related hospitalisation  b) partly alcohol-related hospitalisation  c)  alcohol-related death 
Covariate* Hazard ratio p-value 95%CI  Hazard ratio p-value 95%CI  Hazard ratio p-value 95%CI 
Age at survey date 0.996 0.757 0.974 1.020  1.031 <0.001 1.025 1.037  1.053 <0.001 1.029 1.078 
AUDIT score 1.050 0.165 0.980 1.125  1.002 0.916 0.969 1.035  1.058 0.172 0.976 1.147 
Binge drinking 0.808 0.645 0.327 1.999  0.901 0.454 0.685 1.184  0.919 0.863 0.354 2.389 
CVD 1.466 0.318 0.692 3.106  1.131 0.210 0.933 1.371  1.103 0.773 0.565 2.153 
Diabetes 0.719 0.751 0.093 5.545  0.978 0.923 0.629 1.522  0.863 0.844 0.199 3.744 
Cigarettes per day 1.045 0.001 1.018 1.074  1.015 0.002 1.005 1.025  1.044 0.001 1.017 1.072 
Low physical activity 0.407 0.181 0.109 1.517  0.962 0.795 0.721 1.285  0.349 0.061 0.116 1.050 
Medium physical activity 0.420 0.054 0.174 1.014  0.789 0.047 0.624 0.997  0.373 0.009 0.177 0.785 
High physical activity 0.616 0.308 0.243 1.564  0.635 0.001 0.482 0.837  0.183 0.004 0.058 0.580 
2nd SIMD 0.582 0.248 0.233 1.457  0.841 0.187 0.650 1.088  1.248 0.609 0.534 2.916 
3rd SIMD 0.846 0.702 0.360 1.992  1.021 0.871 0.794 1.313  1.044 0.927 0.418 2.606 
4th SIMD 0.402 0.117 0.128 1.257  0.827 0.161 0.633 1.079  0.767 0.616 0.271 2.166 
5th SIMD (least deprived) 0.481 0.209 0.153 1.506  1.058 0.677 0.813 1.376  1.128 0.812 0.418 3.048 
Hospitalised last year 1.866 0.277 0.606 5.747  1.529 0.005 1.137 2.056  4.923 0.008 1.506 16.096 
Hospitalised over 1 year 1.550 0.278 0.702 3.420  1.381 0.001 1.140 1.674  3.938 0.006 1.495 10.375 
GHQ score (1-3) 1.130 0.779 0.482 2.645  1.149 0.175 0.940 1.404  0.874 0.725 0.412 1.855 
GHQ score (4+worse) 2.243 0.040 1.036 4.857  1.265 0.048 1.002 1.598  1.108 0.803 0.494 2.487 
Constant -7.881 <0.001 -9.560 -6.202  -7.026 0.000 -7.531 -6.521  -11.726 <0.001 -13.777 -9.676 
Gamma -0.030 0.515 -0.120 0.060  0.024 0.028 0.003 0.045  0.099 0.010 0.023 0.175 
Harrell's C-statistic 0.808     0.663     0.809    
*Covariate reference: aged 16 years, AUDIT score=0, non-binge drinking, no CVD, no diabetes, non-smoking, no physical activity, most deprived (1st SIMD), no prior 
hospitalisation, and GHQ score=0 (best) 
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Table 6-7 Cause-specific hazards of non-alcohol related first event after survey date: females 
  a) emergency admission and non-CVD condition    b) emergency admission and CVD condition  
Covariate* Hazard ratio p-value 95%CI   Hazard ratio p-value 95%CI 
Age at survey date 1.014 <0.001 1.012 1.017  1.072 <0.001 1.062 1.082 
AUDIT score 1.003 0.638 0.991 1.015  0.943 0.045 0.890 0.999 
Binge drinking 0.877 0.014 0.790 0.974  0.941 0.792 0.600 1.477 
BMI (25-<30) 0.967 0.449 0.886 1.055  1.556 0.002 1.183 2.048 
BMI (>=30) 1.147 0.002 1.052 1.250  1.058 0.727 0.771 1.451 
CVD 1.234 <0.001 1.142 1.332  1.680 <0.001 1.311 2.153 
Diabetes 1.324 <0.001 1.148 1.527  2.151 <0.001 1.537 3.011 
Cigarettes per day 1.011 <0.001 1.008 1.015  1.041 <0.001 1.030 1.052 
Low physical activity 0.649 <0.001 0.580 0.727  0.731 0.086 0.511 1.045 
Medium physical activity 0.537 <0.001 0.492 0.587  0.681 0.008 0.512 0.904 
High physical activity 0.565 <0.001 0.511 0.624  0.647 0.019 0.449 0.931 
2nd SIMD 0.797 <0.001 0.728 0.872  0.750 0.082 0.543 1.037 
3rd SIMD 0.700 <0.001 0.636 0.771  1.022 0.891 0.749 1.394 
4th SIMD 0.653 <0.001 0.591 0.721  0.922 0.625 0.666 1.277 
5th SIMD (least deprived) 0.630 <0.001 0.566 0.702  0.752 0.139 0.516 1.097 
Hospitalised last year 2.557 <0.001 2.300 2.843  1.387 0.063 0.983 1.956 
Hospitalised over 1 year 1.590 <0.001 1.466 1.724  0.901 0.432 0.695 1.168 
GHQ score (1-3) 1.298 <0.001 1.202 1.402  0.993 0.961 0.751 1.313 
GHQ score (4+worse) 1.417 <0.001 1.299 1.546  1.686 <0.001 1.260 2.256 
Constant -3.919 <0.001 -4.105 -3.733  -9.991 <0.001 -10.823 -9.159 
Gamma -0.023 <0.001 -0.033 -0.014  0.045 0.005 0.013 0.076 
Harrell's C-statistic 0.678         0.867       
*Covariate reference: aged 16 years, AUDIT score=0, non-binge drinking, no CVD, no diabetes, non-smoking, no physical activity, most deprived (1st SIMD), no prior 
hospitalisation, and GHQ score=0 (best) 
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Table 6-7 Cause-specific hazards of non-alcohol related first event after survey date: females (cont.) 
  
c) non-emergency admission and non-CVD 
condition  d) non-emergency admission and CVD condition    e) Non-alcohol related death 
Covariate* Hazard ratio p-value 95%CI   Hazard ratio p-value 95%CI   Hazard ratio p-value 95%CI 
Age at survey date 1.013 <0.001 1.011 1.015  1.052 <0.001 1.037 1.066  1.109 <0.001 1.091 1.127 
AUDIT score 0.997 0.512 0.988 1.006  0.948 0.184 0.875 1.026  0.987 0.774 0.901 1.081 
Binge drinking 0.977 0.533 0.909 1.051  1.762 0.053 0.993 3.126  0.618 0.255 0.270 1.416 
BMI (25-<30) 1.021 0.467 0.965 1.079  1.894 0.006 1.203 2.981          
BMI (>=30) 1.022 0.526 0.956 1.092  1.206 0.467 0.728 1.998          
having CVD 1.074 0.013 1.015 1.136  3.011 <0.001 2.041 4.441  1.226 0.269 0.855 1.759 
having diabetes 1.114 0.096 0.981 1.264  1.756 0.034 1.044 2.952  1.836 0.022 1.091 3.088 
Cigarettes per day 1.003 0.027 1.000 1.006  1.026 0.008 1.007 1.045  1.053 <0.001 1.037 1.069 
Low activity 1.060 0.202 0.969 1.160  1.109 0.702 0.653 1.882  0.434 0.006 0.238 0.790 
Medium activity 1.069 0.066 0.996 1.149  0.984 0.943 0.632 1.532  0.542 0.004 0.356 0.827 
High activity 0.990 0.797 0.915 1.071  0.937 0.813 0.545 1.610  0.291 0.001 0.144 0.590 
2nd 0.918 0.016 0.856 0.984  1.278 0.303 0.801 2.039  0.947 0.805 0.611 1.466 
3rd 0.959 0.241 0.894 1.029  0.755 0.311 0.438 1.301  0.791 0.339 0.488 1.280 
4th 0.866 <0.001 0.805 0.931  0.640 0.132 0.358 1.144  0.939 0.795 0.581 1.516 
5th (least deprived) 0.817 <0.001 0.756 0.883  1.506 0.109 0.913 2.483  0.433 0.015 0.221 0.848 
within last year 2.798 <0.001 2.596 3.015  2.099 0.007 1.225 3.597  1.663 0.091 0.922 2.999 
over 1 year 1.616 <0.001 1.528 1.709  1.336 0.178 0.876 2.036  1.712 0.017 1.100 2.664 
GHQ score (1-3) 1.208 <0.001 1.143 1.277  0.739 0.171 0.480 1.139  1.086 0.684 0.729 1.620 
GHQ score (4+worse) 1.365 <0.001 1.281 1.455  1.262 0.296 0.815 1.953  1.162 0.542 0.716 1.885 
Constant -3.717 <0.001 -3.856 -3.578  -10.435 <0.001 
-
11.643 -9.228  -13.158 <0.001 -14.574 -11.742 
Gamma -0.035 <0.001 -0.041 -0.028  -0.026 0.351 -0.080 0.029  0.115 <0.001 0.067 0.162 
Harrell's C-statistic 0.632         0.849         0.919       
*Covariate reference: aged 16 years, AUDIT score=0, non-binge drinking, no CVD, no diabetes, non-smoking, no physical activity, most deprived (1st SIMD), no prior 
hospitalisation, and GHQ score=0 (best) 
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Figure 6-5 Predicted cumulative incidence of first events: males* 
 
*Risk profiles: males, aged 30 years, AUDIT score=10, binge drinking, overweight, no CVD, no 
diabetes, 7 cigarettes per day, medium physical activity, 3rd SIMD, prior hospitalisation over 
last year, and best GHQ score 
Figure 6-6 Predicted cumulative incidence of first events: females* 
 
*Risk profiles: females, aged 30 years, AUDIT score=6, binge drinking, overweight, no CVD, no 
diabetes, 6 cigarettes per day, low physical activity, 3rd SIMD, prior hospitalisation over last 
year, and best GHQ score 
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Table 6-8 Comparison of observed and predicted first alcohol-related events: males 
  Number of events  
Quintile of linear predictors  
a) wholly alcohol-related 
hospitalisation   
b) partly alcohol-related 
hospitalisation   c)  alcohol-related death p-value 
  Observed Predicted   Observed Predicted   Observed Predicted  
1st (lowest risk) 3 3  11 18  2 2 0.423 
2nd 1 4  31 35  3 4 0.094 
3rd 5 6  65 58  5 5 0.510 
4th 9 10  101 92  10 8 0.377 
5th (highest risk) 33 28   133 138   18 19 0.919 
Table 6-9 Comparison of observed and predicted first alcohol-related events: females 
   Number of events  
Quintile of linear predictors  
a) wholly alcohol-related 
hospitalisation   
b) partly alcohol-related 
hospitalisation   c)  alcohol-related death p-value 
  Observed Predicted   Observed Predicted   Observed Predicted  
1st (lowest risk) 2 2  53 54  0 0 0.423 
2nd 1 3  83 78  3 1 0.497 
3rd 3 4  87 98  3 3 0.373 
4th 10 6  137 129  6 7 0.294 
5th (highest risk) 16 17   142 143   19 19 0.183 
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Table 6-10 Comparison of observed and predicted first non-alcohol related events: males 
  Number of events 
Quintile of linear 
predictors  
a) emergency admission and 
non-CVD condition  
b) emergency admission and 
CVD condition  
 c) non-emergency admission and 
non-CVD condition 
  Observed Predicted   Observed Predicted  Observed Predicted 
1st (lowest risk) 376 348  4 13  620 609 
2nd 406 409  19 28  708 754 
3rd 473 480  61 53  874 852 
4th 495 529  121 106  958 965 
5th (highest risk) 672 656   214 219  1,142 1,123 
 
  Number of events  
Quintile of linear predictors    
d) non-emergency admission 
and CVD condition   e) non-alcohol related death p-value 
    Observed Predicted   Observed Predicted  
1st (lowest risk)  1 8  0 1 0.556 
2nd  13 15  6 4 0.257 
3rd  27 27  6 10 0.505 
4th  60 49  28 24 0.815 
5th (highest risk)   110 113   91 92 0.364 
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Table 6-11 Comparison of observed and predicted first non-alcohol related events: females 
  Number of events 
Quintile of linear 
predictors  
a) emergency admission and 
non-CVD condition  
b) emergency admission and 
CVD condition  
 c) non-emergency admission and 
non-CVD condition 
  Observed Predicted   Observed Predicted  Observed Predicted 
1st (lowest risk) 377 337  3 4  874 862 
2nd 438 424  8 11  1,074 1,031 
3rd 504 518  23 25  1,085 1,147 
4th 600 642  66 61  1,324 1,326 
5th (highest risk) 982 981   169 168  1,506 1,497 
 
  Number of events  
Quintile of linear predictors  
d) non-emergency admission 
and CVD condition e) non-alcohol related death p-value 
  Observed Predicted   Observed Predicted  
1st (lowest risk) 0 2  2 1 0.275 
2nd 5 5  0 2 0.298 
3rd 11 11  5 6 0.253 
4th 35 26  17 19 0.523 
5th (highest risk) 68 75   74 71 0.614 
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6.3.4 Modelling stage II: Survival following hospitalisation 
The hazard ratios (HRs) of all-cause deaths after the first hospitalisation 
(i.e. alcohol-related and non-alcohol related condition) are shown in Table 6-12 
and Table 6-13 for males and females, respectively. All cause-specific hazard 
ratios were derived from a Gompertz regression and multiple imputation using 
chained equations. The non-modifiable risk factors selected were age at the 
first hospitalisation, CVD condition, diabetes, and SIMD quintile. When other 
covariates were adjusted, HR values for males for a one-year increase in age at 
first hospitalisation were 1.047 (95% CI [1.032, 1.062], p<0.001) for death 
following alcohol-related hospitalisation, and 1.084 (95% CI [1.079, 1.089], 
p<0.001) for death following non-alcohol related hospitalisation. HR values for 
females were slightly higher than males at 1.064 (95% CI [1.049, 1.079], 
p<0.001) for death following alcohol-related hospitalisation, and 1.090 (95% CI 
[1.085, 1.095], p<0.001) for death following non-alcohol related 
hospitalisation. CVD and diabetes conditions were shown to increase the risk of 
death, particularly post non-alcohol related hospitalisation. For males, HR 
values were 1.193 (95% CI [1.058, 1.346], p=0.004) for CVD, and 1.564 (95% CI 
[1.309, 1.868], p<0.001) for diabetes. For females, HR values were 1.327 (95% 
CI [1.183, 1.488], p<0.001) for CVD, and 1.274 (95% CI [1.058, 1.535], p=0.011) 
for diabetes.   
Compared with most deprivation (1st SIMD quintile), less deprivation (2nd 
to 5th SIMD quintiles) was shown to have protective effects from all-cause 
deaths following non-alcohol related hospitalisation in both males and females 
with a significant level of p<0.001. Less deprivation was seen reducing risk 
between 26% and 50% for all-cause death for males and 38% and 62% less risk of 
death for females. For all-cause death following alcohol-related hospitalisation, 
less deprivation was not statistically significant in terms of increasing death 
risk. In addition, the shape parameter (gamma) of the Gompertz model was 
shown to increase hazard over time (gamma=0.041, p<0.001 for males and 
0.020, p=0.01 for females) for only all-cause death post non-alcohol related 
hospitalisation.  
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Figure 6-7 to Figure 6-10 present the Kaplan-Meier graphs of observed 
survival after first alcohol-related and non-alcohol related hospitalisations over 
the 20-year follow-up period, classified by gender. The graphs revealed that 
survival for males after alcohol-related hospitalisation were lower than non-
alcohol related hospitalization with survival at 55% versus 75%, respectively. 
For females, survivals were likely similar when comparing between survival 
between alcohol-related and non-alcohol related hospitalisation.  
To estimate the survival for the lifetime period, risk profiles were 
selected to predict survival after first hospitalisation beyond the follow-up 
period, classified by gender as shown in Figure 6-11 for males and Figure 6-12 
for females. The selected risk profile was aged 35 at the time of the first event, 
no CVD, no diabetes, and 3rd SIMD. The predicted survival curves showed that 
survival following alcohol-related hospitalisation is seen to be lower than the 
survival following non-alcohol related admission over time. However, the 
predicted survival curves showed long tails due to the limited follow-up period 
so the linear predictors of survival models would need to be adjusted by 
calibration factors derived from the Scottish life table (National Records of 
Scotland, 2014). The adjusted survival curves are shown in the following 
section.  
6.3.5 Assessment of model performance for predicting 
survival after first hospitalisation 
Model discrimination of survival after first hospitalisation 
Harrell’s C–statistic of the survival models are shown in Table 6-12 and 
Table 6-13 classified by gender and first hospitalisation. Harrell’s C–statistic 
values of models for death following alcohol-related hospitalisation were 0.68 
and 0.76 for males and females, respectively. The C-statistic of models for 
death following non-alcohol related hospitalisation were better at predicting 
discrimination than the previous models, at 0.81 for males and 0.84 for females. 
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Internal validity of predicting survival post hospitalisation  
 The survival model was internally validated by comparing between the 
number of predicted and observed deaths across the linear predictor quintile 
(e.g. the highest fifth of linear predictors are those at highest risk). Table 6-14 
and Table 6-15 present the comparison between observed and predicted 
mortality following alcohol-related and non-alcohol related hospitalisations for 
males and females, respectively. Then, a pair t-test was used to determine 
whether there was a difference in the number of predicted deaths compared 
with observed deaths across the risk quintile. As the p-values are more than 
0.05 across all quintiles, it can be concluded that there was no difference in 
the number of predicted deaths compared with observed death.     
Calibration model predictors using Scottish life table 
 Even though the model performed well for predicting first events and 
death following first events as shown in the internal validation, the model was 
not as good at predicting life expectancy as can be seen by the long tail survival 
curves. Thus, predicted life expectancies were compared with the Scottish life 
table (National Records of Scotland, 2014). Then, the calibration factors 
(gender-specific value) were calculated for adjusting the linear predictors of 
models. This analysis applied a squared-error loss function (corresponding to 
the root mean square error, or RMSE) as shown in the formula below:  
𝑅𝑀𝑆𝐸𝑗 = √
1
𝑛
∑(
𝑛
𝑖=1
𝐿𝐸𝑖 −  𝐿?̂?𝑖
𝑗)2  
 where LEi is the Scottish life expectancy for the most and least 
deprivation of different ages, and 𝐿?̂?𝑖
𝑗  is the predicted life expectancy for j  
alternative multiplying factors which can minimise the RMSE. The selected 
multiplying factor is then applied to the linear predictor adjusting across all 
risk profiles. The results of calibration model predictors are presented in Table 
6-16 and Table 6-17. For males, the multiplying factor was 0.88 and was applied 
across the linear predictors of the first event models and death after first 
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hospitalisation models. The overall RMSEs of different age were 2.19 years and 
1.98 years for the most and least deprivation, respectively. For females, the 
different calibration factors of the predicting hospitalisation models and death 
models were 0.88 and 0.74, respectively. The overall RMSEs were 4.62 years for 
the most deprivation and 4.66 years for the least deprivation.          
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Figure 6-7 Observed survival after alcohol-related hospitalisation: males 
 
Figure 6-8  Observed survival after alcohol-related hospitalisation: females 
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Figure 6-9 Observed survival after non-alcohol related hospitalisation: males 
 
Figure 6-10 Observed survival after non-alcohol related hospitalisation: females 
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Table 6-12 Cause-specific hazards of all-cause death following first hospitalisation: males 
 a) death following alcohol-related hospitalisation  b) death following non-alcohol related hospitalisation  
Covariate* Hazard ratio p-value 95%CI  Hazard ratio p-value 95%CI 
Age at first hospitalisation 1.047 <0.001 1.032 1.062  1.084 <0.001 1.079 1.089 
CVD 1.232 0.268 0.852 1.783  1.193 0.004 1.058 1.346 
Diabetes 0.746 0.464 0.341 1.635  1.564 <0.001 1.309 1.868 
2nd SIMD 0.463 0.005 0.270 0.795  0.842 0.025 0.724 0.979 
3rd SIMD 0.562 0.020 0.347 0.913  0.630 <0.001 0.534 0.742 
4th SIMD 0.741 0.292 0.424 1.294  0.604 <0.001 0.511 0.714 
5th SIMD (least deprived) 0.649 0.109 0.383 1.101  0.501 <0.001 0.414 0.607 
Constant -5.200 <0.001 -6.190 -4.211  -8.498 <0.001 -8.847 -8.149 
Gamma -0.030 0.291 -0.086 0.026  0.041 <0.001 0.026 0.057 
Harrell's C-statistic 0.678     0.808    
 
*Covariate reference: aged 16 years, no CVD, no diabetes, and most deprived (1st SIMD) 
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Table 6-13 Cause-specific hazards of all-cause death following first hospitalisation: females 
  a) death following alcohol-related hospitalisation  b) death following non-alcohol related hospitalisation  
Covariate* Hazard ratio p-value 95%CI   Hazard ratio p-value 95%CI 
Age at first hospitalisation 1.064 <0.001 1.049 1.079  1.090 <0.001 1.085 1.095 
CVD 1.260 0.262 0.842 1.885  1.327 <0.001 1.183 1.488 
Diabetes 0.683 0.418 0.271 1.720  1.274 0.011 1.058 1.535 
2nd SIMD 1.001 0.996 0.574 1.746  0.617 <0.001 0.535 0.711 
3rd SIMD 1.281 0.341 0.769 2.133  0.557 <0.001 0.479 0.648 
4th SIMD 0.841 0.576 0.459 1.541  0.536 <0.001 0.458 0.626 
5th SIMD (least deprived) 0.749 0.351 0.408 1.375  0.381 <0.001 0.314 0.462 
Constant -6.985 <0.001 -8.047 -5.924  -8.927 <0.001 -9.271 -8.582 
Gamma -0.050 0.101 -0.110 0.010  0.020 0.010 0.005 0.035 
Harrell's C-statistic 0.764         0.840       
 
*Covariate reference: aged 16 years, no CVD, no diabetes, and most deprived (1st SIMD) 
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Figure 6-11 Predicted survival after first hospitalisation: males* 
i.unadjusted calibration factor 
 
 
ii.adjusted calibration factor** 
 
*Risk profiles: males, aged 45 at first event, no CVD, no diabetes, and 3rd SIMD  
** The multiplying factor was 0.88 which was applied across the linear predictor of the first 
event models and death after first hospitalisation models. 
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Figure 6-12 Predicted survival after first hospitalisation: females* 
a) unadjusted calibration factor 
 
 
b) adjusted calibration factor** 
 
*Risk profiles: females, aged 45 at first event, no CVD, no diabetes, and 3rd SIMD 
**The different calibration factors of the predicting hospitalisation models and death models 
were 0.88 and 0.74, respectively. 
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Table 6-14 Comparison of observed and predicted death following first hospitalisation events: males 
   Number of events  
Quintile of linear predictors  a) death post alcohol-related hospitalisation b) death post non-alcohol related hospitalisation p value 
  Observed Predicted   Observed Predicted  
1st (lowest risk) 12 13  29 33 0.344 
2nd 18 19  85 84 1.000 
3rd 28 29  197 203 0.395 
4th 38 34  379 371 0.205 
5th (highest risk) 37 37   601 600 0.500 
 
Table 6-15 Comparison of observed and predicted death following first hospitalisation events: females 
   Number of events  
Quintile of linear predictors  a) death post alcohol-related hospitalisation b) death post non-alcohol related hospitalisation p value 
  Observed Predicted   Observed Predicted  
1st (lowest risk) 2 6  29 22 0.831 
2nd 12 12  63 59 0.500 
3rd 22 21  176 166 0.437 
4th 31 31  370 409 0.500 
5th (highest risk) 51 49   776 758 0.430 
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Table 6-16 Calibration model predictors using the Scottish life table: males 
 Life expectancy (years) 
Age Scottish life table  
Model prediction 
(Unadjusted linear predictor)  
Model prediction 
(Multiplied linear predictor)*  
 (years) Most deprivation Least deprivation Most deprivation Least deprivation Most deprivation Least deprivation 
20 70.65 82.79  89.19 100.25  76.40 87.34 
25 70.99 82.86  87.26 98.72  75.19 85.86 
30 71.45 82.97  85.40 96.87  74.24 84.52 
35 72.04 83.1  83.77 95.02  73.55 83.36 
40 72.84 83.23  82.37 93.20  73.24 82.41 
45 73.81 83.4  81.33 91.59  73.32 81.81 
50 74.83 83.67  80.72 90.26  73.83 81.56 
55 76.05 84.00  80.59 89.31  74.82 81.72 
60 77.56 84.52  81.01 88.82  76.29 82.35 
65 79.36 85.23  82.01 88.82  78.22 83.45 
70 81.38 86.19  83.59 89.39  80.64 85.03 
75 83.95 87.60  85.73 90.54  83.47 87.11 
80 86.88 89.44  88.38 92.28  86.71 89.65 
85 90.22 92.04  91.49 94.57  90.26 92.60 
RMSE    9.16 9.24  2.19 1.98 
RMSE: Root mean square error 
* The multiplying factor was 0.88 which was applied across the linear predictor of the first event models and death after first hospitalisation models. 
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Table 6-17 Calibration model predictors using the Scottish life table: females 
 Life expectancy (years) 
Age Scottish life table  
Model prediction 
(Unadjusted linear predictor)  
Model prediction 
(Multiplied linear predictor)* 
(years) Most deprivation Least deprivation  Most deprivation Least deprivation  Most deprivation Least deprivation 
20 76.76 85.16  116.74 125.20  80.94 96.05 
25 76.88 85.19  114.80 125.91  77.98 93.63 
30 77.02 85.26  111.58 125.52  75.40 90.88 
35 77.36 85.31  107.14 123.95  73.40 88.11 
40 77.79 85.42  101.98 121.12  72.16 85.61 
45 78.23 85.54  96.75 117.10  71.67 83.71 
50 78.86 85.75  92.17 112.34  71.96 82.50 
55 79.70 86.11  88.72 107.37  72.97 82.03 
60 80.73 86.50  86.57 102.95  74.63 82.29 
65 82.06 87.07  85.73 99.51  76.86 83.26 
70 83.64 87.79  86.05 97.32  79.60 84.86 
75 85.69 88.85  87.40 96.37  82.77 87.04 
80 88.26 90.29  89.59 96.59  86.30 89.74 
85 91.15 92.31  92.44 97.81  90.10 92.84 
RMSE    9.85 10.52  4.62 4.66 
RMSE: Root mean square error 
* The different calibration factors of the predicting hospitalisation models and death models were 0.88 and 0.74, respectively.
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6.3.6 Modelling stage III: Estimating life years 
Table 6-18 (a-c) and Table 6-19 (a-c) demonstrate the three stages of 
estimating the overall life expectancy of individual risk profiles for males and 
females aged 30 years, respectively. Table 6-18a and Table 6-19a represent the 
first stage which is the sum of the survival time before the events and the 
survival time following the first hospitalisation for 100 annual cycles. For 
example, if the individual risk profile of males aged 30 years had a wholly 
alcohol-related hospitalisation in the first year (first cycle) after the survey 
date, the remaining LYs would be 44.4 years; this figure comprised a survival 
time of one year before having the event and a remaining survival time of 43.4 
years following the hospitalisation. Table 6-18b and Table 6-19b show the 
probabilities of having 8 first events across 100 annual cycles derived from the 
cause-specific hazard model of a particular risk profile as defined. Finally, the 
remaining LYs of each health state (Table 6-18a and Table 6-19a) were 
weighted by the probabilities of having a particular event (Table 6-18b and 
Table 6-19b), resulting in the predicted additional LYs after the survey date as 
shown in Table 6-18c and Table 6-19c. Thus, the estimated overall life 
expectancies of the defined risk profiles were 81.54 years and 84.27 years for 
males and females, respectively.  
To demonstrate the use of the model for predicting the LYs, the selected 
risk profiles were varied by age, group AUDIT score, smoking status and SIMD 
quintile. Subsequently, the predicted life expectancies of these risk profiles are 
illustrated in Table 6-20 and Table 6-21 for males and females, respectively. 
The model shows its ability to discriminate between risk profiles as presented 
by different life expectancies for both males and females. The results revealed 
that higher-risk drinking (higher AUDIT score), more deprived status and current 
smoker reduced life expectancies when other related risk profiles were also 
changed based on the characteristics of the study population .
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Table 6-18 Estimating life years using 3 stages: males* 
a) Life years remaining upon entering model (for hospitalisation, life year is equal to time before event added with the time remaining 
after event)  
Cycle Wholly alcohol-related  Partly alcohol-related  Non-emergency  Non-emergency Emergency Emergency 
Alcohol-
related  
Non-alcohol 
related  
(years) hospitalisation hospitalisation non-CVD admission  CVD admission 
 non-CVD 
admission 
 CVD 
admission 
death death 
         
1 44.4 44.4 55.4 55.4 55.4 55.4 1.0 1.0 
2 44.1 44.1 54.9 54.9 54.9 54.9 2.0 2.0 
3 43.8 43.8 54.5 54.5 54.5 54.5 3.0 3.0 
. . . . . . . . . 
. . . . . . . . . 
22 42.3 42.3 50.0 50.0 50.0 50.0 22.0 22.0 
23 42.5 42.5 49.9 49.9 49.9 49.9 23.0 23.0 
24 42.7 42.7 49.9 49.9 49.9 49.9 24.0 24.0 
. . . . . . . . . 
. . . . . . . . . 
100 101.0 101.0 100.5 100.5 100.5 100.5 100.0 100.0 
*Risk profiles: males, aged 30 years, AUDIT score=10, binge drinking, overweight, no CVD, no diabetes, 7 cigarettes per day, medium physical activity, 3rd SIMD, 
prior hospitalisation over last year, and best GHQ score 
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Table 6-18 Estimating life year using 3 stages: males* (cont.) 
b) Probability of having 8 events over 100 annual cycles  
Cycle Wholly alcohol-related  Partly alcohol-related  Non-emergency  Non-emergency Emergency Emergency 
Alcohol-
related  
Non-alcohol 
related  
(years) hospitalisation hospitalisation non-CVD admission  CVD admission 
 non-CVD 
admission 
 CVD 
admission 
death death 
         
1 0.0012 0.0037 0.0674 0.0013 0.0343 0.0022 0.0003 0.0004 
2 0.0011 0.0034 0.0582 0.0012 0.0299 0.0021 0.0003 0.0004 
3 0.0009 0.0032 0.0504 0.0011 0.0261 0.0019 0.0003 0.0004 
. . . . . . . . . 
. . . . . . . . . 
22 0.0001 0.0012 0.0047 0.0003 0.0028 0.0008 0.0001 0.0004 
23 0.0001 0.0011 0.0042 0.0003 0.0025 0.0008 0.0001 0.0004 
24 0.0001 0.0011 0.0037 0.0003 0.0023 0.0008 0.0001 0.0004 
. . . . . . . . . 
. . . . . . . . . 
100 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
*Risk profiles: males, aged 30 years, AUDIT score=10, binge drinking, overweight, no CVD, no diabetes, 7 cigarettes per day, medium physical activity, 3rd SIMD, 
prior hospitalisation over last year, and best GHQ score 
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Table 6-18 Estimating life year using 3 stages: males* (cont.) 
c) Weighting remaining life years estimated from stage a) multiplied by stage b)  
Cycle 
Wholly alcohol-
related 
Partly alcohol-
related Non-emergency Non-emergency Emergency Emergency 
Alcohol-
related 
Non-alcohol 
related  
(years) hospitalisation hospitalisation 
non-CVD 
admission CVD admission 
non-CVD 
admission 
CVD 
admission death death Sum 
          
1 0.0546 0.1627 3.7308 0.0701 1.9002 0.1226 0.0003 0.0004 6.0417 
2 0.0466 0.1498 3.1980 0.0637 1.6414 0.1138 0.0006 0.0008 3.4582 
3 0.0399 0.1384 2.7489 0.0581 1.4218 0.1058 0.0008 0.0011 2.9854 
. . . . . . . . . . 
. . . . . . . . . . 
22 0.0033 0.0488 0.2347 0.0150 0.1405 0.0406 0.0020 0.0087 0.3019 
23 0.0030 0.0471 0.2094 0.0142 0.1263 0.0392 0.0020 0.0092 0.2737 
24 0.0027 0.0455 0.1870 0.0134 0.1137 0.0379 0.0020 0.0098 0.2486 
. . . . . . . . . . 
. . . . . . . . . . 
100 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
*Risk profiles: males, aged 30 years, AUDIT score=10, binge drinking, overweight, no CVD, no diabetes, 7 cigarettes per day, medium physical activity, 3rd SIMD, 
prior hospitalisation over last year, and best GHQ score 
Total life years remaining (Cumulative sum over 100 cycles) = 51.54 
Overall life expectancy (age upon entering model plus remaining life years) = 81.54 
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Table 6-19 Estimating life year using 3 stages: females*  
a) Life year remaining upon entering model (for hospitalisation, life year is equal to time before event added with the time remaining 
after event)  
Cycle Wholly alcohol-related Partly alcohol-related 
Non-
emergency 
Non-
emergency Emergency Emergency 
Alcohol-
related 
Non-alcohol 
related 
(years) hospitalisation hospitalisation 
non-CVD 
admission CVD admission 
non-CVD 
admission 
CVD 
admission death death 
         
1 36.4 36.4 61.7 61.7 61.7 61.7 1.0 1.0 
2 36.0 36.0 60.9 60.9 60.9 60.9 2.0 2.0 
3 35.7 35.7 60.0 60.0 60.0 60.0 3.0 3.0 
. . . . . . . . . 
. . . . . . . . . 
22 36.2 36.2 49.6 49.6 49.6 49.6 22.0 22.0 
23 36.6 36.6 49.4 49.4 49.4 49.4 23.0 23.0 
24 36.9 36.9 49.2 49.2 49.2 49.2 24.0 24.0 
. . . . . . . . . 
. . . . . . . . . 
100 100.6 100.6 100.5 100.5 100.5 100.5 100.0 100.0 
*Risk profiles: females, aged 30 years, AUDIT score=6, binge drinking, overweight, no CVD, no diabetes, 6 cigarettes per day, low physical activity, 3rd SIMD, prior 
hospitalisation over last year, and best GHQ score 
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Table 6-19 Estimating life year using 3 stages: females* (cont.) 
b) Probability of having 8 events over 100 annual cycles  
Cycle Wholly alcohol-related Partly alcohol-related 
Non-
emergency 
Non-
emergency Emergency Emergency 
Alcohol-
related 
Non-alcohol 
related 
(years) hospitalisation hospitalisation 
non-CVD 
admission CVD admission 
non-CVD 
admission 
CVD 
admission death death 
         
1 0.0009 0.0070 0.0942 0.0008 0.0397 0.0009 0.0010 0.0004 
2 0.0007 0.0061 0.0778 0.0007 0.0332 0.0008 0.0010 0.0004 
3 0.0006 0.0054 0.0646 0.0006 0.0278 0.0007 0.0009 0.0004 
. . . . . . . . . 
. . . . . . . . . 
22 0.0000 0.0009 0.0034 0.0000 0.0018 0.0002 0.0006 0.0003 
23 0.0000 0.0008 0.0029 0.0000 0.0016 0.0002 0.0006 0.0003 
24 0.0000 0.0007 0.0026 0.0000 0.0014 0.0002 0.0006 0.0003 
. . . . . . . . . 
. . . . . . . . . 
100 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
*Risk profiles: females, aged 30 years, AUDIT score=6, binge drinking, overweight, no CVD, no diabetes, 6 cigarettes per day, low physical activity, 3rd SIMD, prior 
hospitalisation over last year, and best GHQ score 
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Table 6-19 Estimating life year using 3 stages: females* (cont.) 
c) Weighting remaining life years estimated from stage a) multiplied by stage b)  
Cycle 
Wholly alcohol-
related 
Partly alcohol-
related Non-emergency Non-emergency Emergency Emergency 
Alcohol-
related 
Non-alcohol 
related  
(years) hospitalisation hospitalisation 
non-CVD 
admission CVD admission 
non-CVD 
admission 
CVD 
admission death death Sum 
          
1 0.0320 0.2543 5.8092 0.0490 2.4478 0.0547 0.0010 0.0004 8.6484 
2 0.0263 0.2205 4.7347 0.0403 2.0177 0.0483 0.0019 0.0008 5.0217 
3 0.0217 0.1921 3.8759 0.0333 1.6705 0.0428 0.0027 0.0011 4.1230 
. . . . . . . . . . 
. . . . . . . . . . 
22 0.0013 0.0311 0.1675 0.0017 0.0895 0.0084 0.0134 0.0071 0.2016 
23 0.0011 0.0291 0.1455 0.0015 0.0786 0.0079 0.0140 0.0075 0.1772 
24 0.0010 0.0272 0.1266 0.0013 0.0692 0.0074 0.0145 0.0080 0.1561 
. . . . . . . . . . 
. . . . . . . . . . 
100 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
*Risk profiles: females, aged 30 years, AUDIT score=6, binge drinking, overweight, no CVD, no diabetes, 6 cigarettes per day, low physical activity, 3rd SIMD, Prior 
hospitalisation over last year, and best GHQ score 
Total life years remaining (Cumulative sum over 100 cycles) = 54.27 
Overall life expectancy (age upon entering model plus remaining life years) = 84.27 
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Table 6-20   Predicted life expectancies classified by risks profiles: males 
    Smoker (5 CPD)         Non-smoker         
    Age 20 years          Age 20 years        
   >20 75.03 79.46 83.81 83.83 86.32 
 
75.18 79.48 83.85 83.91 86.40 
A
U
D
IT
 s
c
o
re
 
16 - 19 75.96 79.81 84.04 84.37 86.88 
 
76.04 79.83 84.06 84.43 86.97 
8 - 15 76.12 79.87 84.08 84.47 86.98 
 
76.20 79.90 84.11 84.52 87.03 
0 - 7 76.40 79.99 84.12 84.60 87.16 
 
76.47 80.02 84.15 84.69 87.21 
  Age 30 years          Age 30 years       
 >20 72.97 76.97 80.97 81.07 83.51   73.11 77.04 81.03 81.19 83.61 
16 - 19 73.84 77.38 81.30 81.67 84.12   73.96 77.45 81.35 81.74 84.20 
8 - 15 74.00 77.45 81.37 81.75 84.25   74.12 77.53 81.42 81.85 84.32 
0 - 7 74.28 77.60 81.50 81.95 84.46   74.40 77.67 81.55 82.01 84.53 
  Age 40 years          Age 40 years       
 >20 72.14 75.57 79.04 79.23 81.43  72.28 75.64 79.15 79.34 81.57 
16 - 19 72.93 76.01 79.47 79.80 82.07  73.03 76.07 79.54 79.89 82.18 
8 - 15 73.08 76.10 79.53 79.92 82.20  73.18 76.16 79.63 80.00 82.31 
0 - 7 73.36 76.23 79.69 80.11 82.43  73.45 76.32 79.76 80.21 82.51 
  Age 50 years         Age 50 years       
 >20 72.93 75.70 78.57 78.77 80.68   73.06 75.79 78.66 78.88 80.80 
  16 - 19 73.59 76.12 79.00 79.30 81.27   73.70 76.20 79.08 79.39 81.40 
  8 - 15 73.73 76.21 79.07 79.41 81.40   73.84 76.29 79.16 79.51 81.50 
  0 - 7 73.99 76.36 79.25 79.60 81.64   74.09 76.44 79.34 79.69 81.74 
    1 2 3 4 5   1 2 3 4 5 
    most deprived  least deprived  most deprived  least deprived 
  SIMD quintile 
Note: binge drinking, BMI, physical activity, CVD, diabetes, prior hospitalisation, and GHQ score were varied but not presented. 
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Table 6-21 Predicted life expectancies classified by risks profiles: females 
    Smoker (4 CPD)         Non-smoker         
    Age 20 years          Age 20 years       
   >17 79.60 86.15 87.32 88.50 92.70   79.67 86.28 87.47 88.62 92.85 
A
U
D
IT
 s
c
o
re
 
13 – 16 80.57 87.74 88.99 89.94 94.72   80.59 87.78 89.05 89.99 94.80 
5 - 12 80.86 88.23 89.50 90.41 95.39   80.86 88.28 89.57 90.41 95.41 
0 - 4 81.13 88.65 89.94 90.79 95.94   81.09 88.67 89.98 90.76 95.96 
  Age 30 years          Age 30 years       
 >17 74.02 80.57 81.84 83.11 87.81   74.14 80.74 82.03 83.28 88.00 
13 – 16 74.83 81.91 83.24 84.31 89.59   74.90 82.01 83.38 84.41 89.68 
5 - 12 75.07 82.33 83.68 84.71 90.14   75.13 82.43 83.79 84.76 90.24 
0 - 4 75.28 82.68 84.05 84.99 90.65   75.33 82.75 84.14 85.06 90.68 
  Age 40 years          Age 40 years       
 >17 70.81 76.28 77.44 78.62 82.87  70.95 76.49 77.66 78.81 83.09 
13 – 16 71.46 77.37 78.56 79.60 84.36  71.58 77.54 78.74 79.73 84.51 
5 - 12 71.66 77.70 78.91 79.87 84.83  71.77 77.85 79.07 80.01 84.94 
0 - 4 71.82 77.98 79.21 80.11 85.22  71.90 78.11 79.32 80.21 85.31 
  Age 50 years         Age 50 years       
 >17 70.72 74.84 75.78 76.76 80.08   70.91 75.07 76.01 76.98 80.36 
  13 – 16 71.24 75.69 76.65 77.50 81.27   71.37 75.87 76.83 77.68 81.48 
  5 - 12 71.39 75.95 76.92 77.70 81.64   71.52 76.11 77.08 77.89 81.80 
  0 - 4 71.49 76.14 77.12 77.88 81.95   71.61 76.31 77.27 78.04 82.09 
    1 2 3 4 5   1 2 3 4 5 
    most deprived  least deprived  most deprived  least deprived 
  SIMD quintile 
Note: binge drinking, BMI, physical activity, CVD, diabetes, prior hospitalisation, and GHQ score were varied but not presented. 
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6.4 Discussion 
This chapter described the stages of developing an alcohol intervention 
model including the conceptualisation of the model, the construction of the 
health state transition model, data source used (i.e. SHeS-SMR/NRS linkage 
data), adjusted under-reporting alcohol consumption and dealing with missing 
data among survey population, and statistical approach used for data 
modelling, model validation, and calibration using the Scottish life table. The 
analyses also incorporated the predicted AUDIT score. Then, the model 
utilisation for predicting LYs of different risk profiles were demonstrated and 
the results presented were classified by modifiable risk factors, i.e. drinking 
status as measured by the AUDIT (Babor et al., 2001, Babor et al., 1989) - which 
was predicted using an OLS regression as described in Chapter 4, binge drinking, 
and other selected behavioural risk factors (e.g. cigarettes per day, BMI, and 
physical activity). The results showed that the developed alcohol intervention 
model was able to predict the hospitalisation and death events of each 
individual risk profile; most of the models indicated good performance in terms 
of predictive discrimination (Harrell’s C–statistic) and comparison between the 
number of predicted and observed events. However, the predicted overall life 
expectancies of different risks profiles were longer than the Scottish life table 
so the Scottish life expectancies were used to calibrate the model (National 
Records of Scotland, 2014). The predicted overall LYs of different drinking 
status can be used in the alcohol intervention model to monitor and evaluate 
the effectiveness of alcohol intervention in terms of morbidity and mortality. 
Furthermore, other modifiable behaviour risk factors were considered in the 
model.  
This study is likely the first one that uses linkage data between health 
surveys and recorded hospitalisations and deaths to model the wide range of 
events of interest, i.e. alcohol-related conditions and all occurring non-alcohol 
related conditions within the follow-up period.  Moreover, the modelling 
approach was applied to extrapolate the survival risk over the lifetime, and life 
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expectancy of different risk profile (including modifiable risk factors and 
socioeconomic status) was then estimated. The approaches used in this study 
can be used as a complimentary analysis to RCTs of an alcohol intervention, 
where effectiveness was estimated only for period of the study (Cowell et al., 
2012, Crawford et al., 2014, Crawford et al., 2015, UKATT Research Team, 
2005a). Therefore, this approach can be conducted to determine its 
effectiveness in terms of decreasing morbidity and mortality beyond study 
period.  
This current modelling study is the first one to incorporate alcohol 
drinking patterns as measured by the AUDIT score to identify individual alcohol 
use disorder by accounting for the average level of alcohol consumption, heavy 
episodic drinking, and other alcohol-related harms. This is different from most 
of the previous modelling studies, e.g. the cost-effectiveness of screening and 
brief intervention (SBI) for alcohol use disorder (Barbosa et al., 2015, Cowell et 
al., 2010, Purshouse et al., 2013, Angus et al., 2014a) as well as meta-analyses 
(Bray et al., 2011, Donoghue et al., 2014, Fachini et al., 2012, Babor et al., 
2007); these studies investigated changes of consumption and/or alcohol-
related harms within the follow-up period, and the changes in consumption 
level were then modelled to estimate the changes of alcohol-related diseases 
and/or other harms over time. Moreover, previous existing alcohol models had 
a limited number of ‘drinking states’ from which to examine the distribution of 
consumption and alcohol-related problems within the cohort, e.g. absenteeism, 
moderate-risk, and high-risk consumptions (Barbosa et al., 2015, Barbosa et al., 
2010b, Purshouse et al., 2013, Cobiac et al., 2009), leading to a limited range 
of drinking subgroups. However, the AUDIT score is able to classify a wider 
range of alcohol use disorders which may cause different alcohol-related 
problems and consequences. 
Not only were the wide range of drinking states presented in the current 
model but other risk factors (i.e. health behaviours and socioeconomic status) 
were combined with the AUDIT score to capture the overall impact of combined 
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risk factors on morbidity and mortality as well. Therefore, the results derived 
from this analysis can be shown via various risk profiles. Many observational 
studies as well as meta-analyses have also shown an increasing shift from 
interest in only alcohol consumption and its harms to focussing on the effects 
of combined risk behaviours (included alcohol drinking) to diseases and 
mortality (Khaw et al., 2008, Kvaavik et al., 2010, Loef and Walach, 2012, 
Petersen et al., 2015, Tamakoshi et al., 2010, Yun et al., 2012, Carlsson et al., 
2013, Klijs et al., 2011). According to methodological issues surrounding this 
analysis as mentioned above, the approach used for the current alcohol 
intervention model differed from other modelling studies so it would be 
difficult to directly compare with other alcohol intervention evaluation studies.   
Moreover, the developed model focussed on the relationship between 
the selected modifiable risk factor and the risk of first events (i.e. 
hospitalisations and deaths). Thus, this model can be applied for the evaluation 
of primary prevention interventions which aim to reduce the risk of a first event 
of interest. Finally, the model was also calibrated using the Scottish life table 
to adjust the linear predictor so it likely has high internal validity but low 
external validity. In particular, a key component of the alcohol intervention 
model in the Scottish context was the indices of deprivation or SIMD quintile 
(Office of the Chief Statistician, 2004), and this is not measured in other 
countries.  However, the linear predictor of the model can be recalibrated using 
country-specific life tables and SIMD quintiles as a covariate that can be 
replaced with other deprivation indices.            
6.5 Conclusions 
Long-term outcome measurements in alcohol intervention models and 
the evaluation of combined health risk behaviours is still scarce. The applicable 
approaches of this study would emphasise and recommend the use of routine 
national health surveys and national hospitalisation and death records as well 
as modelling morbidity and mortality of different combined modifiable risk 
profiles.   
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Chapter 7: The use of alcohol intervention model 
for predicting quality adjusted life years and 
lifetime hospitalisation costs 
7.1 Introduction 
Evaluation public health policy using a modelling approach has become 
increasingly applied to policy analyses which support the design of efficient and 
effective policy options for complex public health problems (Ashley et al., 2015, 
Atkinson et al., 2015, Brennan et al., 2014b). The economic evaluation of the 
alcohol policies has been applied for informing policy-decision makers at both 
population- and individual-levels interventions (Ashley et al., 2015, Barbosa et 
al., 2015, Barbosa et al., 2010b, Brennan et al., 2014a, Brennan et al., 2014b, 
Cadilhac et al., 2011, Chisholm et al., 2004, Galea et al., 2009, Holmes et al., 
2014a, Marsh et al., 2012, Byrnes et al., 2010, Cobiac et al., 2009, Purshouse 
et al., 2013). Thus, the model analysis tool is able to test the interest 
effectiveness and cost-effectiveness through modelling the expected changes 
in modifiable risk factors caused by the intervention. Although RCTs are still 
the gold standard of obtaining a causal estimate of intervention effectiveness, 
there is a limited follow-up period for conducting a cost-effectiveness analysis 
alongside RCTs as well as RCTs would not be appropriate for large-scale public 
health interventions. Thus, modelling studies are often necessary to 
extrapolate longer term outcome in a lifetime horizon beyond the end of the 
trials (Kruger et al., 2014, Barbosa et al., 2010a, Alayli-Goebbels et al., 2014). 
For model-based economic evaluations, lifetime QALYs and costs are widely 
recommended for the purposes of the economic evaluation of healthcare  
interventions to inform policy decision-making (ISPOR, 2014, NICE, 2013, 
Chaikledkaew and Kittrongsiri, 2014, Teerawattananon and Chaikledkaew, 
2008); these standard methods are also applied to public health interventions 
(Edwards et al., 2013, Weatherly et al., 2009).  
This study used a modelling approach, namely the alcohol intervention 
model, to examine the selected risk profiles (e.g. alcohol drinking, smoking and 
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SIMD) and the predicted long-term consequences in terms of life expectancy (as 
illustrated in Chapter 6), QALYs, and lifetime hospitalisation costs. The 
estimated costs and outcomes can be used for further economic evaluations of 
an alcohol intervention which aims to modify selected individual risk 
behaviours. This chapter describes the use of the developed alcohol 
intervention model for predicting health outcome in terms of QALYs as well as 
lifetime hospitalisation cost of the different selected risk profiles. First, the 
relevant health state transition model was specified to model the QALYs and 
hospitalisation costs. Second, using the SHeS-SMR/NRS linked dataset, the data 
modelling for predicting QALYs was performed using three components: 1) the 
baseline HRQoL score and utility decrement due to hospitalisation and the 
increasing AUDIT score as described in Chapter 5; 2) the annual probability of 
having subsequent hospitalisation after the first admission; and 3) adjusting the 
HRQoL of each health state with the survival function as described in Chapter 
6. Finally, based on the NHS perspective, the lifetime hospitalisation costs were 
modelled using three stages: 1) identifying the data source for cost analysis; 2) 
modelling annual hospitalisation costs since the year when the first event 
occurs; and 3) predicting life time hospitalisation costs. Furthermore, the 
results derived from the data model were compared to observed hospitalisation 
records (SMR 01; inpatients and day cases). Then, the estimated QALYs and 
lifetime healthcare costs were presented and classified by different individual 
risk profiles.      
7.2 Methods 
This study aimed to identify the first alcohol-related admissions (incident 
cases) and the following hospital admissions both alcohol and non-alcohol 
related conditions identified by ICD-9/ICD-10 (Appendix 1). Then, the 
associated healthcare costs and outcomes (i.e. life years and QALYs) for all 
individuals hospitalised were estimated and compared between health risk 
profiles classified by age, sex, risk behaviours (e.g. drinking and smoking), 
SIMD, and health conditions (e.g. CVD and DM). Individuals SHeS participants, 
who had hospital admissions, were derived from the SMR01, which is national 
data schemes that record comprehensive information including diagnoses (ICD-
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9/ICD-10) of inpatient/day case activity, procedures and diagnoses, day surgery 
and outpatient procedures, multiple and all emergency admissions, 
unintentional injuries admitted to National Health Service (NHS) hospitals in 
Scotland between 1981-2013 (Information Services Division, Fleming et al., 
2012). However, total long-term healthcare costs of study population will not 
be estimated due to a lack of comprehensive information as linkage record with 
diagnosis e.g. accident and emergency (A&E), outpatient and primary care 
attendances. Thus, this analysis estimated in particular of remaining QALYs and 
hospitalisation costs after survey date in long-term. These estimated QALYs and 
costs will be useful for comparison across risk profiles of the study population. 
7.2.1 Overview of the health state transition model 
Figure 7-1 illustrates the structure of the alcohol intervention model 
used for estimating QALY and lifetime hospitalisation costs. Chapter 6 detailed 
the health state transition model for predicting the competing first events after 
the survey date as well as death following hospitalisation classified by different 
risk profiles. Now, this chapter will focus on predicting the QALY and 
hospitalisation costs in the lifetime horizon after survey date using this model. 
To estimate QALY, there are three components that need to be identified and 
valued using statistical function (Figure 7-1) as follows: 1) baseline HRQoL index 
at the survey date, which is applied as the starting health state of the SHeS 
cohort  as presented by equation HRQoL [1]; 2) reduction in HRQoL (utility 
decrement) due to alcohol-related (i.e. wholly and partly alcohol attributable 
conditions) and non-alcohol related (i.e. four sub-states) hospitalisations, 
which is the impact of the hospitalisation health state on HRQoL as presented 
by equation HRQoL [2]; and 3) the annual probability of incurring subsequent 
hospitalisations (i.e. alcohol-related and non-alcohol related conditions) after 
survival from the first hospitalisation (equation p_2nd event), which is used for 
adjusting  utility decrement classified by alcohol-related and non-alcohol 
related conditions for the cohort’s lifetime horizon.  
For estimating lifetime hospitalisation costs, two costs components were 
estimated as shown in Figure 7-1. Firstly, annual healthcare costs of first events 
Chapter 7: An alcohol intervention model for predicting QALY and costs 191 
 
  
1
9
1
 
after the survey date for SHeS cohorts who had first admission (costs of the 
hospitalisation state) or died within 28 days after admission (costs of the death 
state) were estimated using a statistical function shown as equation Cost (1); 
this was designated as either alcohol-related or non-alcohol related. Secondly, 
annual healthcare costs of subsequent hospitalisations in the following years 
for those who had yet to experience any first hospitalisations were also 
calculated using equation Cost (2).    
  
 
Figure 7-1 Structure of the health state transition model for estimating QALYs 
and lifetime hospitalisation costs 
 
 
 
- - 
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7.2.2 Data modelling for predicting QALY  
Modelling stage I: Estimating the baseline HRQoL score and utility 
decrement due to hospitalisation and increasing AUDIT score 
 The estimation of the HRQoL score and utility decrement associated with 
alcohol drinking was described in Chapter 5. In summary, the SHeS 2003 
participants were measured using the SF-12 (Gray and Leyland, 2005)-a self-
reported generic measure of health status as shown in Appendix 4 (Ware et al., 
2001). However, the measured SF-12 cannot be used for calculating QALY as 
that requires a preference-based single index measure of health in terms of the 
utility index. Brazier and Roberts (2004) developed the estimation of utility 
score from the SF-6D (SF-12) coefficient as presented in Table 5-1 of Chapter 5 
(Brazier and Roberts, 2004). Then, the baseline SF-6D (SF-12) score of the SHeS 
2003 participants were presented as the average HRQoL score classified by aged 
groups, gender and SIMD quintiles. 
To estimate the impact of hospitalisation on HRQoL reduction (utility 
decrement), a multiple linear regression of the current HRQoL was conducted 
inclusive of prior hospitalisation in compared to no prior hospitalisation 
(reference group), and further classified into four groups:  1) prior wholly 
alcohol-related hospitalisation; 2) prior partly alcohol-related hospitalisation; 
3) prior CVD hospitalisation; and 4) prior non-CVD hospitalisation. Moreover, 
the period of each hospitalisation was also categorised to be within the last 
year and over one year. To define each hospitalisation before the interview 
date, the SHeS-SMR linkage data was explored using the ICD-9 and ICD-10 list 
as shown in Appendix 1 to classify those hospitalisations. Additionally, the 
relationship between alcohol use measured by the AUDIT and HRQoL was 
examined via the multivariate analysis. Other covariates, which were found to 
have an independent relationship with HRQoL were also taken into account, 
i.e. age at survey date and SIMD (Gray and Leyland, 2005, Office of the Chief 
Statistician, 2004).  
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Modelling stage II: Estimating risk of having subsequent hospitalisations 
after the first hospitalisation 
 Following the first hospitalisation after the survey date, the model 
predicted survival and life expectancy of the SHeS cohort as detailed in Chapter 
6. Furthermore, individuals who survived after the first hospitalisation are at 
risk of subsequent hospitalisations in the following years, and these re-
admissions affect to the amount of the HRQoL is reduced; therefore, estimating 
QALYs also takes into account the utility decrement due to subsequent 
hospitalisations. Thus, the risks of having subsequent hospitalisations were 
estimated using the SHeS-SMR linkage records of individuals who experienced 
the first hospitalisation, and those hospitalised patient records were analysed 
separately as patients who had either an alcohol-related or non-alcohol related 
hospitalisation as the first hospitalisation. Furthermore, males and females 
were modelled separately. The ICD-9 and ICD-10 codes (Appendix 1) presented 
as the principal diagnosis (the primary reason for admission) was used to 
identify the subsequent hospitalisations classified into be 6 conditions: 1) 
wholly alcohol-attributable hospitalisation; 2) partly alcohol-attributable 
hospitalisation; 3) non-emergency (EM) admission and non-cardiovascular 
disease (CVD); 4) non-EM admission with CVD; 5) EM admission and non-CVD; 
and 6) EM admission with CVD.  
 The aim of the analysis was to predict the annual probability that an 
individual who experienced alcohol-related and non-alcohol related 
hospitalisation would have any of that six-subsequent events conditional upon 
being alive at a certain point in time. The modelling average observed event 
count assumed that all individuals in the same subgroup (classified by gender 
and first hospitalisation) had the same risk profile. The maximum follow-up in 
the SHeS-SMR linkage record was approximately 19 years.  To apply the model, 
developing a multivariate analysis using observed data would allow for the 
extrapolation of a 100-year period as the model cycle length. For the purpose 
of prediction, piecewise polynomials of an order higher than linear was used 
because even though the linear spline is simple and can approximate many 
common relationships, it is not smooth and will not fit highly curved functions 
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well (Harrell, 2015); this method can overcome these problems. Cubic 
polynomials have been found to have nice properties with a good ability to fit 
sharply-curving shapes (Harrell et al., 1988, Smith, 1979). Cubic splines can be 
smoothened at the joint points (knots) by forcing the first and second 
derivatives of the function to agree at the knots. Since cubic spline regression 
models are piecewise polynomials, splines can be fitted to any existing 
regression programme once certain derived predictors are constructed. Thus, 
flexible forms of the relationship between the predictor and response can be 
specified with equal ease in all multiple regression models (Harrell et al., 1988).  
This analysis employed the restricted cubic splines to extrapolate 
observation, because the truncated power for restricted cubic splines allows 
for rational extrapolation beyond the outer knots (Harrell, 2015). For the first 
stage, the observed period was divided into equally-spaced percentiles, and the 
frequency of first event rates was estimated within each percentile. In the 
second stage, a set of knots was chosen which grouped the data into segments. 
Following Harrell’s guideline for STATA (Harrell, 2015), three knots were chosen 
to generate three segments; this allowed for piecewise regression between 
adjacent knots. When using restricted cubic splines, one obtains a continuous 
smooth function that is linear before the first knot, a piecewise cubic 
polynomial between adjacent knots, and linear again after the last knot. The 
restricted cubic splines function in STATA selects knots automatically based on 
the events frequencies across percentiles.   
The average event count per annual cycle of the model was estimated, 
by dividing the number of individuals having an event by the total number of 
alive SHeS cohorts. A multiple regression model was employed to estimate the 
annual risks of experiencing each subsequent hospitalisation utilising the 
covariates age at first hospitalisation and SIMD, and further sub-grouped by 
gender and first hospitalisations as mentioned above. In addition, the restricted 
cubic splines of time from the first hospitalisation were included in the 
modelling to predict the risk of event related to the period. It was noted that 
the time splines were different between the first hospitalisation even though 
these were similar across subsequent events and gender. A probit model was 
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selected based on the assumptions that the event proportions were continuous, 
ranging from 0 to 1, and following a standard normal distribution. 
Modelling stage III: Estimating QALY 
 Following the estimations of baseline utility, utility decrement due to 
hospitalisation, and risk of having subsequent hospitalisation over the lifetime 
period, this stage describes how these estimations are input into the alcohol 
intervention model to estimate QALYs using HRQoL adjusted for survival as 
estimated and detailed in Chapter 6: (Billingham and Abrams, 2002, Billingham 
et al., 1999). This approach combined the amount of time patients spent in a 
number of different health states with weights reflecting the HRQoL of those 
health states to create a composite measure of quality (referred to as utility) 
and quantity of life (Billingham and Abrams, 2002). Figure 7-1 is the health 
state transition model of this analysis. Based on the population level approach, 
the HRQoL of different health states which were derived from modelling stage 
I were combined with the survival function in each health state as represented 
by (Billingham and Abrams, 2002, Gray et al., 2011b): 
𝑄𝐴𝐿𝑌 (𝑇) =  ∫ 𝑄(𝑡)𝑆(𝑡)
𝑇
0
 
where 𝑆(𝑡) is the proportion of cohorts that survive to time t and 𝑄(𝑡) is 
the average HRQoL score of those survivors, which is then integrated between 
zero and fixed time T. Hence, the quality-adjusted survival curve is formed by 
plotting against time t, the product of the mean HRQoL score of patients alive 
at time t, and the probability of surviving to time t.          
There are four stages of the alcohol intervention model for predicting 
QALYs. Firstly, the starting SHeS cohort without any prior alcohol-related event 
was assigned a baseline utility by age at the survey date, gender, SIMD, and 
drinking behaviour as measured by the AUDIT (derived from modelling stage I).  
Secondly, the survival cohort who remained not hospitalised was adjusted by 
only the baseline HRQoL until death. For cohorts who experienced first 
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hospitalisation after the survey date, the reduction of HRQoL (utility 
decrement) was accounted for in the year of life when the first hospitalisation 
occurred and further classified by hospitalisation conditions (derived from 
modelling stage I). Thirdly, hospitalised patients had the risk of incurring 
subsequent admissions (derived from modelling stage II) so the effect of these 
hospitalisations on HRQoL and the annual risk of having following admissions 
were used for adjusting life year. Finally, the sum of quality-adjusted survival 
of each annual cycle in different health states was calculated for over 100 
cycles and presented by the remaining QALYs for cohorts who remained alive. 
7.2.3 Data modelling for predicting lifetime hospitalisation 
costs  
Modelling stage I: Identifying the data source for estimating 
hospitalisation costs 
 Similar to previous analyses, this analysis used the SHeS-SMR linkage data 
(SMR01, acute inpatient and day cases) as described in Chapter 3. For each 
episode of hospitalisation after survey date, ICD-9 and ICD-10 codes were used 
to record the primary diagnosis up to the sixth diagnosis as well as to define 
whether the hospitalisation was alcohol-related or non-alcohol related as shown 
in Appendix 1. The length of stay (LOS) was also recorded. SHeS-SMR01 
participants were followed up from the survey date either until death or the 
end of the study period on 31st December 2013. For estimating healthcare costs, 
the resource of cost information was obtained from the Scottish health services 
costs (‘Cost book’) in 2013 (Information Services Division (ISD), 2013). The costs 
are specified by each of the 14 regional health boards and specialty code 
related to admission condition as provide the listing cost by ISD Scotland 
(Information Services Division (ISD), 2015).   
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Modelling stage II: Estimating annual hospitalisation costs in the year of 
having first event and the following years 
Geue et al. in 2012 compared alternative costing methods of 
hospitalisation episode, and the study recommended the application of the 
healthcare resource groups (HRG) costing method (Geue et al., 2012). This 
method is a measure of case mix by presenting standard groupings for clinically 
similar treatments, which use a common set of healthcare resources (The 
Health and Social Care Information Centre, 2016). However, the limitation of 
this method for Scottish data was that costs for inpatient hospitalisation 
episodes were not available on an HRG level, only at specialty level. The 
purpose of the current study is to model the predicted lifetime healthcare  cost 
among specific risk profiles for economic evaluation which all future costs are 
discounted based on HTA guidelines (ISPOR, 2014, NICE, 2013, Chaikledkaew 
and Kittrongsiri, 2014, Teerawattananon and Chaikledkaew, 2008); as such, the 
actual hospital episode cost might not be estimated. Thus, per diem costing 
(method 3 from Geue et al., 2012) -which has been used for economic 
evaluation- is applied to this study using the Scottish health services costs as 
specified by 14 health boards and specialty (Information Services Division (ISD), 
2015, Information Services Division (ISD), 2013). The total costs per episode 
were calculated by the cost per bed day of the specific specialty and health 
board multiplied by individual LOS (Geue et al., 2012). To define the trim-point 
of cost per episode, any LOS longer than 28 days was excluded from this analysis 
(3,395 of 172,704 episodes) because long stay costs were not included in the 
Cost Book, and the mean of LOS was only 4.38 (95% CI 4.23, 4.53).   
Total annual costs per case were estimated by the sum of all hospital 
episodes in each year. The annual costs were modelled separately to be the 
annual healthcare cost in the year of occurring first event (equation Cost1 in 
Figure 7-1) and the following years after first event (equation Cost2 in Figure 
7-1). To model annual costs of following hospitalisations after the first event, 
the hospitalised patients were divided by first hospitalisation condition, i.e. 
alcohol-related or non-alcohol related hospitalisation; and the annual 
healthcare cost of subsequent hospitalisations in following years were also 
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modelled separately. Based on previous literature, the alternative approaches 
of modelling healthcare costs have been frequently discussed (Basu and 
Manning, 2009, Jones et al., 2015a, Briggs et al., 2005, Nixon and Thompson, 
2004, Dodd et al., 2006). The most recommended approach is fitting a 
generalised linear model (GLM) using a gamma distribution with log-link 
function as described in Chapter 4 (McCullagh and Nelder, 1989). This was found 
to be a good performance predictor for cost distribution (Dodd et al., 2006, 
Jones et al., 2015a).  
The GLM using gamma distribution with log-link function was employed 
to estimate the annual cost of each first hospitalisation (equation Cost1) and 
the annual costs of the following years after the first hospitalisation (equation 
Cost2), sub-grouped by gender. Modelling healthcare costs also used restricted 
cubic splines with three knots, similar to modelling the risk of subsequent 
hospitalisations as mentioned above (Harrell et al., 1988, Smith, 1979). The 
modelling covariates included age at survey date for equation Cost1, age at 
first hospitalisation for equation Cost2, and SIMD. In addition, the restricted 
cubic splines of time from the survey date (equation Cost1) and time spline 
from the first hospitalisation (equation Cost2) were included in the modelling 
to predict annual hospitalisation costs related to the time period; the time 
spline was similar between males and females. These explanatory variables 
were used to model the log of arithmetic mean cost using the GLM with gamma 
distribution and log link function, which was performed as: 
ln[𝐸(𝑦|𝑥)] =  𝑥𝛽 
Modelling stage III: Estimating lifetime hospitalisation costs 
To estimate the lifetime hospitalisation costs, the average yearly 
hospitalisation costs (derived from modelling stage II) were adjusted by 
predicted survival over the lifetime using the same alcohol intervention model 
used for estimating QALY (Billingham and Abrams, 2002, Billingham et al., 
1999); the predicted survival was described in Chapter 6. This modelling stage 
combined the predicted annual cost of each year with predicted survival. There 
were two components of predicting healthcare costs using the alcohol 
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intervention model. Firstly, SHeS cohorts who were not hospitalised had no 
predicted cost. For cohorts who experienced first hospitalisation after survey 
date, the annual hospitalisation cost was estimated in the year of incurring first 
event classified by hospitalisation conditions (derived from equation Cost1). 
Secondly, after first hospitalisation, these survival patients had the risk of 
incurring subsequent admissions in following years, so these subsequent 
hospitalisations costs (derived from equation Cost2) were adjusted by survival 
over lifetime. The sum of those two costs for each annual cycle was calculated 
over 100 cycles and presented as the healthcare costs of the remaining living 
cohorts.  
7.3 Results: Modelling for predicting QALY 
7.3.1 Baseline HRQoL score and utility decrement due to 
hospitalisation and increasing AUDIT score 
The baseline SF-6D (SF-12) HRQoL scores of SHeS participants across 
deprivation quintiles were estimated and classified by gender and aged groups 
showing the mean and 95% CI in Table 7-1 for males and Table 7-2 for females. 
It can be seen these baseline HRQoL scores that scores decreased with 
increasing age and more deprivation status for both males and females. For 
males, the overall HRQoL score decreased from 0.831 (95% CI 0.808, 0.854) in 
the least deprived SIMD to 0.754 (95% CI 0.719, 0.79) in the most deprived SIMD. 
For females, the HRQoL scores between the least and most deprivation were 
0.826 (95% CI 0.806, 0.846) and 0.737 (95% CI 0.707, 0.769), respectively. For 
both genders, the effect of deprivation status on HRQoL was lower in younger 
aged groups.  
As shown in Chapter 5, a multivariate analysis was conducted to 
investigate the impact of prior hospitalisation on current HRQoL score as 
presented in Table 7-3, classified by gender. For males, the decrement on 
HRQoL scores due to prior hospitalisation-where the impacts of having an event 
within the last year were greater than having an event over 1 year ago ranged 
from -0.072 (95% CI [-0.113, -0.031], p=0.001) to -0.123 (95% CI [-0.212, -0.033],  
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p=0.008) for wholly alcohol-related conditions, -0.027 (95% CI [-0.043, -0.012], 
p=0.001) to -0.069 (95% CI[-0.121, -0.018], p=0.008) for partly alcohol-related 
condition, as well as -0.043 (95% CI [-0.059, -0.026], p<0.001) for non-alcohol 
related and non-CVD condition, and a range of -0.078 (95% CI [-0.097, -0.060], 
p<0.001) to -0.134 (95% CI [-0.178, -0.091], p<0.001) for non-alcohol related 
with CVD condition. Each unit increase in the predict AUDIT scores was 
associated with a decrement score of -0.004 (95% CI [-0.006, -0.002], p<0.001).  
For females, the decrement on HRQoL scores due to different year of  
hospitalisations were -0.08 (95% CI [-0.121, -0.039], p<0.001) for wholly 
alcohol-related condition, a range of -0.043 (95% CI [-0.056, -0.031],  p<0.001) 
to -0.126 (95% CI [-0.172, -0.080], p<0.001) for partly alcohol-related condition, 
a range of -0.017 (95% CI [-0.027, -0.008],  p<0.001) to -0.048 (95% CI [-0.062, 
-0.033], p<0.001) for non-alcohol related and non-CVD condition, and a range 
of -0.097 (95% CI [-0.115, -0.078], p<0.001) to -0.109 (95% CI [-0.16, -0.059],  
p<0.001) for non-alcohol related with CVD condition. Each unit increase of the 
predicted AUDIT score was associated with a decrement score of -0.002 (95% CI 
[-0.005, -0.0002], p=0.030), which shows that it had less of an effect on women 
than men. These utility decrements will be used for further modelling to 
estimate QALY.             
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Table 7-1 Baseline SF-6D (SF-12) HRQoL scores of SHeS 2003 participants 
across fifths of deprivation: males  
 
 
 
 
 
Aged group 
(years) 
Scottish Index of Multiple Deprivation (SIMD) 
5th 
(least  deprived) 4th 3rd  2nd  
1st  
(most deprived) 
All (N) (634) (701) (691) (597) (482) 
Mean 0.831 0.826 0.81 0.795 0.754 
95% CI (0.808, 0.854) (0.803, 0.849) (0.785, 0.836) (0.766, 0.825) (0.719, 0.79) 
18-24 (N) (23) (27) (27) (32) (31) 
Mean 0.822 0.853 0.834 0.857 0.787 
95% CI (0.787, 0.857) (0.824, 0.881) (0.795, 0.873) (0.828, 0.887) (0.745, 0.83) 
25-34 (N) (75) (88) (88) (104) (70) 
Mean 0.848 0.849 0.823 0.816 0.774 
95% CI (0.826, 0.871) (0.83, 0.867) (0.796, 0.85) (0.794, 0.839) (0.741, 0.807) 
35-44 (146) (164) (155) (125) (97) 
Mean 0.834 0.838 0.823 0.811 0.777 
95% CI (0.816, 0.852) (0.82, 0.855) (0.805, 0.841) (0.787, 0.835) (0.744, 0.81) 
45-54 (128) (139) (126) (82) (96) 
Mean 0.825 0.827 0.808 0.791 0.762 
95% CI (0.805, 0.845) (0.806, 0.849) (0.783, 0.833) (0.756, 0.826) (0.729, 0.794) 
55-64 (138) (127) (121) (111) (80) 
Mean 0.845 0.803 0.82 0.782 0.718 
95% CI (0.826, 0.865) (0.78, 0.826) (0.796, 0.843) (0.751, 0.813) (0.68, 0.757) 
65-74 (86) (89) (107) (92) (72) 
Mean 0.813 0.822 0.802 0.761 0.732 
95% CI (0.784, 0.841) (0.791, 0.853) (0.775, 0.83) (0.729, 0.792) (0.697, 0.768) 
> 74 (38) (67) (67) (51) (36) 
Mean 0.797 0.802 0.756 0.775 0.732 
95% CI (0.75, 0.843) (0.77, 0.835) (0.722, 0.791) (0.731, 0.818) (0.685, 0.779) 
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Table 7-2 Baseline SF-6D (SF-12) HRQoL scores of SHeS 2003 participants 
across fifths of deprivation: females 
Aged group 
(years) 
Scottish Index of Multiple Deprivation (SIMD) 
 5th 
 (least deprived) 4th 3rd  2nd 
1st  
(most deprived) 
All (N) (784) (873) (858) (749) (685) 
Mean 0.826 0.807 0.785 0.769 0.737 
95% CI (0.806, 0.846) (0.786, 0.828) (0.761, 0.809) (0.743, 0.795) (0.707, 0.766) 
18-24 (N) (30) (37) (36) (48) (59) 
Mean 0.846 0.81 0.78 0.799 0.816 
95% CI (0.813, 0.88) (0.779, 0.842) (0.739, 0.821) (0.765, 0.832) (0.787, 0.845) 
25-34 (N) (105) (122) (114) (128) (104) 
Mean 0.839 0.816 0.822 0.803 0.775 
95% CI (0.822, 0.856) (0.795, 0.836) (0.803, 0.841) (0.78, 0.825) (0.749, 0.8) 
35-44 (N) (176) (198) (172) (150) (142) 
Mean 0.837 0.827 0.794 0.788 0.748 
95% CI (0.823, 0.852) (0.812, 0.841) (0.773, 0.815) (0.769, 0.808) (0.722, 0.774) 
45-54 (N) (180) (166) (157) (128) (117) 
Mean 0.827 0.793 0.78 0.769 0.736 
95% CI (0.812, 0.843) (0.773, 0.812) (0.758, 0.802) (0.745, 0.792) (0.708, 0.764) 
55-64 (N) (133) (162) (167) (126) (105) 
Mean 0.835 0.815 0.791 0.769 0.701 
95% CI (0.816, 0.854) (0.798, 0.832) (0.768, 0.814) (0.742, 0.796) (0.67, 0.732) 
65-74 (N) (96) (102) (118) (86) (87) 
Mean 0.827 0.803 0.792 0.742 0.702 
95% CI (0.803, 0.851) (0.776, 0.83) (0.766, 0.818) (0.709, 0.776) (0.668, 0.736) 
> 74 (N) (64) (86) (94) (83) (71) 
Mean 0.741 0.765 0.715 0.693 0.689 
95% CI (0.702, 0.779) (0.732, 0.798) (0.681, 0.748) (0.655, 0.731) (0.652, 0.726) 
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Table 7-3 Utility decrement due to hospitalisation and increasing AUDIT score 
  Utility decrement* 
Condition Males (n=3,105)   Females (n=3,949) 
 Mean SE p-value 95%CI  Mean SE p-value 95%CI 
                       
Increasing each AUDIT score by 
1**  -0.004 0.001 <0.001 -0.006 -0.002  -0.002 0.001 0.030 -0.005 -0.0002 
Wholly alcohol-related hospitalisation   
 
 
    
within 1 year -0.123 0.046 0.008 -0.212 -0.033  0.031 0.099 0.755 -0.163 0.225 
 over 1 year -0.072 0.021 0.001 -0.113 -0.031  -0.080 0.021 <0.001 -0.121 -0.039 
Partly alcohol-related hospitalisation     
 
    
within 1 year -0.069 0.026 0.008 -0.121 -0.018  -0.126 0.024 <0.001 -0.172 -0.080 
 over 1 year -0.027 0.008 0.001 -0.043 -0.012  -0.043 0.006 <0.001 -0.056 -0.031 
Non-CVD  hospitalisation  
    
 
    
within 1 year -0.043 0.008 <0.001 -0.059 -0.026  -0.048 0.007 <0.001 -0.062 -0.033 
 over 1 year -0.009 0.005 0.085 -0.020 0.001  -0.017 0.005 <0.001 -0.027 -0.008 
CVD hospitalisation        
 
    
within 1 year -0.134 0.022 <0.001 -0.178 -0.091  -0.109 0.026 <0.001 -0.160 -0.059 
 over 1 year -0.078 0.009 <0.001 -0.097 -0.060   -0.097 0.010 <0.001 -0.115 -0.078 
*Utility decrement value after adjusting for age at survey date and SIMD deprivation index 
**The effect of increasing each unit of the AUDIT score from 0 to 40  
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7.3.2 Risk of having subsequent hospitalisation after the first 
hospitalisation 
  
Figure 7-2 to Figure 7-13 illustrate the graphs of observed proportions of 
subsequent hospitalisations after the first hospitalisation (i.e. alcohol-related 
and non-alcohol related hospitalisations), classified by gender and six 
subsequent hospitalisations for a 19-year follow-up period. In general, the 
observed proportions of subsequently hospitalised patients following the first 
alcohol-related hospitalisation were unstable over the follow-up period. In 
contrast, the observed proportions of those patients who experienced the first 
non-alcohol related admission were uniform over time. The highest proportion 
of observed subsequent hospitalisations was non-emergency admission with 
non-CVD condition for both men and women, followed by emergency admission 
and non-CVD condition.  
The modelling predicted the risks of having six subsequent hospitalisations 
after first events by using separate models defined by gender and first 
hospitalisation condition (i.e. alcohol-related and non-alcohol related conditions). 
The coefficients of the probit model are shown in Table 7-4 and Table 7-5, and the 
restricted cubic spline of time since the first event are represented in Table 7-6 for 
subsequent events after first alcohol-related hospitalisation. The probit model 
results of subsequent events post-non-alcohol related admission are shown Table 
7-7 and Table 7-8, and the time spline covariate is shown in Table 7-9. As shown by 
the estimated coefficients, the risks of incurring six subsequent events were 
different compared between two hospitalised patients who had experienced 
alcohol-related and non-alcohol related hospitalisations. In addition, there were 
differences in the coefficients compared between men and women as well, which 
could support the justification of using separated model by first hospitalisation type 
and gender. Moreover, there were subsequent modelled events where the 
coefficients of time spline, age at first events, and SIMD were reported to be 
statistically significant. Overall, the results suggest that the further six 
hospitalisations are related to these modelling covariates and different risks 
between gender as well as between first hospitalisation type. 
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Figure 7-2 Observed proportions of wholly alcohol-related hospitalisation after 
the year of occurring first event: males 
 
 
Figure 7-3 Observed proportions of wholly alcohol-related hospitalisation after 
the year of occurring first event: females 
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Figure 7-4 Observed proportions of partly alcohol-related hospitalisation after 
the year of occurring first event: males 
 
Figure 7-5 Observed proportions of partly alcohol-related hospitalisation after 
the year of occurring first event: females 
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Figure 7-6 Observed proportions of non-emergency and non-CVD admission 
after the year of occurring first event: males 
 
Figure 7-7 Observed proportions of non-emergency and non-CVD admission 
after the year of occurring first event: females 
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Figure 7-8 Observed proportions of non-emergency and CVD admission after 
the year of occurring first event: males 
 
Figure 7-9 Observed proportions of non-emergency and CVD admission after 
the year of occurring first event: females 
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Figure 7-10 Observed proportions of emergency and non-CVD admission after 
the year of occurring first event: males 
 
Figure 7-11 Observed proportions of emergency and non-CVD admission after 
the year of occurring first event: females 
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Figure 7-12 Observed proportions of emergency and CVD admission after the 
year of occurring first event: males 
 
Figure 7-13 Observed proportions of emergency and CVD admission after the 
year of occurring first event: females 
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Table 7-4 Modelling the risk of 6 subsequent events following alcohol-related hospitalisation (n=445): males 
 
a) wholly alcohol-related hospitalisation 
 
b) partly alcohol-related hospitalisation 
 
c) emergency admission 
and non-CVD condition 
Covariate Coefficient 95%CI p-value  Coefficient 95%CI p-value  Coefficient 95%CI p-value 
               
timespline1 -0.079 -0.239 0.081 0.332  -0.365 -0.518 -0.212 <0.001  0.182 0.100 0.263 <0.001 
timespline2 0.074 -0.599 0.746 0.830  0.826 0.264 1.388 0.004  -0.510 -0.814 -0.206 0.001 
Age at first event -0.028 -0.045 -0.011 0.001  0.003 -0.006 0.013 0.503  -0.003 -0.009 0.002 0.228 
SIMD  
(ref.=most deprived)               
2nd -0.335 -1.057 0.388 0.364  -0.186 -0.650 0.278 0.432  0.045 -0.200 0.289 0.721 
3rd -0.383 -0.966 0.200 0.198  -0.142 -0.579 0.295 0.523  0.021 -0.224 0.266 0.866 
4th -0.540 -1.316 0.235 0.172  -0.049 -0.524 0.427 0.841  -0.056 -0.320 0.209 0.680 
5th(least deprived) -0.700 -1.379 -0.021 0.043  -0.079 -0.581 0.422 0.756  -0.017 -0.311 0.277 0.910 
Constant 0.385 -0.683 1.453 0.480  0.503 -0.110 1.115 0.108  -1.095 -1.481 -0.709 <0.001 
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Table 7-4 Modelling the risk of 6 subsequent events following alcohol-related hospitalisation (n=445): males (cont.) 
 
d) emergency admission 
and CVD condition 
 
e) non-emergency admission 
and non-CVD condition 
 
f) non-emergency admission 
and CVD condition 
Covariate Coefficient 95%CI p-value  Coefficient 95%CI p-value  Coefficient 95%CI p-value 
               
Time spline1 0.114 -0.010 0.238 0.072  0.261 0.159 0.363 <0.001  0.107 -0.034 0.248 0.135 
Time spline2 -0.195 -0.617 0.228 0.367  -0.692 -1.060 -0.324 <0.001  -0.105 -0.561 0.352 0.654 
Age at first event 0.020 0.010 0.030 <0.001  0.002 -0.004 0.009 0.493  0.016 0.008 0.024 <0.001 
SIMD  
(ref.=most deprived)               
2nd 0.316 -0.051 0.683 0.092  0.181 -0.144 0.505 0.275  0.120 -0.428 0.668 0.667 
3rd 0.140 -0.255 0.535 0.487  0.169 -0.126 0.464 0.262  0.163 -0.356 0.683 0.538 
4th 0.056 -0.348 0.460 0.788  0.268 -0.074 0.610 0.124  -0.038 -0.590 0.514 0.893 
5th(least deprived) 0.106 -0.376 0.589 0.666  0.184 -0.167 0.535 0.304  0.343 -0.179 0.865 0.198 
Constant -3.736 -4.519 -2.953 <0.001  -1.428 -1.919 -0.938 <0.001  -3.267 -4.042 -2.492 <0.001 
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Table 7-5 Modelling the risk of 6 subsequent events following alcohol-related hospitalisation (n=614): females 
 
a) wholly alcohol-related hospitalisation 
 
b) partly alcohol-related hospitalisation 
 
c) emergency admission 
and non-CVD condition 
Covariate Coefficient 95%CI p-value  Coefficient 95%CI p-value  Coefficient 95%CI p-value 
               
Time spline1 0.060 -0.079 0.200 0.397  -0.543 -0.709 -0.378 <0.001  0.146 0.066 0.226 <0.001 
Time spline2 -0.693 -1.498 0.112 0.091  1.368 0.796 1.940 <0.001  -0.284 -0.562 -0.006 0.045 
Age at first event -0.015 -0.029 -0.002 0.025  -0.010 -0.018 -0.002 0.010  0.007 0.001 0.013 0.019 
SIMD  
(ref.=most deprived)               
2nd 0.238 -0.327 0.802 0.409  -0.117 -0.501 0.268 0.551  -0.268 -0.527 -0.009 0.042 
3rd 0.653 -0.129 1.436 0.102  0.058 -0.326 0.441 0.768  -0.402 -0.625 -0.178 <0.001 
4th -0.340 -0.973 0.293 0.292  0.301 -0.153 0.754 0.194  -0.521 -0.791 -0.252 <0.001 
5th(least deprived) -0.126 -0.876 0.625 0.743  0.147 -0.227 0.522 0.440  -0.371 -0.623 -0.119 0.004 
Constant -1.473 -2.197 -0.749 <0.001  1.520 0.902 2.138 <0.001  -1.467 -1.914 -1.020 <0.001 
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Table 7-5 Modelling the risk of 6 subsequent events following alcohol-related hospitalisation (n=614): females (cont.) 
 
d) emergency admission 
and CVD condition 
 
e) non-emergency admission 
and non-CVD condition 
 
f) non-emergency admission 
and CVD condition 
Covariate Coefficient 95%CI p-value  Coefficient 95%CI p-value  Coefficient 95%CI p-value 
               
Time spline1 0.215 0.074 0.356 0.003  0.428 0.320 0.535 <0.001  0.101 -0.063 0.266 0.228 
Time spline2 -0.481 -0.954 -0.007 0.047  -1.278 -1.643 -0.913 <0.001  -0.115 -0.665 0.435 0.683 
Age at first event 0.022 0.013 0.032 <0.001  0.001 -0.006 0.008 0.752  0.019 0.006 0.031 0.004 
SIMD  
(ref.=most deprived)               
2nd -0.060 -0.467 0.348 0.774  0.290 0.015 0.565 0.039  0.191 -0.364 0.747 0.500 
3rd 0.263 -0.145 0.670 0.206  0.091 -0.163 0.345 0.482  0.293 -0.218 0.803 0.261 
4th -0.069 -0.506 0.368 0.757  0.121 -0.204 0.445 0.467  -0.014 -0.546 0.517 0.958 
5th(least deprived) -0.011 -0.435 0.412 0.958  0.165 -0.155 0.485 0.312  0.081 -0.423 0.585 0.753 
Constant -4.064 -4.816 -3.311 <0.001  -1.567 -2.052 -1.082 <0.001  -3.518 -4.478 -2.557 <0.001 
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Table 7-6 Time spline variable of modelling the risk of subsequent events 
following alcohol-related hospitalisation 
Cycle 
(year) 
Time 
spline1 
Time 
spline2  
Cycle 
(year) 
Time 
spline1 
Time 
spline2  
Cycle 
(year) 
Time 
spline1 
Time 
spline2 
1 1 0  35 35 11.625  68 68 24 
2 2 0.0156  36 36 12  69 69 24.375 
3 3 0.1071  37 37 12.375  70 70 24.75 
4 4 0.279  38 38 12.75  71 71 25.125 
5 5 0.5179  39 39 13.125  72 72 25.5 
6 6 0.8103  40 40 13.5  73 73 25.875 
7 7 1.1429  41 41 13.875  74 74 26.25 
8 8 1.5022  42 42 14.25  75 75 26.625 
9 9 1.875  43 43 14.625  76 76 27 
10 10 2.25  44 44 15  77 77 27.375 
11 11 2.625  45 45 15.375  78 78 27.75 
12 12 3  46 46 15.75  79 79 28.125 
13 13 3.375  47 47 16.125  80 80 28.5 
14 14 3.75  48 48 16.5  81 81 28.875 
15 15 4.125  49 49 16.875  82 82 29.25 
16 16 4.5  50 50 17.25  83 83 29.625 
17 17 4.875  51 51 17.625  84 84 30 
18 18 5.25  52 52 18  85 85 30.375 
19 19 5.625  53 53 18.375  86 86 30.75 
20 20 6  54 54 18.75  87 87 31.125 
21 21 6.375  55 55 19.125  88 88 31.5 
22 22 6.75  56 56 19.5  89 89 31.875 
23 23 7.125  57 57 19.875  90 90 32.25 
24 24 7.5  58 58 20.25  91 91 32.625 
25 25 7.875  59 59 20.625  92 92 33 
26 26 8.25  60 60 21  93 93 33.375 
27 27 8.625  61 61 21.375  94 94 33.75 
28 28 9  62 62 21.75  95 95 34.125 
29 29 9.375  63 63 22.125  96 96 34.5 
30 30 9.75  64 64 22.5  97 97 34.875 
31 31 10.125  65 65 22.875  98 98 35.25 
32 32 10.5  66 66 23.25  99 99 35.625 
33 33 10.875  67 67 23.625  100 100 36 
34 34 11.25         
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Table 7-7 Modelling the risk of 6 subsequent events following non-alcohol related hospitalisation (n=9,053): males 
 
a) wholly alcohol-related hospitalisation 
 
b) partly alcohol-related hospitalisation 
 
c) emergency admission 
and non-CVD condition 
Covariate Coefficient 95%CI p-value  Coefficient 95%CI p-value  Coefficient 95%CI p-value 
               
Time spline1 -0.013 -0.072 0.046 0.672  0.053 0.015 0.091 0.007  0.055 0.036 0.074 <0.001 
Time spline2 0.047 -0.061 0.154 0.393  -0.080 -0.150 -0.010 0.025  -0.074 -0.113 -0.035 <0.001 
Age at first event -0.017 -0.021 -0.013 <0.001  0.010 0.007 0.014 <0.001  -0.004 -0.006 -0.002 0.001 
SIMD  
(ref.=most deprived)               
2nd -0.248 -0.526 0.031 0.081  0.052 -0.096 0.199 0.495  -0.156 -0.248 -0.064 0.001 
3rd -0.322 -0.588 -0.056 0.018  0.050 -0.110 0.210 0.543  -0.129 -0.215 -0.044 0.003 
4th -0.366 -0.672 -0.061 0.019  -0.010 -0.176 0.157 0.910  -0.153 -0.244 -0.061 0.001 
5th(least deprived) -0.391 -0.717 -0.065 0.019  -0.089 -0.254 0.077 0.295  -0.278 -0.400 -0.156 <0.001 
Constant -1.134 -1.476 -0.791 <0.001  -2.333 -2.598 -2.069 <0.001  -0.528 -0.680 -0.375 <0.001 
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Table 7-7 Modelling the risk of 6 subsequent events following non-alcohol related hospitalisation (n=9,053): males (cont.) 
 
d) emergency admission 
and CVD condition 
 
e) non-emergency admission 
and non-CVD condition 
 
f) non-emergency admission 
and CVD condition 
Covariate Coefficient 95%CI p-value  Coefficient 95%CI p-value  Coefficient 95%CI p-value 
               
Time spline1 0.040 0.015 0.065 0.002  -0.026 -0.048 -0.004 0.021  -0.093 -0.123 -0.064 <0.001 
Time spline2 -0.060 -0.107 -0.013 0.013  0.027 -0.017 0.072 0.229  0.146 0.088 0.205 <0.001 
Age at first event 0.013 0.011 0.016 <0.001  -0.005 -0.007 -0.002 <0.001  0.011 0.008 0.013 <0.001 
SIMD  
(ref.=most deprived)               
2nd -0.120 -0.267 0.026 0.108  0.197 0.078 0.317 0.001  -0.092 -0.208 0.024 0.121 
3rd -0.093 -0.241 0.056 0.220  0.099 -0.003 0.201 0.058  0.085 -0.037 0.207 0.173 
4th -0.157 -0.311 -0.004 0.044  0.217 0.103 0.332 <0.001  -0.058 -0.180 0.065 0.355 
5th(least deprived) -0.309 -0.481 -0.136 <0.001  0.372 0.213 0.531 <0.001  -0.074 -0.218 0.070 0.316 
Constant -2.592 -2.792 -2.393 <0.001  0.358 0.179 0.537 <0.001  -1.744 -1.933 -1.555 <0.001 
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Table 7-8 Modelling the risk of 6 subsequent events following non-alcohol related hospitalisation (n=11,666): females 
 
a) wholly alcohol-related hospitalisation 
 
b) partly alcohol-related hospitalisation 
 
c) emergency admission 
and non-CVD condition 
Covariate Coefficient 95%CI p-value  Coefficient 95%CI 
p-
value  Coefficient 95%CI p-value 
               
Time spline1 -0.055 -0.128 0.018 0.143  0.033 -0.004 0.069 0.081  0.041 0.026 0.055 <0.001 
Time spline2 0.110 -0.030 0.249 0.123  -0.036 -0.100 0.029 0.278  -0.059 -0.086 -0.033 <0.001 
Age at first event -0.016 -0.021 -0.010 <0.001  0.003 -0.0002 0.006 0.071  -0.002 -0.004 -0.001 0.002 
SIMD  
(ref.=most deprived)               
2nd -0.116 -0.414 0.182 0.446  0.079 -0.104 0.262 0.396  -0.021 -0.082 0.040 0.503 
3rd -0.090 -0.434 0.253 0.607  0.071 -0.086 0.229 0.376  -0.065 -0.134 0.003 0.061 
4th -0.156 -0.465 0.152 0.320  0.154 -0.016 0.323 0.077  -0.097 -0.167 -0.028 0.006 
5th(least deprived) 0.072 -0.349 0.494 0.737  0.076 -0.102 0.255 0.403  -0.159 -0.245 -0.074 <0.001 
Constant -1.684 -2.032 -1.337 <0.001  -1.789 -2.023 -1.554 <0.001  -0.562 -0.664 -0.461 <0.001 
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Table 7-8 Modelling the risk of 6 subsequent events following non-alcohol related hospitalisation (n=11,666): females (cont.) 
 
d) emergency admission 
and CVD condition 
 
e) non-emergency admission 
and non-CVD condition 
 
f) non-emergency admission 
and CVD condition 
Covariate Coefficient 95%CI p-value  Coefficient 95%CI p-value  Coefficient 95%CI p-value 
               
Time spline1 0.039 0.015 0.064 0.001  -0.036 -0.053 -0.020 <0.001  -0.052 -0.083 -0.020 0.001 
Time spline2 -0.037 -0.083 0.008 0.111  0.039 0.009 0.070 0.010  0.111 0.052 0.171 <0.001 
Age at first event 0.018 0.016 0.020 <0.001  -0.004 -0.006 -0.003 <0.001  0.019 0.017 0.021 <0.001 
SIMD  
(ref.=most deprived)               
2nd -0.066 -0.166 0.034 0.197  0.026 -0.045 0.097 0.472  -0.108 -0.220 0.005 0.060 
3rd -0.024 -0.121 0.073 0.629  0.053 -0.024 0.129 0.177  -0.080 -0.204 0.043 0.202 
4th -0.029 -0.134 0.076 0.590  0.057 -0.024 0.137 0.167  -0.109 -0.244 0.026 0.112 
5th(least deprived) -0.216 -0.340 -0.091 0.001  0.145 0.045 0.244 0.004  -0.060 -0.206 0.085 0.416 
Constant -3.163 -3.342 -2.984 <0.001  0.546 0.434 0.658 <0.001  -2.711 -2.908 -2.514 <0.001 
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Table 7-9 Time spline variable of modelling the risk of subsequent events 
following non-alcohol related hospitalisation 
Cycle 
(year) 
Time 
spline1 
Time 
spline2  
Cycle 
(year) 
Time 
spline1 
Time 
spline2  
Cycle 
(year) 
Time 
spline1 
Time 
spline2 
1 1 0   35 35 24.0003   68 68 51.0009 
2 2 0.00826   36 36 24.8185   69 69 51.8191 
3 3 0.06612   37 37 25.6367   70 70 52.6373 
4 4 0.22314   38 38 26.4549   71 71 53.4555 
5 5 0.51756   39 39 27.2731   72 72 54.2737 
6 6 0.94215   40 40 28.0913   73 73 55.0919 
7 7 1.47831   41 41 28.9095   74 74 55.9101 
8 8 2.10744   42 42 29.7277   75 75 56.7283 
9 9 2.81095   43 43 30.5459   76 76 57.5465 
10 10 3.57025   44 44 31.3641   77 77 58.3647 
11 11 4.36674   45 45 32.1823   78 78 59.1829 
12 12 5.18182   46 46 33.0005   79 79 60.0011 
13 13 6   47 47 33.8187   80 80 60.8193 
14 14 6.81818   48 48 34.6369   81 81 61.6375 
15 15 7.63636   49 49 35.4551   82 82 62.4557 
16 16 8.45455   50 50 36.2733   83 83 63.2739 
17 17 9.27273   51 51 37.0915   84 84 64.0921 
18 18 10.0909   52 52 37.9097   85 85 64.9103 
19 19 10.9091   53 53 38.7279   86 86 65.7285 
20 20 11.7273   54 54 39.5461   87 87 66.5467 
21 21 12.5455   55 55 40.3643   88 88 67.3649 
22 22 13.3637   56 56 41.1825   89 89 68.1831 
23 23 14.1819   57 57 42.0007   90 90 69.0013 
24 24 15.0001   58 58 42.8189   91 91 69.8195 
25 25 15.8183   59 59 43.6371   92 92 70.6377 
26 26 16.6365   60 60 44.4553   93 93 71.4559 
27 27 17.4547   61 61 45.2735   94 94 72.2741 
28 28 18.2729   62 62 46.0917   95 95 73.0923 
29 29 19.0911   63 63 46.9099   96 96 73.9105 
30 30 19.9093   64 64 47.7281   97 97 74.7287 
31 31 20.7275   65 65 48.5463   98 98 75.5469 
32 32 21.5457   66 66 49.3645   99 99 76.3651 
33 33 22.3639   67 67 50.1827   100 100 77.1833 
34 34 23.1821                 
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7.3.3 Using the alcohol intervention model to predict 
subsequent hospitalisations and reduction of HRQoL 
When using the alcohol intervention model to predict the risks of six 
hospitalisations following first alcohol-related and non-alcohol related 
hospitalisations, modifiable risk factors were defined and classified by gender 
and the first hospitalisation conditions as shown in Figure 7-14 and Figure 7-16 
for males following alcohol-related and non-alcohol related conditions, 
respectively. Figure 7-15 and Figure 7-17 show the predicted risks of those 
events for females following alcohol-related and non-alcohol related 
conditions, respectively. The selected risk profiles for males were aged 30 
years, AUDIT score = 10, binge drinking, overweight, no CVD, no diabetes, 7 
cigarettes per day, medium physical activity, 3rd SIMD, prior hospitalisation over 
the last year, and best GHQ score. For females, the selected risk profiles were 
aged 30 years, AUDIT score=6, binge drinking, overweight, no CVD, no diabetes, 
6 cigarettes per day, low physical activity, 3rd SIMD, prior hospitalisation over 
the last year, and best GHQ score. This prediction assumed that the first event 
occurred immediately in the first year of entering the model based on the 
suggestion from (Holmes et al., 2012)).  
In the same way as the observed data, the predicted risks of subsequent 
events post alcohol-related hospitalisation were changeable over time, while 
the risks of these events post non-alcohol related hospitalisation were more 
reliable. When comparing between the two types of hospitalisations, alcohol-
related hospitalised patients were found to be higher risk of subsequent events. 
The probability of subsequent non-emergency and non-CVD admission was 
found the highest risk followed by emergency and non-CVD hospitalisation both 
men and women. After the first alcohol-related hospitalisation, the risks of 
subsequent wholly and partly alcohol-related events were high after the year 
of incurring the first event and fell dramatically during the first five years. On 
the contrary, the probability of having CVD hospitalisation (emergency and non-
emergency admissions) was very low during the first 10-years and rose gradually 
after that. Following non-alcohol related hospitalisation, the risks of having six 
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subsequent events remained steady over the lifetime, and the risk of CVD 
hospitalisation showed a slight increase 20-years after the first admission. 
Figure 7-18 to Figure 7-21 illustrate the predicted utility decrement of 
the 6 hospitalisations following alcohol-related and non-alcohol related events, 
of which Figure 7-18 and Figure 7-19 are for males and Figure 7-20 and Figure 
7-21 are for females. The scenarios of risk profiles and first events were the 
same as described in the risk prediction scenario above. The predicting effect 
of subsequent events on HRQoL was estimated from the risks of each event 
weighted by the associated utility decrement. As can be seen from these graphs 
compared with the predicted risks graphs (Figure 7-14 to Figure 7-17), similar 
trends were observed for each of the six events with different magnitudes, 
depending on the utility decrement of each event. For post alcohol-related 
hospitalisation, a very high effect on HRQoL during the five years after the first 
event was seen following a wholly alcohol-related hospitalisation, and females 
were more affected than males. Moreover, readmission with CVD condition 
affected the HRQoL more than the non-CVD condition for both post alcohol-
related and non-alcohol related event so the predicted utility decrement of 
subsequent CVD hospitalisation was higher than non-CVD condition for both 
males and females. Furthermore, Figure 7-22 to Figure 7-25 show the predicted 
reduction of overall HRQoL due to hospitalisation and survival following alcohol-
related and non-alcohol related conditions as classified by gender and first 
hospitalisation. From these graphs, the area under the survival curve but above 
the utility decrement area is summed to calculate the remaining QALY.  
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Figure 7-14 Predicted risk of 6 subsequent events following alcohol related 
hospitalisation: males* 
 
*Risk profiles: males, aged 30 years, AUDIT score=10, binge drinking, overweight, no CVD, no 
diabetes, 7 cigarettes per day, medium physical activity, 3rd SIMD, prior hospitalisation over 
last year, and best GHQ score. First event occurred at the same age. 
Figure 7-15 Predicted risk of 6 subsequent events following non-alcohol 
related hospitalisation: males* 
 
*Risk profiles: males, aged 30 years, AUDIT score=10, binge drinking, overweight, no CVD, no 
diabetes, 7 cigarettes per day, medium physical activity, 3rd SIMD, prior hospitalisation over 
last year, and best GHQ score. First event occurred at the same age. 
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Figure 7-16 Predicted risk of 6 subsequent events following alcohol related 
hospitalisation: females* 
 
*Risk profiles: females, aged 30 years, AUDIT score=6, binge drinking, overweight, no CVD, no 
diabetes, 6 cigarettes per day, low physical activity, 3rd SIMD, prior hospitalisation over last 
year, and best GHQ score. First event occurred at the same age. 
Figure 7-17 Predicted risk of 6 subsequent events following non-alcohol 
related hospitalisation: females 
 
*Risk profiles: females, aged 30 years, AUDIT score=6, binge drinking, overweight, no CVD, no 
diabetes, 6 cigarettes per day, low physical activity, 3rd SIMD, prior hospitalisation over last 
year, and best GHQ score. First event occurred at the same age. 
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Figure 7-18 Predicted utility decrement of 6 subsequent events following 
alcohol related hospitalisation: males* 
 
*Risk profiles: males, aged 30 years, AUDIT score=10, binge drinking, overweight, no CVD, no 
diabetes, 7 cigarettes per day, medium physical activity, 3rd SIMD, prior hospitalisation over 
last year, and best GHQ score. First event occurred at the same age. 
Figure 7-19 Predicted utility decrement of 6 subsequent events following non-
alcohol related hospitalisation: males* 
 
*Risk profiles: males, aged 30 years, AUDIT score=10, binge drinking, overweight, no CVD, no 
diabetes, 7 cigarettes per day, medium physical activity, 3rd SIMD, prior hospitalisation over 
last year, and best GHQ score. First event occurred at the same age. 
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Figure 7-20 Predicted utility decrement of 6 subsequent events following 
alcohol related hospitalisation: females* 
 
*Risk profiles: females, aged 30 years, AUDIT score=6, binge drinking, overweight, no CVD, no 
diabetes, 6 cigarettes per day, low physical activity, 3rd SIMD, prior hospitalisation over last 
year, and best GHQ score. First event occurred at the same age. 
Figure 7-21 Predicted utility decrement of 6 subsequent events following non-
alcohol related hospitalisation: females 
 
*Risk profiles: females, aged 30 years, AUDIT score=6, binge drinking, overweight, no CVD, no 
diabetes, 6 cigarettes per day, low physical activity, 3rd SIMD, prior hospitalisation over last 
year, and best GHQ score. First event occurred at the same age. 
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Figure 7-22 Predicted reduction in HRQoL (utility decrement) due to 
subsequent events and survival after alcohol-related hospitalisation: males* 
 
*Risk profiles: males, aged 30 years, AUDIT score=10, binge drinking, overweight, no CVD, no diabetes, 7 
cigarettes per day, medium physical activity, 3rd SIMD, prior hospitalisation over last year, and best GHQ 
score. First event occurred at the same age. 
 
Figure 7-23 Predicted reduction in HRQoL (utility decrement) due to 
subsequent events and survival after non-alcohol related hospitalisation: 
males* 
 
*Risk profiles: males, aged 30 years, AUDIT score=10, binge drinking, overweight, no CVD, no diabetes, 7 
cigarettes per day, medium physical activity, 3rd SIMD, prior hospitalisation over last year, and best GHQ 
score. First event occurred at the same age. 
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Figure 7-24 Predicted reduction in HRQoL (utility decrement) due to 
subsequent events and survival after alcohol-related hospitalisation: females* 
 
*Risk profiles: females, aged 30 years, AUDIT score=6, binge drinking, overweight, no CVD, no diabetes, 
6 cigarettes per day, low physical activity, 3rd SIMD, prior hospitalisation over last year, and best GHQ 
score. First event occurred at the same age. 
 
Figure 7-25 Predicted reduction in HRQoL (utility decrement) due to 
subsequent events and survival after non-alcohol related hospitalisation: 
females* 
 
*Risk profiles: females, aged 30 years, AUDIT score=6, binge drinking, overweight, no CVD, no diabetes, 
6 cigarettes per day, low physical activity, 3rd SIMD, prior hospitalisation over last year, and best GHQ 
score. First event occurred at the same age. 
Chapter 7: An alcohol intervention model for predicting QALY and costs  229 
 
  
2
2
9
 
7.3.4 Estimating the remaining QALY 
 Table 7-10 and Table 7-11 a) to c) demonstrate the three stages of 
estimating the remaining QALYs after entering the model of individual risk 
profile for males and females aged 30 years, respectively. Table 7-10a and 
Table 7-11a represent the first stage which is the QALYs following first 
hospitalisations for 100 annual cycles. For example, if the individual risk profile 
of males aged 30 years had a wholly alcohol-related hospitalisation in the first 
year (first cycle) after the survey date, the remaining QALYs would then be 36.7 
years. Table 7-10b and Table 7-11b show the probabilities of having eight first 
events across 100 yearly cycles derived from the cause specific hazard model 
of particular risk profiles as detailed in Chapter 6. Finally, the remaining QALYs 
of each health state (Table 7-10a and Table 7-11a) were weighted by the 
probabilities of having a particular event (Table 7-10b and Table 7-11b), and 
the predicted remaining QALYs after the survey date were calculated as shown 
in Table 7-10c and Table 7-11c. As a result, the estimated remaining QALYs of 
the defined risk profiles were 38.85 years and 40.11 years for males and females 
aged 30, respectively.  
To demonstrate the use of the alcohol intervention model for predicting 
QALYs, the selected risk profiles were varied by age, smoking status and SIMD 
quintile. Then, the predicted remaining QALYs after entering the model of 
these risk profiles are illustrated in Table 7-12 and 7-13 for males and females, 
respectively. The alcohol intervention model shows its ability to discriminate 
between risk profiles as presented by the different remaining QALY for both 
males and females. The results revealed that higher-risk drinking (higher AUDIT 
score), more deprived status and current smoker resulted in less remaining 
QALYs when other related risk profiles were also changed based on the 
characteristics of the study population.  
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Table 7-10 Estimating quality adjusted life year (QALY) using 3 stages: males* 
a) QALY remaining upon entering model (for hospitalisation, QALY is equal to time before event added by time remaining after event)  
Cycle Wholly alcohol-related  Partly alcohol-related  Non-emergency  Non-emergency Emergency Emergency 
Alcohol-
related  
Non-alcohol 
related  
(years) hospitalisation hospitalisation non-CVD admission  CVD admission 
 non-CVD 
admission 
 CVD 
admission 
death death 
         
1 36.7 36.7 41.7 41.7 41.7 41.7 0.8 0.8 
2 36.3 36.3 41.4 41.4 41.4 41.4 1.6 1.6 
3 35.9 35.9 41.0 41.0 41.0 41.0 2.3 2.3 
. . . . . . . . . 
. . . . . . . . . 
22 33.0 33.0 37.6 37.6 37.6 37.6 17.1 17.1 
23 33.1 33.1 37.6 37.6 37.6 37.6 17.9 17.9 
24 33.3 33.3 37.6 37.6 37.6 37.6 18.6 18.6 
. . . . . . . . . 
. . . . . . . . . 
100 74.9 74.9 74.5 74.5 74.5 74.5 74.2 74.2 
*Risk profiles: males, aged 30 years, AUDIT score=10, binge drinking, overweight, no CVD, no diabetes, 7 cigarettes per day, medium physical activity, 3rd SIMD, 
prior hospitalisation over last year, and best GHQ score 
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Table 7-10 Estimating quality adjusted life year (QALY) using 3 stages: males* (cont.) 
b) Probability of having eight events over yearly 100 cycles  
Cycle Wholly alcohol-related  Partly alcohol-related  Non-emergency  Non-emergency Emergency Emergency 
Alcohol-
related  
Non-alcohol 
related  
(years) hospitalisation hospitalisation non-CVD admission  CVD admission 
 non-CVD 
admission 
 CVD 
admission 
death death 
         
1 0.0012 0.0037 0.0674 0.0013 0.0343 0.0022 0.0003 0.0004 
2 0.0011 0.0034 0.0582 0.0012 0.0299 0.0021 0.0003 0.0004 
3 0.0009 0.0032 0.0504 0.0011 0.0261 0.0019 0.0003 0.0004 
. . . . . . . . . 
. . . . . . . . . 
22 0.0001 0.0012 0.0047 0.0003 0.0028 0.0008 0.0001 0.0004 
23 0.0001 0.0011 0.0042 0.0003 0.0025 0.0008 0.0001 0.0004 
24 0.0001 0.0011 0.0037 0.0003 0.0023 0.0008 0.0001 0.0004 
. . . . . . . . . 
. . . . . . . . . 
100 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
*Risk profiles: males, aged 30 years, AUDIT score=10, binge drinking, overweight, no CVD, no diabetes, 7 cigarettes per day, medium physical activity, 3rd SIMD, 
prior hospitalisation over last year, and best GHQ score 
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Table 7-10 Estimating quality adjusted life year (QALY) using 3 stages: males* (cont.) 
c) Weighting remaining QALY estimated from stage a) multiplied by stage b)  
Cycle 
Wholly alcohol-
related 
Partly alcohol-
related Non-emergency Non-emergency Emergency Emergency 
Alcohol-
related 
Non-alcohol 
related  
(years) hospitalisation hospitalisation 
non-CVD 
admission CVD admission 
non-CVD 
admission 
CVD 
admission death death Sum 
          
1 0.0452 0.1345 2.8124 0.0529 1.4324 0.0924 0.0002 0.0003 4.5703 
2 0.0384 0.1234 2.4089 0.0480 1.2364 0.0857 0.0005 0.0006 2.6187 
3 0.0328 0.1136 2.0692 0.0437 1.0702 0.0797 0.0006 0.0009 2.2593 
. . . . . . . . . . 
. . . . . . . . . . 
22 0.0026 0.0381 0.1766 0.0113 0.1057 0.0306 0.0015 0.0068 0.2286 
23 0.0023 0.0367 0.1577 0.0107 0.0951 0.0295 0.0015 0.0072 0.2074 
24 0.0021 0.0354 0.1409 0.0101 0.0857 0.0286 0.0015 0.0076 0.1885 
. . . . . . . . . . 
. . . . . . . . . . 
100 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
*Risk profiles: males, aged 30 years, AUDIT score=10, binge drinking, overweight, no CVD, no diabetes, 7 cigarettes per day, medium physical activity, 3rd SIMD, 
prior hospitalisation over last year, and best GHQ score 
Total QALY remaining (Cumulative sum over 100 cycles) = 38.85 
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Table 7-11 Estimating quality adjusted life year (QALY) using 3 stages: females*  
a) QALY remaining upon entering model (for hospitalisation, QALY is equal to time before event added by time remaining after event)  
Cycle Wholly alcohol-related Partly alcohol-related 
Non-
emergency 
Non-
emergency Emergency Emergency 
Alcohol-
related 
Non-alcohol 
related 
(years) hospitalisation hospitalisation 
non-CVD 
admission CVD admission 
non-CVD 
admission 
CVD 
admission death death 
         
1 28.5 28.5 45.5 45.5 45.5 45.5 0.8 0.8 
2 28.1 28.1 44.9 44.9 44.9 44.9 1.6 1.6 
3 27.8 27.8 44.3 44.3 44.3 44.3 2.4 2.4 
. . . . . . . . . 
. . . . . . . . . 
22 27.9 27.9 36.8 36.8 36.8 36.8 17.1 17.1 
23 28.1 28.1 36.7 36.7 36.7 36.7 17.9 17.9 
24 28.5 28.5 36.6 36.6 36.6 36.6 18.7 18.7 
. . . . . . . . . 
. . . . . . . . . 
100 73.9 73.9 73.8 73.8 73.8 73.8 73.4 73.4 
*Risk profiles: females, aged 30 years, AUDIT score=6, binge drinking, overweight, no CVD, no diabetes, 6 cigarettes per day, low physical activity, 3rd SIMD, prior 
hospitalisation over last year, and best GHQ score 
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Table 7-11 Estimating quality adjusted life year (QALY) using 3 stages: females* (cont.) 
b) Probability of having eight events over yearly 100 cycles  
Cycle Wholly alcohol-related Partly alcohol-related 
Non-
emergency 
Non-
emergency Emergency Emergency 
Alcohol-
related 
Non-alcohol 
related 
(years) hospitalisation hospitalisation 
non-CVD 
admission CVD admission 
non-CVD 
admission 
CVD 
admission death death 
         
1 0.0009 0.0070 0.0942 0.0008 0.0397 0.0009 0.0010 0.0004 
2 0.0007 0.0061 0.0778 0.0007 0.0332 0.0008 0.0010 0.0004 
3 0.0006 0.0054 0.0646 0.0006 0.0278 0.0007 0.0009 0.0004 
. . . . . . . . . 
. . . . . . . . . 
22 0.0000 0.0009 0.0034 0.0000 0.0018 0.0002 0.0006 0.0003 
23 0.0000 0.0008 0.0029 0.0000 0.0016 0.0002 0.0006 0.0003 
24 0.0000 0.0007 0.0026 0.0000 0.0014 0.0002 0.0006 0.0003 
. . . . . . . . . 
. . . . . . . . . 
100 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
*Risk profiles: females, aged 30 years, AUDIT score=6, binge drinking, overweight, no CVD, no diabetes, 6 cigarettes per day, low physical activity, 3rd SIMD, prior 
hospitalisation over last year, and best GHQ score 
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Table 7-11 Estimating quality adjusted life year (QALY) using 3 stages: females* (cont.) 
c) Weighting remaining QALY estimated from stage a) multiplied by stage b)  
Cycle 
Wholly alcohol-
related 
Partly alcohol-
related Non-emergency Non-emergency Emergency Emergency 
Alcohol-
related 
Non-alcohol 
related  
(years) hospitalisation hospitalisation 
non-CVD 
admission CVD admission 
non-CVD 
admission 
CVD 
admission death death Sum 
          
1 0.0250 0.1989 4.2874 0.0362 1.8066 0.0404 0.0008 0.0003 6.3957 
2 0.0205 0.1722 3.4921 0.0297 1.4882 0.0356 0.0016 0.0006 3.7145 
3 0.0169 0.1498 2.8570 0.0245 1.2314 0.0315 0.0022 0.0009 3.0483 
. . . . . . . . . . 
. . . . . . . . . . 
22 0.0010 0.0239 0.1243 0.0013 0.0664 0.0062 0.0104 0.0055 0.1505 
23 0.0009 0.0224 0.1082 0.0011 0.0584 0.0058 0.0109 0.0059 0.1325 
24 0.0008 0.0209 0.0942 0.0010 0.0515 0.0055 0.0113 0.0062 0.1169 
. . . . . . . . . . 
. . . . . . . . . . 
100 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
*Risk profiles: females, aged 30 years, AUDIT score=6, binge drinking, overweight, no CVD, no diabetes, 6 cigarettes per day, low physical activity, 3rd SIMD, prior 
hospitalisation over last year, and best GHQ score 
Total QALY remaining (Cumulative sum over 100 cycles) = 40.11 
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Table 7-12   Predicted remaining QALY classified by risks profiles: males 
    Smoker (5 CPD)         Non-smoker         
    Age 20 years          Age 20 years        
   >20 34.07 39.11 42.61 43.70 45.54 
 
34.15 39.10 42.61 43.75 45.58 
A
U
D
IT
 s
c
o
re
 
16 - 19 38.11 43.01 46.73 48.10 50.08 
 
38.16 43.02 46.75 48.14 50.15 
8 - 15 39.10 43.99 47.77 49.19 51.21 
 
39.15 44.00 47.78 49.23 51.24 
0 - 7 41.06 45.95 49.81 51.33 53.46 
 
41.11 45.96 49.83 51.40 53.49 
  Age 30 years          Age 30 years       
 >20 25.98 30.17 33.47 34.30 36.19 
 
26.06 30.21 33.50 34.39 36.25 
16 - 19 29.25 33.36 36.88 37.96 40.00 
 
29.34 33.41 36.92 38.02 40.05 
8 - 15 30.05 34.16 37.74 38.84 40.94 
 
30.14 34.21 37.78 38.92 40.99 
0 - 7 31.64 35.75 39.46 40.63 42.82 
 
31.73 35.81 39.50 40.69 42.87 
  Age 40 years          Age 40 years       
 >20 19.00 22.42 25.28 25.92 27.64 
 
19.08 22.47 25.34 26.00 27.73 
16 - 19 21.53 24.94 28.02 28.82 30.70 
 
21.61 24.99 28.08 28.89 30.80 
8 - 15 22.16 25.56 28.69 29.54 31.46 
 
22.23 25.61 28.77 29.61 31.56 
0 - 7 23.40 26.80 30.06 30.95 32.98 
 
23.47 26.87 30.12 31.03 33.05 
  Age 50 years         Age 50 years       
 >20 13.21 15.95 18.31 18.76 20.31 
 
13.29 16.01 18.38 18.84 20.39 
  16 - 19 15.08 17.84 20.41 20.96 22.67 
 
15.16 17.90 20.48 21.04 22.77 
  8 - 15 15.54 18.31 20.92 21.51 23.26 
 
15.62 18.38 20.99 21.59 23.34 
  0 - 7 16.47 19.25 21.97 22.59 24.43 
 
16.55 19.31 22.04 22.67 24.52 
    1 2 3 4 5   1 2 3 4 5 
    most deprived  least deprived  most deprived  least deprived 
  SIMD quintile 
Note: binge drinking, BMI, physical activity, CVD, diabetes, prior hospitalisation, and GHQ score were varied but not presented. 
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Table 7-13 Predicted remaining QALY classified by risks profiles: females 
    Smoker (4 CPD)         Non-smoker         
    Age 20 years          Age 20 years       
   >17 38.64 44.47 46.55 49.24 53.02   38.68 44.56 46.66 49.32 53.12 
A
U
D
IT
 s
c
o
re
 
13 – 16 41.29 47.81 50.01 52.61 56.99   41.29 47.84 50.05 52.65 57.05 
5 - 12 42.35 49.14 51.38 53.99 58.58   42.35 49.17 51.43 53.98 58.59 
0 - 4 43.42 50.42 52.71 55.29 60.10   43.39 50.44 52.74 55.27 60.12 
  Age 30 years          Age 30 years       
 >17 27.77 33.42 35.35 37.74 41.58   27.84 33.53 35.48 37.86 41.71 
13 – 16 29.77 36.05 38.08 40.41 44.85   29.82 36.11 38.18 40.49 44.92 
5 - 12 30.58 37.09 39.16 41.50 46.13   30.62 37.16 39.25 41.54 46.20 
0 - 4 31.36 38.09 40.21 42.50 47.38   31.40 38.15 40.28 42.55 47.41 
  Age 40 years          Age 40 years       
 >17 19.02 23.57 25.13 27.06 30.41   19.11 23.71 25.29 27.19 30.57 
13 – 16 20.47 25.52 27.17 29.07 32.95   20.55 25.64 27.30 29.17 33.07 
5 - 12 21.05 26.29 27.97 29.83 33.94   21.13 26.40 28.09 29.95 34.03 
0 - 4 21.61 27.03 28.74 30.59 34.87   21.67 27.13 28.83 30.67 34.95 
  Age 50 years         Age 50 years       
 >17 12.55 15.94 17.21 18.62 21.12   12.67 16.10 17.37 18.78 21.32 
  13 – 16 13.57 17.35 18.67 20.05 22.99   13.66 17.47 18.81 20.19 23.15 
  5 - 12 13.97 17.89 19.24 20.59 23.71   14.06 18.01 19.37 20.74 23.84 
  0 - 4 14.33 18.38 19.76 21.11 24.38   14.42 18.51 19.88 21.24 24.50 
    1 2 3 4 5   1 2 3 4 5 
    most deprived  least deprived  most deprived  least deprived 
  SIMD quintile 
Note: binge drinking, BMI, physical activity, CVD, diabetes, prior hospitalisation, and GHQ score were varied but not presented. 
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7.4  Results: Modelling for predicting lifetime 
hospitalisation costs 
7.4.1 Estimated annual hospitalisation costs in the year of 
having the first event 
Figure 7-26 and Figure 7-27 illustrate the graphs of observed mean 
annual hospitalisation costs in the year of having the first event during a 20-
year follow up period for males and females, respectively. Almost all the 
observed first event costs are unstable except non-emergency admission with 
non-CVD condition, which is stable over the follow-up period for both males 
and females. The annual costs of alcohol-related hospitalisation were higher 
than non-alcohol related hospitalisation. The modelled annual hospitalisation 
costs in the year of having first hospitalisations were separated by gender, and 
the results are shown from Table 7-14 to Table 7-17 where the restricted cubic 
spline of time since the survey date are represented in Table 7-18. These 
modelling costs were performed particularly for SHeS cohorts who experienced 
the first hospitalisation after the survey date. As shown by the estimated 
coefficients of each first event costs, the results were different between men 
and women, which could support the justification of having separate models. 
Moreover, there were annual hospitalisation cost models where the age at 
survey date coefficient was statistically significant, whereas time spline and 
SIMD were not likely statistical significant for hospitalisation cost models.  
The alcohol intervention model was used to predict healthcare costs of 
first alcohol-related and non-alcohol related events in each year after survey 
date, and the annual costs was adjusted by the annual risks of each event. The 
predicted mean of annual hospitalisation costs in the year of having first 
hospitalisation are presented in Figure 7-28 and Figure 7-29 for males and 
females, respectively. The selected risk profiles were defined for males, i.e. 
aged 30 years, AUDIT score=10, binge drinking, overweight, no CVD, no 
diabetes, 7 cigarettes per day, medium physical activity, 3rd SIMD, prior 
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hospitalisation over last year, and best GHQ score. For females, the selected 
risk profiles were aged 30 years, AUDIT score=6, binge drinking, overweight, no 
CVD, no diabetes, 6 cigarettes per day, low physical activity, 3rd SIMD, prior 
hospitalisation over last year, and best GHQ score. It can be clearly seen that 
the predicted annual healthcare costs plateau over time, and the costs for 
males are higher than females with different costs of alcohol-related and non-
alcohol related hospitalisations. For males, the predicted annual costs of partly 
alcohol-related hospitalisation were found to be the highest costs followed by 
the predicted costs of emergency and non-emergency admission with CVD 
condition, and wholly alcohol-related hospitalisation. For females, the highest 
annual hospitalisation costs were wholly alcohol-related hospitalisation 
followed by emergency admission with and without CVD condition, and non-
emergency admission without CVD condition.  
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Figure 7-26 Observed mean annual hospitalisation cost in the year of having 
first event: males 
 
*Cost of death event derived from hospitalised patient and died within 28 days.  
 
Figure 7-27 Observed mean annual hospitalisation cost in the year of having 
first event: females 
 
*Cost of death event derived from hospitalised patient and died within 28 days.  
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Table 7-14 Modelling annual hospitalisation costs in year of having first alcohol-related hospitalisation and death: males 
 
a) wholly alcohol-related hospitalisation 
 
b) partly alcohol-related hospitalisation 
 
c) alcohol-related death 
Covariate* Coefficient 95%CI p-value  Coefficient 95%CI p-value  Coefficient 95%CI p-value 
               
Time spline1 0.256 -0.133 0.645 0.196  0.087 -0.051 0.226 0.216  -0.627 -1.184 -0.070 0.027 
Time spline2 -0.598 -1.392 0.195 0.140  -0.131 -0.407 0.145 0.353  1.142 0.147 2.136 0.024 
Age at survey date 0.020 -0.006 0.046 0.136  0.010 -0.003 0.022 0.137  -0.035 -0.082 0.012 0.148 
SIMD  
(ref.=most deprived)               
2nd -0.294 -1.220 0.633 0.534  -0.689 -1.143 -0.234 0.003  -0.423 -1.389 0.544 0.391 
3rd -0.095 -1.045 0.855 0.844  -0.478 -0.901 -0.055 0.027  -0.316 -1.333 0.701 0.542 
4th 0.128 -0.966 1.223 0.818  0.061 -0.452 0.574 0.816  -1.322 -3.002 0.359 0.123 
5th(least deprived) 0.352 -0.871 1.576 0.572  -0.208 -0.727 0.311 0.432  0.901 -0.773 2.576 0.291 
Constant 7.538 5.859 9.217 <0.001  8.772 7.839 9.706 <0.001  11.699 8.063 15.335 <0.001 
*Covariates were derived from generalised linear model using gamma family with log link function. 
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Table 7-15 Modelling annual hospitalisation costs in year of having first non-alcohol related hospitalisation and death: males 
 
a) emergency admission and non-CVD 
condition 
 
b) emergency admission and CVD 
condition 
 
c) non-emergency admission and non-
CVD condition   
Covariate* Coefficient 95%CI p-value  Coefficient 95%CI p-value  Coefficient 95%CI p-value 
               
Time spline1 0.026 -0.068 0.120 0.591  -0.094 -0.226 0.037 0.161  -0.073 -0.148 0.003 0.059 
Time spline2 -0.049 -0.244 0.146 0.623  0.208 -0.075 0.491 0.149  0.168 -0.010 0.345 0.064 
Age at survey date 0.028 0.023 0.033 <0.001  0.020 0.008 0.032 0.001  0.016 0.010 0.021 <0.001 
SIMD  
(ref.=most deprived)               
2nd 0.047 -0.275 0.369 0.776  0.271 -0.128 0.670 0.183  0.071 -0.144 0.287 0.516 
3rd -0.294 -0.556 -0.033 0.027  0.142 -0.237 0.522 0.462  0.053 -0.200 0.307 0.682 
4th 0.012 -0.294 0.319 0.938  0.264 -0.132 0.659 0.192  0.222 -0.099 0.544 0.175 
5th(least deprived) -0.190 -0.485 0.104 0.206  -0.170 -0.577 0.238 0.414  0.035 -0.183 0.253 0.751 
Constant 7.323 7.007 7.639 <0.001  7.862 6.964 8.759 <0.001  7.339 6.933 7.745 <0.001 
*Covariates were derived from generalised linear model using gamma family with log link function. 
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Table 7-15 Modelling annual hospitalisation costs in year of having first non-alcohol related hospitalisation and death: males (cont.) 
 
d) non-emergency admission and CVD 
condition 
 
e) non-alcohol related death 
Covariate* Coefficient 95%CI p-value  Coefficient 95%CI p-value 
          
Time spline1 0.105 -0.053 0.264 0.192  0.495 0.017 0.973 0.042 
Time spline2 -0.239 -0.576 0.099 0.166  -0.900 -1.802 0.002 0.051 
Age at survey date 0.011 -0.006 0.027 0.197  0.011 -0.033 0.055 0.632 
SIMD  
(ref.=most deprived)          
2nd 0.230 -0.313 0.773 0.406  -0.147 -1.345 1.051 0.810 
3rd 0.662 0.157 1.168 0.010  -0.152 -1.330 1.027 0.801 
4th 0.081 -0.368 0.530 0.722  -1.477 -3.174 0.219 0.088 
5th(least deprived) 0.154 -0.354 0.663 0.552  0.427 -0.775 1.628 0.487 
Constant 7.784 6.671 8.897 <0.001  6.022 2.902 9.142 <0.001 
*Covariates were derived from generalised linear model using gamma family with log link function. 
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Table 7-16 Modelling annual hospitalisation costs in year of having first alcohol-related hospitalisation and death: females 
 
a) wholly alcohol-related hospitalisation 
 
b) partly alcohol-related hospitalisation 
 
c) alcohol-related death 
Covariate* Coefficient 95%CI p-value  Coefficient 95%CI p-value  Coefficient 95%CI p-value 
               
Time spline1 0.008 -0.366 0.383 0.965  0.182 0.079 0.286 0.001  -0.199 -0.863 0.466 0.558 
Time spline2 -0.038 -0.927 0.851 0.934  -0.313 -0.525 -0.100 0.004  0.428 -0.902 1.758 0.528 
Age at survey date 0.032 0.006 0.057 0.015  0.023 0.015 0.030 <0.001  -0.023 -0.069 0.023 0.328 
SIMD  
(ref.=most deprived)               
2nd -0.073 -0.954 0.808 0.871  0.234 -0.090 0.557 0.157  0.081 -1.193 1.355 0.901 
3rd -0.140 -1.027 0.748 0.758  0.049 -0.247 0.344 0.747  -0.115 -1.409 1.179 0.862 
4th 0.005 -1.228 1.238 0.993  0.319 -0.130 0.769 0.164  0.178 -1.630 1.986 0.847 
5th(least deprived) -0.364 -1.356 0.629 0.473  0.197 -0.154 0.549 0.272  0.077 -1.906 2.059 0.939 
Constant 7.524 5.970 9.077 <0.001  7.029 6.526 7.533 <0.001  9.350 6.053 12.647 <0.001 
*Covariates were derived from generalised linear model using gamma family with log link function. 
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Table 7-17 Modelling annual hospitalisation costs in year of having first non-alcohol related hospitalisation and death: females 
 
a) emergency admission and non-CVD 
condition 
 
b) emergency admission and CVD 
condition 
 
c) non-emergency admission and non-
CVD condition   
Covariate* Coefficient 95%CI p-value  Coefficient 95%CI p-value  Coefficient 95%CI p-value 
               
Time spline1 -0.016 -0.091 0.059 0.678  -0.035 -0.180 0.111 0.641  -0.089 -0.146 -0.033 0.002 
Time spline2 0.029 -0.126 0.185 0.713  0.111 -0.194 0.417 0.475  0.191 0.053 0.329 0.007 
Age at survey date 0.025 0.021 0.028 <0.001  0.030 0.018 0.042 <0.001  0.021 0.018 0.024 <0.001 
SIMD  
(ref.=most deprived)               
2nd 0.185 -0.014 0.385 0.068  -0.366 -0.740 0.009 0.055  -0.050 -0.225 0.125 0.574 
3rd 0.180 -0.091 0.451 0.192  -0.142 -0.580 0.296 0.525  -0.097 -0.270 0.075 0.268 
4th 0.163 -0.057 0.382 0.146  -0.469 -0.840 -0.098 0.013  0.006 -0.211 0.222 0.960 
5th(least deprived) -0.088 -0.286 0.111 0.386  -0.055 -0.658 0.548 0.858  -0.090 -0.294 0.114 0.390 
Constant 7.447 7.163 7.730 <0.001  7.309 6.412 8.207 <0.001  7.234 7.023 7.446 <0.001 
*Covariates were derived from generalised linear model using gamma family with log link function. 
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Table 7-17 Modelling annual hospitalisation costs in year of having first non-alcohol related hospitalisation and death: females (cont.) 
 
d) non-emergency admission and CVD 
condition 
 
e) non-alcohol related death 
Covariate* Coefficient 95%CI p-value  Coefficient 95%CI p-value 
          
Time spline1 0.089 -0.120 0.298 0.405  0.264 -0.098 0.626 0.153 
Time spline2 -0.097 -0.527 0.334 0.660  -0.516 -1.260 0.229 0.175 
Age at survey date 0.054 0.029 0.079 <0.001  -0.028 -0.063 0.007 0.115 
SIMD  
(ref.=most deprived)          
2nd 0.237 -0.370 0.845 0.444  -0.342 -1.348 0.664 0.506 
3rd 0.273 -0.460 1.007 0.466  -0.087 -0.936 0.762 0.841 
4th 0.039 -0.861 0.938 0.933  -0.416 -1.465 0.634 0.437 
5th(least deprived) 0.750 -0.049 1.549 0.066  -0.132 -2.141 1.878 0.898 
Constant 4.945 3.342 6.548 <0.001  8.926 6.415 11.437 <0.001 
*Covariates were derived from generalised linear model using gamma family with log link function. 
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Table 7-18 Time spline variable of annual hospitalisation costs in year of 
having first event 
Cycle 
(year) 
Time 
spline1 
Time 
spline2  
Cycle 
(year) 
Time 
spline1 
Time 
spline2  
Cycle 
(year) 
Time 
spline1 
Time 
spline2 
1 1 0  35 35 20.222  68 68 42.222 
2 2 0.012  36 36 20.889  69 69 42.889 
3 3 0.099  37 37 21.556  70 70 43.556 
4 4 0.317  38 38 22.222  71 71 44.222 
5 5 0.663  39 39 22.889  72 72 44.889 
6 6 1.115  40 40 23.556  73 73 45.556 
7 7 1.651  41 41 24.222  74 74 46.222 
8 8 2.250  42 42 24.889  75 75 46.889 
9 9 2.892  43 43 25.556  76 76 47.556 
10 10 3.556  44 44 26.222  77 77 48.222 
11 11 4.222  45 45 26.889  78 78 48.889 
12 12 4.889  46 46 27.556  79 79 49.556 
13 13 5.556  47 47 28.222  80 80 50.222 
14 14 6.222  48 48 28.889  81 81 50.889 
15 15 6.889  49 49 29.556  82 82 51.556 
16 16 7.556  50 50 30.222  83 83 52.222 
17 17 8.222  51 51 30.889  84 84 52.889 
18 18 8.889  52 52 31.556  85 85 53.556 
19 19 9.556  53 53 32.222  86 86 54.222 
20 20 10.222  54 54 32.889  87 87 54.889 
21 21 10.889  55 55 33.556  88 88 55.556 
22 22 11.556  56 56 34.222  89 89 56.222 
23 23 12.222  57 57 34.889  90 90 56.889 
24 24 12.889  58 58 35.556  91 91 57.556 
25 25 13.556  59 59 36.222  92 92 58.222 
26 26 14.222  60 60 36.889  93 93 58.889 
27 27 14.889  61 61 37.556  94 94 59.556 
28 28 15.556  62 62 38.222  95 95 60.222 
29 29 16.222  63 63 38.889  96 96 60.889 
30 30 16.889  64 64 39.556  97 97 61.556 
31 31 17.556  65 65 40.222  98 98 62.222 
32 32 18.222  66 66 40.889  99 99 62.889 
33 33 18.889  67 67 41.556  100 100 63.556 
34 34 19.556        42.222 
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Figure 7-28 Predicted mean of annual hospitalisation cost in year of having 
first hospitalisation: males* 
 
*Risk profiles: males, aged 30 years, AUDIT score=10, binge drinking, overweight, no CVD, no 
diabetes, 7 cigarettes per day, medium physical activity, 3rd SIMD, prior hospitalisation over 
last year, and best GHQ score. 
 
Figure 7-29 Predicted mean of annual hospitalisation cost in year of having 
first hospitalisation: females* 
 
*Risk profiles: females, aged 30 years, AUDIT score=6, binge drinking, overweight, no CVD, no 
diabetes, 6 cigarettes per day, low physical activity, 3rd SIMD, prior hospitalisation over last 
year, and best GHQ score.  
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7.4.2 Estimated annual hospitalisation costs in following years 
after first event 
Figure 7-30 and Figure 7-31 illustrate the observed mean of annual 
hospitalisation costs post-first hospitalisation during a 20-year follow-up period 
classified by gender and first hospitalisation (i.e. alcohol-related and non-
alcohol related hospitalisations). For males, Figure 7-30 shows that the annual 
costs are approximately comparable between alcohol-related and non-alcohol 
related hospitalisations during the first 10 years, and then non-alcohol related 
hospitalisation is shown to be the higher afterwards. Figure 7-31 shows the 
annual costs for females which show that the trends of observed hospitalisation 
costs are similar to males with slightly lower costs.  
Furthermore, the annual hospitalisation costs in following years after 
first hospitalisations were modelled and separated by gender and first 
hospitalisations. The model coefficients are reported in Table 7-19 for males 
and Table 7-20 for females where the restricted cubic spline of time since the 
first event was the same as Table 7-6 and Table 7-9 for the post alcohol-related 
event model and post non-alcohol related event model, respectively. As shown 
by the estimated coefficients of each cost model, the age at first event 
coefficient was reported to be statistically significant, particularly for the post 
non-alcohol related hospitalisation cost model for males. For females, the age 
at first event coefficient was statistically significant in both post alcohol-
related and non-alcohol related hospitalisation cost models, whereas time 
spline was shown to be significant only in the post non-alcohol related 
hospitalisation cost model. Nevertheless, SIMD was not statistically significant 
for all cost models.  
Afterwards, the model was used to predict annual healthcare costs in 
following years after first alcohol-related and non-alcohol related 
hospitalisations. The predicted mean of annual hospitalisation costs and 
survival following first hospitalisation are demonstrated from Figure 7-32 to 
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Figure 7-35, classified by gender and first hospitalisations. The selected risk 
profiles for males were aged 30 years, AUDIT score=10, binge drinking, 
overweight, no CVD, no diabetes, 7 cigarettes per day, medium physical 
activity, 3rd SIMD, prior hospitalisation over last year, and best GHQ score. For 
females, the selected risk profiles were aged 30 years, AUDIT score=6, binge 
drinking, overweight, no CVD, no diabetes, 6 cigarettes per day, low physical 
activity, 3rd SIMD, prior hospitalisation over last year, and best GHQ score. This 
prediction assumed that the first event occurred immediately in the first year 
of entering the model based on the suggestion from (Holmes et al., 2012). For 
males, when comparing annual hospitalisation costs weighted by survival 
probability between post alcohol-related and post non-alcohol related 
admissions, the predicted costs of the post alcohol-related event was 
approximately 1.5 times higher. In contrast, for females, the predicted costs of 
post non-alcohol-related event was higher than the costs of post alcohol-related 
hospitalisation.        
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Figure 7-30 Observed mean annual hospitalisation cost post first 
hospitalisation: males 
 
 
Figure 7-31 Observed mean annual hospitalisation costs post first 
hospitalisation: females 
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Table 7-19 Modelling annual hospitalisation costs post first hospitalisation: males 
 
a) post alcohol-related hospitalisation 
 
b) post non-alcohol related 
hospitalisation 
Covariate* Coefficient 95%CI p-value  Coefficient 95%CI p-value 
          
Time spline1** 0.130 -0.086 0.345 0.239  0.046 -0.029 0.120 0.229 
Time spline2** -0.494 -1.211 0.224 0.177  -0.014 -0.148 0.120 0.839 
Age at first event 0.006 -0.002 0.015 0.163  0.012 0.005 0.018 <0.001 
SIMD  
(ref.=most deprived)          
2nd -0.149 -0.563 0.265 0.480  0.069 -0.161 0.299 0.557 
3rd -0.447 -0.808 -0.085 0.016  -0.009 -0.268 0.251 0.948 
4th -0.367 -0.680 -0.053 0.022  -0.033 -0.294 0.228 0.804 
5th(least deprived) -0.292 -0.660 0.076 0.120  0.105 -0.531 0.740 0.747 
Constant 8.751 7.876 9.626 <0.001  8.274 7.782 8.765 <0.001 
*Covariates were derived from generalised linear model using gamma family with log link function. 
**Time spline variables are the same as shown in Table 7-6 for post alcohol-related hospitalisation model and Table 7-9 for post non-alcohol 
related hospitalisation model. 
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Table 7-20 Modelling annual hospitalisation costs post first hospitalisation: females 
 
a) post alcohol-related hospitalisation 
 
b) post non-alcohol related 
hospitalisation 
Covariate* Coefficient 95%CI p-value  Coefficient 95%CI p-value 
          
Time spline1** -0.033 -0.288 0.223 0.802  -0.103 -0.174 -0.033 0.004 
Time spline2** -0.025 -0.880 0.830 0.954  0.171 0.063 0.279 0.002 
Age at first event 0.011 0.002 0.020 0.018  0.008 0.003 0.013 0.003 
SIMD  
(ref.=most deprived)          
2nd -0.024 -0.601 0.553 0.935  0.065 -0.179 0.308 0.601 
3rd -0.192 -0.743 0.360 0.496  -0.019 -0.219 0.182 0.856 
4th 0.165 -0.461 0.792 0.605  -0.069 -0.252 0.115 0.465 
5th(least deprived) -0.177 -0.710 0.356 0.515  -0.029 -0.265 0.208 0.813 
Constant 8.634 7.792 9.475 <0.001  9.016 8.531 9.501 <0.001 
*Covariates were derived from generalised linear model using gamma family with log link function. 
**Time spline variables are the same as shown in Table 7-6 for post alcohol-related hospitalisation model and Table 7-9 for post non-alcohol 
related hospitalisation model. 
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Figure 7-32 Predicted mean annual hospitalisation cost and survival post 
alcohol-related hospitalisation: males* 
 
*Risk profiles: males, aged 30 years, AUDIT score=10, binge drinking, overweight, no CVD, no diabetes, 7 
cigarettes per day, medium physical activity, 3rd SIMD, prior hospitalisation over last year, and best GHQ 
score. First event occurred at the same age. 
 
Figure 7-33 Predicted mean annual hospitalisation cost and survival post non-
alcohol related hospitalisation: males* 
 
*Risk profiles: males, aged 30 years, AUDIT score=10, binge drinking, overweight, no CVD, no diabetes, 7 
cigarettes per day, medium physical activity, 3rd SIMD, prior hospitalisation over last year, and best GHQ 
score. First event occurred at the same age. 
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Figure 7-34 Predicted mean annual hospitalisation cost and survival post 
alcohol-related hospitalisation: females* 
 
 
*Risk profiles: females, aged 30 years, AUDIT score=6, binge drinking, overweight, no CVD, no diabetes, 
6 cigarettes per day, low physical activity, 3rd SIMD, prior hospitalisation over last year, and best GHQ 
score. First event occurred at the same age. 
 
Figure 7-35  Predicted mean annual hospitalisation cost and survival post non-
alcohol related hospitalisation: females* 
 
*Risk profiles: females, aged 30 years, AUDIT score=6, binge drinking, overweight, no CVD, no diabetes, 
6 cigarettes per day, low physical activity, 3rd SIMD, prior hospitalisation over last year, and best GHQ 
score. First event occurred at the same age. 
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7.4.3 Estimated lifetime hospitalisation costs 
Table 7-21 and Table 7-22 a) to c) demonstrate the three stages of 
predicted remaining lifetime hospitalisation costs after entering the model of 
individual risk profile for males and females aged 30 years, respectively. Table 
7-21a and Table 7-22a represent the first stage which is the annual 
hospitalisation costs. It includes the costs of the first event and costs of 
following the first event for 100 yearly cycles. For example, if the individual 
risk profile of males aged 30 years had a wholly alcohol-related hospitalisation 
in the first year (first cycle) after the survey date, the remaining lifetime 
hospitalisation costs would be £279,769. Table 7-21b and Table 7-22b show the 
probabilities of having eight first events across 100 yearly cycles derived from 
the cause specific hazard model of a particular risk profile as detailed in 
Chapter 6. Finally, the remaining lifetime hospitalisation costs of each health 
state (Table 7-21a and Table 7-22a) were weighted by the probabilities of 
having a particular event (Table 7-21b and Table 7-22b). Subsequently, the 
predicted remaining lifetime hospitalisation costs after the survey date were 
calculated as shown in Table 7-21c and Table 7-22c. Then, the estimated 
remaining lifetime hospitalisation cost of defined risk profiles were £173,123 
and £383,751 for males and females aged 30, respectively.  
To demonstrate the use of the model for predicting lifetime 
hospitalisation costs, the selected factors were varied by age, group AUDIT 
score, smoking status and SIMD. The predicted remaining lifetime 
hospitalisation costs after entering model of those risk profiles are illustrated 
in Table 7-23 and Table 7-24 for males and females, respectively.  The model 
shows its ability to discriminate between risk profiles as presented by different 
lifetime hospitalisation costs for both males and females. When other related 
risk profiles were changed based on the characteristic of the study population 
- different drinking status classified by AUDIT score - the results revealed that 
higher-risk drinking and more deprived status resulted in less lifetime costs. 
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Table 7-21 Estimating lifetime hospitalisation cost using 3 stages: males* 
a) Hospitalisation cost upon entering model [Cost of first event + cost of post first event] 
Cycle Wholly alcohol-related  Partly alcohol-related  Non-emergency  Non-emergency Emergency Emergency 
Alcohol-
related  
Non-alcohol 
related  
(years) hospitalisation hospitalisation non-CVD admission  CVD admission 
 non-CVD 
admission 
 CVD 
admission 
death death 
         
1 279,769 284,343 219,050 221,497 219,333 220,197 120,490 445 
2 271,227 275,801 213,350 215,797 213,632 214,496 120,490 447 
3 262,781 267,356 207,703 210,153 207,986 208,850 120,491 449 
. . . . . . . . . 
. . . . . . . . . 
22 112,544 117,119 97,179 99,698 97,463 98,325 120,548 492 
23 108,187 112,761 93,374 95,896 93,658 94,520 120,550 494 
24 103,995 108,570 89,662 92,187 89,946 90,808 120,553 496 
. . . . . . . . . 
. . . . . . . . . 
100 8,231 12,806 3,600 6,352 3,888 4,745 120,742 634 
*Risk profiles: males, aged 30 years, AUDIT score=10, binge drinking, overweight, no CVD, no diabetes, 7 cigarettes per day, medium physical activity, 3rd SIMD, 
prior hospitalisation over last year, and best GHQ score 
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Table 7-21 Estimating lifetime hospitalisation cost using 3 stages: males* (cont.) 
b) Probability of having eight events over yearly 100 cycles  
Cycle Wholly alcohol-related  Partly alcohol-related  Non-emergency  Non-emergency Emergency Emergency 
Alcohol-
related  
Non-alcohol 
related  
(years) hospitalisation hospitalisation non-CVD admission  CVD admission 
 non-CVD 
admission 
 CVD 
admission 
death death 
         
1 0.0012 0.0037 0.0674 0.0013 0.0343 0.0022 0.0003 0.0004 
2 0.0011 0.0034 0.0582 0.0012 0.0299 0.0021 0.0003 0.0004 
3 0.0009 0.0032 0.0504 0.0011 0.0261 0.0019 0.0003 0.0004 
. . . . . . . . . 
. . . . . . . . . 
22 0.0001 0.0012 0.0047 0.0003 0.0028 0.0008 0.0001 0.0004 
23 0.0001 0.0011 0.0042 0.0003 0.0025 0.0008 0.0001 0.0004 
24 0.0001 0.0011 0.0037 0.0003 0.0023 0.0008 0.0001 0.0004 
. . . . . . . . . 
. . . . . . . . . 
100 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
*Risk profiles: males, aged 30 years, AUDIT score=10, binge drinking, overweight, no CVD, no diabetes, 7 cigarettes per day, medium physical activity, 3rd SIMD, 
prior hospitalisation over last year, and best GHQ score 
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Table 7-21 Estimating lifetime hospitalisation cost using 3 stages: males* (cont.) 
c) Weighting hospitalisation cost estimated from stage a) multiplied by stage b)  
Cycle 
Wholly alcohol-
related 
Partly alcohol-
related Non-emergency Non-emergency Emergency Emergency 
Alcohol-
related 
Non-alcohol 
related  
(years) hospitalisation hospitalisation 
non-CVD 
admission CVD admission 
non-CVD 
admission 
CVD 
admission death death Sum 
          
1 343.88 1,040.71 14,763.99 280.59 7,529.23 487.83 37.82 0.17 24,484.22 
2 286.79 936.91 12,420.18 250.29 6,383.12 444.23 34.94 0.17 20,756.64 
3 239.67 845.17 10,471.14 223.75 5,423.22 405.42 32.36 0.17 17,640.90 
. . . . . . . . . . 
. . . . . . . . . . 
22 8.86 135.26 456.36 29.93 274.01 79.94 10.82 0.19 995.38 
23 7.57 124.98 391.59 27.25 236.97 74.28 10.34 0.20 873.18 
24 6.48 115.52 335.95 24.81 204.90 69.01 9.88 0.20 766.76 
. . . . . . . . . . 
. . . . . . . . . . 
100 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
*Risk profiles: males, aged 30 years, AUDIT score=10, binge drinking, overweight, no CVD, no diabetes, 7 cigarettes per day, medium physical activity, 3rd SIMD, 
prior hospitalisation over last year, and best GHQ score 
Remaining lifetime hospitalisation cost (Cumulative sum over 100 cycles) = £173,123 
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Table 7-22 Estimating lifetime hospitalisation cost using 3 stages: females* 
a) Hospitalisation cost upon entering model [Cost of first event + cost of post first event] 
Cycle Wholly alcohol-related  Partly alcohol-related  Non-emergency  Non-emergency Emergency Emergency 
Alcohol-
related  
Non-alcohol 
related  
(years) hospitalisation hospitalisation non-CVD admission  CVD admission 
 non-CVD 
admission 
 CVD 
admission 
death death 
         
1 203,368 202,645 507,461 507,241 507,132 505,888 11,533 7,558 
2 195,576 194,854 492,325 492,105 491,996 490,752 11,533 7,559 
3 187,964 187,242 477,229 477,009 476,901 475,657 11,534 7,561 
. . . . . . . . . 
. . . . . . . . . 
22 69,142 68,421 193,422 193,203 193,095 191,851 11,575 7,599 
23 66,145 65,425 184,738 184,518 184,410 183,166 11,577 7,601 
24 63,283 62,562 176,356 176,137 176,029 174,785 11,579 7,603 
. . . . . . . . . 
. . . . . . . . . 
100 5,433 4,715 6,444 6,228 6,120 4,875 11,711 7,725 
*Risk profiles: females, aged 30 years, AUDIT score=6, binge drinking, overweight, no CVD, no diabetes, 6 cigarettes per day, low physical activity, 3rd SIMD, prior 
hospitalisation over last year, and best GHQ score 
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Table 7-22 Estimating lifetime hospitalisation cost using 3 stages: females* (cont.) 
b) Probability of having eight events over yearly 100 cycles  
Cycle Wholly alcohol-related  Partly alcohol-related  Non-emergency  Non-emergency Emergency Emergency 
Alcohol-
related  
Non-alcohol 
related  
(years) hospitalisation hospitalisation non-CVD admission  CVD admission 
 non-CVD 
admission 
 CVD 
admission 
death death 
         
1 0.0012 0.0037 0.0674 0.0013 0.0343 0.0022 0.0003 0.0004 
2 0.0011 0.0034 0.0582 0.0012 0.0299 0.0021 0.0003 0.0004 
3 0.0009 0.0032 0.0504 0.0011 0.0261 0.0019 0.0003 0.0004 
. . . . . . . . . 
. . . . . . . . . 
22 0.0001 0.0012 0.0047 0.0003 0.0028 0.0008 0.0001 0.0004 
23 0.0001 0.0011 0.0042 0.0003 0.0025 0.0008 0.0001 0.0004 
24 0.0001 0.0011 0.0037 0.0003 0.0023 0.0008 0.0001 0.0004 
. . . . . . . . . 
. . . . . . . . . 
100 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 
*Risk profiles: females, aged 30 years, AUDIT score=6, binge drinking, overweight, no CVD, no diabetes, 6 cigarettes per day, low physical activity, 3rd SIMD, prior 
hospitalisation over last year, and best GHQ score 
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Table 7-22 Estimating lifetime hospitalisation cost using 3 stages: females* (cont.) 
c) Weighting hospitalisation cost estimated from stage a) multiplied by stage b)  
Cycle 
Wholly alcohol-
related 
Partly alcohol-
related Non-emergency Non-emergency Emergency Emergency 
Alcohol-
related 
Non-alcohol 
related  
(years) hospitalisation hospitalisation 
non-CVD 
admission CVD admission 
non-CVD 
admission 
CVD 
admission death death Sum 
          
1 178.68 1,415.18 47,807.54 403.19 20,131.60 448.90 11.75 2.96 70,399.78 
2 142.60 1,191.85 38,307.17 325.93 16,313.83 389.39 11.10 2.84 56,684.69 
3 114.24 1,007.61 30,805.46 264.42 13,267.74 338.98 10.53 2.73 45,811.72 
. . . . . . . . . . 
. . . . . . . . . . 
22 2.41 58.82 653.54 6.63 348.46 32.36 7.04 2.46 1,111.72 
23 2.02 52.03 544.45 5.57 293.57 29.18 7.02 2.49 936.33 
24 1.69 46.04 453.53 4.68 247.30 26.31 7.01 2.52 789.09 
. . . . . . . . . . 
. . . . . . . . . . 
100 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
*Risk profiles: females, aged 30 years, AUDIT score=6, binge drinking, overweight, no CVD, no diabetes, 6 cigarettes per day, low physical activity, 3rd SIMD, prior 
hospitalisation over last year, and best GHQ score 
Remaining lifetime hospitalisation cost (Cumulative sum over 100 cycles) = £383,751 
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Table 7-23   Predicted remaining lifetime hospitalisation cost classified by risks profiles: males 
 
Note: binge drinking, BMI, physical activity, CVD, diabetes, prior hospitalisation, and GHQ score were varied but not presented. 
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Table 7-24 Predicted remaining lifetime hospitalisation cost classified by risks profiles: females 
 
Note: binge drinking, BMI, physical activity, CVD, diabetes, prior hospitalisation, and GHQ score were varied but not presented. 
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7.5 Discussion 
This study used the alcohol intervention model which was developed 
from the analyses of SHeS-SMR linked datasets combined with the health state 
transition model to estimate long-term consequences, i.e. life expectancy (as 
shown in Chapter 6), QALYs, and lifetime hospitalisation costs as presented in 
this chapter. Lifetime QALYs and costs are widely recommended for the purpose 
of economic evaluation informing policy decision-making regarding healthcare  
intervention (ISPOR, 2014, NICE, 2013, Chaikledkaew and Kittrongsiri, 2014, 
Teerawattananon and Chaikledkaew, 2008); these standard methods are also 
applied for public health intervention (Edwards et al., 2013, Weatherly et al., 
2009). Key components that were also modelled to calculate QALYs are shown 
as follows: 1) estimating baseline HRQoL score by gender and SIMD (as detailed 
in Chapter 5); 2) modelling utility decrement due to hospitalisation and 
increasing AUDIT score (as detailed in Chapter 5); 3) modelling risks of having 
six subsequent hospitalisations after first events via separated models classified 
by gender and first hospitalisation condition (i.e. alcohol-related and non-
alcohol related conditions) - which assessed internal validity by comparing to 
the observed data; and 4) modelling survival following the first hospitalisation 
conditions (as described in Chapter 6). Eventually, the predicted remaining 
QALYs after entering the model were derived from those components.   
For estimating lifetime hospitalisation costs, the main inputs were: 1) 
Scottish health services costs (‘Cost book’), which detailed the cost per bed day 
of the specific specialty and health board; 2) modelling annual hospitalisation 
costs in the year of having the first event; and 3) annual hospitalisation costs 
in following years after the first event. Then, the lifetime hospitalisation costs 
after entering the model were estimated using the average yearly 
hospitalisation costs adjusted by predicted survival, the same method as 
estimating QALY. Moreover, the estimated costs and QALYs were presented via 
different selected risk profiles classified by age, gender, socioeconomic status, 
and selected risk behaviours. Drinking status, one of the selected risk 
behaviours, varied from low-risk to high-risk drinking depending on the AUDIT 
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score. These results can demonstrate the use of model to estimate and compare 
lifetime QALYs and healthcare costs across drinking patterns and other relevant 
risk profiles. The results of this study indicate how the consequences on health 
and healthcare cost can change in the long-term, attributable to either an 
increase or decrease alcohol consumption (measured by the AUDIT). When 
comparing different drinking statuses classified by the AUDIT score, higher-risk 
drinking (higher score) was found to have resulted in lower remaining predicted 
QALYs and predicted lifetime costs than low-risk drinking for both males and 
females.  
The use of a modelling approach for the evaluation of alcohol policies 
and interventions has been increasingly applied for informing policy decision-
makers (Ashley et al., 2015, Barbosa et al., 2015, Barbosa et al., 2010b, 
Brennan et al., 2014a, Brennan et al., 2014b, Cadilhac et al., 2011, Chisholm 
et al., 2004, Galea et al., 2009, Holmes et al., 2014a, Marsh et al., 2012, Byrnes 
et al., 2010, Cobiac et al., 2009, Purshouse et al., 2013). Nevertheless, the 
findings of the current study could not be compared to the findings of previous 
studies because of the various issues surrounding the methodology as described 
in Chapter 6. In addition, the current alcohol intervention model analysed 
Scottish longitudinal data (SHeS-SMR linkage data) to estimate HRQoL, QALYs, 
and healthcare costs so it can be seen that these estimations were based on a 
Scottish-specific setting. As generally suggested by economic evaluation 
guidelines, those outcomes and costs should be setting-specific, and hence are 
not transferable across jurisdictions (Barbieri et al., 2010, Drummond et al., 
2015, Drummond et al., 2009, Goeree et al., 2007, Goeree et al., 2011). Even 
though this study estimated healthcare costs and QALYs similar to Barbosa et 
al. (Barbosa et al., 2015, Barbosa et al., 2010b) - which modelled long-term 
costs and outcomes from multiple sources of input parameters - this study 
analysed single longitudinal linkage data. The results of this study could be 
specifically applied to the Scottish context with good internal validity (as 
presented in Chapter 6), whereas the results may be lack external validity. 
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However, the use of model calibration can be applied to make this model more 
transferable to other settings.              
Some important limitations need to be considered for estimating QALYs 
and lifetime hospitalisation costs. First, this study constructed a model of 
health-related harms to the individual drinker, i.e. morbidity and mortality, 
whereas wider harms were discussed in the literature and recommended for 
inclusion in the evaluation of public health interventions (e.g. effects on family 
members and workplace, risks of social harms, and loss of work productivity) 
(Edwards et al., 2013, Weatherly et al., 2009). However, these harms were 
excluded due to limited resources for primary research within this study. Thus, 
the lifetime consequences of drinking at a high-risk level would be 
underestimated. Further studies should take into account the societal 
perspective of both costs and outcomes combined with the long-term 
consequences of individual drinkers to capture a wider range of alcohol-related 
harms. Second, there were no longitudinal data related to drinking status 
(measured by the predicted AUDIT). As HRQoL changes over time, the analyses 
of long-term consequences assumed that the AUDIT score of the study cohort 
were unchanged from the baseline at survey date. However, age-related HRQoL 
might be varied over time.  
Third, the reduction of HRQoL due to hospitalisation was estimated from 
past admission under the assumption that it affected current health status of 
the study population. Due to the lack of longitudinal HRQoL data after the 
survey date, the analysis applied these values to estimate the effects of further 
hospitalisations on utility decrement, as well as to estimate lifetime QALYs.  
Fourth, the hospitalisation conditions in this analysis were classified by alcohol 
attribute and emergency admission with or without CVD of primary diagnosis. 
As such, the different severity of diseases related to HRQoL and LOS of each 
hospitalisation episode (used for estimating healthcare costs) were combined 
in each classification. However, the magnitude of any estimation bias is difficult 
to define. Finally, this study used per diem costing and employed the Scottish 
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‘Cost book’ at the specialty level classified by each NHS regional health board 
since there were no Scottish data at the healthcare  groups (HRG)-level 
(Information Services Division (ISD), 2013). HRG-level data would have been 
able to define the use of healthcare resources for clinically similar treatments 
commonly used for healthcare cost estimation. The approach used in this study 
explained that derived costs were higher than using HRG estimation (Geue et 
al., 2012). Thus, the lifetime healthcare costs might not represent the actual 
healthcare costs of the Scottish population. However, these costs would be 
useful for comparison across risk profiles of the study population.       
7.6 Conclusions  
Lifetime QALYs and costs are generally recommended for the purposes 
of economic evaluation of healthcare interventions to inform policy decision-
making. This chapter illustrated the use of a current alcohol intervention model 
to estimate the economic evaluation outcome, i.e. QALYs and costs over 
lifetime, generating these outcomes for different risk profiles. The results also 
presented the estimated QALYs and healthcare costs of alcohol consumption at 
various levels of risk so the application of the model can be used for the 
economic evaluation of alcohol interventions which aim to modify drinking 
pattern (as measured by the AUDIT) among various target groups (e.g. age, 
gender, and socioeconomic status). The full economic evaluation will be 
described in the next chapter.         
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Chapter 8: The use of an alcohol intervention 
model for economic evaluation 
8.1 Introduction 
This chapter demonstrates an economic evaluation of a hypothetical 
alcohol intervention for high-risk alcohol drinking assessed by the AUDIT by 
using the alcohol intervention model developed in earlier chapters. Moreover, 
the model will be used to predict lifetime healthcare cost and outcomes (i.e. 
LYs and QALYs) related to other selected risk behaviours (e.g. cigarette per 
day) which were included in the model as covariates (as described in Chapters 
6 and 7). Thus, the developed model to determine cost-effectiveness can be 
used to perform not only an alcohol intervention evaluation but it can also be 
combined with other modified risk behaviours intervention, e.g. increased 
cigarette tax and anti-smoking legislation, which were found to be associated 
with reductions in alcohol consumption among populations in the U.S. and Italy, 
respectively (Young-Wolff et al., 2014, Pieroni et al., 2013). Moreover, 
modified multiple unhealthy behavioural changes was suggested by previous 
RCTs to be more effective than single targeted behaviour changes (Prochaska 
et al., 2012, Kruger et al., 2014, Schulz et al., 2014).  
This analysis illustrates the model-based economic evaluation of the 
hypothetical intervention which aims to change alcohol drinking and smoking. 
The purpose of the analysis is to supplement a within-trial cost-effectiveness 
analysis using a modelling approach to estimate long-term cost-effectiveness. 
This chapter details the framework of conducting the economic evaluation as 
follows: 1) study design and analytical model structure; 2) required input 
parameters and uncertainty analysis of input parameters; and 3) discounting 
future cost and outcome. Furthermore, cost-effectiveness results will be 
presented using a probabilistic model which takes into account parameter 
uncertainty; the results will then be compared to a cost-effective threshold 
based on the UK advisory body's judgement of £20,000 per QALY gained for 
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which interventions are considered to be cost-effective (National Institute for 
Health and Care Excellence (NICE), 2012).                      
8.2 Methods 
8.2.1 Study design 
To conduct an economic evaluation comparing the costs and benefits of 
new interventions with the control group, a within-trial analysis is used to 
estimate the short-term cost-effectiveness of interventions while longer-term 
cost-effectiveness is assessed by an economic model to estimate lifetime costs 
and benefits of the compared interventions. This study developed an alcohol 
intervention model which will be used to estimate the long-term cost-
effectiveness of an intervention that aims to change selected risk factors. The 
model was designed to convert changes in risk factors into long-term LYs, 
QALYs, and lifetime healthcare costs, and its structure is illustrated in Figure 
8-1. The selected risk factors i.e. alcohol drinking (the AUDIT, and binge 
drinking), number of cigarettes per day, physical activity, and BMI will be 
measured during the within-trial follow-up period, and this session assumes that 
a hypothetical intervention will result in study cohorts quitting their drinking 
and smoking behaviours. A within-trial cost-effectiveness analysis (short-term) 
will be performed using cost analysis and the outcome measurement (i.e. 
HRQoL) within the follow-up period. Then, the health state transition model 
(Figure 8-1) will be used to conduct a long-term cost-effectiveness analysis to 
predict the lifetime cost, LYs, and QALYs due to changes in risk behaviours in 
the follow-up period when comparing between the intervention and control 
groups.  
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Figure 8-1 Structure of the health state transition model and intervention 
effect for economic evaluation  
Cost-utility analysis (CUA) 
 To estimate the cost-effectiveness of an intervention that aims to modify 
selected risk factors, two scenarios of the model are performed for each 
individual risk profile. The first scenario estimates lifetime costs and health 
outcomes (i.e. LYs and QALYs) of baseline risk profiles where the functions of 
risk profiles were presented in Chapter 6: and the function of costs and HRQoL 
were described in Chapter 7:. The second scenario estimates the costs and 
outcomes of changes in risk behaviours (e.g. quitting smoking and drinking) 
brought about by the intervention’s effects on these modifiable risk factors, 
leading to changes of first hospitalisation and death risks (as described in 
Chapter 6:) as well as healthcare costs and QALY (as described in Chapter 7:). 
Next, the estimated lifetime hospitalisation costs and health outcomes are 
compared between the baseline and intervention scenarios. Incremental-cost 
effectiveness ratio (ICER) - the additional cost per additional unit of effect (i.e. 
QALY) from a new intervention – is also computed as the ICER of CUA is the 
- - 
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incremental cost per QALY gained (Briggs et al., 2006c, Drummond MF et al., 
1997, Gray et al., 2011a). Then, the ICER of the intervention will be compared 
to the threshold ICER based on the UK advisory body's judgement that 
interventions with an ICER of less than £20,000 per QALY gained are considered 
to be cost effective (National Institute for Health and Care Excellence (NICE), 
2012).   
8.2.2 Input parameters 
This stage describes the input parameters required for an economic 
evaluation using the developed model to predict LYs, QALYs, and lifetime costs. 
This model can be used for generating a hypothetical intervention and 
determining its cost-effectiveness. To demonstrate how the model works, this 
analysis assumed that a hypothetical intervention aimed at stopping smoking 
and hazardous alcohol drinking (AUDIT score of 8-15 for males and 5-12 for 
females) in different aged groups and gender had a combined cost of £60 per 
person per year. This analysis performed the estimated costs and health 
outcomes of two scenarios as mentioned above. For the control group, the base-
case scenario estimated the lifetime consequences of different baseline risk 
profiles of the SHeS population; this was done during the development of 
alcohol intervention model. For the second intervention scenario, the effects 
of the intervention on modifying risk behaviours (i.e. stopping smoking and 
drinking) resulted in the changes of morbidity and mortality risks from the 
baseline, leading to differences in estimated lifetime costs and health 
outcomes compared to the base-case.     
Intervention effectiveness 
To apply one of the recommended frameworks for evaluating the public 
health impact of health promotion interventions (Glasgow et al., 1999) - namely 
the RE-AIM framework - intervention effectiveness should be assessed via five 
dimensions as follows: 
1) Reach: proportion of the target population that participated in the 
intervention 
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2) Efficacy: success rate if implemented as recommended in the guidelines, 
defined  as positive outcomes minus negative outcomes  
3) Adoption: proportion of settings, practices, and plans that will adopt the 
intervention  
4) Implementation: extent to which the intervention is implemented as 
intended in the real world 
5) Maintenance: extent to which the intervention is sustained overtime 
   
These dimensions can be evaluated at multiple levels, e.g. individual, 
healthcare setting, community or population.     
To analyse the cost-effectiveness of a health promotion intervention, the 
intervention effectiveness should take these dimensions in the model into 
account. Firstly, the coverage rate and acceptance rate of the intervention 
should be defined to estimate the proportion of the target population and the 
proportion of setting that would adopt the intervention (Glasgow et al., 1999). 
Secondly, the efficacy of intervention on modifying selected risk behaviours (as 
shown in Figure 8-1) within the follow-up period should be collected from 
individual who participated in an RCT or as an evidence synthesis of RCTs and 
observational studies, where the target population should be clearly described 
and relevant to the population of the intervention under evaluation. Thirdly, 
since the effect of a health promotion intervention may change over time 
(Green and Tones, 1999), the lag time of partial and full effects of the 
intervention should be defined and take into account in the effectiveness of 
the modelled intervention. Moreover, the lag time of these effects should be 
captured either within-trial (short-term period), e.g. change of risk behaviours, 
or in a longer-term period, e.g. changes of morbidity and mortality (Holmes et 
al., 2012). Finally, to examine the long-term maintenance of behaviour change 
due to the intervention, the duration of the intervention’s effects should be 
considered as well as the extent to which the intervention is implemented in a 
real-world situation (Glasgow et al., 1999). For the hypothetical intervention 
in this analysis, it was assumed that the intervention resulted in participants 
quitting their drinking and smoking behaviours in the first year of 
implementation. Subsequently, all the participants would then receive this 
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intervention every year to maintain the same risk behaviours as in the first year. 
To simplify the demonstration of the model, a coverage rate and acceptance 
rate of 100% were applied.      
Intervention costs 
This analysis was conducted from an NHS perspective so direct medical 
costs and intervention costs incurred on provider’s side were included. To 
analyse short-term cost-effectiveness, the intervention costs were collected 
within-trial which consisted of the cost of development and implementation in 
an RCT setting, and the cost of full implementation to other settings were 
estimated to reflect the real-world situation of the adopted intervention 
(Kruger et al., 2014). To demonstrate the use of model, this analysis assumed 
the intervention costs were £60 per year. For the longer-term cost-
effectiveness analysis, the lifetime hospitalisation costs were estimated with 
the same approach as the base-case (as described in Chapter 7); it should be 
noted that the healthcare costs of the intervention were affected by the 
intervention’s effectiveness, leading to a change in the risk of hospitalisation. 
Both short-term costs and long-term costs were then combined to achieve the 
estimated total costs of the intervention.       
8.2.3  Discounting 
As recommended by NICE, a discount rate of 1.5% for all costs and 
benefits was used since public health interventions usually show their effect 
over the long-term (National Institute for Health and Care Excellence (NICE), 
2012). Thus, this analysis employed a discounting rate of 1.5% for all future 
costs and QALYs.  
8.2.4 Uncertainty analysis 
A probabilistic sensitivity analysis (PSA) was conducted to assess the 
uncertainty surrounding the input parameters of the model (Appendix 8) that 
were mostly derived from multivariate regression analyses, where these 
parameters were known their covariance relationship in the regression 
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frameworks (Briggs, 2000). Thus, the uncertainty analysis was performed using 
a variance-covariance matrix of these parameters to show the covariance 
relationship, and the Cholesky decomposition was employed to generate 
correlated random parameters from the multivariate standard normal 
distribution as presented in Appendix 9 (Briggs et al., 2006a). The next stage, 
a Monte Carlo simulation performed in Microsoft Excel 2010 (Microsoft Corp., 
Redmond, WA) was employed to generate 5,000 iterations to demonstrate a 
range of plausible lifetime costs, health outcomes (LYs and QALYs), and ICERs 
(Appendix 9).  
The result of the analysis was plotted in a cost-effectiveness plane 
(Briggs et al., 2006b, Black, 1990) which shows the difference (intervention 
minus base case) in effectiveness (E) per patient on the horizontal axis versus 
the difference in cost (C) per patient on the vertical axis. The slope of the 
graph was computed using the equation ICER =C/E. When the ICER 
simulations were compared to the cost-effectiveness (CE) threshold of 
£20,000/QALY gained, the simulations which had a lower slope than the 
threshold line were considered to be cost-effective. Moreover, to summarise 
uncertainty by considering how many of the ICER simulations on the cost-
effectiveness plane fall below and to the right of different thresholds, a cost-
effectiveness acceptability curve (CEAC) was used to illustrate this uncertainty 
(van Hout et al., 1994, Briggs et al., 2006b, Fenwick et al., 2001, Briggs, 2000). 
The results were then further analysed for to determine a relationship between 
the different values of the threshold and the likelihood of being a cost-effective 
option compared between the base-case and hypothetical intervention using a 
net monetary benefit framework. The net monetary benefit (NMB) employs the 
cost-effectiveness decision rule (ICER< ceiling threshold referred as λ) by 
rearranging the equation as follows: 
∆𝐶
∆𝐸 
<  𝜆 
∆𝐸 × 𝜆 − ∆𝐶 > 0 
The intervention is considered cost-effective if its NMB is positive at any 
value of the ceiling threshold. Using the results of the Monte Carlo simulation 
(5,000 iterations), the NMB of each iteration of the intervention was calculated 
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and compared to the base-case at the specific threshold, and the proportion of 
these cost-effective iterations (NMB>0) were then plotted CEAC.  
8.3 Demonstrating results 
8.3.1 Cost-utility analysis 
Table 8-1 to Table 8-6 demonstrate the results derived from probabilistic 
model, where the uncertainty of input parameters was accounted for using 
Monte Carlo simulations. The results present the average and 95% credible 
interval of undiscounted LYs, remaining discounted QALYs and remaining 
discounted costs compared between the base-case and hypothetical 
intervention - where it was assumed that the intervention’s effect would result 
in the quitting of smoking and drinking among study cohorts, and the 
intervention would cost £60 per person per year. The “best-case” scenario was 
demonstrated based on the existing alcohol interventions in Thailand which the 
developed model will be adapted. The first importance intervention is a 
campaign known as “No alcohol during Buddhist Lent” which has been launched 
to encourage people to refrain from drinking alcoholic beverage during the 
three-month period of Buddhist Lent in every year since 2003 (SAB and 
(Research Centre for Social and Business Development Co., 2016). Moreover, 
two national surveys reported concurrent cigarette smoking and alcohol 
consumption, so the combined interventions between control alcohol drinking 
and smoking have been increasingly interested by Thai stakeholders as well as 
screening and concurrent brief intervention of conjoint hazardous or harmful 
alcohol and tobacco use in hospital is developing (Aekplakorn et al., 2008, 
Intarut and Pukdeesamai, 2017, Pengpid et al., 2015).   
For the comparison of LYs between the base-case and the intervention 
(as shown in Table 8-1 for males and Table 8-2 for females), the average LYs of 
the interventions for those who stopped smoking and alcohol drinking showed 
a longer life expectancy than the base-case across all age groups and risk 
profiles. Life expectancies of the intervention group ranged from 74.05 to 85.90 
years for males and 72.45 to 88.47 years for females, whereas life expectancies 
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of the base-case ranged from 72.09 to 85.79 years for males and 71.24 to 88.28 
years for females.  
Table 8-3 and Table 8-4 present the remaining discounted QALYs from age 
at the start of input into the model and varied by risk profiles for males and 
females, respectively. These average QALYs can be used for future cost-
effectiveness analyses that compare the difference of discounted QALYs (E) 
and discounted costs (C) between the base-case and intervention since the 
beginning of the model’s cohort, so QALYs and costs prior starting cohort are 
not included for estimating ICERs (C/E). When comparing the base-case to 
the intervention in terms of estimated remaining discounted QALYs, it was 
revealed that the intervention had higher discounted QALYs than the base-case 
across all age groups, drinking patterns, and smoking status. The additional 
QALYs (years) obtained from quitting drinking and smoking ranged from 0.07 to 
0.90 for males and 0.06-0.97 for females. 
 The remaining discounted costs based on the provider perspective of the 
base-case (including healthcare costs) and the intervention (i.e. intervention 
cost and healthcare costs) are illustrated in Table 8-5 for males and Table 8-6 
females in the same fashion as how QALYs were earlier presented. For males, 
the intervention resulted in less costs than the base-case for all drinking and 
smoking patterns in study cohorts aged 20 and 30 years. In this case, the 
intervention – which aimed to stop drinking and smoking for these groups - 
dominates the base-case due to more cost-savings in the long run as well as 
more QALYs as mentioned above. For older males aged 40 and 50 years as well 
as females of all ages, the results showed variation of incremental costs across 
risk profiles which varied from intervention being cost-saving to higher cost 
than base-case.  
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Table 8-1   Predicted life expectancy compared between the base-case and intervention classified by risks profiles: males 
Age (years) 20   30 
Base case  
modifiable risk factors          
Drinking status 
low-risk 
drinking 
hazardous 
drinking 
harmful 
drinking 
possible 
alcohol 
dependence  
low-risk 
drinking 
hazardous 
drinking 
harmful 
drinking 
possible 
alcohol 
dependence 
AUDIT score 0 - 7 8 - 15 16 - 19 >20  0 - 7 8 - 15 16 - 19 >20 
Predicted life expectancy 
(years): base case 
85.78 80.06 79.79 79.06  83.04 77.72 77.63 72.87 
95% credible interval (85.63,85.93) (79.92,80.19) (79.66,79.93) (78.92,79.2)  (82.92,83.17) (77.62,77.82) (77.53,77.73) (72.78,72.97) 
Predicted life expectancy 
(years): intervention* 
85.90 80.92 80.76 80.83  83.19 78.35 78.40 75.25 
95% credible interval (85.74,86.05) (80.78,81.05) (80.63,80.9) (80.69,80.96)  (83.07,83.31) (78.25,78.45) (78.3,78.5) (75.16,75.34) 
 
*The results of intervention demonstrate that the intervention result in the stoppage of drinking and smoking for all groups.  
Note: The results were derived from a probabilistic model using 5,000 simulations. BMI, SIMD, CVD, diabetes, prior hospitalisation, and GHQ score were varied for 
baseline risk profiles but not presented. 
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Table 8-1 Predicted life expectancy compared between the base-case and the intervention classified by risks profiles: males (cont.) 
Age (years) 40  50 
Base case  
modifiable risk factors          
Drinking status 
low-risk 
drinking 
hazardous 
drinking 
harmful 
drinking 
possible 
alcohol 
dependence  
low-risk 
drinking 
hazardous 
drinking 
harmful 
drinking 
possible 
alcohol 
dependence 
AUDIT score 0 - 7 8 - 15 16 - 19 >20  0 - 7 8 - 15 16 - 19 >20 
Predicted life expectancy 
(years): base case 
80.62 80.43 73.13 72.09  77.44 77.08 76.89 76.04 
95% credible interval (80.54,80.7) (80.35,80.51) (73.08,73.19) (72.03,72.15)  (77.39,77.49) (77.04,77.13) (76.85,76.94) (75.99,76.09) 
Predicted life expectancy 
(years): intervention* 
80.98 81.03 74.05 74.08  77.64 77.60 77.61 77.62 
95% credible interval (80.89,81.06) (80.95,81.11) (73.99,74.11) (74.02,74.13)  (77.6,77.69) (77.55,77.64) (77.57,77.66) (77.57,77.66) 
 
*The results of intervention demonstrate that the intervention would result in the stoppage of drinking and smoking for all groups.  
Note: The results were derived from a probabilistic model using 5,000 simulations. BMI, SIMD, CVD, diabetes, prior hospitalisation, and GHQ score were varied for 
baseline risk profiles but not presented. 
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Table 8-2 Predicted life expectancy compared between the base-case and the intervention classified by risks profiles: females 
Age (years) 20   30 
Base case  
modifiable risk factors          
Drinking status 
low-risk 
drinking 
hazardous 
drinking 
harmful 
drinking 
possible 
alcohol 
dependence 
 low-risk 
drinking 
hazardous 
drinking 
harmful 
drinking 
possible 
alcohol 
dependence 
AUDIT score 0-4 5-12 13-16 >17  0-4 5-12 13-16 >17 
Predicted life expectancy 
(years): base case 
88.28 87.52 80.20 79.24  85.24 75.52 75.18 74.30 
95% credible interval (88.1,88.46) (87.34,87.69) (80.03,80.37) (79.07,79.42)  (85.08,85.4) (75.39,75.64) (75.06,75.31) (74.17,74.42) 
Predicted life expectancy 
(years): intervention* 
88.47 88.46 81.02 81.08  85.45 75.92 75.79 75.78 
95% credible interval (80.86,81.08) (80.81,81.04) (80.91,81.13) (72.38,72.53)  (75.33,75.43) (74.84,74.95) (74.25,74.36) (74.22,74.32) 
 
*The results of intervention demonstrate that the intervention would result in the stoppage of drinking and smoking for all groups.  
Note: The results were derived from a probabilistic model using 5,000 simulations. BMI, SIMD, CVD, diabetes, prior hospitalisation, and GHQ score were varied for 
baseline risk profiles but not presented. 
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Table 8-2 Predicted life expectancy compared between the base-case and the intervention classified by risks profiles: females (cont.) 
Age (years) 40  50 
Base case  
modifiable risk factors 
         
Drinking status 
low-risk 
drinking 
hazardous 
drinking 
harmful 
drinking 
possible 
alcohol 
dependence 
 low-risk 
drinking 
hazardous 
drinking 
harmful 
drinking 
possible 
alcohol 
dependence 
AUDIT score 0-4 5-12 13-16 >17  0-4 5-12 13-16 >17 
Predicted life expectancy 
(years): base case 
80.77 80.54 80.41 71.24  75.20 74.67 73.82 72.20 
95% credible interval (88.1,88.46) (87.34,87.69) (80.03,80.37) (79.07,79.42)  (85.08,85.4) (75.39,75.64) (75.06,75.31) (74.17,74.42) 
Predicted life expectancy 
(years): intervention* 
80.97 80.93 81.02 72.45  75.38 74.90 74.31 74.27 
95% credible interval (80.86,81.08) (80.81,81.04) (80.91,81.13) (72.38,72.53)  (75.33,75.43) (74.84,74.95) (74.25,74.36) (74.22,74.32) 
 
*The results of intervention demonstrate that the intervention would result in the stoppage of drinking and smoking for all groups.  
Note: The results were derived from a probabilistic model using 5,000 simulations. BMI, SIMD, CVD, diabetes, prior hospitalisation, and GHQ score were varied for 
baseline risk profiles but not presented. 
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Table 8-3 Predicted remaining discounted QALY compared between the base-case and the intervention classified by risks profiles: males 
Age (years) 20   30 
Base case  
modifiable risk factors          
Drinking status 
low-risk 
drinking 
hazardous 
drinking 
harmful 
drinking 
possible 
alcohol 
dependence  
low-risk 
drinking 
hazardous 
drinking 
harmful 
drinking 
possible 
alcohol 
dependence 
AUDIT score 0 - 7 8 - 15 16 - 19 >20  0 - 7 8 - 15 16 - 19 >20 
Predicted remaining 
discounted QALY (years)  
: base case 
32.02 27.91 27.24 24.46  27.48 23.47 22.91 18.15 
95% credible interval (31.97,32.06) (27.87,27.95) (27.2,27.28) (24.41,24.51)  (27.44,27.52) (23.44,23.51) (22.87,22.94) (18.11,18.19) 
Predicted remaining 
discounted QALY (years)  
: intervention* 
32.09 28.26 27.65 25.18  27.56 23.76 23.26 19.05 
95% credible interval (32.05,32.13) (28.22,28.3) (27.6,27.69) (25.13,25.23)  (27.53,27.6) (23.72,23.79) (23.22,23.29) (19.02,19.09) 
 
*The results of intervention demonstrate that the intervention would result in the stoppage of drinking and smoking for all groups.  
Note: The results were derived from a probabilistic model using 5,000 simulations. BMI, SIMD, CVD, diabetes, prior hospitalisation, and GHQ score were varied for 
baseline risk profiles but not presented. 
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Table 8-3 Predicted remaining discounted QALY compared between the base-case and the intervention classified by risks profiles: males 
(cont.) 
Age (years) 40  50 
Base case  
modifiable risk factors          
Drinking status 
low-risk 
drinking 
hazardous 
drinking 
harmful 
drinking 
possible 
alcohol 
dependence  
low-risk 
drinking 
hazardous 
drinking 
harmful 
drinking 
possible 
alcohol 
dependence 
AUDIT score 0 - 7 8 - 15 16 - 19 >20  0 - 7 8 - 15 16 - 19 >20 
Predicted remaining 
discounted QALY (years)  
: base case 
22.51 21.49 16.36 14.35  16.33 15.47 15.02 13.25 
95% credible interval (22.48,22.54) (21.46,21.52) (16.34,16.38) (14.32,14.38)  (16.3,16.35) (15.45,15.49) (14.99,15.04) (13.23,13.28) 
Predicted remaining 
discounted QALY (years)  
: intervention* 
22.67 21.77 16.77 15.16  16.45 15.75 15.41 14.04 
95% credible interval (22.64,22.7) (21.74,21.8) (16.75,16.79) (15.13,15.19)  (16.43,16.47) (15.73,15.77) (15.39,15.43) (14.01,14.06) 
 
*The results of intervention demonstrate that the intervention would result in the stoppage of drinking and smoking for all groups.  
Note: The results were derived from a probabilistic model using 5,000 simulations. BMI, SIMD, CVD, diabetes, prior hospitalisation, and GHQ score were varied for 
baseline risk profiles but not presented. 
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Table 8-4 Predicted remaining discounted QALY compared between the base-case and the intervention classified by risks profiles: 
females 
Age (years) 20   30 
Base case  
modifiable risk factors          
Drinking status 
low-risk 
drinking 
hazardous 
drinking 
harmful 
drinking 
possible 
alcohol 
dependence 
 low-risk 
drinking 
hazardous 
drinking 
harmful 
drinking 
possible 
alcohol 
dependence 
AUDIT score 0-4 5-12 13-16 >17  0-4 5-12 13-16 >17 
Predicted remaining 
discounted QALY (years)  
: base case 
29.46 28.46 25.21 23.54  26.84 20.68 20.27 18.92 
95% credible interval (29.42,29.51) (28.41,28.5) (25.17,25.25) (23.48,23.59)  (26.8,26.89) (20.64,20.71) (20.24,20.31) (18.88,18.96) 
Predicted remaining 
discounted QALY (years)  
: intervention* 
29.56 28.77 25.47 24.22  26.96 20.81 20.49 19.46 
95% credible interval (21.65,21.72) (21.09,21.16) (20.83,20.9) (14.84,14.91)  (15.05,15.09) (14.3,14.34) (13.36,13.41) (12.67,12.72) 
 
*The results of intervention demonstrate that the intervention would result in the stoppage of drinking and smoking for all groups.  
Note: The results were derived from a probabilistic model using 5,000 simulations. BMI, SIMD, CVD, diabetes, prior hospitalisation, and GHQ score were varied for 
baseline risk profiles but not presented. 
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Table 8-4 Predicted remaining discounted QALY compared between the base-case and the intervention classified by risks profiles: 
females (cont.) 
Age (years) 40  50 
Base case  
modifiable risk factors 
         
Drinking status 
low-risk 
drinking 
hazardous 
drinking 
harmful 
drinking 
possible 
alcohol 
dependence 
 low-risk 
drinking 
hazardous 
drinking 
harmful 
drinking 
possible 
alcohol 
dependence 
AUDIT score 0-4 5-12 13-16 >17  0-4 5-12 13-16 >17 
Predicted remaining 
discounted QALY (years)  
: base case 
21.57 20.99 20.62 14.39  14.97 14.26 13.19 11.72 
95% credible interval (29.42,29.51) (28.41,28.5) (25.17,25.25) (23.48,23.59)  (26.8,26.89) (20.64,20.71) (20.24,20.31) (18.88,18.96) 
Predicted remaining 
discounted QALY (years)  
: intervention* 
21.68 21.12 20.86 14.87  15.07 14.32 13.39 12.69 
95% credible interval (21.65,21.72) (21.09,21.16) (20.83,20.9) (14.84,14.91)  (15.05,15.09) (14.3,14.34) (13.36,13.41) (12.67,12.72) 
 
*The results of intervention demonstrate that the intervention would result in the stoppage of drinking and smoking for all groups.  
Note: The results were derived from a probabilistic model using 5,000 simulations. BMI, SIMD, CVD, diabetes, prior hospitalisation, and GHQ score were varied for 
baseline risk profiles but not presented. 
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Table 8-5 Predicted remaining lifetime hospitalisation discounted cost compared between the base-case and the intervention classified 
by risks profiles: males 
Age (years) 20   30 
Base case  
modifiable risk 
factors          
Drinking status low-risk drinking 
hazardous 
drinking 
harmful 
drinking 
possible alcohol 
dependence  
low-risk 
drinking 
hazardous 
drinking 
harmful 
drinking 
possible alcohol 
dependence 
AUDIT score 0 - 7 8 - 15 16 - 19 >20  0 - 7 8 - 15 16 - 19 >20 
Predicted lifetime 
hospitalisation 
discounted cost (£): 
base case 
132,375 126,717 127,327 134,987  118,322 111,706 112,841 110,608 
95% credible interval (131,007-133,744) (125,488-127,947) (126,119-128,536)  (133,737-136,238)  (117,106-119,538) (110,581-112,831) (111,745-113,936) (109,602-111,614) 
Predicted lifetime 
hospitalisation 
discounted cost (£): 
intervention* 
130,878 125,527 124,474 125,271  117,278 110,768 110,665 104,426 
95% credible interval (129,521-132,235) (124,273-126,782) (123,244-125,705) (123,994-126,549)  (116,071-118,486) (109,617-111,919) (109,538-111,793) (103,384-105,468) 
 
*The results of intervention demonstrate that intervention would result in the stoppage of drinking and smoking for all groups.  
Note: The results were derived from a probabilistic model using 5,000 simulations. BMI, SIMD, CVD, diabetes, prior hospitalisation, and GHQ score were varied for 
baseline risk profiles but not presented. 
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Table 8-5 Predicted remaining lifetime hospitalisation discounted cost compared between the base-case and the intervention classified 
by risks profiles: males (cont.) 
Age (years) 40  50 
Base case  
modifiable risk factors          
Drinking status 
low-risk 
drinking 
hazardous 
drinking 
harmful 
drinking 
possible 
alcohol 
dependence  
low-risk 
drinking 
hazardous 
drinking 
harmful 
drinking 
possible 
alcohol 
dependence 
AUDIT score 0 - 7 8 - 15 16 - 19 >20  0 - 7 8 - 15 16 - 19 >20 
Predicted lifetime 
hospitalisation discounted 
cost (£): base case 
97,382 98,943 87,331 90,259  75,747 75,661 76,115 78,329 
95% credible interval (96,398-98,367) (97,948-99,939) (85,448-89,215) (89,434-91,084)  (75,009-76,485) (74,911-76,411) (75,381-76,848) (77,610-79,048) 
Predicted lifetime 
hospitalisation discounted 
cost (£): intervention* 
98,746 99,080 85,859 85,370  75,440 75,576 75,463 75,763 
95% credible interval (97,737-99,756) (98,063-100,097) (83,995-87,723) (84,517-86,222)  (74,696-76,185) (74,808-76,344) (74,709-76,217) (75,014-76,513) 
 
*The results of intervention demonstrate that the intervention would result in the stoppage of drinking and smoking for all groups.  
Note: The results were derived from a probabilistic model using 5,000 simulations. BMI, SIMD, CVD, diabetes, prior hospitalisation, and GHQ score were varied for 
baseline risk profiles but not presented. 
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Table 8-6 Predicted remaining lifetime hospitalisation discounted cost compared between the base-case and the intervention classified 
by risks profiles: females 
Age (years) 20   30 
Base case  
modifiable risk factors          
Drinking status 
low-risk 
drinking 
hazardous 
drinking 
harmful 
drinking 
possible 
alcohol 
dependence 
 low-risk 
drinking 
hazardous 
drinking 
harmful 
drinking 
possible 
alcohol 
dependence 
AUDIT score 0-4 5-12 13-16 >17  0-4 5-12 13-16 >17 
Predicted lifetime 
hospitalisation discounted 
cost (£): base case 
276,050 271,291 252,345 257,047  243,969 209,984 210,550 208,911 
95% credible interval 
(272,981-279119) (268,643-273,938) (250,312-254,378) (254,543-259,550)  (230,686-257,252) (207,900-212,068) (207,877-213,224) (206,098-211,725) 
Predicted lifetime 
hospitalisation discounted 
cost (£): intervention* 
275,633 274,085 255,324 257,703  241,816 211,535 210,733 210,872 
95% credible interval 
(187,815-192,904) (186,333-192,730) (188,389-191,568) (159,659-162,525)  (128,716-130,624) (134,280-140,653) (135,695-140,230) (133,975-137,459) 
 
*The results of intervention demonstrate that intervention would result in the stoppage of drinking and smoking for all groups.  
Note: The results were derived from a probabilistic model using 5,000 simulations. BMI, SIMD, CVD, diabetes, prior hospitalisation, and GHQ score were varied for 
baseline risk profiles but not presented. 
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Table 8-6 Predicted remaining lifetime hospitalisation discounted cost compared between the base-case and the intervention classified 
by risks profiles: females (cont.) 
Age (years) 40  50 
Base case  
modifiable risk factors 
         
Drinking status 
low-risk 
drinking 
hazardous 
drinking 
harmful 
drinking 
possible 
alcohol 
dependence 
 low-risk 
drinking 
hazardous 
drinking 
harmful 
drinking 
possible 
alcohol 
dependence 
AUDIT score 0-4 5-12 13-16 >17  0-4 5-12 13-16 >17 
Predicted lifetime 
hospitalisation discounted 
cost (£): base case 
191,114 189,256 189,033 164,616  129,708 140,199 140,078 139,732 
95% credible interval (272,981-279,119) (268,643-273,938) (250,312-254,378) (254,543-259,550)  (230,686-257,252) (207,900-212,068) (207,877-213,224) (206,098-211,725) 
Predicted lifetime 
hospitalisation discounted 
cost (£): intervention* 
190,359 189,532 189,978 161,092  129,670 137,467 137,962 135,717 
95% credible interval (187,815-192,904) (186,333-192,730) (188,389-191,568) (159,659-162,525)  (128,716-130,624) (134,280-140,653) (135,695-140,230) (133,975-137,459) 
 
*The results of intervention demonstrate that intervention would result in the stoppage of drinking and smoking for all groups.  
Note: The results were derived from a probabilistic model using 5,000 simulations. BMI, SIMD, CVD, diabetes, prior hospitalisation, and GHQ score were varied for 
baseline risk profiles but not presented.
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8.3.2 Uncertainty analysis 
Cost-effectiveness plane 
To take account of the uncertainty of input parameters which could 
impact the uncertainty of cost-effectiveness outputs, the PSA was performed 
using Monte Carlo simulations. Then, the results were presented via scatter 
plots of the 5,000 iterations on a cost-effectiveness plane as shown in Figure 
8-2 to Figure 8-9. These results demonstrate the intervention that aimed to 
stop smoking and drinking at a hazardous level (AUDIT score of 7-15 for males 
and 5-12 for females) in ages 20, 30, 40 and 50 years and classified by gender. 
For males (as shown in Figure 8-2 to Figure 8-5), considering where the data 
points are located on the cost-effectiveness plane, it can be seen that the 
majority of these data points are in either the southeast quadrant that - 
suggesting the intervention would be dominant (cost-saving and increased 
effectiveness) especially in the younger ages, or the northeast quadrant (i.e. 
the intervention yielded more QALYs but at a higher cost) and located below 
the threshold of £20,000/QALY gained. 
For females (Figure 8-6 to Figure 8-9), the scatter plots appear less 
precise than the plots for males since the input parameters used for the female 
model indicated higher uncertainty. The overall results showed that the 
intervention for stopping hazardous drinking and smoking for females would be 
less cost-effective compared to males. For females aged 20 and 30 years (Figure 
8-6 and Figure 8-7), the majority of the data points shown on the cost-
effectiveness plane are in the northeast quadrant and a small proportion of 
data points are in either the southeast quadrant or northwest quadrant (i.e. 
the intervention is yielded less QALYs but at a higher cost referred as dominated 
by the base-case). When comparing the ICER simulations (data points) to the 
cost-effectiveness threshold of £20,000, approximately half of these data points 
were below the threshold. For older cohort aged 40 and 50 years (Figure 8-8 
and Figure 8-9), the majority of these data points appeared in either the 
northeast quadrant and over the threshold or northwest quadrant. This might 
suggest that the intervention for females of older ages would be unlikely cost-
effective due to higher costs and less QALY gained.   
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Cost-effectiveness acceptability curve 
Figure 8-10 to Figure 8-17 present the CEAC to show the probability of 
either the hypothetical intervention or base case being cost-effectiveness at 
different ceiling thresholds ranging from £0 to £240,000, with the dashed line 
representing the threshold of £20,000/QALY gained. In the same manner, the 
target population for the intervention was hazardous drinkers (measured by the 
AUDIT) combined with other risk profiles (e.g. smoking) at ages 20, 30, 40, and 
50 years classified by gender, and the intervention aimed to stop alcohol 
drinking as well as smoking. For males (Figure 8-10 to Figure 8-13), the results 
plotted on the cost-effectiveness plane showed that the probability of the 
intervention being cost-effective at the threshold of £20,000/QALY gained was 
over 95% as compared to less than 5% for the base-case. For females, the 
probability of the intervention being cost-effective was around 60% for those 
aged 20 years (Figure 8-14) as compared to 40% for the base-case. Nevertheless, 
for females of older age (30, 40, and 50 years), the probabilities of the 
intervention being cost-effective were lower than 40% (as shown in Figure 8-15 
to Figure 8-17).              
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Figure 8-2 Scatterplot on the cost-effectiveness plane: base-case vs. 
intervention for hazardous drinker: males aged 20 years 
 
Note: The results of the intervention demonstrate that intervention would stop drinking and 
smoking for base-case risk profiles: males, aged 20 years, AUDIT score=15 (hazardous drinker), 
binge drinking, normal BMI, no CVD, no diabetes, 5 cigarettes per day, high physical activity, 
4th SIMD, prior hospitalisation over last year, and best GHQ score. 
 
Figure 8-3 Scatterplot on the cost-effectiveness plane: base-case vs. 
intervention for hazardous drinker: males aged 30 years 
 
Note: The results of the intervention demonstrate that intervention stop drinking and smoking 
for base-case risk profiles: males, aged 30 years, AUDIT score=15 (hazardous drinker), binge 
drinking, overweight, no CVD, no diabetes, 5 cigarettes per day, high physical activity, 4th SIMD, 
prior hospitalisation over last year, and best GHQ score. 
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Figure 8-4 Scatterplot on the cost-effectiveness plane: base-case vs. 
intervention for hazardous drinker: males aged 40 years 
 
Note: The results of the intervention demonstrate that intervention would stop drinking and 
smoking for base case risk profiles: males, aged 40 years, AUDIT score=15 (hazardous drinker), 
binge drinking, overweight, no CVD, no diabetes, 6 cigarettes per day, high physical activity, 
2nd SIMD, prior hospitalisation over last year, and best GHQ score. 
 
Figure 8-5 Scatterplot on the cost-effectiveness plane: base-case vs. 
intervention for hazardous drinker: males aged 50 years 
 
Note: The results of intervention demonstrate that the intervention would stop drinking and 
smoking for base-case risk profiles: males, aged 50 years, AUDIT score=15 (hazardous drinker), 
binge drinking, overweight, having CVD, no diabetes, 6 cigarettes per day, medium physical 
activity, 2nd SIMD, prior hospitalisation over last year, and best GHQ score. 
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Figure 8-6 Scatterplot on the cost-effectiveness plane: base-case vs. 
intervention for hazardous drinker: females aged 20 years 
 
Note: The results of the intervention demonstrate that intervention would stop drinking and 
smoking for base case risk profiles: females, aged 20 years, AUDIT score=12 (hazardous drinker), 
binge drinking, normal BMI, no CVD, no diabetes, 5 cigarettes per day, medium physical activity, 
4th SIMD, prior hospitalisation over last year, and best GHQ score. 
 
Figure 8-7 Scatterplot on the cost-effectiveness plane: base-case vs. 
intervention for hazardous drinker: females aged 30 years 
 
Note: The results of the intervention demonstrate that intervention would stop drinking and 
smoking for base case risk profiles: females, aged 30 years, AUDIT score=12 (hazardous drinker), 
binge drinking, overweight, no CVD, no diabetes, 5 cigarettes per day, medium physical 
activity, 5th SIMD, prior hospitalisation over last year, and best GHQ score. 
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Figure 8-8 Scatterplot on the cost-effectiveness plane: base-case vs. 
intervention for hazardous drinker: females aged 40 years 
 
Note: The results of the intervention demonstrate that the intervention would stop drinking 
and smoking for base-case risk profiles: females, aged 40 years, AUDIT score=12 (hazardous 
drinker), binge drinking, overweight, no CVD, no diabetes, 5 cigarettes per day, high physical 
activity, 2nd  SIMD, prior hospitalisation over last year, and best GHQ score. 
 
Figure 8-9 Scatterplot on the cost-effectiveness plane: base-case vs. 
intervention for hazardous drinker: females aged 50 years 
 
Note: The results of the intervention demonstrate that intervention would stop drinking and 
smoking for base-case risk profiles: females, aged 50 years, AUDIT score=12 (hazardous 
drinker), binge drinking, overweight, having CVD, no diabetes, 4 cigarettes per day, no physical 
activity, 2nd SIMD, prior hospitalisation over last year, and best GHQ score. 
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Figure 8-10 Cost-effectiveness acceptability curve: base-case vs. intervention 
for hazardous drinker: males aged 20 years 
 
Note: The results of the intervention demonstrate that intervention would stop drinking and 
smoking for base-case risk profiles: males, aged 20 years, AUDIT score=15 (hazardous drinker), 
binge drinking, normal BMI, no CVD, no diabetes, 5 cigarettes per day, high physical activity, 
4th SIMD, prior hospitalisation over last year, and best GHQ score. 
 
Figure 8-11 Cost-effectiveness acceptability curve: base-case vs. intervention 
for hazardous drinker: males aged 30 years 
 
Note: The results of the intervention demonstrate that intervention would stop drinking and 
smoking for base-case risk profiles: males, aged 30 years, AUDIT score=15 (hazardous drinker), 
binge drinking, overweight, no CVD, no diabetes, 5 cigarettes per day, high physical activity, 
4th SIMD, prior hospitalisation over last year, and best GHQ score. 
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Figure 8-12 Cost-effectiveness acceptability curve: base-case vs. intervention 
for hazardous drinker: males aged 40 years 
 
Note: The results of the intervention demonstrate that intervention would stop drinking and 
smoking for base case risk profiles: males, aged 40 years, AUDIT score=15 (hazardous drinker), 
binge drinking, overweight, no CVD, no diabetes, 6 cigarettes per day, high physical activity, 
2nd SIMD, prior hospitalisation over last year, and best GHQ score. 
 
Figure 8-13 Cost-effectiveness acceptability curve: base-case vs. intervention 
for hazardous drinker: males aged 50 years 
 
Note: The results of the intervention demonstrate that intervention would stop drinking and 
smoking for base-case risk profiles: males, aged 50 years, AUDIT score=15 (hazardous drinker), 
binge drinking, overweight, having CVD, no diabetes, 6 cigarettes per day, medium physical 
activity, 2nd SIMD, prior hospitalisation over last year, and best GHQ score. 
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Figure 8-14 Cost-effectiveness acceptability curve: base-case vs. intervention 
for hazardous drinker: females aged 20 years 
 
Note: The results of the intervention demonstrate that intervention would stop drinking and 
smoking for base case risk profiles: females, aged 20 years, AUDIT score=12 (hazardous drinker), 
binge drinking, normal BMI, no CVD, no diabetes, 5 cigarettes per day, medium physical activity, 
4th SIMD, prior hospitalisation over last year, and best GHQ score. 
 
Figure 8-15 Cost-effectiveness acceptability curve: base-case vs. intervention 
for hazardous drinker: females aged 30 years 
 
Note: The results of the intervention demonstrate that intervention would stop drinking and 
smoking for base-case risk profiles: females, aged 30 years, AUDIT score=12 (hazardous 
drinker), binge drinking, overweight, no CVD, no diabetes, 5 cigarettes per day, medium 
physical activity, 5th SIMD, prior hospitalisation over last year, and best GHQ score. 
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Figure 8-16 Cost-effectiveness acceptability curve: base-case vs. intervention 
for hazardous drinker: females aged 40 years 
 
Note: The results of the intervention demonstrate that intervention would stop drinking and 
smoking for base-case risk profiles: females, aged 40 years, AUDIT score=12 (hazardous 
drinker), binge drinking, overweight, no CVD, no diabetes, 5 cigarettes per day, high physical 
activity, 2nd  SIMD, prior hospitalisation over last year, and best GHQ score. 
 
Figure 8-17 Cost-effectiveness acceptability curve: base-case vs. intervention 
for hazardous drinker: females aged 50 years 
 
Note: The results of the intervention demonstrate that intervention would stop drinking and 
smoking for base case risk profiles: females, aged 50 years, AUDIT score=12 (hazardous drinker), 
binge drinking, overweight, having CVD, no diabetes, 4 cigarettes per day, no physical activity, 
2nd SIMD, prior hospitalisation over last year, and best GHQ score. 
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8.4 Discussion 
The economic evaluation shown compared the no intervention case with 
the hypothetical health promotion intervention. The hypothetical intervention 
of this analysis aimed to change drinking (measured by the AUDIT) and smoking 
(measured by the number of cigarette per day) behaviours so the cohorts quit, 
whereas other selected risk factors (e.g. SIMD, physical activity, and BMI) were 
assumed to be the same as the baseline. Comparing the costs and benefits of 
new intervention and control over the lifetime period, a within-trial analysis 
combined with the developed model was able to capture both short- and longer-
term consequences to estimate the cost-effectiveness of the intervention. This 
study developed the structure of the analysis model and specified the input 
parameters needed to conduct further cost-effectiveness analyses of other 
health promotion interventions. Finally, the presented cost-effectiveness 
results were shown using a probabilistic model, which accounted for parameter 
uncertainty, and the results were compared to the cost-effective threshold of 
the UK (£20,000 per QALY gained). Moreover, the cost-effectiveness results 
were sub-grouped by age, gender, and different risk factors so they can inform 
the policy decision-making process on defining target groups of the intervention 
based on cost-effectiveness information.      
The previous studies conducted an economic evaluation of an alcohol 
intervention alongside RCTs with a short-term follow-up period by using a 
modelling approach to extrapolate the costs and outcomes beyond the end-of-
trial for the lifetime horizon (Barbosa et al., 2010b, Purshouse et al., 2013, 
Barbosa et al., 2015, Cowell et al., 2010, Navarro et al., 2011, Tariq et al., 
2009). Most of modelling studies evaluated the cost-effectiveness of screening 
and brief intervention (SBI) for alcohol use disorder (Barbosa et al., 2015, 
Cowell et al., 2010, Purshouse et al., 2013, Angus et al., 2014b). The results 
showed the SBI’s efficacy in terms of reducing alcohol drinking problems, and 
it was also reported in many systematic reviews and meta-analyses (Bray et al., 
2011, Donoghue et al., 2014, Fachini et al., 2012, Babor et al., 2007). Those 
studies examined the relationships between SBI and changes in consumption 
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and/or alcohol-related harms within the follow-up period; the changes in 
consumption level were then modelled to estimate the changes of alcohol-
related diseases and/or other harms over time.  
The estimated QALYs from this study may not be directly comparable to 
other studies because of the differences in modelling methods, utility 
measurement, and defined drinking status; however, there is an only one UK 
study where the QALYs of harmful drinking (defined as grams of alcohol 
consumption per day) may be compared with the QALYs of this study (Barbosa 
et al., 2010a). Discounted QALYs derived from the UK study was 12.98 years 
(male cohort aged 40 years with harmful drinking defined as alcohol 
consumption ≥80 g/day) while discounted QALYs of the current model was 16.36 
years for male aged 40 years with an AUDIT score of 16-19, i.e. harmful 
drinking. The approximately three-year difference between the two studies 
may be due to the difference in the utility measurement tool; the previous 
study obtained its utility value from the EQ-5D while this study used the SF-12 
(SF-6D). Moreover, Barbosa et.al. applied a discounting rate of 3.5% per year 
following previous NICE recommendations (National Institute for Clinical 
Excellence (NICE), 2004), whereas this study followed a later recommendation 
specific to public health interventions and utilised a discounting rate of 1.5% 
per year (National Institute for Health and Care Excellence (NICE), 2012).   
However, this current study is the first one that measured the outcome 
measurement of an alcohol intervention using the AUDIT. The AUDIT was chosen 
because it can capture the range of alcohol drinking problems by assessing 10 
categories and computing a score between 0-40 for a final drinking problem 
assessment, and it has been widely used for alcohol drinking problem screening 
before provided brief intervention (as described in Chapter 4). Other issues of 
those existing models are the limited number of drinking states and alcohol-
related problems within the study cohort, e.g. absenteeism, moderate-risk 
consumption, high-risk consumption (Barbosa et al., 2015, Barbosa et al., 
2010b, Purshouse et al., 2013, Cobiac et al., 2009). In addition, the cut-off for 
classifying high-risk alcohol consumption as a drinking state is likely to change 
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in the future so this would limit the application of existing alcohol models which 
used different cut-off values of drinking states. Moreover, the existing studies 
modelled long-term health consequences including alcohol-related conditions 
but the range of included diseases may not cover all the possible conditions 
that may cause an underestimation of the results (Barbosa et al., 2015, Barbosa 
et al., 2010b, Purshouse et al., 2013, Cobiac et al., 2009).  
The most recent systematic review reported the cost-effectiveness of 
SBIs for alcohol misuse in the primary care setting, and almost all the studies 
suggested that SBIs were cost-effective (Angus et al., 2014a). However, this 
systematic review found that there was heterogeneity in the methods of the 
included studies such as estimated costs and health outcomes. As such, results 
obtained from this model in other settings might be invalid due to 
transferability issues. Moreover, 22 of the 23 studies were conducted in high-
income countries so there is still a lack of evidence in low- and middle-income 
countries which may have substantial heterogeneity compared to high-income 
countries due to the local context and limited resources (Angus et al., 2014a). 
It can be seen that the cost-effectiveness results of the alcohol intervention 
were less transferable to other settings. Further studies should be conducted 
regarding methodological transferability, especially in the low- and middle-
income country context (as demonstrated in Chapter 9).   
As recommended by the economic evaluation for public health guidelines 
(Weatherly et al., 2009), the research should consider health inequality, e.g. 
the effectiveness of an intervention among different socio-economic status 
and/or individual health risk. The effectiveness study evaluated the effects of 
minimum unit pricing for alcohol in the UK on different income and 
socioeconomic groups (Holmes et al., 2014a). However, the measured primary 
outcome was the percentage change of consumption classified into moderate, 
hazardous, and harmful drinkers in different income quintiles, and drinking 
patterns - which were an intermediate outcome - were then modelled using 
morbidity and mortality risks classified by those drinkers. Therefore, long-term 
inequality would not be tackled if the interventions found that there were 
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different effects on the hospitalisations and deaths of drinkers who were of 
different socioeconomic status and other risk behaviours (Jones and Bellis, 
2014, Probst et al., 2014, Probst et al., 2015b).       
Although the current analytical framework has successfully 
demonstrated the cost-effectiveness analysis of this health promotion 
intervention, it has certain limitations. Firstly, the SIMD quintile was selected 
to be the measurement of socioeconomic status in order to investigate health 
inequality among the Scottish population.  As such, this index cannot be applied 
to other settings; further research in other countries will need to explore the 
standard tool used for socioeconomic status assessment in their context. 
Secondly, the estimated costs of the study captured, particularly the 
healthcare costs of drinkers, would underestimate the total lifetime costs and 
the costs of other people affected by the drinkers. The societal perspective 
should be used to account for the wider impacts of alcohol consumption on 
society as a whole. Thirdly, The cost-effectiveness result of study accounted 
for parameter uncertainty using PSA as well as heterogeneity of risk profiles 
(e.g. drinking, smoking and BMI), while other uncertainties have been 
presented in the majority of models; the type of model, model structure, and 
method use (Briggs, 2000). These uncertainties were dealt with the different 
approaches (Appendix 8). The reference case for appropriate methodology can 
be used for methodological uncertainties i.e. by following good practice 
guidelines for undertaking modelling (ISPOR, 2014). Uncertainty regarding the 
structure of the model can be dealt with by one-way sensitivity analyses and 
scenario analyses, modifying one or more structural aspects or assumptions of 
the model and determining the impact on outcomes (Bojke et al., 2009). Thus, 
a further study should concern other types of uncertainty which would likely 
affect an intervention cost-effectiveness. Finally, the hypothetical intervention 
assumed the best-case scenario that the intervention would result in no more 
drinking and smoking in the first year of implementation, and then all 
participants would receive this intervention every year to maintain their risk 
behaviours same as in the first year. To simplify the demonstration of the 
model, a coverage rate and acceptance rate of 100% were applied in the 
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analysis. Thus, further studies should consider all required input parameters to 
quantify the effectiveness of the intervention under evaluation. 
8.5 Conclusions 
Using the analysis framework for cost-effectiveness of the health 
promotion intervention, not only was an alcohol intervention evaluation 
performed - which was the main analysis of the model - but it was also combined 
with other modified risk behaviours such as smoking cessation to reduce 
multiple unhealthy behaviours that was suggested to be more effective than a 
single targeted behaviour change.  
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Chapter 9: Methodological transferability of 
developing a health promotion model for 
economic evaluation in Thailand: a case study of 
alcohol control interventions 
9.1 Introduction 
9.1.1 Health-related risk behaviour and health promotion 
interventions in Thailand  
The magnitude of chronic non-communicable diseases (NCDs) has been 
gradually increasing in Thailand (Kaufman et al., 2011). In 2013, the major 
diseases that cause death in some Thais as well as years of good health for other 
were NDCs, e.g. stroke, ischemic heart disease (IHD), diabetes, chronic 
obstructive pulmonary disease (COPD), chronic kidney disease (CKD), or liver 
cancer (Livingston and Callinan, 2015). These diseases contributed to more than 
70%  of Thai deaths  in 2014, equivalent to approximately more than 350,000 
deaths per year (WHO, 2014). Many studies have shown the link between 
precarious lifestyles and NCDs - which driven primarily by four major risk 
factors: tobacco use, physical inactivity, the harmful use of alcohol and 
unhealthy diets (Doll et al., 2004, N.C.D. Risk Factor Collaboration, 2016, Parry 
et al., 2011, Thakur et al., 2011, Wakabayashi et al., 2015, Webber et al., 
2012). For instance, the data in 2010 showed that Thai males consumed 
approximately 14 litres of pure alcohol per year. Additionally, 50 per cent of 
Thai males also smoked in 2011 (WHO, 2014).  
Health promotion has become an interesting issues since 1986, where it 
was defined as “a process of enabling people to increase control over, and to 
improve, their health”(WHO, 2014). Health promotion was recommended as an 
effective approach for decreasing and preventing NCDs (International Union for 
Health Promotion and Education, 2011). In Thailand, health promotion has been 
developed and implemented for over a decade. The tobacco control movement 
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in Thailand became a global example in advocacy to establish policies, 
legislation and regulation to reduce and ultimately prevent the consumption of 
cigarettes (Galbally et al., 2012).  In 2001, the Thai Health Promotion 
Foundation (ThaiHealth) was established to promote and increase a healthy life 
for Thai people by using multiple approaches: increasing tobacco and alcohol 
taxes, promoting a healthy sponsorship of sports and culture, developing 
healthy environments, developing multi-sectoral support for health promotion, 
taking a social determinants approach, and promoting innovation and new 
knowledge. In the past decade, ThaiHealth and partner organisations were able 
to modify major health risk factors (e.g. alcohol and tobacco consumption, and 
road accidents) through a wide range of interventions (Galbally et al., 2012), 
e.g. increasing the excise tax of tobacco and alcoholic beverages, the Tobacco 
Control Act and Alcohol Control Act, drink-driving countermeasures and 
increased penalties, controlling accessibility, reducing underage smoking and 
drinking, banning advertisement and social marketing such as the annual “No 
alcohol during Buddhist Lent” campaign for the 3-month period, and Road 
Safety Campaigns during annual festivals. 
9.1.2 Alcohol consumption and alcohol-related death in Thailand 
compared to the UK 
Alcohol consumption in Thailand has increased steadily since 1990 
leading to the higher magnitude of alcohol-related problems comparing South-
East Asia countries (WHO, 2014). Table 9-1 presents a comparison of alcohol 
consumption measured by the AUDIT score among Thailand, Scotland, and 
England. In 2015, the Scottish Health Survey on alcohol consumption reported 
hazardous and harmful levels of drinking (measured by weekly unit 
consumption) for 36% of men and 17% of women (Gray and Leyland, 2015). The 
proportion of binge drinking (drinking more than 8 units for men and 6 units for 
women) on the heaviest drinking day were 32% and 14% of men and women, 
respectively. Using the AUDIT measurement, the majority of SHeS participants 
(75% for males and 88% for females) were classified as low-risk drinkers. 
Meanwhile, SHeS participants with alcohol use disorders (i.e. hazardous 
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drinker, harmful drinker, and possible alcohol dependence) comprised 25% and 
12% for males and females, respectively.  
According to the Adult Psychiatric Morbidity Survey and Health Survey 
2014, most adults in England aged 16-64 drank at lower risk levels based on the 
AUDIT measurement (72% of men and 85% of women). About 23% of men and 
13% of women drank at hazardous levels, and 5% of men and 2% of women were 
harmful drinkers and possibly alcohol dependent (Drummond et al., 2016). The 
prevalence of drinking at harmful or dependent levels was highest among young 
adults -particularly men aged 25–34 and women aged 16–24 - but this declined 
gradually with age increased. Among men who drank alcohol in the last week 
(Fuller, 2015), 57% had consumed more than 4 units on at least one day and 29% 
had consumed more than 8 units in a day. Among women, 50% of those who had 
consumed alcohol in the last week exceeded 3 units on at least one day, and 
22% had exceeded 6 units. It was unfortunate that these comparisons could not 
be shown for Wales and Northern Ireland due to lack of data. Mean weekly 
alcohol consumption statistics are not available for Wales, and estimates of 
consumption on the heaviest drinking day are not available for Northern Ireland 
(Government Statistical Service, 2014). 
Similar to Scottish and British alcohol use disorder surveys, the majority 
of adults aged 15 years and over (n = 19,468) was low-risk drinking (64% of men 
and 90% of women) according to the Thai National Health Examination Survey 
V (Aekplakorn et al., 2015). The proportion of hazardous and harmful drinkers 
among Thai population was higher both men and women. Males aged group 25-
34 years reported highest average AUDIT score, and 29% of this aged group had 
binge drinking behaviour which was also found in British surveys (Drummond et 
al., 2016).  
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Table 9-1 A comparison of AUDIT scores by country and gender 
AUDIT scores classification 
Thailand 
(2015)a 
Scotland 
(2015)b 
England 
(2016)c 
Male    
Non-drinker/low risk (0-7) 64% 75% 72% 
Hazardous drinking (8-15) 30% 21% 23% 
Harmful drinking (16-19) 4% 2% 3% 
Probable dependence (20+) 2% 2% 2% 
    
Female    
Non-drinker/low risk (0-7) 90% 88% 85% 
Hazardous drinking (8-15) 9% 10% 13% 
Harmful drinking (16-19) 6% 1% 1% 
Probable dependence (20+) 5% 1% 1% 
    
a Aekplakorn, W., Pakchareon, H., Thaikla, K., & Sateannoppakao, W. (2015). Thai National Health 
Examination Survey V. Bangkok: Health System Research Institute. 
b Gray, L., & Leyland, A. H. (2015). Chapter 4: Alcohol. In D. Campbell-Jack, S. Hinchliffe & L. Rutherford 
(Eds.), The Scottish Health Survey 2015 edition: Volumn 1 main report. Edinburgh: The Scottish 
Government. 
c Drummond, C., McBride, O., Fear, N., & Fuller, E. (2016). Alcohol dependence. In S. McManus, P. 
Bebbington, R. Jenkins & T. Brugha (Eds.), Mental Health and Wellbeing in England: Adult Psychiatric 
Morbidity Survey 2014. Leeds: NHS Digital. 
 
For alcohol-related death (Table 9-2), the Thai burden of disease 
reported 2,204 alcohol-related deaths for males and 310 deaths for females 
(Burden of Disease (BOD) and International Health Policy Program, 2014). To 
compare with alcohol-related deaths in the UK where the alcohol intervention 
model was developed, there were 8,697 alcohol-related deaths registered in 
the UK in 2014, equivalent to an age-standardised rate of 14.3 deaths per 
100,000 population (Office for National Statistics, 2016). Of these, 5,687 deaths 
were among males (65% of the deaths) and 3,010 among females (35% of the 
deaths), with rates of 19.4 deaths per 100,000 males and 9.6 per 100,000 
females. As presented in Table 9-2, Scotland had the highest age-standardised 
alcohol-related death rate for males at 31.2 deaths per 100,000 which it was 
likely similar figure in Thailand with rate of 28.2 deaths per 100,000 males. This 
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rate is significantly higher than those of any other constituent country of the 
UK; rates in Northern Ireland (20.3 per 100,000 males), Wales (19.9 per 100,000 
males), and England (18.1 deaths per 100,000) were not statistically 
significantly different from each other. Moreover, Scotland also had the highest 
alcohol-related death rate for females at 13.3 deaths per 100,000 (Office for 
National Statistics, 2016). This rate is significantly higher than that in England, 
Northern Ireland and Thailand, but not different from that in Wales. Rates in 
Wales (10.4 deaths per 100,000), England (9.1 per 100,000), Northern Ireland 
(8.5 deaths per 100,000 females) and Thailand (8.7 deaths per 100,000 females) 
were not likely different from each other. Remarkably, deaths due to road 
traffic accidents in Thailand were substantially higher than in the UK with age-
standardised death rates of 70.3 deaths per 100,000 males and 18.5 per 100,000 
females for Thailand, but only 5.9 deaths per 100,000 males and 1.8 per 100,000 
females for the UK (WHO, 2014). 
Table 9-2 A comparison of alcohol-related death and age adjusted death rate 
by country and gender 
 Male 
 
Female 
Alcohol-related deaths registered    
Thailand a  2,204 310 
UK b  5,687 3,010 
Age-standardised alcohol-related death rate 
per 100,000 males/females  
  
Thailand a  28.2 8.7 
UK b  19.4 9.6 
Scotland 31.2 13.3 
Northern Ireland 20.3 8.5 
Wales 19.9 10.4 
England 18.1 9.1 
Age-standardised death rate due to road traffic 
accidents c 
  
Thailand  70.3 18.5 
UK  5.9 1.8 
a Burden of disease (BOD) & International Health Policy Program (2014) 
b Office for National Statistics, National Records of Scotland, Northern Ireland Statistics and Research Agency (2016) 
c WHO. Global status report on alcohol and health (2014) 
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9.2 Conceptual framework of developing the Thai 
Health Promotion Intervention model for economic 
evaluation   
To estimate the cost-effectiveness of a health promotion intervention, 
and particularly for this study which focussed on an alcohol intervention on 
different levels (e.g. individual and population), an economic evaluation 
alongside RCTs might be limited. As such, a combined approach would be 
needed to estimate the costs and outcomes of the alcohol intervention while 
avoiding biased estimates. Even though existing economic evaluations alongside 
RCTs were conducted to assess intervention cost-effectiveness (Cowell et al., 
2012, Crawford et al., 2014, Crawford et al., 2015, UKATT Research Team, 
2005a), these estimates were measured within the follow-up period and may 
not have captured the results of the alcohol intervention because they often 
become noticeable many years after implementation. Thus, the extrapolation 
of costs and outcomes beyond the end of the trial using observational data to 
link intermediate outcomes with final outcomes should be considered to extend 
the time horizon analysis (e.g. for the lifetime of different drinking patterns). 
This study will develop a health promotion intervention model that can evaluate 
the effectiveness and cost-effectiveness of interventions to inform health 
policy decision-making (Lewsey et al., 2015).   
To account for the range of related risk factors that would likely affect 
hospitalisations and death, the development of the health promotion 
intervention model focussed on the association between related risk factors and 
harms (i.e. morbidity and mortality) to predict LYs and QALYs of different 
health risk profiles. These risk factors were identified to be the patterns and 
levels of alcohol consumption, socioeconomic status (Probst et al., 2015a, Jones 
et al., 2015b), as well as other factors which were found to have a relationship 
with alcohol drinking such as smoking status (Aekplakorn et al., 2008, De Leon 
et al., 2007, Falk et al., 2006, Harrison et al., 2008, McKee et al., 2010), 
physical activity (Kendzor et al., 2008), and body mass index or BMI (Hart et 
al., 2010). This study examines whether the selected risk factors are able to 
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accurately predict hospitalisations and death. Then, the model will be 
developed to estimate the LYs, QALYs, and lifetime healthcare costs, and those 
outcomes will be presented via different risk profiles. Moreover, the findings 
can be used for the evaluation of interventions that aim to change these 
selected risk factors, and it can show the association between the modified risk 
factors (intermediate outcome) and health outcomes.   
To evaluate the effect of the alcohol intervention in the long-term using 
an intermediate outcome, a conceptual model of the relationship between 
biomarkers, surrogate endpoints, and the process of evaluating therapeutic 
interventions can be applied (Biomarkers Definitions Working Group, 2001, 
Buyse et al., 2010).  The biomarker measurements (as compared to the risk 
behaviour in this study) can help explain the empirical results of clinical trials 
by investigating the relationship between the effects of interventions on 
molecular and cellular pathways and overall clinical responses. The biomarkers 
that represent highly-sensitive and specific indicators of disease pathways have 
been used as substitutes for the final outcomes in clinical trials when evidence 
indicates that they predict clinical risk or benefit. Figure 9-2 presents a 
conceptual framework of the development of the Thai Health Promotion 
Intervention model adapted from the Biomarkers Definitions Working Group 
2001(Biomarkers Definitions Working Group, 2001, Buyse et al., 2010). A health 
promotion intervention can have direct and indirect effects on a wide range of 
an individual’s modifiable risk factors, e.g. an alcohol consumption control 
intervention could change the alcohol drinking pattern and other related risk 
behaviours (e.g. cigarettes per day). Consequently, a mathematical analysis 
will examine that subset of risk factors, represented in the figure by a quadrant 
that can achieve surrogate endpoint status in terms of accuracy (correlation of 
measure) and precision (reproducibility); these are required to be reasonably 
likely to predict the endpoints in term of morbidity and mortality. 
Subsequently, the final outcomes can be converted to LYs, QALYs, and lifetime 
costs, and then the cost-effectiveness of the intervention can be estimated.  
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Figure 9-1 A conceptual framework of developing a health promotion 
intervention model for economic evaluation 
*adapted from the (Biomarkers Definitions Working Group, 2001) 
9.3 The objectives of study 
1) To develop the Thai Health Promotion intervention model which can be used 
for the economic evaluation of health promotion interventions. 
2) To demonstrate the usefulness of the Thai Health Promotion intervention 
model by conducting an economic evaluation of a selected existing alcohol 
intervention.  
9.4 Methods 
Based on the literature review about the effectiveness of interventions 
on reducing harm caused by alcohol consumption, a stakeholder consultation 
meeting will be conducted to discuss two main purposes as follows: 1) selecting 
an alcohol intervention of interest in the Thai context for economic evaluation 
which public health policy decision-makers would have an interest in, and 2) 
discussing the appropriateness of the approach used for the development of 
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Thai Health Promotion intervention model. To demonstrate the usefulness of 
the model, this study will apply a mathematical approach which was primarily 
developed to evaluate the alcohol intervention in the Scottish setting, namely 
the Scottish alcohol intervention model. The Scottish model was structured 
using a health state transition model to characterise the plausible consequences 
(i.e. hospitalisation and death) of different drinking behaviours (as detailed in 
Chapter 8: Section 8.2.1). The Scottish model was well-validated and 
calibrated, and is consistent with the key features of economic evaluation, such 
as perspective, time horizon, and measured costs and outcomes (Briggs et al., 
2006c, Drummond MF et al., 1997, Gray et al., 2011a).  
Then, the LYs, QALYs, and lifetime economic costs will be estimated 
from the Scottish alcohol intervention model, categorised by alcohol drinking 
patterns. These outcomes and costs of different drinking behaviours can be 
used to determine the benefits in terms of cost-effectiveness in the event that 
an alcohol intervention can change alcohol consumption, i.e. LY gained, QALY 
gained, lifetime economic costs and ICER. Therefore, the Scottish alcohol 
intervention model will be applied for developing the Thai Health Intervention 
model since the estimated outcomes and costs are suitable for health economic 
evaluation purposes. Additionally, these outcomes are widely recommended for 
the purposes of economic evaluation of health interventions, including 
recommendations from the Thai HTA guidelines to inform policy decision-
making in the Thai context based on these outcomes  (ISPOR, 2014, NICE, 2013, 
Chaikledkaew and Kittrongsiri, 2014, Teerawattananon and Chaikledkaew, 
2008). Initially, The Thai Health Intervention model will introduce the model 
for the economic evaluations of alcohol interventions.  
9.4.1 Estimating risk of hospitalisation and death among 
difference drinking pattern 
To develop an analytical model for predicting LY, QALY, and lifetime 
costs, an extensive individual linked health data set between baseline risk 
behaviours measured from health surveys and administrative data set (i.e. 
hospitalisation and death record) after the survey date were required. In 
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Thailand, a linked dataset between national health surveys and national 
hospitalisation and death records is very scarce so this was an important 
limitation when developing the Thai Health Intervention model by using the 
same method as the Scottish model. The alternative used was to adapt the well-
validated model using longitudinal data derived from other settings (Daniel 
Mullins et al., 2014, Stout et al., 2009);all data sets would be used to calibrate 
the cause-specific hazard model derived from the Scottish setting, and a 
multiplying factor would then be derived for adjusting the linear predictor of 
the original equation. Then, the calibrated model would be applied to estimate 
the risks of hospitalisation and death (as shown in Figure 2).  There are four 
existing data sets that will be investigated using these alternatives as listed 
below: 
1) The National Health Examination Survey V (2013) conducted by the 
National Health Examination Survey Office, where alcohol consumption and the 
Alcohol Use Disorder Identification Test (AUDIT) were collected. 
2) The 2007 National Household Survey for Substance and Alcohol Use 
(N=26,633), which includes information on pattern of alcohol consumption, the 
AUDIT and consequences of drinking 
3) The national survey of willingness to pay for selected health promotion 
programmes under ThaiHealth conducted by the Health Intervention 
Technology Assessment Program (HITAP) in 2012, which measured modifiable 
risk factors including alcohol consumption, smoking, physical activity, and 
socioeconomic status (N=7,311). 
4) Baseline morbidity and mortality of alcohol-related condition reported 
by the Thai Burden of Diseases (BOD) 
After data access requirements were approved, all researchers needed 
to correspond to the safe use of individual patient data with good practice 
methods and awareness patient data protection in order to analyse the 
administrative data. Thus, all researchers who accessed individual patient data 
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and produced the report were required to attend the Safe Researcher Training 
(http://www.adls.ac.uk/safe-researcher-training/) to have basic knowledge on 
how to treat administrative data in a responsible manner. Additionally, the 
study protocol was approved by the Institute for the Development of Human 
Research Protections (IHRP) as shown in Appendix 6. 
9.4.2 Cost-utility analysis (CUA) 
To estimate the cost-effectiveness of an intervention which aims to 
modify selected risk factors, two scenarios are performed for each individual 
risk profile. The first scenario model estimates the lifetime costs and health 
outcomes (i.e. LYs and QALYs) of the baseline risk profiles. The second scenario 
estimates these costs and outcomes of changes in risk behaviours (e.g. 
reduction of alcohol consumption) where the intervention affects these 
modifiable risk factors, leading to changes of first hospitalisation and death 
risks as well as healthcare costs and QALY. Next, the estimated lifetime 
hospitalisation costs and health outcomes are compared between the baseline 
and intervention effect scenarios, and incremental-cost effectiveness ratio 
(ICER) - that is, the additional cost per additional unit of effect (i.e. QALY) from 
a new intervention; thus, the ICER of a CUA is the incremental cost per QALY 
gained (Briggs et al., 2006c, Drummond MF et al., 1997, Gray et al., 2011b). 
Then, the ICER of the intervention will be compared to the threshold ICER of 
160,000 THB per QALY gained as recommended by the Thai Subcommittee for 
Development of the National List of Essential Medicines (NLEM) and the 
Subcommittee of the Development of Benefit Package and Service System, 
National Health Security Office.   
9.4.3 Input parameters 
This stage describes the input parameters required for the model-based 
economic evaluation to estimate LYs, QALYs, and lifetime costs of the selected 
alcohol intervention; these parameters will be derived from expert consultation 
meeting. This analysis will estimate the costs and health outcomes of the two 
scenarios (providing the intervention and baseline). The base-case scenario will 
estimate the lifetime consequences of baseline risk behaviours (i.e. drinking 
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and related-behaviours) while the second scenario - the intervention - will 
compare the results in the changes of morbidity and mortality risks due to the 
intervention’s effect on modifying risk behaviours (e.g. stopping drinking) to 
the baseline. This should lead to differences in the estimated lifetime costs and 
health outcomes compared to base-case.     
Intervention effectiveness 
To apply a recommended framework for evaluating the public health 
impact of health promotion interventions (Glasgow et al., 1999), namely the 
RE-AIM framework as described in Chapter 8. This study will explore the 
intervention’s effect on alcohol consumption in the first year of 
implementation, duration of maintenance of intervention effectiveness, 
percent coverage rate, and acceptance rate in the Thai context. All 
effectiveness parameters will be verified by an alcohol expert panel. In 
addition, to generate QALYs, the baseline utility will be derived from the EQ-
5D-5L measurement. The existing data were collected by the National 
Epidemiological Survey of Mental Health 2013-2014 (N~5,000) conducted by the 
Department of Mental Health, the Ministry of Public Health using Composite 
International Diagnostic Interview or CIDI, where alcohol abuse and alcohol 
dependence were diagnosed, as well as the EQ-5D-5L of respondents. The EQ-
5D-5L measurement will be converted into a utility score using the Thai EQ-5D-
5L preference (Pattanaphesaj and Thavorncharoensap, 2015).  
The impact of hospitalisation will be estimated as utility decrements 
which will be collected from alcohol-related hospitalised patients. For non-
alcohol related hospitalisation, the utility decrements of specific diseases will 
be derived from literature review using the Thai HTA research database 
(http://db.hitap.net/). The utility decrements will then be applied to decrease 
the baseline utility for the hospitalised health state. Moreover, the annual 
probabilities of re-admission will be estimated until the lifetime horizon. To 
calculate overall QALYs using the Kaplan-Meier Sample Average (KMSA) 
estimator approach (Gray et al., 2011a), the sum of survival time in each health 
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state weighted by the utility index adjusted by probabilities of re-admission 
and utility decrements will be calculated over 100-year cycle.   
Intervention costs 
The economic evaluation will be conducted from a societal perspective 
so lifetime costs will take into account direct medical care cost, direct non-
medical care costs (i.e. transportation, meal, and accommodation related to 
medical care), and costs of productivity loss due to sick leave for hospitalised 
patients as well as costs of reduced productivity related to alcohol drinking 
(Thavorncharoensap et al., 2010). Estimating each cost parameter is described 
as follows:  
1) Intervention costs will be collected, which consists of the cost of 
development and implementation in setting. Subsequently, the cost of full 
implementation to other settings should be estimated to reflect the real- world 
situation of the adopted intervention (Kruger et al., 2014). 
 2) Direct medical care costs due to hospitalisation will be obtained from 
the NHSO hospitalisation data from years 2001-2015 that covers around 70% of 
the Thai population. This administrative hospitalisation data set – which 
includes the diagnosis-related group (DRG) of each episode - will be used to 
model the average annual cost due to the 1-year cycle length of health state 
transition model. The modelling costs of yearly hospitalisation classified by the 
ICD-9 and ICD-10 will be estimated (Appendix 1). According to the plausible 
range and distribution of cost data, the generalised linear model (GLM) 
framework will be applied for modelling healthcare cost using the gamma 
family and  log-link function (McCullagh and Nelder, 1989, Dobson and Barnett, 
2008). 
3) Direct non-medical costs related to treatment (i.e. transportation, 
meals, and accommodation related to medical care) will be estimated using the 
Thai standard cost list database (http://costingmenu.hitap.net/) and the 
amount of healthcare utilisation.   
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4) For alcohol drinkers without any hospitalisation, the costs of reduced 
productivity related to alcohol drinking will be applied (Thavorncharoensap et 
al., 2010). The costs will be assumed constant until the age of 60 years or until 
retirement.  
The lifetime costs of the intervention will be affected by intervention 
effectiveness, leading to change in alcohol drinking behaviour and the risk of 
hospitalisation.  
9.4.4  Discounting 
As recommended by the Thai HTA guidelines to inform policy decision 
making in the Thai context (ISPOR, 2014, NICE, 2013, Chaikledkaew and 
Kittrongsiri, 2014, Teerawattananon and Chaikledkaew, 2008), the guideline 
decided to use a discounting rate at 3% annually for all costs and outcome since 
public health interventions usually show their effect over the long-term. 
Afterwards, the rate will change to 4% for cost and 1.5% for outcome in the 30th 
year and onwards (Permsuwan et al., 2014).  
9.4.5 Uncertainty analysis 
A probabilistic sensitivity analysis (PSA) will be conducted to assess the 
uncertainty surrounding input parameters of the analytical model that will be 
mostly derived from multivariate regression analyses, where these parameters 
are correlated with others (Briggs, 2000). Thus, the uncertainty analysis will be 
performed using a variance-covariance matrix of those parameters to show the 
covariance relationship. Afterwards, an applied approach, namely the Cholesky 
decomposition, can be employed to generate correlated draws of random 
parameters from the multivariate standard normal distribution (Briggs et al., 
2006a). For the next stage, a Monte Carlo simulation performed in Microsoft 
Excel 2010 (Microsoft Corp., Redmond, WA) will be employed to generate 5,000 
iterations to demonstrate a range of plausible lifetime costs, health outcomes 
(LYs and QALYs), and ICERs.  
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The result of the analysis will be plotted in a cost-effectiveness plane 
(Briggs et al., 2006b, Black, 1990), which shows the difference (intervention 
minus base case) in effectiveness (E) per patient on the horizontal axis versus 
the difference in cost (C) per patient on the vertical axis. The slope of the 
graph is equal to ICER =C/E. When the ICER simulations are compared to 
the cost-effectiveness (CE) threshold at 160,000 THB per QALY gained, the 
simulations which have a lower slope than the threshold line are considered to 
be cost-effective. Moreover, to summarise uncertainty by considering how 
many of the ICER simulations on the cost-effectiveness plane fall below and to 
the right of different thresholds, a cost-effectiveness acceptability curve 
(CEAC) will be illustrated (van Hout et al., 1994, Briggs et al., 2006b, Fenwick 
et al., 2001, Briggs, 2000). The results will be further analysed for a relationship 
between the different values of the threshold and the likelihood of being a cost-
effective option compared between base case and the selected intervention 
using a net monetary benefit (NMB) framework. The NMB employs the cost-
effectiveness decision rule (ICER< ceiling threshold referred as λ) by 
rearrangement as follows: 
∆𝐶
∆𝐸 
<  𝜆 
∆𝐸 × 𝜆 − ∆𝐶 > 0 
The intervention is considered cost-effective if its NMB is positive at any 
value of the ceiling threshold. Using the results of the Monte Carlo simulation 
(5,000 iterations), the NMB of each iteration of the intervention can be 
calculated and NMB compared to the base-case at the specific threshold, and 
the proportion of these iterations being cost-effective (NMB>0) can then be 
plotted on the CEAC.   
9.5 Discussion 
To conduct a model-based economic evaluation of a health promotion 
intervention to capture short- and long-term outcomes for various sub-
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populations by different health profiles, the individual records of linkage data 
between the national health survey, morbidity, and mortality are needed. In 
Thailand, there is no such adequate linkage data similar to the one in Scotland 
because the Thai health surveys, morbidity, and mortality data are separately 
managed by different organisations (as detailed in Section 9.4.1); there is the 
lack of a process to link those data. As a result, the study conducted in the Thai 
context will transfer the decision modelling of the health promotion 
intervention developed in the Scottish setting using individual linkage data 
between the SHeS and Scottish morbidity and death records. The study will use 
the Scottish model structure and coefficient derived from multivariate 
regression models which carried out a wide range of model input parameters 
(e.g. transitional probabilities, hospitalisation costs and utility values).  
However, the level of transferability of each parameter used needs to 
be considered as described in Chapter 2 (Barbieri et al., 2010). Additionally, an 
external validation of the applied model should be conducted to prove that the 
model structure and parameter used are adequate in the Thai context. 
According to the Thai expert consultation meeting on 26th November 2014 
(Appendix 7), an expert suggested that the external validation of the alcohol-
related harm prediction model should be conducted using a survey design to 
interview about the drinking status and the AUDIT as well as QALYs directly or 
comparing to an existing cohort in Thailand.  
Due to the limitation of available linkage data, a model calibration of 
the Scottish model will be employed using the national health survey for 
comparing health profiles as well as individual hospitalisation and death 
records. These data will be used to separately calibrate the Scottish model to 
fit with the Thai baseline data. However, the Thai data have several limitations 
that need to be considered prior to further analyses. Firstly, the Scottish model 
is adjusted for the under-reporting of alcohol consumption among survey 
participants using alcohol sales data before conducting the multivariate 
regression analysis (as described in Chapter 6: Section 6.2.4). Nevertheless, 
under-reported alcohol drinking information among the Thai survey population 
is scarce; moreover, sufficient alcohol sales data in Thailand does not exist. 
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Thus, the Thai model will employ the same level of under-reporting alcohol 
consumption and relevant assumptions as the Scottish model. Secondly, the 
national hospitalisation and death records in Thailand seem to under-report 
alcohol-related conditions, e.g. accidents and injuries caused by alcohol 
drinking have been under-reporting due to drink-driving legislation, or it was 
not defined to be the primary diagnosis for the hospitalised patient because it 
is not covered by universal health coverage scheme.  
For utility and cost parameters, local data will be required due to the 
low level of transferability from other jurisdiction (Barbieri et al., 2010). There 
are two issues where the Thai study will be different from the original model. 
The first issue is due to the study using a societal perspective; as such the 
components of included costs are different from the Scottish study which used 
the healthcare provider perspective. The second issue is the HRQoL 
measurement, where the Scottish model estimated HRQoL using SF-6D (SF-12) 
HRQoL score (as described in Chapter 5). For the Thai study, EQ-5D-5L will be 
used based on recommendations by the Thai HTA guideline, and the Thai 
preference weights is also available (Chaikledkaew and Kittrongsiri, 2014, 
Pattanaphesaj and Thavorncharoensap, 2015). For these two parameters, the 
multivariate analysis should be re-analysed using country-specific dataset.   
For intervention effectiveness, conducting an RCT in Thailand might not 
be suitable due to limited resources. Moreover, it might take a long time until 
the effects of the health promotion intervention become noticeable. Thus, this 
study prefers to combine relative risk estimates from international RCTs with 
the estimates of baseline risk from local epidemiological data (Barbieri et al., 
2010). When data from more than one trial are available, a meta-analysis is the 
preferred method for synthesising clinical data. In particular, for one 
intervention that has been implemented only in Thailand, e.g. the annual “No 
alcohol during Buddhist Lent” campaign for a 3-month period, an observational 
study in the implemented setting will be used to estimate intervention effect 
while taking into account plausible confounders to reduce bias estimate.  
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9.6 Conclusions 
This study will demonstrate an economic evaluation of an alcohol 
intervention in Thailand using the Thai Health Promotion intervention model, 
which will be developed via country-specific information. Therefore, this model 
will be suitable for the purpose of health promotion intervention evaluation to 
inform policy decision-making whether the intervention under evaluation is 
cost-effective in the Thai context. As a result, it is indeed fundamental, not 
only for justifying the public’s investment in health promotion but also in 
enabling public health managers or healthcare workers to monitor the progress 
or success of their work. As mentioned above, economic evaluation for health 
promotion interventions in Thailand has been in high demand.   
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9.8 Budget estimation 
Items 
 Cost per 
unit (THB)  
Unit 
 Total cost 
(THB)  
Staff  
Researcher (per month) 30,000 12 360,000 
Research assistant (per month) 15,000 12 180,000 
Research assistant (per month) 15,000 12 180,000 
Materials 
Stakeholder meetings  20,000 4 80,000 
International experts consultation meeting 100,000 2 200,000 
Safe researcher training (per researcher) 5,000 3 15,000 
Administration cost of data set 20,000 4 80,000 
Statistic software  60,000 2 120,000 
Office materials 50,000 1 50,000 
Published report and policy brief 310 500 155,000 
Publication  45,000 2 90,000 
Financial statement audit 10,000 1 10,000 
Total staff cost 720,000 
Total material cost 800,000 
Administrative cost  (10% of material cost) 80,000 
Total 1,600,000 
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Chapter 10: Discussion and conclusions 
10.1  Introduction 
 The overall purpose of the thesis was to develop an alcohol intervention 
model that can be used to evaluate the long-term effectiveness and cost-
effectiveness of alcohol interventions to inform health policy decision making. 
Moreover, the Thai public health and health promotion policy-makers are 
considering adopting the screening and treatment for alcohol use disorders so 
the alcohol intervention model will be useful for policy-making. The thesis 
explored the approaches used in previous alcohol intervention modelling and 
considered whether a new approach was need, and if so, what was an 
appropriate methodology to follow. Following gold-standard practices for 
developing an economic model, the current model required information as well 
as country-specific data, especially utility weight and cost data (NICE, 2013). 
Eight waves of a nationally-linked to morbidity and mortality data to develop 
cause-specific morbidity and mortality statistical models derived from 
individual risk factor profiles. Due to well-known under-reporting bias among 
the survey population, this study explored and demonstrated a potential 
approach to adjust under-reported alcohol consumption using alcohol sales 
data (Boniface and Shelton, 2013). Moreover, this study employed the Alcohol 
Use Disorder Identification Test (AUDIT), which has been widely used for 
screening and monitoring of alcohol use disorders – hazardous use, harmful use, 
and alcohol dependence - to examine the change of morbidity and mortality 
risks after modified alcohol use disorder (Babor et al., 2001).  
 Using a wide range of analytical methods for individual-level 
longitudinal data, the important components of the health state transition 
model for economic evaluation were estimated, i.e. time-dependent 
transitional probabilities of all possible events (alcohol-related and non-alcohol 
related diseases, and death), associated utility weight, and long-term 
healthcare costs related to hospitalisation and day cases. These input 
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parameters were used to estimate health outcomes (i.e. LYs and QALYs) and 
long-term healthcare costs classified by individual risk profiles e.g. age, sex, 
SIMD, and drinking risk. Then, the application of the alcohol intervention model 
was demonstrated for the economic evaluation of intervention that aims to 
change the selected risk factors. The results of cost-effectiveness could be 
detailed a large number of subgroups varied by such risk profiles. The 
additional proposal of methodological transferability to an LMIC country (i.e. 
Thailand) was included to plan for further study. This chapter discuss the 
overall thesis and provides a conclusion to the thesis. There are four parts that 
include a summary of main findings as well as a comparison with previous 
studies, strengths and limitations of the current alcohol intervention model, 
suggestions for improvement and speculating on future research, implications 
for policy-makers, and conclusions.    
10.2  Summary of the thesis and main findings 
10.2.1 Chapter 1 
Chapter 1 introduced the background and overview information about 
the conceptual causal model of alcohol consumption and alcohol-related harm, 
and highlighted how alcohol-related harm is an increasing global public health 
problem. The harm caused by alcohol drinking impacts both at the individual- 
and society-levels. Accordingly, monitoring alcohol consumption per capita was 
described both at aggregate-level (i.e. alcohol sales) and individual-level 
through national health surveys which measure self-reported alcohol 
consumption. It is well recognised that self-reported alcohol consumption 
generally represents an underestimate of actual consumption (ranged from 40% 
to 60%) compared to per capita sales data due to the three main issues, namely 
sampling frame, non-response bias, and under-reporting bias. To measure 
alcohol misuse prevalence, and to evaluate the association of alcohol misuse 
with alcohol-related morbidity and mortality, this underestimation needed to 
be accounted for. A screening tool for alcohol use disorder, namely the AUDIT, 
was described in terms of the content and application in healthcare settings 
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and general population surveys. Consequently, effective and cost-effective 
alcohol interventions to reduce alcohol-related harms were listed and 
summarised the findings of literature. Since the current study was conducting 
using the framework of a model-based economic evaluation of public health 
interventions, methodological issues for evaluating cost-effectiveness using the 
modelling approach of public health intervention were summarised based on 
the published guidance. The guidelines addressed the various methodological 
challenges due to wider impacts and longer-term measured outcomes of public 
health intervention compared to the evaluation of healthcare intervention. 
Finally, the issue of transferability to other settings was addressed. 
10.2.2 Chapter 2 
This chapter reviewed the published literature of model-based economic 
evaluations of alcohol interventions to explore how the current study could fill 
the evidence gap. There are various methodological challenges related to 
developing an economic evaluation of alcohol intervention using modelling 
approaches to tackle a range of alcohol-related consequences and alcohol 
intervention effects. The review found the high levels of heterogeneity in terms 
of type of economic evaluation and model use, model structure, considering 
costs and consequences, and sensitivity analysis. Furthermore, the previous 
modelling studies encountered some limitations that the current study 
attempted to address by adding evidence in the following areas: limited 
adjustment for under-reporting consumption; multiple sources of evidence on 
a range of model parameters which may increase the degree of parameter 
uncertainty; limited essential country-specific data; a lack of longitudinal data 
at the individual level to model incidence of morbidity and mortality; a limited 
number of identified drinking states and related consequences; and a lack of 
consideration for equity or inequality. Accordingly, this study developed an 
alcohol intervention model to evaluate the costs, outcomes and cost-
effectiveness of alcohol interventions by applying the QALY-framework to 
inform healthcare policy-makings (National Institute for Health and Care 
Excellence (NICE), 2012). 
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10.2.3 Chapter 3 
Chapter 3 described the main purposes and conceptual framework of this 
study, which examined the impact of alcohol intervention on drinking problems, 
e.g. alcohol misuse and binge drinking (intermediate outcome) as measured by 
the AUDIT (Babor et al., 2001), and morbidity and mortality (final outcomes). 
These outcomes can then be converted to LYs, QALYs, and long-term costs, and 
intervention cost-effectiveness can subsequently be estimated. Since several 
analyses would be conducted to retrieve the fundamental inputs of the 
economic model, the stages of data analyses were then summarised in the form 
of an analytical framework. The Scottish linkage data between national health 
surveys, namely Scottish Health Surveys (SHeS), and Scottish morbidity records 
(SMR) as well as death records (National Record Scotland: NRS) were mainly 
used for the whole study (Information Services Division, Fleming et al., 2012); 
this demonstrated the use of country-specific administrative data to develop 
an economic evaluation for informing local policy-makers. Even though there 
are some published studies that conducted such linkage data analysis to explore 
alcohol consumption and its harms, these epidemiological studies have not 
demonstrated any economic evaluation of an alcohol intervention (Gray et al., 
2013, Gorman et al., 2014, Fleming et al., 2012, Katikireddi et al., 2017). The 
current study performed an epidemiological model analysis and used the model 
outputs to develop an alcohol intervention model for economic evaluation. 
Then, a cohort Markov model to simulate multiple diseases including all possible 
hospitalisation and death over lifetime for estimating long-term costs and 
health outcomes was detailed.  However, this study could not deal with the 
change of individual risk behaviours overtime, so the key assumption was the 
stability of health behaviours (i.e. alcohol drinking and related behaviours) over 
time with same age, where health behaviours classified by age can be derived 
from SHeS; this approach was also applied in other UK studies (Brennan et al., 
2014b, Brennan et al., 2016). However, due to limited time and resources, the 
developed economic model could illustrate only a hypothetical intervention (as 
shown in Chapter 8) instead of an implemented alcohol intervention in the 
Scottish context.     
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10.2.4 Chapters 4 and 5    
There were two initial analyses that were necessary for the developing 
alcohol intervention model. Firstly, the AUDIT would be used for the estimation 
of the outcomes but it was not measured in the early Scottish Health Survey 
waves. In Chapter 4, the initial analysis was done on nine alternative statistical 
methods for predicting AUDIT scores. The best-fitted model was able to 
generate the overall score (i.e. OLS regression model separated by gender), yet 
each AUDIT question could not be specifically predicted. Moreover, the 
observed AUDIT scores were derived from general population surveys which 
addressed that when using the AUDIT in the context of surveys, it would have 
the possibility of a false positive in the total score compared to using it in the 
healthcare setting (Knibbe et al., 2006). Although the OLS method could 
properly predict the scores, these scores for most of the SHeS study samples 
was an important assumption of the further analyses. The latest meta-analysis 
showed the significant difference between mortality risk of alcohol use disorder 
and non-alcohol use disorder (Roerecke and Rehm, 2013). Although there are a 
variety of alcohol misuse assessment tools, this study selected the widely used 
tool, i.e. AUDIT, to examine the association of alcohol use disorders and related 
health consequences. This is because the AUDIT has been widely recommended 
for detecting alcohol use disorder as identified by the WHO ICD-10 in the UK 
healthcare setting and many other countries with translation into their own 
languages as well (National Collaborating Centre for Mental Health, 2011, Dybek 
et al., 2006, Gache et al., 2005, Li et al., 2011). The AUDIT has also been 
applied for mass-screening and national health surveys for detecting prevalence 
of alcohol use disorder among the general population as a means of supporting 
national policy-makers, and Thailand will be the setting for a further study 
(Aalto et al., 2009, Knibbe et al., 2006, Assanangkornchai et al., 2010). 
Currently, public health and health promotion policy-makers in Thailand are 
considering adopting the screening and treatment programmes for alcohol use 
disorders, and they are monitoring the magnitude of alcohol use disorder among 
the Thai population using routine national health surveys. It could be seen that 
using AUDIT seems to be suitable for this current study which ultimately aimed 
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to inform these policy-makers - who are focussing on drinkers with alcohol use 
disorders rather than alcohol consumption volume in general.  
The second initial analysis shown in Chapter 5 presented the estimation 
of HRQoL scores (i.e. utility value) using the SF-6D (SF-12) preferences-based 
index that was measured in only the SHeS 2003. The baseline HRQoL scores of 
the general population classified by age, sex, and SIMD quintile were estimated. 
In addition, a multivariate analysis was also performed to estimate the 
decrement of HRQoL or disutility score associated with different alcohol 
drinking statuses classified by the AUDIT score, and alcohol-related and non-
alcohol related hospitalisations. Baseline HRQoL and disutility scores were used 
for the further analysis of estimating QALY as presented in Chapter 7. The 
relationship between drinking (measured by the AUDIT) and HRQoL supported 
the J-shaped morbidity curve as suggested in the previous studies, where those 
who have never consumed alcohol reported a worse HRQoL than low-risk 
drinkers, and higher-risk drinkers showed a worse HRQoL (Petrie et al., 2008, 
Saarni et al., 2008, Valencia-Martin et al., 2013, Van Dijk et al., 2004). For the 
reduction of HRQoL related to hospitalisations, having either alcohol-related 
hospitalisations or CVD-related conditions affected the current HRQoL 
(measured utility), at approximately the same utility values (around 0.65-0.70) 
found in previous studies (Currie et al., 2005, Dan et al., 2008). However, the 
HRQoL derived from survey populations may find that healthy people are more 
likely recruited in the health survey, and unhealthy people - especially heavy 
drinkers – may participate less, so they would be less likely to respond 
regardless of their alcohol drinking levels – an issue of selection and non-
response biases (Meiklejohn et al., 2012).  
10.2.5 Chapter 6  
The alcohol intervention model was initially developed and presented in 
Chapter 6. The stages of developing the model started with constructing a 
health state transition model which included first- and following 
hospitalisations, and subsequently modelling various scenarios until death. A 
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parametric survival analysis using the SHeS-SMR/NRS linkage data separated by 
gender were listed as follows: stage 1 was the estimation of risk of having first 
events; stage 2 was the estimation of risk of having following hospitalisations 
and survival after hospitalisations; and stage 3 was estimating total life years. 
Individual risk profiles were used for each stage, i.e. age, SIMD, health 
conditions (DM and CVD), drinking status measured by predicted AUDIT scores, 
binge drinking and other selected behavioural risk factors (e.g. smoking, BMI, 
and physical activity). In conjunction with developing the analytical model, 
under-reporting alcohol consumption was adjusted using alcohol sales data and 
multiple imputation of missing data among survey population. After modelling, 
the model validation (i.e. internal validation) and calibration of the linear 
predictor using the Scottish life table were also employed.  
Then, the model utilisation for predicting life years of different risk 
profiles were demonstrated and the results were presented classified by age, 
gender, SIMD, alcohol misuse (i.e. shown as the AUDIT and binge drinking), and 
other related behavioural risk factors (e.g. smoking, BMI, and physical activity). 
The results showed that the developed alcohol intervention model could predict 
the hospitalisation and death events of each individual risk profile, and the 
model validation showed good performance. However, the predicted overall 
survival of different risks profiles was likely longer than the life table of the 
population so the linear predictor was adjusted with a multiplying factor 
generated from the Scottish life table (National Records of Scotland, 2014). 
Finally, predicting the overall LYs of different drinking statuses were 
demonstrated the use of the alcohol intervention model in evaluating the effect 
of alcohol intervention on morbidity and mortality. According to the method 
used as mentioned above, the current alcohol intervention model differed from 
other modelling studies so it would be difficult to directly compare with other 
alcohol intervention evaluation studies. The current study would be an 
alternative approach to develop a model-based economic evaluation. Where 
the previous modelling studies commonly gathered the model parameters from 
various sources, this study used national administrative data to generate the 
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various components of the analytical model. This can be a new area for linked 
health data analysis, of which almost all of previous studies focussed on dealing 
with survey population bias (i.e. non-response bias), assessing the 
representativeness of study population, and epidemiology of alcohol-related 
harm (Gray et al., 2013, Gorman et al., 2014, Katikireddi et al., 2017).      
10.2.6 Chapter 7 
Chapter 7 illustrated the use of the alcohol intervention model to 
estimate QALYs and long-term healthcare costs (i.e. hospitalised admission and 
day case) over the lifetime, and the results were comparable across risk 
behaviours (e.g. drinking status, smoking, physical activity, and BMI), subgroups 
by age, gender, and socioeconomic status. The results indicated how future 
healthcare costs and outcomes would change based on either an increase or 
decrease in alcohol use (measured by the AUDIT). To model the occurring 
plausible events in the long-term, the annual risk of subsequent hospitalisations 
for individuals who survived after first hospitalisations classified as alcohol-
related and non-alcohol related conditions were estimated since these 
following events had effects on both the reduction of HRQoL and future 
treatment costs.  
For estimating QALYs, baseline HRQoL values (categorised by age, 
gender, and SIMD) and the reduction of HRQoL values due to hospitalisations 
and increasing AUDIT scores (derived from initial analysis in Chapter 5) were 
multiplied by the annual risk of subsequent hospitalisations and weighted by 
LYs (as mentioned in Chapter 6). Finally, the sum of quality-adjusted survival 
of each annual cycle in different health states was calculated over the lifetime, 
and were presented as the remaining QALYs after entering the cohort model; 
the results showed the differences of the remaining QALYs compared across risk 
profiles. For each drinking risk categorised by the AUDIT score band, the results 
revealed that higher-risk drinking resulted in less remaining QALYs when other 
related risk profiles were also changed based on the characteristics of the study 
population. The estimated QALYs from this study may not be directly 
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comparable to other studies because of the differences in modelling methods, 
utility measurement, and defined drinking status; however, there is an only one 
UK study where the QALYs of harmful drinking (defined as grams of alcohol 
consumption per day) may be compared with the QALYs of this study (Barbosa 
et al., 2010a). Discounted QALYs derived from the UK study was 12.98 years 
(male cohort aged 40 years with harmful drinking defined as alcohol 
consumption ≥80 g/day) while discounted QALYs of the current model was 16.36 
years for male aged 40 years with an AUDIT score of 16-19, i.e. harmful 
drinking. The approximately three-year difference between the two studies 
may be due to the difference in the utility measurement tool; the previous 
study obtained its utility value from the EQ-5D while this study used the SF-12 
(SF-6D). Moreover, Barbosa et.al. applied a discounting rate of 3.5% per year 
following previous NICE recommendations (National Institute for Clinical 
Excellence (NICE), 2004), whereas this study followed a later recommendation 
specific to public health interventions and utilised a discounting rate of 1.5% 
per year (National Institute for Health and Care Excellence (NICE), 2012).          
For estimating long-term costs using the healthcare perspective, this 
analysis used the SMR01 morbidity records which includes acute inpatient and 
day cases, and the health service costs of each episode was identified as 
alcohol-related and non-alcohol related condition. The annual costs in the year 
of having first hospitalisation and subsequent admissions in following years were 
then estimated using per diem costing; moreover, based on the previous study, 
fitting GLM was applied for predicting long-term costs (Jones et al., 2015a, 
Geue et al., 2012, Dodd et al., 2006). Nevertheless, the total long-term 
healthcare costs of the study population were not estimated due to a lack of 
diagnoses with ICD-9/ICD-10 for patients in the A&E department, outpatient, 
and primary care setting.  Thus, the estimated costs will be useful only for 
comparison across risk profiles of the study population. The methods of 
measurement and valuation of relevant costs and included diseases in this study 
were difficult to compare with other settings so the comparison cannot be made 
for this discussion.  This study analysed the Scottish linkage data as well as 
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applied Scottish health services costs. The results of this study could be 
specifically applied to the Scottish context with good internal validity, whereas 
the results may be lack external validity. However, the use of model adaptation 
can be applied to make this policy model more transferable to other settings 
(Daniel Mullins et al., 2014, Stout et al., 2009).    
10.2.7 Chapter 8    
Chapter 8 showed how the alcohol intervention model applies the 
economic evaluation of an intervention which aims to change the selected risk 
factors. The intervention was assumed that it would be able to stop drinking 
(measured baseline alcohol consumption by the AUDIT) and smoking (measured 
baseline by the number of cigarette per day) in all selected subgroups (best 
scenario), whereas other selected risk factors (e.g. SIMD, physical activity, and 
BMI) were assumed to be the same as baseline.  Heterogeneity in patient 
characteristics were explored using a series of separate scenarios.  These 
scenarios are explored by varying the mortality and morbidity rates according 
to the characteristics considered. The impact of the intervention on changing 
LYs, QALYs, and long-term hospitalisation costs were illustrated. Then, the full 
economic evaluation using a cost-utility analysis to compare between the base 
case and hypothetical intervention was conducted. Comparing the costs and 
benefits of the intervention and baseline over the lifetime period, a within-trial 
analysis combined with the developed model can capture both short- and 
longer- term consequences. For a further cost-effectiveness analysis of other 
health promotion interventions, this study demonstrated the structure of 
analysis model and specified the input parameter needed. Finally, the cost-
effectiveness results were presented using a probabilistic model that took into 
account input parameter uncertainty, and the results were compared to the 
cost-effective threshold of the UK. Moreover, the cost-effectiveness results 
were classified into subgroups based on age, gender and different risk profiles; 
this would be used to inform the policy-making process and define target groups 
for interventions based on cost-effectiveness results. 
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10.2.8 Chapter 9 
Finally, the protocol of methodological transferability study in Thailand 
and potential problems surrounding transferability to the Thai context were 
addressed. The Thai study’s framework was developed to evaluate the alcohol 
intervention implemented in Thailand. The method used was developed and 
validated in the Scottish setting, and consisted of an alcohol intervention 
mathematic model for predicting LYs, QALYs, lifetime healthcare costs, and 
cost-effectiveness analysis.  
10.3  Strengths and limitations  
10.3.1 Strengths  
 The major strengths of this thesis are detailed in the numbered sections 
below. 
1. High quality data sources: The model development has exploited the high-
quality routine health data sets of Scotland known as the linkage data of SHeS-
SMR/NRS; this study has developed a model-based economic evaluation after 
creating a nationally-representative cohort study following people up from 
survey participation for a maximum of 19 years (from 1995 to the end of 2013); 
very large cohort sample size (n = 46,230) as well as numbers of events (the 
total numbers of first alcohol related events = 1,150 cases and non-alcohol 
related events = 21,051 events).  
2. High internal validity: The alcohol intervention model classified by 
individual risk profile is extremely data-demanding and needs country-specific 
data such as annual risk of morbidity and mortality - which varied by strata 
formed by the variables of age, gender, socioeconomic status, alcohol drinking, 
and other behaviours. Such variable often cluster or co-occur with drinking such 
as smoking and physical activity and this model has captured such co-variation 
and is built into the economic model. Moreover, alcohol intervention 
effectiveness and cost data, cost data for alcohol-related conditions, and utility 
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weights for health state transition model were required. These input 
parameters were derived from the single source longitudinal data at the 
individual level, which produces high internal validity. The same data sources 
(from Scotland) were used for developing all the components of the decision 
analytic model (e.g. baseline risk classified by risk profiles, morbidity and 
mortality incidence data over time, health related quality of life, and 
healthcare costs). When compared to other existing alcohol intervention 
models, those studies employed evidence synthesis to generate transitional 
probability and relative risk of morbidity and mortality of higher risk drinking.    
3. New high-quality evidence on association between AUDIT and health outcomes: 
There is scarce evidence that reveals the association between the measured AUDIT 
score and alcohol-related consequences (e.g. mortality and morbidity). This study 
explored the association of measured AUDIT scores in survey population and 
alcohol-related diseases and death. Nowadays, the validated AUDIT is 
recommended for alcohol use disorder screening and treatment in the primary 
healthcare setting in the UK, and has been translated into other languages in 
many other countries including Thailand. It can evaluate the effects of 
treatment by measuring the impact of treatment on general alcohol problems 
using self-completed questionnaires. Thus, the use of predicted AUDIT scores 
for modelling can extrapolate the health impact caused by alcohol use disorder 
which is generally defined as the same ICD-10 across countries. This will be an 
advantage as the current model can be adapted to other jurisdictions where 
the AUDIT is applied in their healthcare settings and general population surveys 
for estimating alcohol use disorder prevalence.  
4. Incidence-based model: Several alcohol models exist. In particular, the 
Sheffield model is the most well-known in the UK and focusses on the expected 
disease prevalence for various population cohorts (prevalence-based approach) 
related to alcohol consumption. As such, this needs to deal with time lag effects 
for chronic conditions where the development of a disease often occurs over 
many years. While the Sheffield model assumed the time lag of obtaining the 
full benefits associated with a reduction of consumption based on the best 
Chapter 10: Discussion and conclusions  337 
 
 
available evidence, this study used incidence-based approaches to estimate 
time-dependent risk of hospitalisations and deaths due to such chronic 
conditions for individual risk profile including alcohol consumption.   
5. Broad modelling scope: More possible health states of study cohort were 
modelled using the health state transition model of a single individual cohort, 
and the transitional probability of each heath state was estimated from 
parametric survival models to extrapolate health-related consequences over a 
lifetime horizon. This study applied the AUDIT for the outcome measurement 
of the alcohol intervention because the AUDIT can capture a wider range of 
alcohol drinking problems based on 0 to 40 scores so the subgroup analysis could 
be performed as classified by the scores. Moreover, this study was concerned 
about the under-reporting bias of alcohol consumption; therefore, the level of 
alcohol consumption among the survey population used for predicting AUDIT 
scores and identifying binge drinking was adjusted by using alcohol sales data.  
6. Strong comparability between model development and initial model use 
settings: This study aims not only to develop an alcohol intervention economic 
model but also to transfer the approach used to an LMIC setting (Thailand). 
This thesis showed strong comparability between two settings in terms of the 
magnitude of alcohol consumption and its related-problems – which Scotland 
and Thailand were found similar figures of alcohol use disorder problem and 
alcohol-related death rate among men. Thus, this model has been potentially 
transferred to Thailand as well as the framework of future study in Thailand 
has been detailed. 
10.3.2 Limitations  
1. From the health state transition model (shown as Figure 3-3), the change 
of service provision for disease screening and other primary care services would 
not affect the analysis since only hospitalisations were included. However, if 
service provision related to hospitalisation was improved such as reducing the 
waiting time for cancer treatment, the probability of hospitalisation due to 
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such conditions would increase. Thus, this analysis was based on the service 
deliveries at the time period of the occurring event only.         
2. There were time and resource constraints within this study which did not 
allow for a societal perspective to be analysed. Moreover, some costs and 
outcomes might be difficult to capture due to limited resources for primary 
research within this area. Non-health consequences were not included i.e. 
socioeconomic consequences (loss of earnings, unemployment, homelessness, 
poverty, family disruption, and stigmatisation) (WHO, 2004, Schmidt et al., 
2010). Harm to other individuals (e.g. spouse or partner, child, co-worker, case 
of traffic crashes and violence) was also not included, e.g. death or a lifelong 
disability for accident victims. 
3. Over half (53% for males and 51% for females) of the SHeS participants who 
had no prior alcohol-related hospitalisation were alive and did not yet 
experience one of the first events. In addition, over 85% of those who 
experienced first hospitalisation after the survey date were still alive. These 
might result in potential survey bias and limited duration of follow up, 
especially for most recent survey year as described below: 
3.1) Selection bias and non-response bias of the SHeS since healthy people 
are more likely to be recruited in the health survey. At the same time, if 
unhealthy heavy drinkers were recruited, they would be less likely to respond 
regardless of their alcohol drinking levels. As a result, the probability that this 
study lacks data from unhealthy people would be high, which would 
underestimate the effect of high-risk drinking on health.  
3.2) The SHeS-SMR/NRS linkage data was limited to hospitalisation and death 
in hospital events (i.e. SMR01), so it would likely underestimate the risk of 
diseases which will occur in a primary care setting, non-hospitalised conditions, 
and death due to road traffic accident. The follow-up time of later SHeS (e.g. 
survey year 2010-2012) would be too short for developing chronic diseases (e.g. 
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CVD and cancers), so these conditions might not present in hospitalisation 
records and especially death from the conditions. 
 These would likely affect the long tail survival curves without any model 
calibration. Although the parametric survival models were shown to be highly 
statistically significant, these models can be updated to re-predict life 
expectancy using updated linkage data (see section 10.4). Furthermore, for 
health economics analysis, the estimated outcomes and healthcare costs, 
especially an expensive condition such as cancer will not yet have captured in 
the linkage data, and this is likely underestimate cost effectiveness results of 
an alcohol intervention. 
4. HRQoL status might vary among individuals with the same health status 
since other variables related to health status were not taken into account. This 
analysis adjusted for some confounders which were available, but possibly not 
all because data was not available; some may not have been measured or 
recorded while some were unknown confounders.  
5. The use of the predicted overall AUDIT score for almost all of the SHeS data 
sets (7 of 8 survey years) is an important assumption in predicting outcomes 
(i.e. hospitalisation and death). The overall AUDIT was predicted using self-
reporting long term health condition (having CVD), and the following analysis 
as cause-specific hazard model of first CVD hospitalisation was also included 
the predicted AUDIT. This is leading to a lack of independence between AUDIT 
and the first CVD hospitalisation. Although the results showed that there were 
no statistically significant increasing risks of having first CVD hospitalisation for 
a unit increase in the predicted AUDIT score, care should be taken when 
interpreting the relationships between the predicted AUDIT score and outcomes 
of interest due to its limitation.  
6. There were no longitudinal risk behaviour profiles of the survey study 
population, whereas the developed model focussed on the relationship between 
the selected modifiable risk factor and the risk of first events (i.e. 
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hospitalisations and deaths) without information about risk behaviours on the 
date of having first event. Thus, the model would be applied only for the 
evaluation of a primary intervention which aims to reduce the risk of the first 
event of interest under the assumption that the respondent who has the first 
event will not change his/her risk behaviours from the survey date. Moreover, 
socioeconomic deprivation is measured by the Scottish Index of Multiple 
Deprivation (SIMD). This was classed as non-modifiable risk factor so the study 
population assumed the same status over time. In addition, the SIMD quintile 
was selected to be the measurement of socioeconomic status of this analysis to 
investigate health inequality among study population, so the index cannot apply 
for other settings. However, the linear predictor of the model can be 
recalibrated using country-specific life tables and SIMD quintiles as a covariate 
that can be replaced with other deprivation indices.            
10.4  Areas for further research 
The key areas for future research are listed below, in order of priority.  
1.  The current study focussed on alcohol use disorder and its impact on 
individual hospitalisations, deaths and lifetime hospitalisation costs. It is 
possible that intervention may reduce A&E incidence and primary care 
consultations, and increase admission or vice versa. Further studies should 
explore a more comprehensive linkage beyond inpatient data. Therefore, the 
total healthcare costs and other health conditions should be estimated using 
alternative longitudinal data e.g. SHeS linked to SMR00 (outpatient attendance) 
and Accident and Emergency when they are completely linked to the SHeS 
record and diagnoses are identified for all individual patient. Moreover, the 
Prescribing Information System (PIS) would be explored; PIS includes 
prescribing, dispensing and reimbursed data by a range of healthcare 
practitioners including GPs, nurses, dentists, pharmacists and an expanding 
range of other non-medical prescribers (Alvarez-Madrazo et al., 2016). PIS has 
been connected to further datasets by using electronic record linkage e.g. 
SMR00 and SMR01. Therefore, the resource use (i.e. prescribed medicines) in 
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primary care setting would be possible to include in estimating healthcare 
costs. Currently, in Scotland, the linkage of primary care records is ongoing 
work, namely the SPIRE project (http://spire.scot/), so the use of general 
practitioners (GPs) patient records is possible for use in the future study. For 
example, it would provide repeated measurement on individual behaviours such 
as alcohol drinking, smoking, and BMI. In the UK, the CPRD is currently the best 
way forward for linking primary and secondary care records 
(https://www.cprd.com/intro.asp).   
2. There will be an opportunity to acquire updated SHeS-SMR/NRS linkage data 
(i.e. 2013 onward) where the AUDIT has already included in the survey, and the 
current study population will have a longer follow-up period as well as new 
cohorts. This updated data can then be used to re-analyse the following: 1) the 
analysis of predictive performance of all predicting AUDIT score models to test 
whether OLS regression will obtain the best predictive model; and 2) the 
modelling risk of events derived from recent linkage data where more event of 
interest will have been observed. These analyses can provide an opportunity to 
re-estimate models with higher statistical power.  
3. The societal perspective has been recommended for the economic evaluation 
of public health and health promotion intervention because of its wider 
perspective (Weatherly et al., 2009, Lorgelly et al., 2010, Chalkidou et al., 
2008). Further research should be conducted to account for the wider impacts 
of alcohol consumption on the whole society such as productivity loss due to 
sick leave or blackout from high-risk drinking, harms to others, and crime and 
violence. widening linkage beyond healthcare data. It is also possible that the 
future research will use the increasing types of linkage data beyond healthcare, 
e.g. link to work and pensions data and criminal records.     
4. An important issue for further research is a health outcome measurement of 
alcohol drinking control intervention; therefore, these studies should 
prospectively investigate the change of HRQoL along with the AUDIT over time. 
Moreover, these studies should consider the measurements for alcohol use and 
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HRQoL since they should be able to capture the effect of alcohol consumption 
on HRQoL unless it is found that the reduction of alcohol drinking risk does not 
show any significant improvement in HRQoL (Essex et al., 2014, UKATT Research 
Team, 2005b). 
5. Alcohol related harm is an important public health issue worldwide. This 
issues also seems to relate to specific cultures and inequalities in health. This 
model could classify the effect of alcohol intervention by socioeconomic status, 
so adapting this model to different countries would be valuable e.g. research 
in LMIC. Since socioeconomic status (as measured by the SIMD) is a key factor 
of the current alcohol intervention model, it can reflect the inequality in health 
that has been the focus of public health policy. Hence, future studies in other 
countries should define the standard tool for measuring socioeconomic status 
in their context and apply the measurement across the same geographical area 
(e.g. country level); the measured socioeconomic status should be a key 
covariate of a further alcohol intervention model in the future alcohol 
intervention model.  
6. The model was constructed to evaluate the effectiveness and cost-
effectiveness of an intervention which aimed to change individual risk profile 
as demonstrated. However, it would be interesting to apply the model for an 
evaluation of a public health intervention which aims to shift the distribution 
of population risk (e.g. population-level intervention). Other modelling 
approaches such as system dynamics, discrete event simulation describe the 
interactions of heterogeneous individuals with their environment. There is 
therefore a need to justify the model structures which are developed and the 
level of complexity employed (Squires et al., 2016). 
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10.5 Implications for policy-makers 
The information is useful for policy-makers who are focussing on alcohol 
interventions which aim to reduce harms caused by alcohol consumption; 
moreover, the results derived from model could classify a large number of 
subgroups varied by heterogeneity characteristic of population, so this could be 
used to help policy-makers in targeting groups of such intervention based on 
cost-effectiveness results. In addition, the results derived from the alcohol 
intervention model using the Scottish linkage data can be specifically applied 
to the Scottish context with good internal validity. This can demonstrate 
usefulness of collecting and linking routine data, i.e. national health surveys 
and national healthcare administrative data, and such data can be applied for 
generating a wide range of health research to inform the policy-making process. 
Public health policy-makers may be interested in widening their perspectives 
apart from the health sector so the linkage for routine non-health data (e.g. 
crime records and employment data) should be improved for capturing a 
broader impact of alcohol intervention. Moreover, the protocol for future 
studies in other settings was detailed to guide local researchers who will 
transfer this method and conduct an economic evaluation of an alcohol 
intervention to inform their local public health policy-makers. 
10.6 Conclusions 
The study highlights the potential and importance of developing health 
economic models utilising data from routine national health surveys linked to 
national hospitalisation and death records. The developed framework can be 
used for further economic evaluation of alcohol interventions and other health 
behaviour change interventions. The framework can further be transferred to 
other country settings. 
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Appendix 1 
 Alcohol conditions and International Classification of Diseases (ICD-9 and -10) codes 
  ICD-9 codes ICD-10 codes 
Wholly attributable conditions 
Mental and behavioural disorders due to use of alcohol 291, 303, 305 F10 
Degeneration of nervous system due to alcohol   G31.2 
Alcoholic polyneuropathy 357.5 G62.1 
Alcoholic myopathy   G72.1 
Alcoholic cardiomyopathy 425.5 I42.6 
Alcoholic gastritis 535.3 K29.2 
Chronic (incl.) alcoholic liver disease 571.0-571.5, 571.8, 571.9 
K70 K73, K74.0-K74.2, 
K74.6 
Alcohol-induced chronic pancreatitis 577.1 K86.0 
Excessive blood level of alcohol 790.3 R78.0 
Toxic effect of alcohol (Ethanol&Metanol poisoning) 980 T51.0, T51.1, T51.9 
Accidental or intentional poisoning by and exposure to 
alcohol E860.0, E860.9 X45 X65 
Poisoning by and exposure to alcohol, undetermined 
intent 9805 Y15 
Evidence of alcohol involvement determined by blood 
alcohol level   Y90 
Evidence of alcohol involvement determined by level 
intoxication   Y91 
Alcohol-induced acute pancreatitis (2014) 577 K85.2 
Alcohol rehabilitation (excluded  2014) V57 Z50.2 
Alcohol deterrents (excluded  2014) E947.3 Y57.3 
Alcohol abuse counselling and surveillance (excluded  
2014)   Z71.4 
Alcohol use (excluded  2014)   Z72.1 
   
Partly attributable-chronic conditions 
Malignant neoplasm of lip, oral cavity and pharynx 140,141-146,148-149 C00-C14 
Malignant neoplasm of oesophagus  150,151 C15 
Malignant neoplasm of colon 153 C18, C19, C21 
Malignant neoplasm of rectum 154 C20 
Malignant neoplasm of liver and intrahepatic bile ducts 155 C22 
Malignant neoplasm of larynx 161 C32 
Malignant neoplasm of breast 174 C50 
Diabetes mellitus (type II) 250 E11 
Epilepsy and Status epilepticus 345 G40-G41 
Hypertensive diseases 401-405 I10-I15 
Ischaemic heart disease 410-414 I20-I25 
Cardiac arrhythmias 427.0,427.2,427.3 I47-I48 
Haemorrhagic stroke 430-438 I60-I62, I69.0-I69.2 
Ischaemic stroke   I63-I66, I69.3-I69.4 
 ICD-9 codes ICD-10 codes 
Partly attributable-chronic conditions (cont.) 
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Oesophageal varices 456.0-456.2 I85 
Unspecified liver disease 571.5-571.9 K73, K74 
Cholelithiasis 574 K80 
Acute and chronic pancreatitis 577, 577.1 K85, K86.1 
Spontaneous abortion 634, 656.5 O03 
Tuberculosis 10-18 A15-A19 
Pneumonia 
480.8, 481, 482.41, 482.8, 
484, 486, 487 J10,J11,J12-15, J18 
Partly attributable-acute consequences 
Road/ Pedestrian traffic accidents  E810-E819, E826,E829 § 
Fall injuries E880-E888 W00-W19 
Other unintentional injuries E980-E989 §§ 
Drowning E910 W65-W74 
Fire injuries E890-E899 X00-X09 
Intentional self-harm/Event of undetermined intent E950-E959 
X60-X84, Y10-
Y34,Y87,Y87.2 
Poisoning X40-X49 E860-E869, V15.6 
Assault E960,E965,E966,E968,E969 X85-Y09, Y87.1 
§ = V021-V029, V031-V039, V041-V049, V092, V093, V123-V129, V133-V139, V143-V149, V194-V196, V203-V209, V213-V219, V223-V229, V233-
V239, V243-V249, V253-V259, V263-V269, V273-V279, V283-V289, V294-V299, V304-V309, V314-V319, V324-V329,V334-V339, V344-V349, V354-
V359, V364-V369, V374-V379, V384-V389, V394-V399, V404-V409, V414-V419, V424-V429, V434-V439, V444-V449, V454-V459, V464-V469, V474-
V479, V484-V489, V494-V499, V504-V509, V514-V519, V524-V529, V534-V539,V544-V549, V554-V559, V564-V569, V574-V579, V584-V589, V594-
V599, V604-V609, V614-V619, V624-V629, V634-V639, V644-V649, V654-V659, V664-V669, V674-V679, V684-V689, V694-V699, V704-V709, V714-
V719, V724-V729, V734-V739, V744-V749,V754-V759, V764-V769, V774-V779, V784-V789, V794-V799, V803-V805, V811, V821, V830-V833, V840-
V843, V850-V853, V860-V863, V870-V878, V892 
 §§ = V01, V090, V091, V099, V100-V109, V110-V119, V120-122, V130-132, V140-V142, V150-V159, V160-V169,V170-V179, V180-V189, V191-V193, 
V20-V28: 0.1–0.2; V290-V293, V30-V38: 0.1–0.2; V390-V393, V40-V48: 0.1–0.2; V490-V493, V50-V58: 0.1–0.2; V590-V593, V60-V68: 0.1–0.2; V690-
V693, V70-V78: 0.1–0.2; V790-V793, V800, V801, V806–V809, V810, V812–V819,V820, V822–V829, V834–V839, V844–V849, V854–V859, V864–V869, 
V879, V88, V890, V891, V893–V899, V90-V94, V95-V97, V98-V99, W20-W52, W75-W84, W85–W99, X10-X19, X20-X29, X30-X33, X50-X57, X58, X59, 
Y40-Y84 Y85, Y86, Y88, Y89 
Source:  
1. Jones L, Bellis MA. Updating England-Specific Alcohol-Attributable Fractions. Liverpool: Centre for Public Health, Liverpool John Moores 
University 2013. 
2. Jones L, Bellis MA, Dedman D, Sumnall H, Tocque K. Alcohol-Attributable Fractions for England. Liverpool: Centre for Public Health, Liverpool 
John Moores Universitythe and North West Public Health Observatory 2008. 
3. Grant I, Springbett A, Graham L. Alcohol attributable mortality and morbidity: alcohol population attributable fractions for Scotland. Edinburgh: 
Information Services Division, NHS National Services Scotland 2009. 
 
Cardiovascular disease International Classification of Diseases (ICD-9 and -10) codes 
(Excluded CVD attributable to alcohol consumption) 
  ICD-9 codes ICD-10 codes 
Cardiovascular diseases 390-409, 415-429, 440-459 I10-I19, I26-I59, I70-I74 
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Appendix 2 
Search terms for the methodological review 
Search terms used in NHS EED (search conducted on the 18/12/2016): 
1 MeSH DESCRIPTOR Alcohol-Related Disorders EXPLODE 1 2 
2 MeSH DESCRIPTOR alcohol drinking EXPLODE 1 
3 "alcohol drinking" 
4 alcoholism 
5 "alcohol consumption" 
6 drink* NEAR excess* 
7 drink* NEAR binge 
8 drink* NEAR heavy 
9 drink* NEAR hazard* 
10 drink* NEAR problem* 
11 drink* NEAR abuse 
12 drink* NEAR misus* 
13 drink* NEAR dependen* 
14 drink* NEAR harm* 
15 alcohol* NEAR excess* 
16 alcohol* NEAR binge 
17 alcohol* NEAR heavy 
18 alcohol* NEAR hazard* 
19 alcohol* NEAR problem* 
20 alcohol* NEAR abuse 
21 alcohol* NEAR misus* 
22 alcohol* NEAR dependen* 
23 alcohol* NEAR harm* 
24 "alcohol intake" 
#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 
or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24  
NHS EED = 188  
Hand searching 2 
 
Search term used in Ovid MEDLINE(R) <1946 to December Week 1 2016>  
Search conducted 30/12/2016 
1 exp "Costs and Cost Analysis"/ (221402) 
2 "Value of Life"/ (6038) 
3 Economics/ (9758) 
4 Economics, Nursing/ or Economics, Medical/ or exp Economics, Hospital/ or Economics, 
Pharmaceutical/ (40151) 
5 or/1-4 (276274) 
6 (econom$ or cost$ or pric$ or pharmacoeconomic$).ti,ab. (611907) 
7 (expenditure$ not energy).ti,ab. (22252) 
8 (value adj1 money).ti,ab. (29) 
9 budget$.ti,ab. (21156) 
10 or/6-9 (634121) 
11 5 or 10 (758489) 
12 letter.pt. (962103) 
13 editorial.pt. (424974) 
14 historical article.pt. (512545) 
15 12 or 13 or 14 (1875501) 
16 11 not 15 (721901) 
17 Animals/ (6734766) 
18 Humans/ (18009599) 
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19 17 not (17 and 18) (4782110) 
20 16 not 19 (662455) 
21 (metabolic adj cost).ti,ab. (1053) 
22 ((energy or oxygen) adj cost).ti,ab. (3212) 
23 20 not (21 or 22) (659154) 
24 *Alcohol Drinking/ (41229) 
25 exp Alcohol-Related Disorders/ (116132) 
26 *Temperance/ (1124) 
27 Alcohol Deterrents/ (1464) 
28 exp Self-Help Groups/ (10346) 
29 "alcohol drinking".mp. (69502) 
30 Alcoholism.mp. (85677) 
31 dipsomania.mp. (28) 
32 "alcohol consumption".mp. (35505) 
33 (drink$ adj excess$).tw. (166) 
34 (drink$ adj binge).tw. (151) 
35 (drink$ adj heavy).tw. (172) 
36 (drink$ adj hazard$).tw. (65) 
37 (drink$ adj problem$).tw. (1013) 
38 (drink$ adj abuse).tw. (15) 
39 (drink$ adj misus$).tw. (3) 
40 (drink$ adj dependen$).tw. (22) 
41 (drink$ adj harm$).tw. (26) 
42 (alcohol$ adj excess$).tw. (187) 
43 (alcohol$ adj binge).tw. (173) 
44 (alcohol$ adj heavy).tw. (58) 
45 (alcohol$ adj hazard$).tw. (23) 
46 (alcohol$ adj problem$).tw. (4092) 
47 (alcohol$ adj abuse).tw. (13751) 
48 (alcohol$ adj misus$).tw. (2120) 
49 (alcohol$ adj dependen$).tw. (11781) 
50 (alcohol$ adj harm$).tw. (143) 
51 "alcohol intake".tw. (12132) 
52 or/24-51 (203355) 
53 23 and 52 (7363) 
54 Rehabilitation Centers/ (8187) 
55 Health Behavior/ (47408) 
56 Health Education/ (61517) 
57 Preventive Health Services/ (13277) 
58 Preventive Psychiatry/ (236) 
59 Directive Counseling/ (2257) 
60 exp Behavior Therapy/ (68102) 
61 exp Cognitive Therapy/ (23998) 
62 exp Evidence-Based Medicine/ (68560) 
63 Hospitalization/ (92438) 
64 (Referral and Consultation).mp. [mp=title, original title, abstract, name of substance word, 
subject heading word] (63337) 
65 Health Promotion/ (69457) 
66 Health Maintenance Organizations/ (16205) 
67 "relapse prevention".mp. (2594) 
68 "harm reduction".mp. (4164) 
69 (naltrexone or acamprosate or disulfiram or opioid-antagonist).tw. (11693) 
70 campral.mp. (32) 
71 anti?craving.tw. (93) 
72 dis?lfiram.tw. (2837) 
73 disulfiram.tw. (2837) 
74 dissulfiram.tw. (1) 
75 disulfuram.mp. (11) 
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76 "brief intervention".tw. (2179) 
77 "motivational interviewing".tw. (2759) 
78 "motivational enhancement therapy".tw. (304) 
79 "social behavio?r".tw. (7820) 
80 "cognitive behavio?ral therapy".tw. (8093) 
81 "aversion therapy".tw. (172) 
82 "relapse prevention".tw. (2565) 
83 "skills training".tw. (4689) 
84 treatment.mp. (3915653) 
85 or/54-84 (4297698) 
86 53 and 85 (3008) 
87 limit 86 to yr="2014-Current" (464) 
87 limit 86 to yr="2015-Current" (219) 
Yield 219 studies 
Duplicate 56+5 studies 
Total 163 (219-56-5) studies 
 
Search term used in Ovid Embase 1947-Present, updated daily 
Search conducted 30/12/2016 
1 exp "Costs and Cost Analysis"/ (307717) 
2 "Value of Life"/ (122806) 
3 Economics/ (226172) 
4 Economics, Nursing/ or Economics, Medical/ or exp Economics, Hospital/ or Economics, 
Pharmaceutical/ (745135) 
5 or/1-4 (1000104) 
6 (econom$ or cost$ or pric$ or pharmacoeconomic$).ti,ab. (868900) 
7 (expenditure$ not energy).ti,ab. (31328) 
8 (value adj1 money).ti,ab. (37) 
9 budget$.ti,ab. (30426) 
10 or/6-9 (897960) 
11 5 or 10 (1536285) 
12 letter.pt. (970999) 
13 editorial.pt. (528311) 
14 historical article.pt. (0) 
15 12 or 13 or 14 (1499310) 
16 11 not 15 (1445834) 
17 Animals/ (1549367) 
18 Humans/ (11631562) 
19 17 not (17 and 18) (1220999) 
20 16 not 19 (1425042) 
21 (metabolic adj cost).ti,ab. (1168) 
22 ((energy or oxygen) adj cost).ti,ab. (3798) 
23 20 not (21 or 22) (1420469) 
24 *Alcohol Drinking/ (13967) 
25 exp Alcohol-Related Disorders/ (125740) 
26 *Temperance/ (1100) 
27 Alcohol Deterrents/ (668) 
28 exp Self-Help Groups/ (13454) 
29 "alcohol drinking".mp. (7778) 
30 Alcoholism.mp. (132149) 
31 dipsomania.mp. (52) 
32 "alcohol consumption".mp. (119316) 
33 (drink$ adj excess$).tw. (233) 
34 (drink$ adj binge).tw. (178) 
35 (drink$ adj heavy).tw. (207) 
36 (drink$ adj hazard$).tw. (78) 
37 (drink$ adj problem$).tw. (1232) 
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38 (drink$ adj abuse).tw. (17) 
39 (drink$ adj misus$).tw. (4) 
40 (drink$ adj dependen$).tw. (27) 
41 (drink$ adj harm$).tw. (31) 
42 (alcohol$ adj excess$).tw. (418) 
43 (alcohol$ adj binge).tw. (270) 
44 (alcohol$ adj heavy).tw. (78) 
45 (alcohol$ adj hazard$).tw. (29) 
46 (alcohol$ adj problem$).tw. (4947) 
47 (alcohol$ adj abuse).tw. (19000) 
48 (alcohol$ adj misus$).tw. (2651) 
49 (alcohol$ adj dependen$).tw. (15918) 
50 (alcohol$ adj harm$).tw. (220) 
51 "alcohol intake".tw. (16147) 
52 or/24-51 (259254) 
53 23 and 52 (18169) 
54 Rehabilitation Centers/ (14480) 
55 Health Behavior/ (57248) 
56 Health Education/ (92914) 
57 Preventive Health Services/ (28005) 
58 Preventive Psychiatry/ (3688) 
59 Directive Counseling/ (723) 
60 exp Behavior Therapy/ (42300) 
61 exp Cognitive Therapy/ (43570) 
62 exp Evidence-Based Medicine/ (1002636) 
63 Hospitalization/ (315576) 
64 (Referral and Consultation).mp. (12784) 
65 Health Promotion/ (84802) 
66 Health Maintenance Organizations/ (18736) 
67 "relapse prevention".mp. (3879) 
68 "harm reduction".mp. (6106) 
69 (naltrexone or acamprosate or disulfiram or opioid-antagonist).tw. (13817) 
70 campral.mp. (239) 
71 anti?craving.tw. (154) 
72 dis?lfiram.tw. (3571) 
73 disulfiram.tw. (3571) 
74 dissulfiram.tw. (1) 
75 disulfuram.mp. (14) 
76 "brief intervention".tw. (2179) 
77 "motivational interviewing".tw. (3717) 
78 "motivational enhancement therapy".tw. (311) 
79 "social behavio?r".tw. (9772) 
80 "cognitive behavio?ral therapy".tw. (12007) 
81 "aversion therapy".tw. (250) 
82 "relapse prevention".tw. (3633) 
83 "skills training".tw. (6504) 
84 treatment.mp. (5818355) 
85 or/54-84 (6810673) 
86 53 and 85 (8338) 
87 limit 86 to yr="2014-Current" (1843) 
87 limit 86 to yr="2015-Current" (1139) 
Yield 1139 studies 
Duplicate 208+13 studies 
Total 931 (1139-208-13) studies 
Hand searching 3 
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Appendix 4 
 
Self-completed SF-12 Physical and Mental Health Questionnaire in Scottish Health Survey 2003  
Please read this carefully 
These questions ask for your views about your health.  This information will help keep track of how you feel 
and how well you are able to do your usual activities. 
Please answer every question by marking one box.  If you are unsure about how to answer, please give the best 
answer you can. 
    Tick one box 230  
   Excellent 
 
Very good Good Fair Poor 
Q10 In general, would you say your 
health is: 
  
1 
  
2 
  
3 
  
4 
  
5 
 
 The following items are about activities you might do 
during a typical day. Does your health now limit  
you in these activities? If so, how much? 
  Tick one box  
on each line 
 
 
   Yes, limited a 
lot 
 Yes, limited a 
little 
 
 No, not limited  
at all 
10.6.1.1.1.1.1.1      
231   
Q11 Moderate activities such as moving a table, pushing 
a vacuum cleaner, bowling, or playing golf 
  
1 
   
2 
   
3 
 
10.6.1.1.1.1.1.2      
232   
Q12 Climbing several flights of stairs    
1 
   
2 
   
3 
 
 During the past 4 weeks, have you had any of the 
following problems with your work or other regular daily 
activities as a result of your physical health? 
 Tick one box  
on each line 
    
Yes 
   
No 
  
10.6.1.1.1.1.1.3      
233   
Q13 Accomplished less than you would like   
1 
   
2 
  
10.6.1.1.1.1.1.4      
234   
Q14 
 
 
 
Were limited in the kind of work or other activities   
1 
   
2 
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 During the past 4 weeks, have you had any of the  
following problems with your work or other regular  
daily activities as a result of any emotional problems  
(such as feeling depressed or anxious)? 
 Tick one box  
on each line 
    
Yes 
   
No 
  
10.6.1.1.1.1.1.5      
235   
Q15 Accomplished less than you would like   
1 
   
2 
  
10.6.1.1.1.1.1.6      
236   
Q16 
 
 
Didn’t do work or other activities as carefully as usual   
1 
   
2 
  
    Tick one box 
237 
 
   Not at all 
 
A little bit Moderately Quite a bit Extremely 
Q17 During the past 4 weeks, how much did 
pain interfere with your normal work 
(including both work outside the home and 
housework)? 
  1   2   3   4   5  
       
 
 
These next questions are about how you feel and how things 
have been with you during the past 4 weeks. For each 
question, please give the one answer that comes closest to the 
way you have been feeling.  
How much of the time during the past 4 weeks – 
 Tick one box  
on each line   
10.6.1.1.1.1.1.7          
   All of the 
time 
Most of the 
time 
A good bit of 
the time 
Some of the 
time 
A little of the 
time 
None of the 
time 
10.6.1.1.1.1.1.8         
238 
Q18 Have you felt calm and peaceful?   
1 
  
2 
  
3 
  
4 
  
5 
  
6 
 
        
239 
Q19 Did you have a lot of energy?   
1 
  
2 
  
3 
  
4 
  
5 
  
6 
 
        
240 
Q20 Have you felt downhearted and low?   
1 
  
2 
  
3 
  
4 
  
5 
  
6 
 
        
241 
Q21 During the past 4 weeks, how much 
of the time has your physical health 
or emotional problems interfered 
with your social activities (like 
visiting with friends, relatives, etc.)? 
  
1 
  
2 
  
3 
  
4 
  
5 
  
6 
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Appendix 5 
 
 
Source: Brazier JE, Roberts J. The estimation of a preference-based measure of health from the 
SF-12. Med Care2004 Sep;42(9):851-9.
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Appendix 7 
Thai Expert Consultation Meeting minutes 
Research title “Development and validation of alcohol-use disorder prediction 
model for monitoring and evaluation of alcohol consumption control programmes” 
HITAP meeting room I, Health Intervention and Technology Assessment 
Programme (HITAP) 
26th November 2014 at 1:30-3:30 pm 
 
Participants:   
1. Prof. Dr. Paibul Suriyawongpaisal  Department of Community Medicine, 
       Faculty of Medicine, Mahidol University 
2. Assoc. Prof. Dr. Sawitree Ausanangkornchai Epidemiology Unit, Faculty of Medicine, 
       Prince of Songkla University 
3. Dr. Nopporn Tantirangsee   Songkhlarajanagarindra Psychiatric  
       Hospital 
4. Dr. Piya Hanvoravongchai   Department of Preventive and Social 
       Medicine, Faculty of Medicine,  
       Chulalongkorn University 
5. Assist. Prof. Montarat Thavorncharoensap  Faculty of Pharmacy, Mahidol University 
6. Dr. Yot Teerawattananon   HITAP 
7. Dr. Sripen Tantivess    HITAP 
8. Pattara Leelahavarong   HITAP 
9. Waranya Rattanawipapong   HITAP 
10.Varit Chantarastapornchit   HITAP 
 
 
Meeting objectives 
1. To discuss and comment on the research methods and preliminary results of 
analyses using Scottish linkage dataset. 
2.  To consult about the possibility and availability of Thai dataset to do a 
methodological transferability.  
3.  To recommend the further applications of research methods and findings to 
conduct the future research for evaluation and monitoring the alcohol 
consumption control programmes and another health promotion interventions 
in Thailand     
Meeting summary 
I. Researcher’s presentation 
o This study aims to develop a surrogate outcome of alcohol consumption control 
interventions, which the outcome provides early and accurate prediction of 
both a clinical endpoint and the effect of intervention on this endpoint, and 
then lifetime quality-adjusted life years (QALYs) of different drinking status 
would be estimated in the Thai context. The linkage data between Scottish 
Health Surveys (SHeS) and Scottish Morbidity Records (SMRs) would be used for 
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analysis. The preliminary results showed that Alcohol Use Disorders 
Identification Test (AUDIT) associated with HRQoL in term of SF-6D utility index 
as well as the risk of alcohol-related hospitalisations and deaths. 
II. Discussion and comments 
o The foundation and justification of using AUDIT should be well described i.e. 
the validation of using AUDIT to measure the drinking status in the Thai setting, 
the importance of each increasing scale in each component (not only overall 
score), the cardinal scale property of AUDIT, the comparison among alcohol 
drinking measurement. 
o Binge drinking (3rd item of AUDIT) and each component of AUDIT should be also 
investigated the association with alcohol-related harms. 
o This study aims to estimate the lifetime alcohol-related harms and convert to 
QALYs classified by drinking status. Nonetheless, the limitation of cross-
sectional design which the participants’ drinking status as well as AUDIT score 
measured in SHeS could not be followed up the change of drinking status over 
lifetime period, so the experts suggested that the developed model for QALY 
estimation should take into account a changeable drinking pattern overtime.      
o When this study could estimate the QALYs of drinkers in the Thai context, an 
external validation of alcohol-related harm prediction model might be 
conducted for example, using a survey design to interview the drinking status 
and AUDIT as well as QALYs directly, or comparing to an existing cohort in 
Thailand. However, the agreement of Thai experts suggested to conduct a 
further study for the external validation and include the study plan in discussion 
of the current study.  
o Since AUDIT is a behaviour measurement related to alcohol consumption and 
alcohol use disorder, the implication of AUDIT for monitoring and evaluation of 
any health promotion intervention might be the intervention which aims to 
change particularly the behaviour of target population. Nevertheless, many 
health promotion programmes aim for knowledge and attitude changed, so the 
further study might include the association between knowledge/attitude 
changed and the developed behaviour surrogate outcome.  
o The association of alcohol drinking, alcohol-related harms, and deprivation is 
interesting, and it may be a further health research in Thailand.   
o Relevant and existing data in Thailand: 1) the national epidemiological survey 
of mental health 2013-2014 (N~5,000) conducted by Department of Mental 
Health, Ministry of Public Health using Composite International Diagnostic 
Interview or CIDI, which an alcohol abuse  and alcohol dependence were 
diagnosed, as well as EQ-5D-5L of respondents were also collected (Thai tariff 
can be applied for utility index calculation); 2) National Health Examination 
Survey V (2013) conducted by National Health Examination Survey Office, which 
alcohol consumption was included; 3) a cohort in Ubonrachathani province 
(N~20,000); 4) a hospitalisation records of Central Office of Health Care (ICD-
10 of alcohol-related conditions might be under-reported); and 5) baseline  
mortality and alcohol-related death reported by Thai Burden of Diseases (BOD). 
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o In summary, the Thai experts agreed with the methodology using Scottish 
linkage dataset, and the main suggestions surrounding analyses were 1) whether 
using another measurements of alcohol drinking e.g. binge drinking or using 
each component of AUDIT not only overall score would affect to the association 
between those measurements and alcohol-related harms compared to using 
overall AUDIT score, and 2) according to the limited study period and data 
sources in Thailand, the completed transferability of this study to the Thai 
context would likely need the further study in Thailand after finished PhD 
study, so almost all of Thai experts suggested to add a thesis chapter to 
describe the further study plan and framework rather than the final results in 
the Thai context with substantial assumptions.     
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Appendix 8 
Uncertainty in decision analytic model  
In healthcare decision-making, decision analysis provides a statistical or 
mathematical process that brings together multiple sources of evidence on a 
range of parameters in order to estimate the costs and outcomes of all 
alternative interventions. Decision analysis provides a systematic and explicit 
approach to decision-making under conditions of uncertainty (Briggs, 2000). It 
is intended to assist conventional decision-making. Although analysts seek to 
develop models and incorporate data that most accurately inform the costs and 
outcomes associated with a particular disease and intervention, some degree 
of uncertainty is present in the majority of models; uncertainty about the true 
parameter values, the type of model used and the model results. More formally 
the dimensions of uncertainty have been categorised as parameter, 
heterogeneity, methodological and structural (Briggs, 2000). Each dimension 
requires to be dealt with differently. Assessing heterogeneity employ methods 
to adjust for patient characteristics, geographical location or to compute cost-
effectiveness results for particular sub-groups of patients or locations (Sculpher 
et al., 2004). Moreover, it requires consideration whether other factors 
inherent to these groups influence the study outcomes by confounding or 
overriding the actual treatment effects, i.e. different age groups, differences 
in gender or disease specification (NICE, 2013). Methodological uncertainty 
refers to uncertainty regarding whether the methods used were the most 
appropriate (Briggs, 2000). Methodological uncertainties can be dealt with 
through the use of a reference case for appropriate methodology, i.e. by 
following good practice guidelines for undertaking modelling (ISPOR, 2014). 
Structural uncertainty is classified into the following general types: (i) 
inclusion/exclusion of potentially relevant comparators; (ii) inclusion/exclusion 
of potentially relevant events; (iii) statistical models to estimate specific 
parameters and (iv) clinical uncertainty or lack of clinical evidence (Bojke et 
al., 2009).  Uncertainty regarding the structure of the model can be dealt with 
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by one-way sensitivity analyses and scenario analyses, modifying one or more 
structural aspects or assumptions of the model and determining the impact on 
outcomes.  More recently it has been suggested that a formal framework is 
required to addressed structural uncertainty, whereby a global model could be 
developed including parameters which encompass all possible structural 
choices so that they can be addressed using probabilistic methods (Jackson et 
al., 2011).  
Parameter uncertainty refers to uncertainty in the point estimates used 
to reflect the specific parameters in the model, i.e. uncertainty in the mean 
utility value assigned to a specific disease group, or uncertainty in the 
probability of an event.  A decision model can explicitly represent this 
uncertainty and quantify it through the use of probabilistic sensitivity analysis 
(PSA), which is detailed in the next section (Briggs, 2000, Fenwick et al., 2001, 
Briggs et al., 2006a). PSA can be conducted for as many uncertain parameters 
as the model may contain, concurrently. Uncertainty about a parameter is 
represented by a probability distribution. The choice of distribution is informed 
by the type and shape of the data observed, for example cost data are usually 
represented by gamma distributions and probability data by beta distributions 
(Briggs et al., 2006a). Markov Chain Monte Carlo (MCMC) simulation methods 
are then used to simulate the expected costs and outcomes of the various 
interventions, by sampling from the distributions that feed into the estimation. 
In this way, PSA enables uncertainty surrounding all input parameters to be 
propagated through the decision model in order that uncertainty surrounding 
the decision itself can be quantified.  Finally, decision uncertainty should also 
be explored.  Decision uncertainty refers to the level of uncertainty in the cost-
effectiveness outcome from the model, i.e. uncertainty in the estimated cost-
effectiveness of the treatment in comparison to the alternative(s) (Fenwick et 
al., 2001, Briggs et al., 2006b).  
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Assessing parameter uncertainty 
In a probabilistic sensitivity analysis (PSA), uncertainty in the mean 
parameter estimates is accounted for by assigning a distribution to each 
parameter and drawing a random estimate from that distribution to represent 
the point estimate (Briggs et al., 2006a).  By drawing randomly from the 
parameter distributions simultaneously for all parameters in the model and 
repeating this random draw numerous times (in a Monte Carlo simulation) 
uncertainty in the parameter estimates is accounted for cost, effect and cost-
effectiveness results from the model can be calculated for each simultaneous 
random draw (iteration). The average cost, effect and cost-effectiveness across 
all the iterations in the Monte Carlo simulation are taken to represent the 
probabilistic outcomes which account for uncertainty in the input parameters. 
Using any number of iterations greater than 1000 is generally considered to be 
acceptable to reflect uncertainty in the model parameters.  If there are 
negligible or minimal changes to the incremental cost and incremental 
effectiveness outcomes between variations in the number of iterations then the 
outcomes can be considered stable.  
Defining and choosing distributions for parameters 
In dealing with parameter uncertainty, the model parameters need to 
represent the sampling distribution. This has important implications for the 
choice of distribution for any of the parameters to represent the uncertainty in 
any parameter of the model, which vary depending on the family or from of 
distribution (Briggs et al., 2006a). However, the probability distribution that 
represents uncertainty in a decision analytic model is not chosen randomly but 
decided based on the type of data, the parameter type and estimation process 
as follows:  
Normal distribution: The most commonly used continuous distribution is 
the normal distribution. The Standard Normal Distribution has an expected 
mean value of zero, and a variance of one N(0,1). Therefore, a random variable 
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(parameter) on the normal distribution is of any value between negative and 
positive infinity (-∞, ∞). Many distributions can be approximated to the normal 
distribution under an assumption based on the central limit theorem which 
assumes that as a sample size gets very large (tending towards infinity) the 
sampling distribution of the mean will be normally distributed regardless of the 
underlying distribution of the data. Therefore, in a decision analytic model, the 
normal distribution can be considered a candidate for any of the parameters in 
the model; however, this is only as the parameter which is of a large enough 
sample size to justify a normal assumption. 
Log normal distribution: The log normal distribution is a continuous 
probability distribution that ranges from zero to positive infinity (0, ∞) and is 
positively skewed. This distribution does not cover any negative values. This 
distribution is suitable for parameters that are non-negative as well as highly 
skewed or are multiplicative, such as ratios. A normal distribution is generated 
if the natural logarithms of the parameters of such a distribution are calculated. 
Beta distribution: In probability theory and statistics, the beta 
distribution is employed to model the proportion of successes (n) in a binomial 
trial and define the interval (0,1). Two positive shape parameters that appear 
as exponents of the random variable and control the shape of the distribution 
are α and β.  α is the number of events that occur and β is the number of non-
events. 
Dirichlet distribution: The Dirichlet distribution, being multivariate in 
nature, is generally considered to be the multinomial extension of the beta 
distribution with one parameter per category. It is thought of as flexible and 
convenient, computationally, as its components take values (0,1) (Briggs et al., 
2003).  
   Gamma distribution: The gamma distribution is useful for continuous 
variables, particularly those considered to be highly skewed. It is constrained 
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within the interval zero to positive infinity (0, ∞). Gamma distribution is 
represented by α and β. 
For choosing distributions for parameters, the common distributions in 
PSA are normal, log-normal, beta and gamma distributions (Briggs et al., 
2006a). First, probability parameters can only take values between zero and 
one (0,1). Beta distributions are commonly representative of such parameters 
as prevalence, diagnostic test accuracy, and the probabilities exclusive events 
must sum to one. Uncertainty in this probability can be presented by two 
parameters, α and β, as mentioned in the previous section, β = (sample size (n) 
– the number of events occurring (α)).  Normally, α and n are reported in 
publications, and these are used to calculate the β for the beta distribution. 
On the other hand, as opposed to binomial data, multinomial data with 
numerous categories, each represented by proportions that sum to one, are 
appropriate for the Dirichlet distribution (Briggs et al., 2003). If the overall 
sample size and the number of events of interest for each category are reported 
in a publication, the data can then be used to calculate proportions for each 
category to fit the Dirichlet distribution.   
   Second, costs data are calculated from resource usage, weighted by 
unit costs (Briggs et al., 2006a). Therefore, cost parameters should not be lower 
than zero, as it is not possible to have a negative result, although they can 
range up to infinity. When considering which distribution best fits the costs 
parameter, gamma distribution can be selected as it is constrained to value 
zero and upward to infinity (0, ∞). If cost estimates of a suitably large sample 
are found to be symmetric around the mean, it can be assumed that the central 
limit theorem applies and a normal distribution fitted to the data. However, if 
the data is highly skewed, a more characteristic situation for cost data, both 
log-normal and gamma distribution are used to fit the distribution.  
   Third, utility can be suited to the Beta distribution only if it is 
appropriate to assume that the utility range is between close to zero and close 
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to one (Briggs et al., 2006a). However, in cases of severe life-threatening 
illness, the utility can be very low or negative utility and so utility ranges 
between negative infinity and one (-∞, 1). Therefore, the beta distribution 
should be avoided in such cases.  When the transformation of disutility = 1 - 
utility, where disutility is a utility decrement, the distribution is constrained on 
the scale zero to infinity (0, ∞) and is better fitted to a Gamma or Log-normal 
distribution.   
    In cases where only partial evidence has been reported, i.e. a mean 
value with no standard error, assumptions can be used to determine an 
appropriate standard error (which is large enough to reflect a wide range of 
uncertainty). Additionally, if 95% confidence intervals have been reported 
rather than a specification of the standard error, then the standard error can 
be calculated using the 95% confidence limits.  
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Appendix 9 
Male – 1. cause specific hazard model of first hospitalisation with wholly alcohol-attributable conditions  
Cholesky decomposition 
 
 
age AUDIT Binge CVD DM Cigarettes 
/day 
Phys. 
actv. 
(Low) 
Phys. 
actv. 
(Med) 
Phys. 
actv. 
(High) 
SIMD 
(2) 
SIMD 
(3) 
SIMD 
(4) 
SIMD 
(Least 
Deprived) 
Other 
Hos 
LastYr 
Other 
Hos 
Over 
LastYr 
GHQ 
(1-3) 
GHQ 
(4+ 
worse) 
Constant Gamma 
age 0.009 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
AUDIT 0.003 0.019 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Binge 0.018 -0.191 0.259 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
CVD -0.101 -0.011 0.004 0.268 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
DM -0.020 0.016 0.029 -0.137 1.014 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Cigarettes 
/day 
0.000 -0.001 -0.001 0.000 0.000 0.005 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. actv. 
 (Low) 
0.025 -0.007 -0.018 0.025 0.020 0.066 0.394 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. actv. 
 (Med) 
0.058 -0.008 -0.012 0.057 0.025 0.044 0.184 0.299 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. actv. 
 (High) 
0.104 -0.026 -0.037 0.072 0.030 0.069 0.182 0.130 0.264 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(2) -0.005 0.011 0.004 0.001 0.000 0.009 -0.016 -0.018 0.002 0.340 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(3) -0.014 0.023 0.020 -0.002 0.001 -0.041 -0.003 -0.001 0.005 0.115 0.334 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(4) -0.009 0.034 0.015 -0.002 0.004 0.027 -0.016 -0.009 -0.013 0.116 0.082 0.364 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD 
(Least 
Deprived) 
-0.021 0.025 0.017 0.002 0.003 0.038 -0.021 -0.017 -0.015 0.116 0.082 0.058 0.378 0.000 0.000 0.000 0.000 0.000 0.000 
OtherHos 
LastYr 
-0.023 0.019 0.027 -0.034 -0.011 -0.009 0.033 0.021 0.012 -0.010 -0.011 0.014 0.015 0.423 0.000 0.000 0.000 0.000 0.000 
OtherHos 
OverLastYr 
-0.012 0.015 0.013 -0.010 -0.009 -0.031 0.024 0.015 -0.008 0.004 -0.001 0.007 0.011 0.122 0.247 0.000 0.000 0.000 0.000 
GHQ 
(1-3) 
0.024 -0.019 -0.002 -0.001 0.003 -0.046 0.019 0.010 0.009 0.007 -0.022 0.011 0.010 -0.021 -0.007 0.307 0.000 0.000 0.000 
GHQ 
(4+worse) 
0.030 -0.064 -0.003 -0.016 0.007 -0.021 0.028 0.023 0.021 0.015 0.029 0.030 0.022 -0.027 -0.005 0.114 0.263 0.000 0.000 
Constant -0.486 -0.073 -0.114 -0.128 -0.040 -0.082 -0.196 -0.131 -0.083 -0.121 -0.083 -0.073 -0.060 -0.126 -0.153 -0.117 -0.090 0.173 0.000 
Gamma 0.005 0.001 -0.002 0.002 0.001 0.000 -0.002 -0.003 -0.001 0.000 0.001 0.000 0.000 0.005 0.004 0.000 0.002 -0.023 0.023 
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Male – 2. cause specific hazard model of first hospitalisation with partly alcohol-attributable conditions 
Cholesky decomposition 
 
 
 
age AUDIT Binge CVD DM Cigarette
s 
/day 
Phys. 
actv. 
(Low) 
Phys. 
actv. 
(Med) 
Phys. 
actv. 
(High) 
SIMD 
(2) 
SIMD 
(3) 
SIMD 
(4) 
SIMD 
(Least 
Deprived) 
Other 
Hos 
LastYr 
Other 
Hos 
Over 
LastYr 
GHQ 
(1-3) 
GHQ 
(4+ 
worse) 
Constant Gamma 
age 0.004 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
AUDIT 0.002 0.013 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Binge 0.009 -0.093 0.109 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
CVD -0.035 0.003 0.006 0.113 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
DM 0.003 0.007 0.006 -0.049 0.211 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Cigarettes 
/day 
0.000 -0.001 -0.001 0.000 0.000 0.004 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. actv. 
(Low) 
0.018 -0.004 -0.014 0.009 0.009 0.008 0.175 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. actv. 
(Med) 
0.026 -0.006 -0.009 0.022 0.014 0.006 0.077 0.120 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. actv. 
(High) 
0.044 -0.010 -0.016 0.027 0.017 0.012 0.076 0.066 0.127 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(2) -0.002 0.001 0.006 -0.003 0.000 0.004 -0.001 -0.007 -0.003 0.167 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(3) -0.003 0.002 0.011 -0.001 0.002 0.007 -0.001 -0.005 -0.004 0.081 0.129 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(4) -0.002 0.004 0.009 -0.002 0.003 0.014 -0.002 -0.005 -0.010 0.081 0.055 0.147 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD 
(Least 
Deprived) 
-0.005 -0.006 0.006 0.001 0.004 0.019 -0.004 -0.010 -0.008 0.081 0.055 0.028 0.132 0.000 0.000 0.000 0.000 0.000 0.000 
OtherHos 
LastYr 
-0.013 0.005 0.011 -0.020 -0.009 0.003 0.015 0.018 0.010 -0.004 -0.004 0.006 0.005 0.169 0.000 0.000 0.000 0.000 0.000 
OtherHos 
OverLastY
r 
-0.009 0.003 0.004 -0.010 -0.007 0.000 0.009 0.009 0.003 -0.001 0.002 0.003 0.002 0.055 0.104 0.000 0.000 0.000 0.000 
GHQ 
(1-3) 
0.012 -0.002 0.003 0.001 0.002 -0.011 0.007 0.007 0.004 0.004 -0.002 0.003 0.004 -0.011 0.003 0.129 0.000 0.000 0.000 
GHQ 
(4+worse) 
0.020 -0.019 0.003 -0.003 0.002 -0.010 0.010 0.013 0.008 0.005 0.011 0.008 0.007 -0.017 0.001 0.032 0.165 0.000 0.000 
Constant -0.277 -0.044 -0.043 -0.066 -0.027 -0.032 -0.077 -0.061 -0.026 -0.082 -0.057 -0.033 -0.028 -0.061 -0.065 -0.033 -0.020 0.074 0.000 
age 0.003 0.000 -0.001 0.002 0.001 -0.001 -0.001 -0.002 0.000 0.000 0.000 0.000 0.000 0.003 0.002 0.000 0.000 -0.009 0.009 
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Male – 3. cause specific hazard model of first hospitalisation with non-emergency& non-CVD conditions 
Cholesky decomposition 
 
 
age AUDIT Binge BMI 
(over 
weigh
t) 
BMI 
(obesi
ty) 
CVD DM Cigarettes/
day 
Phys. 
actv. 
(Low) 
Phys. 
actv. 
 (Med) 
Phys. 
actv. 
 (High) 
SIMD 
(2) 
SIMD 
(3) 
SIMD 
(4) 
SIMD 
(Least 
Deprived) 
Other
Hos 
Last 
Yr 
Other 
Hos 
Over 
LastYr 
GHQ  
(1-3) 
GHQ  
(4+ 
worse) 
Constant Gamma 
age 0.001 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
AUDIT 0.001 0.004 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Binge 0.001 -0.026 0.029 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
BMI 
(over 
weight) 
-0.004 0.001 0.000 0.035 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
BMI 
(obesity) 
-0.003 0.000 0.000 0.022 0.034 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
CVD -0.011 0.001 0.002 -0.003 -0.004 0.032 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
DM 0.000 0.003 0.002 0.000 -0.006 -0.018 0.062 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Cigarettes 
/day 
0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. actv. 
 (Low) 
0.004 -0.001 -0.003 0.001 0.000 0.003 0.003 0.001 0.052 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. actv. 
 (Med) 
0.006 -0.002 -0.002 0.001 0.001 0.006 0.005 0.000 0.025 0.035 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. actv. 
 (High) 
0.011 -0.003 -0.004 0.003 0.003 0.008 0.006 0.002 0.024 0.020 0.029 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(2) 0.000 0.000 0.001 -0.001 0.000 0.000 0.000 0.002 -0.001 -0.001 -0.001 0.044 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(3) -0.001 0.000 0.002 -0.002 0.000 0.000 0.000 0.003 -0.001 -0.001 -0.001 0.023 0.037 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(4) -0.001 0.000 0.001 -0.001 0.000 0.000 0.001 0.005 -0.001 -0.001 -0.002 0.023 0.013 0.035 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD 
(Least 
Deprived) 
-0.002 -0.002 0.001 -0.002 0.001 0.000 0.001 0.006 -0.001 -0.002 -0.002 0.023 0.013 0.009 0.037 0.000 0.000 0.000 0.000 0.000 0.000 
OtherHos 
LastYr 
-0.003 0.001 0.002 -0.002 -0.001 -0.005 -0.003 0.000 0.004 0.004 0.002 -0.001 0.000 0.002 0.002 0.044 0.000 0.000 0.000 0.000 0.000 
OtherHos 
OverLastY
r 
-0.001 0.000 0.001 -0.002 -0.001 -0.002 -0.002 0.000 0.002 0.002 0.000 0.000 0.000 0.001 0.001 0.016 0.028 0.000 0.000 0.000 0.000 
GHQ (1-3) 0.003 0.000 0.001 0.001 0.000 0.000 0.000 -0.001 0.001 0.001 0.001 0.001 0.000 0.001 0.001 -0.002 0.001 0.033 0.000 0.000 0.000 
GHQ 
(4+worse) 
0.004 -0.004 0.001 0.002 -0.001 -0.001 0.000 -0.003 0.002 0.003 0.003 0.001 0.002 0.002 0.001 -0.004 0.001 0.010 0.041 0.000 0.000 
Constant -0.059 -0.012 -0.010 -0.021 -0.009 -0.015 -0.008 -0.010 -0.025 -0.019 -0.010 -0.023 -0.014 -0.011 -0.007 -0.017 -0.017 -0.010 -0.006 0.020 0.000 
Gamma 0.001 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.000 0.000 0.000 -0.003 0.003 
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Male – 4. cause specific hazard model of first hospitalisation with non-emergency& CVD conditions 
Cholesky decomposition 
 
 
age AUDIT Binge BMI 
(over 
weight) 
BMI 
(obesity) 
CVD DM Cigarettes 
/day 
Phys. 
actv. 
(Low) 
Phys. 
actv. 
(Med) 
Phys. 
actv. 
High) 
SIMD 
(2) 
SIMD 
(3) 
SIMD 
(4) 
SIMD 
(Least 
Deprived) 
Other 
Hos 
LastYr 
OtherHos 
OverLastYr 
GHQ 
(1-3) 
GHQ 
(4+worse) 
Constant Gamma 
age 0.005 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
AUDIT 0.003 0.019 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Binge 0.007 -0.128 0.137 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
BMI 
(over 
weight) 
-0.005 -0.002 0.000 0.163 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
BMI 
(obesity) 
0.001 0.005 -0.007 0.119 0.152 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
CVD -0.046 0.005 0.009 -0.013 -0.013 0.144 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
DM 0.002 0.008 0.008 -0.004 -0.027 -0.039 0.205 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Cigarettes 
/day 
0.001 -0.001 -0.001 0.001 0.000 0.000 0.000 0.006 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. actv. 
(Low) 
0.022 -0.006 -0.017 0.002 -0.003 0.007 0.010 0.009 0.194 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. actv. 
(Med) 
0.033 -0.011 -0.010 0.004 0.003 0.022 0.015 0.005 0.082 0.146 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. actv. 
(High) 
0.053 -0.016 -0.018 0.011 0.008 0.029 0.019 0.011 0.082 0.068 0.155 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(2) -0.005 -0.001 0.005 -0.001 -0.003 -0.002 0.002 0.007 -0.001 -0.009 -0.004 0.195 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(3) -0.002 -0.002 0.011 -0.007 -0.001 -0.001 0.006 0.007 -0.002 -0.003 -0.005 0.089 0.169 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(4) -0.004 0.000 0.008 -0.002 0.002 -0.002 0.005 0.019 -0.002 -0.006 -0.013 0.089 0.057 0.154 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD 
(Least 
Deprived) 
-0.007 -0.013 0.003 -0.006 0.005 0.002 0.009 0.023 -0.006 -0.015 -0.010 0.089 0.057 0.042 0.171 0.000 0.000 0.000 0.000 0.000 0.000 
OtherHos 
LastYr 
-0.017 0.008 0.013 -0.013 -0.003 -0.023 -0.013 0.003 0.017 0.022 0.017 -0.006 -0.005 0.007 0.004 0.181 0.000 0.000 0.000 0.000 0.000 
OtherHos 
Over 
LastYr 
-0.012 0.006 0.004 -0.011 -0.007 -0.012 -0.011 0.001 0.011 0.013 0.007 -0.001 0.003 0.004 0.002 0.089 0.125 0.000 0.000 0.000 0.000 
GHQ (1-3) 0.013 -0.001 0.004 0.001 0.000 0.001 0.003 -0.011 0.008 0.009 0.004 0.004 -0.003 0.005 0.004 -0.016 0.008 0.153 0.000 0.000 0.000 
GHQ 
(4+worse) 
0.023 -0.022 0.004 0.006 0.005 -0.005 0.003 -0.010 0.012 0.016 0.013 0.007 0.012 0.011 0.007 -0.023 0.006 0.044 0.167 0.000 0.000 
Constant -0.345 -0.054 -0.045 -0.101 -0.032 -0.104 -0.037 -0.039 -0.084 -0.066 -0.035 -0.089 -0.060 -0.049 -0.030 -0.095 -0.070 -0.048 -0.029 0.087 0.000 
Gamma 0.004 0.000 -0.001 0.001 0.000 0.002 0.001 -0.001 -0.002 -0.002 0.000 0.000 0.000 0.000 0.000 0.004 0.002 0.001 0.000 -0.011 0.012 
 
   
 
  
3
6
9
 
Male – 5. cause specific hazard model of first hospitalisation with emergency & Non-CVD conditions 
Cholesky decomposition 
 
 
age AUDIT Binge BMI 
(over 
weight) 
BMI 
(obesity) 
CVD DM Cigarettes 
/day 
Phys. 
actv. 
(Low) 
Phys. 
actv. 
(Med) 
Phys. 
actv. 
(High) 
SIMD 
(2) 
SIMD 
(3) 
SIMD 
(4) 
SIMD 
(Least 
Deprived) 
Other 
Hos 
LastYr 
Other 
Hos 
Over 
LastYr 
GHQ 
(1-3) 
GHQ 
(4+worse) 
Constant Gamma 
age 0.001 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
AUDIT 0.001 0.005 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Binge 0.001 -0.034 0.038 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
BMI 
(over 
weight) 
-0.006 0.000 0.001 0.045 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
BMI 
(obesity) 
-0.004 0.000 0.000 0.026 0.045 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
CVD -0.015 0.001 0.002 -0.004 -0.005 0.042 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
DM -0.001 0.003 0.003 -0.001 -0.008 -0.022 0.072 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Cigarettes 
/day 
0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.002 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. 
actv. 
(Low) 
0.005 -0.001 -0.004 0.001 0.000 0.004 0.005 0.002 0.066 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. 
actv. 
(Med) 
0.008 -0.002 -0.003 0.002 0.002 0.008 0.007 0.001 0.025 0.045 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. 
actv. 
(High) 
0.015 -0.004 -0.005 0.004 0.004 0.011 0.008 0.003 0.025 0.023 0.039 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(2) 0.000 0.000 0.001 -0.002 0.000 -0.001 0.000 0.003 -0.001 -0.002 -0.001 0.053 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(3) -0.001 0.000 0.003 -0.003 0.000 -0.001 0.001 0.004 -0.001 -0.001 -0.001 0.025 0.049 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(4) -0.001 0.001 0.002 -0.002 0.000 -0.001 0.001 0.006 -0.002 -0.002 -0.003 0.025 0.014 0.047 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD 
(Least 
Deprived) 
-0.002 -0.002 0.002 -0.003 0.001 0.000 0.001 0.008 -0.002 -0.003 -0.003 0.025 0.014 0.011 0.050 0.000 0.000 0.000 0.000 0.000 0.000 
OtherHos 
LastYr 
-0.003 0.001 0.003 -0.003 -0.001 -0.007 -0.004 -0.001 0.005 0.006 0.003 -0.001 0.000 0.002 0.002 0.058 0.000 0.000 0.000 0.000 0.000 
OtherHos 
Over 
LastYr 
-0.001 0.001 0.001 -0.002 -0.001 -0.003 -0.002 -0.001 0.003 0.003 0.000 0.000 0.001 0.001 0.001 0.022 0.036 0.000 0.000 0.000 0.000 
GHQ 
(1-3) 
0.004 0.000 0.001 0.001 0.000 0.000 0.001 -0.002 0.001 0.002 0.001 0.001 -0.001 0.001 0.001 -0.003 0.001 0.044 0.000 0.000 0.000 
GHQ 
(4+worse) 
0.005 -0.007 0.001 0.003 0.001 -0.002 0.001 -0.004 0.003 0.004 0.004 0.002 0.003 0.003 0.002 -0.005 0.000 0.013 0.050 0.000 0.000 
Constant -0.074 -0.015 -0.014 -0.024 -0.012 -0.019 -0.011 -0.012 -0.025 -0.023 -0.012 -0.025 -0.015 -0.013 -0.009 -0.023 -0.022 -0.013 -0.009 0.025 0.000 
Gamma 0.001 0.000 0.000 0.000 0.000 0.001 0.000 0.000 0.000 -0.001 0.000 0.000 0.000 0.000 0.000 0.001 0.000 0.000 0.000 -0.003 0.003 
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Male – 6. cause specific hazard model of first hospitalisation with emergency & CVD conditions 
Cholesky decomposition 
 
 
age AUDIT Binge BMI 
(over 
weight) 
BMI 
(obesity) 
CVD DM Cigarettes 
/day 
Phys. 
actv. 
(Low) 
Phys. 
actv. 
(Med) 
Phys. 
actv. 
(High) 
SIMD 
(2) 
SIMD 
(3) 
SIMD 
(4) 
SIMD 
(Least 
Deprived) 
Other 
Hos 
LastYr 
Other 
Hos 
Over 
LastYr 
GHQ 
(1-3) 
GHQ 
(4+worse) 
Constant Gamma 
age 0.004 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
AUDIT 0.002 0.013 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Binge 0.007 -0.090 0.099 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
BMI 
(over 
weight) 
-0.003 -0.001 0.002 0.122 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
BMI 
(obesity) 
0.002 0.000 0.001 0.090 0.107 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
CVD -0.030 0.004 0.005 -0.008 -0.010 0.099 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
DM 0.004 0.005 0.005 -0.003 -0.019 -0.036 0.141 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Cigarettes 
/day 
0.000 -0.001 0.000 0.001 0.000 0.000 0.000 0.002 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. 
actv. 
(Low) 
0.016 -0.003 -0.011 0.001 -0.003 0.006 0.009 0.010 0.140 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. 
actv. 
(Med) 
0.023 -0.006 -0.006 0.002 0.002 0.017 0.014 0.009 0.058 0.103 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. 
actv. 
(High) 
0.038 -0.010 -0.012 0.007 0.006 0.021 0.016 0.013 0.058 0.049 0.113 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(2) -0.004 0.001 0.006 -0.002 -0.003 -0.002 0.000 0.001 -0.002 -0.007 -0.003 0.131 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(3) -0.004 -0.001 0.009 -0.004 -0.002 -0.001 0.003 -0.006 0.000 -0.003 -0.004 0.068 0.117 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(4) -0.004 0.001 0.007 -0.002 -0.001 -0.002 0.003 0.008 -0.002 -0.005 -0.010 0.068 0.037 0.117 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD 
(Least 
Deprived) 
-0.006 -0.009 0.003 -0.004 0.003 0.001 0.005 0.011 -0.004 -0.010 -0.008 0.068 0.037 0.026 0.128 0.000 0.000 0.000 0.000 0.000 0.000 
OtherHos 
LastYr 
-0.011 0.004 0.010 -0.007 -0.003 -0.018 -0.009 0.006 0.013 0.015 0.010 -0.004 -0.003 0.005 0.004 0.146 0.000 0.000 0.000 0.000 0.000 
OtherHos 
Over 
LastYr 
-0.009 0.002 0.003 -0.007 -0.004 -0.010 -0.008 -0.003 0.008 0.009 0.004 -0.001 0.001 0.003 0.002 0.057 0.091 0.000 0.000 0.000 0.000 
GHQ 
(1-3) 
0.008 -0.005 0.002 0.001 -0.001 0.000 0.001 -0.015 0.008 0.007 0.004 0.004 -0.004 0.004 0.003 -0.011 0.002 0.111 0.000 0.000 0.000 
GHQ 
(4+worse) 
0.019 -0.012 0.004 0.003 0.003 -0.003 0.002 -0.008 0.011 0.010 0.009 0.006 0.009 0.008 0.006 -0.015 0.002 0.029 0.131 0.000 0.000 
Constant -0.259 -0.037 -0.035 -0.082 -0.025 -0.061 -0.028 -0.020 -0.060 -0.045 -0.023 -0.069 -0.038 -0.031 -0.021 -0.062 -0.059 -0.031 -0.018 0.063 0.000 
Gamma 0.003 0.000 -0.001 0.000 0.000 0.002 0.001 -0.001 -0.001 -0.002 0.000 0.000 0.000 0.000 0.000 0.003 0.002 0.000 0.000 -0.008 0.008 
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Male – 7. cause specific hazard model of first event as alcohol-related death 
Cholesky decomposition 
 
 
age AUDIT Binge CVD DM Cigarettes 
/day 
Phys. actv. 
(Low) 
Phys. actv. 
(Med) 
Phys. actv. 
(High) 
SIMD 
(2) 
SIMD 
(3) 
SIMD 
(4) 
SIMD 
(Least 
Deprived) 
Other 
Hos 
LastYr 
Other 
Hos 
Over 
LastYr 
GHQ 
(1-3) 
GHQ 
(4+worse) 
Constant Gamma 
age 0.011 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
AUDIT 0.005 0.026 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Binge 0.029 -0.226 0.312 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
CVD -0.115 0.002 0.021 0.335 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
DM -0.007 0.014 0.034 -0.170 0.492 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Cigarettes 
/day 
0.000 -0.002 -0.001 0.000 0.001 0.009 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. 
actv. 
(Low) 
0.035 -0.005 -0.033 0.025 0.041 0.022 0.579 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. 
actv. 
(Med) 
0.073 0.000 -0.021 0.061 0.058 0.000 0.151 0.373 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. 
actv. 
(High) 
0.135 -0.026 -0.042 0.082 0.072 0.030 0.150 0.178 0.312 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(2) -0.002 0.009 0.016 -0.002 0.006 0.029 -0.012 -0.024 -0.007 0.366 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(3) -0.014 0.023 0.037 -0.010 0.011 -0.012 -0.009 -0.009 -0.009 0.172 0.534 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(4) -0.010 0.024 0.025 -0.013 0.015 0.046 -0.014 -0.017 -0.028 0.172 0.064 0.417 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD 
(Least 
Deprived) 
-0.019 0.011 0.025 -0.001 0.012 0.065 -0.020 -0.030 -0.028 0.172 0.064 0.074 0.439 0.000 0.000 0.000 0.000 0.000 0.000 
OtherHos 
LastYr 
-0.018 0.020 0.033 -0.037 -0.034 -0.002 0.029 0.036 0.022 -0.005 -0.004 0.017 0.019 0.422 0.000 0.000 0.000 0.000 0.000 
OtherHos 
Over 
LastYr 
-0.008 0.015 0.011 -0.020 -0.023 -0.022 0.020 0.026 -0.001 0.004 0.001 0.008 0.012 0.216 0.293 0.000 0.000 0.000 0.000 
GHQ 
(1-3) 
0.030 -0.021 0.015 -0.003 0.006 -0.022 0.013 0.015 0.004 0.006 -0.014 0.007 0.011 -0.025 0.010 0.362 0.000 0.000 0.000 
GHQ 
(4+worse) 
0.045 -0.085 0.003 -0.015 0.021 -0.032 0.029 0.037 0.032 0.016 0.020 0.030 0.023 -0.036 0.008 0.113 0.371 0.000 0.000 
Constant -0.698 -0.087 -0.186 -0.162 -0.113 -0.091 -0.149 -0.165 -0.101 -0.176 -0.066 -0.091 -0.071 -0.236 -0.160 -0.117 -0.083 0.210 0.000 
Gamma 0.008 0.001 -0.002 0.004 0.003 -0.001 -0.003 -0.006 -0.002 0.000 0.001 0.001 -0.001 0.008 0.003 0.000 0.001 -0.025 0.024 
 
   
 
  
3
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Male – 8. cause specific hazard model of first event as non-alcohol related death 
Cholesky decomposition 
 
 
age AUDIT Binge CVD DM Cigarettes 
/day 
Phys. actv. 
(Low) 
Phys. actv. 
(Med) 
Phys. actv. 
(High) 
SIMD 
(2) 
SIMD 
(3) 
SIMD 
(4) 
SIMD 
(Least 
Deprived) 
Other 
Hos 
LastYr 
Other 
Hos 
Over 
LastYr 
GHQ 
(1-3) 
GHQ 
(4+worse) 
Constant Gamma 
age 0.007 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
AUDIT 0.004 0.023 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Binge 0.012 -0.162 0.177 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
CVD -0.040 0.009 0.006 0.172 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
DM 0.015 0.009 0.007 -0.058 0.228 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Cigarettes 
/day 
0.000 -0.001 -0.001 0.000 0.000 0.004 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. 
actv. 
(Low) 
0.032 -0.007 -0.021 0.011 0.009 0.015 0.253 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. 
actv. 
(Med) 
0.043 -0.009 -0.010 0.030 0.019 0.012 0.059 0.177 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. 
actv. 
(High) 
0.069 -0.015 -0.020 0.035 0.020 0.017 0.058 0.071 0.226 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(2) -0.012 0.001 0.010 -0.006 0.001 0.005 -0.001 -0.014 -0.005 0.228 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(3) -0.011 0.000 0.017 -0.001 0.007 -0.015 0.002 -0.010 -0.007 0.106 0.197 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(4) -0.014 0.001 0.013 -0.005 0.005 0.018 0.001 -0.010 -0.014 0.106 0.067 0.189 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD 
(Least 
Deprived) 
-0.016 -0.016 0.009 0.000 0.010 0.020 -0.004 -0.019 -0.014 0.106 0.067 0.047 0.216 0.000 0.000 0.000 0.000 0.000 0.000 
OtherHos 
LastYr 
-0.020 0.007 0.016 -0.029 -0.014 0.011 0.018 0.030 0.022 -0.011 -0.006 0.009 0.005 0.281 0.000 0.000 0.000 0.000 0.000 
OtherHos 
Over 
LastYr 
-0.015 0.006 0.005 -0.017 -0.012 -0.005 0.013 0.021 0.014 -0.004 0.000 0.005 0.002 0.142 0.163 0.000 0.000 0.000 0.000 
GHQ 
(1-3) 
0.012 -0.001 0.006 -0.002 0.000 -0.036 0.012 0.011 0.009 0.005 -0.009 0.006 0.007 -0.018 0.008 0.191 0.000 0.000 0.000 
GHQ 
(4+worse) 
0.035 -0.015 0.009 -0.006 0.001 -0.014 0.017 0.022 0.016 0.008 0.017 0.015 0.012 -0.022 0.006 0.052 0.196 0.000 0.000 
Constant -0.508 -0.069 -0.053 -0.106 -0.041 -0.021 -0.063 -0.062 -0.037 -0.104 -0.068 -0.057 -0.035 -0.152 -0.125 -0.056 -0.038 0.104 0.000 
Gamma 0.007 0.000 -0.001 0.003 0.002 -0.002 -0.002 -0.004 -0.001 0.000 0.000 0.001 0.000 0.005 0.002 0.001 0.000 -0.014 0.014 
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Female – 1. cause specific hazard model of first hospitalisation with wholly alcohol-attributable conditions  
Cholesky decomposition 
 
 
 
age AUDIT Binge CVD DM Cigarettes 
/day 
Phys. 
actv. 
(Low) 
Phys. 
actv. 
 (Med) 
Phys. 
actv. 
 (High) 
SIMD 
(2) 
SIMD 
(3) 
SIMD 
(4) 
SIMD 
(Least 
Deprived) 
Other 
Hos 
LastYr 
OtherHos 
OverLastY
r 
GHQ 
(1-3) 
GHQ 
(4+ 
worse) 
Constant Gamma 
age 0.012 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
AUDIT 0.006 0.035 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Binge 0.027 -0.283 0.364 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
CVD -0.128 0.023 0.020 0.359 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
DM -0.030 0.014 0.027 -0.195 1.023 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Cigarettes 
/day 
0.000 -0.002 -0.002 0.000 0.000 0.013 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. actv. 
 (Low) 
0.076 -0.009 -0.023 0.033 0.025 -0.006 0.665 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. actv. 
 (Med) 
0.089 -0.001 -0.029 0.058 0.035 -0.020 0.164 0.402 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. actv. 
 (High) 
0.123 -0.004 -0.056 0.070 0.044 0.026 0.164 0.208 0.361 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(2) -0.018 -0.006 0.006 0.001 0.003 0.045 -0.014 -0.018 -0.009 0.465 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(3) -0.036 -0.006 0.001 0.006 0.003 0.045 -0.023 -0.018 -0.018 0.158 0.401 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(4) -0.049 -0.018 0.002 0.006 0.007 0.090 -0.018 -0.022 -0.036 0.159 0.125 0.534 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD 
(Least 
Deprived) 
-0.042 0.003 -0.007 0.017 0.005 0.093 -0.025 -0.028 -0.033 0.159 0.125 0.066 0.530 0.000 0.000 0.000 0.000 0.000 0.000 
OtherHos 
LastYr 
-0.014 0.010 0.017 -0.038 -0.021 -0.015 0.031 0.043 0.026 0.015 0.022 0.018 0.020 0.567 0.000 0.000 0.000 0.000 0.000 
OtherHos 
OverLastYr 
-0.024 -0.012 -0.015 -0.027 -0.010 -0.010 0.023 0.023 0.018 0.010 0.018 0.017 0.025 0.209 0.339 0.000 0.000 0.000 0.000 
GHQ 
(1-3) 
0.024 -0.002 0.017 -0.010 0.002 -0.012 0.012 0.021 0.008 0.014 0.014 0.017 0.008 -0.019 -0.003 0.431 0.000 0.000 0.000 
GHQ 
(4+worse) 
0.038 -0.042 0.005 -0.013 0.000 -0.071 0.021 0.034 0.027 0.025 0.038 0.019 0.012 -0.042 -0.016 0.143 0.346 0.000 0.000 
Constant -0.584 -0.065 -0.089 -0.152 -0.059 -0.129 -0.168 -0.204 -0.122 -0.171 -0.154 -0.085 -0.077 -0.211 -0.225 -0.147 -0.130 0.230 0.000 
Gamma 0.005 0.001 0.003 0.003 0.002 -0.001 -0.003 -0.007 0.000 -0.001 0.000 0.000 -0.001 0.006 0.005 0.000 0.002 -0.031 0.031 
 
   
 
  
3
7
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Female – 2. cause specific hazard model of first hospitalisation with partly alcohol-attributable conditions  
Cholesky decomposition 
 
 
age AUDIT Binge CVD DM Cigarettes 
/day 
Phys. 
actv. 
(Low) 
Phys. 
actv. 
 (Med) 
Phys. 
actv. 
 (High) 
SIMD 
(2) 
SIMD 
(3) 
SIMD 
(4) 
SIMD 
(Least 
Deprived) 
Other Hos 
LastYr 
OtherHos 
Over 
LastYr 
GHQ  
(1-3) 
GHQ 
(4+ 
worse) 
Constant Gamma 
age 0.003 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
AUDIT 0.004 0.016 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Binge 0.001 -0.092 0.105 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
CVD -0.031 0.005 0.007 0.093 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
DM 0.002 0.007 0.006 -0.047 0.220 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Cigarettes 
/day 
0.000 0.000 0.000 0.000 0.000 0.005 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. actv. 
 (Low) 
0.019 -0.007 -0.006 0.011 0.007 -0.003 0.145 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. actv. 
 (Med) 
0.026 -0.009 -0.008 0.018 0.011 -0.007 0.060 0.097 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. actv. 
 (High) 
0.035 -0.015 -0.015 0.022 0.013 0.001 0.060 0.055 0.104 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(2) -0.005 -0.004 0.001 0.001 0.001 0.009 -0.004 -0.003 -0.001 0.131 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(3) -0.007 -0.007 -0.001 0.002 0.002 0.012 -0.004 -0.003 -0.004 0.062 0.111 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(4) -0.008 -0.007 0.000 0.004 0.003 0.021 -0.005 -0.004 -0.006 0.062 0.039 0.112 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD 
(Least 
Deprived) 
-0.007 -0.007 -0.004 0.007 0.004 0.022 -0.007 -0.005 -0.006 0.062 0.039 0.025 0.106 0.000 0.000 0.000 0.000 0.000 0.000 
OtherHos 
LastYr 
-0.005 0.003 0.003 -0.012 -0.006 0.002 0.008 0.012 0.007 0.001 0.004 0.003 0.003 0.149 0.000 0.000 0.000 0.000 0.000 
OtherHos 
OverLastY
r 
-0.004 0.001 -0.002 -0.008 -0.004 0.002 0.005 0.006 0.005 0.001 0.004 0.003 0.003 0.045 0.086 0.000 0.000 0.000 0.000 
GHQ 
(1-3) 
0.006 0.002 0.002 -0.004 0.000 -0.002 0.006 0.006 0.002 0.005 0.005 0.005 0.002 -0.006 -0.002 0.101 0.000 0.000 0.000 
GHQ 
(4+worse) 
0.012 -0.008 0.001 -0.003 -0.002 -0.014 0.007 0.008 0.003 0.005 0.009 0.005 0.002 -0.011 -0.002 0.032 0.111 0.000 0.000 
Constant -0.194 -0.023 -0.018 -0.047 -0.019 -0.028 -0.058 -0.051 -0.022 -0.063 -0.045 -0.029 -0.023 -0.047 -0.057 -0.033 -0.020 0.060 0.000 
age 0.002 0.000 0.001 0.001 0.001 -0.001 -0.001 -0.002 0.000 0.000 0.000 0.000 0.000 0.002 0.001 0.000 0.000 -0.007 0.007 
 
   
 
  
3
7
5
 
 
Female – 3. cause specific hazard model of first hospitalisation with non-emergency& non-CVD conditions 
Cholesky decomposition 
 
 
age AUDIT Binge BMI 
(over 
weight
) 
BMI 
(obesity
) 
CVD DM Cigarettes/
day 
Phys. 
actv. 
(Low) 
Phys. 
actv. 
 (Med) 
Phys. 
actv. 
 (High) 
SIMD 
(2) 
SIMD 
(3) 
SIMD 
(4) 
SIMD 
(Least 
Deprived) 
OtherHos 
Last 
Yr 
Other 
Hos 
Over 
LastYr 
GHQ  
(1-3) 
GHQ  
(4+ 
worse) 
Constant Gamma 
age 0.001 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
AUDIT 0.001 0.004 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Binge -0.001 -0.025 0.028 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
BMI 
(over 
weight) 
-0.003 0.000 0.000 0.028 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
BMI 
(obesity) 
-0.003 0.000 0.000 0.015 0.030 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
CVD -0.009 0.002 0.002 -0.002 -0.004 0.027 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
DM 0.000 0.002 0.002 -0.002 -0.005 -0.015 0.063 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Cigarettes 
/day 
0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. actv. 
 (Low) 
0.005 -0.002 -0.002 0.000 0.002 0.003 0.002 -0.001 0.045 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. actv. 
 (Med) 
0.007 -0.002 -0.002 0.000 0.003 0.005 0.004 -0.002 0.020 0.029 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. actv. 
 (High) 
0.009 -0.003 -0.004 0.002 0.005 0.006 0.004 0.000 0.020 0.018 0.026 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(2) -0.002 -0.001 0.000 0.000 0.001 0.000 0.000 0.003 -0.001 -0.001 0.000 0.035 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(3) -0.002 -0.002 -0.001 0.000 0.001 0.000 0.000 0.004 -0.001 -0.001 -0.001 0.017 0.031 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(4) -0.003 -0.002 0.000 0.000 0.002 0.001 0.001 0.006 -0.001 -0.001 -0.001 0.017 0.010 0.030 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD 
(Least 
Deprived) 
-0.003 -0.002 -0.001 0.001 0.003 0.001 0.001 0.006 -0.002 -0.001 -0.002 0.017 0.010 0.007 0.032 0.000 0.000 0.000 0.000 0.000 0.000 
OtherHos 
LastYr 
-0.002 0.001 0.001 0.000 0.000 -0.003 -0.002 0.000 0.002 0.003 0.002 0.000 0.001 0.001 0.001 0.038 0.000 0.000 0.000 0.000 0.000 
OtherHos 
OverLastY
r 
-0.001 0.000 -0.001 0.000 -0.001 -0.002 -0.001 0.000 0.001 0.001 0.001 0.000 0.001 0.001 0.001 0.016 0.024 0.000 0.000 0.000 0.000 
GHQ (1-3) 0.002 0.000 0.000 0.000 0.000 -0.001 0.000 -0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.000 -0.001 0.000 0.028 0.000 0.000 0.000 
GHQ 
(4+worse) 
0.003 -0.002 0.001 0.000 0.000 -0.001 0.000 -0.004 0.002 0.002 0.001 0.001 0.002 0.001 0.000 -0.003 0.000 0.009 0.030 0.000 0.000 
Constant -0.047 -0.007 -0.005 -0.014 -0.012 -0.012 -0.006 -0.007 -0.020 -0.018 -0.008 -0.018 -0.012 -0.008 -0.006 -0.016 -0.015 -0.009 -0.006 0.016 0.000 
Gamma 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 -0.002 0.002 
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Female – 4. cause specific hazard model of first hospitalisation with non-emergency& CVD conditions 
Cholesky decomposition 
 
 
age AUDIT Binge BMI 
(over 
weight) 
BMI 
(obesity) 
CVD DM Cigarettes 
/day 
Phys. 
actv. 
(Low) 
Phys. 
actv. 
 (Med) 
Phys. 
actv. 
 High) 
SIMD 
(2) 
SIMD 
(3) 
SIMD 
(4) 
SIMD 
(Least 
Deprived) 
Other 
Hos 
LastYr 
OtherHos 
OverLastYr 
GHQ 
(1-3) 
GHQ 
(4+worse) 
Constant Gamma 
age 0.007 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
AUDIT 0.009 0.039 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Binge 0.008 -0.207 0.206 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
BMI 
(over 
weight) 
-0.013 -0.010 0.000 0.231 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
BMI 
(obesity) 
-0.001 -0.011 -0.003 0.168 0.195 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
CVD -0.055 0.007 0.017 -0.013 -0.020 0.188 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
DM 0.006 0.015 0.016 -0.014 -0.028 -0.051 0.257 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Cigarettes 
/day 
0.002 -0.001 -0.001 0.000 0.001 0.001 0.000 0.009 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. actv. 
 (Low) 
0.036 -0.012 -0.015 -0.006 0.013 0.014 0.011 0.005 0.266 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. actv. 
 (Med) 
0.059 -0.022 -0.022 0.002 0.021 0.027 0.025 -0.011 0.097 0.188 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. actv. 
 (High) 
0.078 -0.034 -0.037 0.013 0.030 0.037 0.029 0.003 0.098 0.094 0.215 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(2) -0.007 -0.008 0.001 0.004 0.010 0.002 0.005 0.024 -0.002 -0.006 -0.002 0.236 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(3) -0.010 -0.018 -0.003 -0.003 0.007 0.002 0.009 0.030 -0.004 -0.008 -0.010 0.134 0.240 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(4) -0.009 -0.017 -0.002 0.001 0.015 0.005 0.013 0.044 -0.006 -0.009 -0.012 0.134 0.059 0.252 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD 
(Least 
Deprived) 
-0.009 -0.020 -0.012 0.009 0.020 0.012 0.015 0.042 -0.010 -0.013 -0.013 0.134 0.059 0.042 0.196 0.000 0.000 0.000 0.000 0.000 0.000 
OtherHos 
LastYr 
-0.007 0.007 0.005 -0.002 0.001 -0.024 -0.015 0.013 0.012 0.027 0.021 0.000 0.006 0.009 0.011 0.270 0.000 0.000 0.000 0.000 0.000 
OtherHos 
Over 
LastYr 
-0.008 0.004 -0.004 -0.006 -0.003 -0.019 -0.012 0.007 0.009 0.015 0.016 0.003 0.005 0.007 0.006 0.128 0.169 0.000 0.000 0.000 0.000 
GHQ (1-3) 0.007 0.003 0.005 -0.002 -0.002 -0.007 0.003 0.000 0.014 0.019 0.008 0.010 0.011 0.009 0.003 -0.015 -0.004 0.218 0.000 0.000 0.000 
GHQ 
(4+worse) 
0.027 -0.011 0.005 0.003 -0.006 -0.004 -0.008 -0.028 0.016 0.017 0.010 0.008 0.018 0.010 0.009 -0.024 0.002 0.053 0.208 0.000 0.000 
Constant -0.476 -0.032 -0.038 -0.155 -0.070 -0.138 -0.050 -0.062 -0.099 -0.090 -0.048 -0.137 -0.069 -0.052 -0.052 -0.134 -0.109 -0.056 -0.043 0.113 0.000 
Gamma 0.006 -0.001 0.001 0.001 0.000 0.002 0.002 -0.002 -0.002 -0.004 -0.001 -0.001 0.000 0.000 0.000 0.005 0.002 0.001 0.001 -0.018 0.019 
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Female – 5. cause specific hazard model of first hospitalisation with emergency & Non-CVD conditions 
Cholesky decomposition 
 
 
age AUDIT Binge BMI 
(over 
weight) 
BMI 
(obesity) 
CVD DM Cigarettes 
/day 
Phys. 
actv. 
(Low) 
Phys. 
actv. 
(Med) 
Phys. 
actv. 
(High) 
SIMD 
(2) 
SIMD 
(3) 
SIMD 
(4) 
SIMD 
(Least 
Deprived) 
Other 
Hos 
LastYr 
Other 
Hos 
Over 
LastYr 
GHQ 
(1-3) 
GHQ 
(4+worse) 
Constant Gamma 
age 0.001 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
AUDIT 0.001 0.006 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Binge 0.000 -0.035 0.040 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
BMI 
(over 
weight) 
-0.005 -0.001 0.000 0.044 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
BMI 
(obesity) 
-0.003 0.001 0.001 0.020 0.039 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
CVD -0.013 0.002 0.003 -0.003 -0.006 0.036 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
DM 0.000 0.002 0.002 -0.002 -0.006 -0.018 0.070 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Cigarettes 
/day 
0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.002 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. 
actv. 
(Low) 
0.007 -0.002 -0.002 0.000 0.003 0.004 0.003 -0.001 0.057 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. 
actv. 
(Med) 
0.009 -0.003 -0.003 0.000 0.005 0.007 0.005 -0.003 0.018 0.038 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. 
actv. 
(High) 
0.013 -0.004 -0.006 0.002 0.007 0.009 0.006 0.000 0.018 0.019 0.039 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(2) -0.002 -0.001 0.000 0.000 0.002 0.000 0.000 0.003 -0.001 -0.001 -0.001 0.046 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(3) -0.003 -0.003 -0.001 -0.001 0.001 0.001 0.000 0.005 -0.002 -0.001 -0.002 0.020 0.044 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(4) -0.003 -0.002 0.000 0.000 0.003 0.001 0.001 0.008 -0.002 -0.002 -0.002 0.020 0.012 0.044 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD 
(Least 
Deprived) 
-0.003 -0.002 -0.001 0.000 0.004 0.002 0.001 0.008 -0.003 -0.002 -0.003 0.020 0.012 0.009 0.047 0.000 0.000 0.000 0.000 0.000 0.000 
OtherHos 
LastYr 
-0.002 0.001 0.001 0.000 -0.001 -0.005 -0.003 0.000 0.003 0.005 0.003 0.001 0.001 0.002 0.001 0.053 0.000 0.000 0.000 0.000 0.000 
OtherHos 
Over 
LastYr 
-0.002 0.000 -0.001 0.000 -0.001 -0.003 -0.001 0.000 0.002 0.003 0.002 0.001 0.001 0.002 0.002 0.023 0.033 0.000 0.000 0.000 0.000 
GHQ  
(1-3) 
0.002 0.001 0.000 0.000 0.000 -0.002 0.000 -0.001 0.002 0.003 0.001 0.002 0.002 0.002 0.001 -0.002 0.000 0.039 0.000 0.000 0.000 
GHQ 
(4+worse) 
0.004 -0.003 0.000 0.001 0.000 -0.001 -0.001 -0.005 0.003 0.004 0.002 0.002 0.003 0.002 0.001 -0.005 0.000 0.014 0.041 0.000 0.000 
Constant -0.065 -0.009 -0.007 -0.020 -0.016 -0.018 -0.008 -0.010 -0.018 -0.019 -0.010 -0.021 -0.014 -0.011 -0.008 -0.024 -0.022 -0.014 -0.009 0.023 0.000 
Gamma 0.001 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 -0.001 0.000 0.000 0.000 0.000 0.000 0.001 0.000 0.000 0.000 -0.003 0.003 
 
   
 
  
3
7
8
 
Female – 6. cause specific hazard model of first hospitalisation with emergency & CVD conditions 
Cholesky decomposition 
 
 
age AUDIT Binge BMI 
(over 
weight) 
BMI 
(obesity) 
CVD DM Cigarettes 
/day 
Phys. 
actv. 
(Low) 
Phys. 
actv. 
(Med) 
Phys. 
actv. 
(High) 
SIMD 
(2) 
SIMD 
(3) 
SIMD 
(4) 
SIMD 
(Least 
Deprived) 
Other 
Hos 
LastYr 
Other 
Hos 
Over 
LastYr 
GHQ 
(1-3) 
GHQ 
(4+worse) 
Constant Gamma 
age 0.005 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
AUDIT 0.006 0.029 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Binge 0.005 -0.147 0.177 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
BMI 
(over 
weight) 
-0.004 -0.001 0.002 0.140 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
BMI 
(obesity) 
0.005 0.000 0.002 0.098 0.128 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
CVD -0.030 0.004 0.008 -0.008 -0.014 0.122 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
DM 0.007 0.009 0.005 -0.011 -0.016 -0.041 0.165 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Cigarettes 
/day 
0.001 0.000 0.000 0.000 0.000 0.000 0.000 0.005 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. 
actv. 
(Low) 
0.025 -0.011 -0.007 -0.005 0.008 0.009 0.006 0.001 0.180 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. 
actv. 
(Med) 
0.040 -0.015 -0.010 -0.001 0.012 0.018 0.015 -0.010 0.050 0.126 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. 
actv. 
(High) 
0.051 -0.023 -0.018 0.005 0.020 0.023 0.018 0.002 0.050 0.059 0.154 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(2) -0.005 -0.005 0.000 0.003 0.008 0.004 0.002 0.015 -0.002 -0.002 -0.001 0.164 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(3) -0.007 -0.009 -0.001 -0.001 0.004 0.005 0.008 0.015 -0.003 -0.004 -0.007 0.071 0.140 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(4) -0.005 -0.010 -0.001 0.001 0.009 0.006 0.009 0.027 -0.003 -0.005 -0.008 0.071 0.049 0.138 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD 
(Least 
Deprived) 
-0.004 -0.013 -0.007 0.006 0.012 0.009 0.009 0.026 -0.005 -0.007 -0.008 0.071 0.049 0.032 0.165 0.000 0.000 0.000 0.000 0.000 0.000 
OtherHos 
LastYr 
-0.005 0.006 0.004 0.000 -0.002 -0.016 -0.011 0.003 0.009 0.021 0.015 -0.001 0.001 0.008 0.005 0.172 0.000 0.000 0.000 0.000 0.000 
OtherHos 
Over 
LastYr 
-0.002 0.002 -0.002 -0.005 -0.003 -0.012 -0.010 0.006 0.007 0.013 0.011 0.001 0.005 0.006 0.002 0.069 0.110 0.000 0.000 0.000 0.000 
GHQ 
(1-3) 
0.006 0.006 0.004 0.007 -0.002 -0.007 0.002 -0.002 0.010 0.009 0.007 0.007 0.009 0.009 0.001 -0.014 -0.003 0.140 0.000 0.000 0.000 
GHQ 
(4+worse) 
0.019 0.000 0.003 0.002 0.000 -0.005 -0.005 -0.020 0.012 0.015 0.008 0.007 0.016 0.008 0.004 -0.020 -0.003 0.041 0.135 0.000 0.000 
Constant -0.354 -0.030 -0.019 -0.089 -0.043 -0.080 -0.032 -0.035 -0.050 -0.053 -0.028 -0.073 -0.057 -0.041 -0.023 -0.072 -0.066 -0.044 -0.034 0.075 0.000 
Gamma 0.004 -0.001 0.001 0.000 0.000 0.002 0.001 -0.002 -0.001 -0.003 -0.001 0.000 0.000 0.000 0.000 0.003 0.002 0.001 0.001 -0.010 0.010 
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Female – 7. cause specific hazard model of first event as alcohol-related death 
Cholesky decomposition 
 
 
age AUDIT Binge CVD DM Cigarettes 
/day 
Phys. actv. 
(Low) 
Phys. actv. 
(Med) 
Phys. actv. 
(High) 
SIMD 
(2) 
SIMD 
(3) 
SIMD 
(4) 
SIMD 
(Least 
Deprived) 
Other 
Hos 
LastYr 
Other 
Hos 
Over 
LastYr 
GHQ 
(1-3) 
GHQ 
(4+worse) 
Constant Gamma 
age 0.012 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
AUDIT 0.007 0.041 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Binge 0.047 -0.314 0.369 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
CVD -0.092 0.014 0.021 0.328 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
DM 0.016 0.025 0.029 -0.148 0.733 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Cigarettes 
/day 
0.002 -0.002 -0.001 0.001 0.000 0.013 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. 
actv. 
(Low) 
0.071 -0.006 -0.020 0.035 0.016 -0.009 0.556 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. 
actv. 
(Med) 
0.101 -0.003 -0.033 0.062 0.029 -0.035 0.113 0.339 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. 
actv. 
(High) 
0.143 -0.021 -0.061 0.080 0.035 0.001 0.111 0.159 0.527 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(2) -0.017 0.008 0.016 0.009 0.006 0.035 -0.011 -0.011 -0.004 0.430 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(3) -0.026 -0.005 -0.001 0.011 0.013 0.035 -0.012 -0.013 -0.009 0.239 0.398 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(4) -0.022 -0.009 0.004 0.014 0.013 0.084 -0.015 -0.021 -0.018 0.239 0.119 0.448 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD 
(Least 
Deprived) 
-0.021 0.004 -0.006 0.026 0.017 0.084 -0.021 -0.024 -0.020 0.239 0.118 0.074 0.413 0.000 0.000 0.000 0.000 0.000 0.000 
OtherHos 
LastYr 
-0.014 0.019 0.014 -0.041 -0.019 0.003 0.026 0.037 0.022 0.001 0.005 0.015 0.013 0.600 0.000 0.000 0.000 0.000 0.000 
OtherHos 
Over 
LastYr 
-0.010 -0.006 -0.011 -0.031 -0.006 0.017 0.017 0.021 0.016 0.002 0.013 0.015 0.019 0.354 0.340 0.000 0.000 0.000 0.000 
GHQ 
(1-3) 
0.014 0.015 0.018 -0.018 0.002 -0.016 0.021 0.030 0.012 0.024 0.017 0.022 0.008 -0.032 0.009 0.377 0.000 0.000 0.000 
GHQ 
(4+worse) 
0.036 -0.045 -0.001 -0.002 -0.009 -0.077 0.022 0.036 0.018 0.034 0.040 0.024 0.017 -0.040 -0.001 0.112 0.375 0.000 0.000 
Constant -0.801 -0.073 -0.076 -0.181 -0.062 -0.105 -0.102 -0.122 -0.055 -0.246 -0.142 -0.097 -0.083 -0.366 -0.262 -0.113 -0.080 0.219 0.000 
Gamma 0.010 0.001 0.002 0.004 0.002 -0.003 -0.004 -0.010 -0.001 -0.001 0.001 0.000 -0.001 0.006 0.003 0.001 0.000 -0.025 0.024 
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Female – 8. cause specific hazard model of first event as non-alcohol related death 
Cholesky decomposition 
 
age AUDIT Binge CVD DM Cigarettes 
/day 
Phys. actv. 
(Low) 
Phys. actv. 
(Med) 
Phys. actv. 
(High) 
SIMD 
(2) 
SIMD 
(3) 
SIMD 
(4) 
SIMD 
(Least 
Deprived) 
Other 
Hos 
LastYr 
Other 
Hos 
Over 
LastYr 
GHQ 
(1-3) 
GHQ 
(4+worse) 
Constant Gamma 
age 0.008 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
AUDIT 0.009 0.045 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Binge 0.009 -0.262 0.331 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
CVD -0.027 0.002 0.008 0.182 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
DM 0.017 0.014 0.007 -0.063 0.257 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Cigarettes 
/day 
0.002 -0.001 0.000 0.001 0.000 0.007 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. 
actv. 
(Low) 
0.041 -0.013 -0.012 0.011 0.004 -0.003 0.302 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. 
actv. 
(Med) 
0.064 -0.024 -0.014 0.027 0.016 -0.022 0.054 0.192 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Phys. 
actv. 
(High) 
0.083 -0.040 -0.021 0.031 0.020 0.000 0.053 0.084 0.331 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(2) -0.010 -0.007 0.001 0.009 0.006 0.018 -0.002 -0.002 -0.002 0.222 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(3) -0.014 -0.013 -0.001 0.011 0.014 0.013 -0.003 -0.009 -0.008 0.110 0.218 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD(4) -0.007 -0.019 -0.003 0.010 0.012 0.038 -0.004 -0.010 -0.009 0.110 0.059 0.205 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
SIMD 
(Least 
Deprived) 
-0.013 -0.019 -0.009 0.013 0.014 0.036 -0.006 -0.008 -0.009 0.109 0.058 0.046 0.313 0.000 0.000 0.000 0.000 0.000 0.000 
OtherHos 
LastYr 
-0.009 0.016 0.008 -0.022 -0.014 -0.006 0.014 0.029 0.021 -0.008 -0.006 0.014 0.007 0.296 0.000 0.000 0.000 0.000 0.000 
OtherHos 
Over 
LastYr 
0.001 0.005 -0.003 -0.019 -0.012 0.012 0.008 0.021 0.017 -0.004 0.006 0.011 0.003 0.137 0.175 0.000 0.000 0.000 0.000 
GHQ 
(1-3) 
0.003 -0.002 0.007 -0.014 0.005 -0.004 0.011 0.016 0.008 0.014 0.015 0.020 0.001 -0.022 -0.001 0.199 0.000 0.000 0.000 
GHQ 
(4+worse) 
0.022 -0.014 -0.003 -0.006 -0.010 -0.035 0.014 0.023 0.010 0.011 0.021 0.013 0.007 -0.027 -0.004 0.061 0.229 0.000 0.000 
Constant -0.647 -0.040 -0.020 -0.115 -0.042 -0.042 -0.048 -0.061 -0.032 -0.108 -0.067 -0.064 -0.027 -0.143 -0.129 -0.073 -0.042 0.113 0.000 
Gamma 0.007 -0.001 0.001 0.002 0.002 -0.003 -0.002 -0.007 -0.001 -0.001 0.000 0.000 0.000 0.005 0.003 0.001 0.001 -0.014 0.015 
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